Because O
so O
few O
viruses O
in O
the O
family O
Barnaviridae O
have O
been O
reported O
, O
we O
searched O
for O
more O
of O
them O
in O
public O
sequence O
databases O
. O
Here O
, O
we O
report O
the O
complete O
coding O
sequence O
of O
Colobanthus O
quitensis O
associated O
barnavirus O
1 O
, O
mined O
from O
a O
transcriptome O
of O
the O
Antarctic O
pearlwort O
Colobanthus O
quitensis O
. O
The O
4.2-kb B-DNA
plus-strand I-DNA
sequence E-DNA
of O
this O
virus O
encompasses O
four O
main O
open B-DNA
reading I-DNA
frames E-DNA
( O
ORFs S-DNA
) O
, O
as O
expected O
for O
barnaviruses S-DNA
, O
including O
ORFs S-DNA
for O
a O
protease-containing B-DNA
polyprotein E-DNA
, O
an O
RNA-dependent B-protein
RNA I-protein
polymerase E-protein
whose O
translation O
appears O
to O
rely O
on O
− O
1 O
ribosomal O
frameshifting O
, O
and O
a O
capsid B-protein
protein E-protein
that O
is O
likely O
to O
be O
translated O
from O
a O
subgenomic B-RNA
RNA E-RNA
. O
The O
possible O
derivation O
of O
this O
virus O
from O
a O
fungus O
associated O
with O
C. O
quitensis O
is O
discussed O
. O
Attenuated O
, O
live O
viral O
vaccines O
have O
been O
extraordinarily O
successful O
in O
protecting O
against O
many O
diseases O
. O
The O
main O
drawbacks O
in O
their O
development O
and O
use O
have O
been O
reliance O
on O
an O
unpredictable O
method O
of O
attenuation O
and O
the O
potential O
for O
evolutionary O
reversion O
to O
high O
virulence O
. O
Methods O
of O
genetic O
engineering O
now O
provide O
many O
safer O
alternatives O
to O
live O
vaccines O
, O
so O
if O
live O
vaccines O
are O
to O
compete O
with O
these O
alternatives O
in O
the O
future O
, O
they O
must O
either O
have O
superior O
immunogenicity O
or O
they O
must O
be O
able O
to O
overcome O
these O
former O
disadvantages O
. O
Several O
live O
vaccine O
designs O
that O
were O
historically O
inaccessible O
are O
now O
feasible O
because O
of O
advances O
in O
genome O
synthesis O
. O
Some O
of O
those O
methods O
are O
addressed O
here O
, O
with O
an O
emphasis O
on O
whether O
they O
enable O
predictable O
levels O
of O
attenuation O
and O
whether O
they O
are O
stable O
against O
evolutionary O
reversion O
. O
These O
new O
designs O
overcome O
many O
of O
the O
former O
drawbacks O
and O
position O
live O
vaccines O
to O
be O
competitive O
with O
alternatives O
. O
Not O
only O
do O
new O
methods O
appear O
to O
retard O
evolutionary O
reversion O
enough O
to O
prevent O
vaccine-derived O
epidemics O
, O
but O
it O
may O
even O
be O
possible O
to O
permanently O
attenuate O
live O
vaccines O
that O
are O
transmissible O
but O
can O
not O
evolve O
to O
higher O
virulence O
under O
prolonged O
adaptation O
. O
The O
recent O
outbreak O
of O
H7N9 O
influenza O
in O
China O
is O
of O
high O
concern O
to O
public O
health O
. O
H7 B-protein
hemagglutinin E-protein
( O
HA S-protein
) O
plays O
a O
critical O
role O
in O
influenza O
entry O
and O
thus O
HA O
presents O
an O
attractive O
target O
for O
antivirals O
. O
Previous O
studies O
have O
suggested O
that O
the O
small O
molecule O
tert-butyl O
hydroquinone O
( O
TBHQ O
) O
inhibits O
the O
entry O
of O
influenza B-protein
H3 I-protein
HA E-protein
by O
binding O
to O
the O
stem O
loop O
of O
HA S-protein
and O
stabilizing O
the O
neutral O
pH O
conformation O
of O
HA S-protein
, O
thereby O
disrupting O
the O
membrane O
fusion O
step O
. O
Based O
on O
amino O
acid O
sequence O
, O
structure O
and O
immunogenicity O
, O
H7 S-protein
is O
a O
related O
Group B-protein
2 I-protein
HA E-protein
. O
In O
this O
work O
we O
show O
, O
using O
a O
pseudovirus O
entry O
assay O
, O
that O
TBHQ O
inhibits O
H7 O
HA-mediated O
entry O
, O
as O
well O
as O
H3 S-protein
HA-mediated O
entry O
, O
with O
an O
IC50,6 O
mM O
. O
Using O
NMR O
, O
we O
show O
that O
TBHQ O
binds O
to O
the O
H7 B-protein
stem I-protein
loop I-protein
region E-protein
. O
STD O
NMR O
experiments O
indicate O
that O
the O
aromatic O
ring O
of O
TBHQ O
makes O
extensive O
contact O
with O
the O
H7 B-protein
HA E-protein
surface O
. O
Limited O
proteolysis O
experiments O
indicate O
that O
TBHQ O
inhibits O
influenza O
entry O
by O
stabilizing O
the O
H7 O
HA O
neutral O
pH O
conformation O
. O
Together O
, O
this O
work O
suggests O
that O
the O
stem O
loop O
region O
of O
H7 B-protein
HA E-protein
is O
an O
attractive O
target O
for O
therapeutic O
intervention O
and O
that O
TBHQ O
, O
which O
is O
a O
widely O
used O
food O
preservative O
, O
is O
a O
promising O
lead O
compound O
. O
The O
first O
imported O
case O
of O
Middle O
East O
respiratory O
syndrome O
( O
MERS O
) O
in O
China O
recently O
occurred O
, O
allowing O
for O
the O
characterization O
of O
antibody O
titers O
in O
a O
series O
of O
the O
patient O
's O
sera O
using O
the O
following O
methods O
based O
on O
recombinant B-protein
viral I-protein
structural I-protein
antigens E-protein
: O
inactivated O
MERS O
coronavirus O
( O
MERS-CoV O
) O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
recombinant O
MERS-CoV O
spike O
( O
S O
, O
or O
fragments O
of O
S O
) O
ELISA O
, O
nucleoprotein O
( O
NP O
) O
ELISA O
and O
MERS O
S O
pseudovirus O
particle-based O
neutralization O
test O
( O
ppNT O
) O
. O
A O
longitudinal O
profile O
of O
the O
infection O
showed O
that O
seroconversion O
detected O
by O
ELISAs O
based O
on O
the O
recombinant B-protein
extracellular I-protein
domain I-protein
, I-protein
S I-protein
, I-protein
S1 I-protein
and I-protein
receptor-binding I-protein
domain I-protein
( I-protein
RBD I-protein
) I-protein
antigens E-protein
occurred O
as O
early O
as O
neutralizing B-protein
antibodies E-protein
were O
detected O
by O
the O
ppNT S-protein
and O
earlier O
than O
antibodies S-protein
were O
detected O
by O
the O
inactivated O
MERS-CoV S-protein
and O
N-terminal B-protein
domain E-protein
( O
NTD S-protein
) O
ELISAs O
. O
Antibodies O
detected O
by O
the O
NP O
ELISA O
occurred O
last O
. O
Strong O
correlations O
were O
found O
between O
the O
S1 S-protein
, O
RBD S-protein
and O
NP O
ELISAs O
and O
the O
inactivated O
MERS-CoV O
ELISA O
. O
The O
S O
and O
RBD O
ELISAs O
were O
highly O
correlated O
with O
the O
commercial O
S1 O
ELISA O
. O
The O
S O
ELISA O
strongly O
correlated O
with O
the O
ppNT S-protein
, O
although O
the O
MERS-CoV B-RNA
, I-RNA
S1 I-RNA
, I-RNA
NTD I-RNA
and I-RNA
RBD I-RNA
ELISAs E-RNA
were O
also O
significantly O
correlated O
with O
the O
ppNT S-DNA
( O
Po0.001 S-DNA
) O
. O
Short B-DNA
linear I-DNA
motifs E-DNA
( O
SLiM S-DNA
) O
are O
short O
peptides O
that O
facilitate O
protein O
function O
and O
protein-protein O
interactions O
. O
Viruses O
utilize O
these O
motifs O
to O
enter O
into O
the O
host O
, O
interact O
with O
cellular B-protein
proteins E-protein
, O
or O
egress O
from O
host B-cell_type
cells E-cell_type
. O
Studying O
functional O
motifs O
may O
help O
to O
predict O
protein O
characteristics O
, O
interactions O
, O
or O
the O
putative O
cellular O
role O
of O
a O
protein O
. O
In O
virology O
, O
it O
may O
reveal O
aspects O
of O
the O
virus O
tropism O
and O
help O
find O
antiviral O
therapeutics O
. O
This O
review O
highlights O
the O
recent O
understanding O
of O
functional O
motifs O
utilized O
by O
viruses O
. O
Special O
attention O
was O
paid O
to O
the O
function O
of O
proteins O
harboring O
these O
motifs O
, O
and O
viruses O
encoding O
these O
proteins O
. O
The O
review O
highlights O
motifs O
involved O
in O
( O
i O
) O
immune O
response O
and O
post-translational O
modifications O
( O
e.g. O
, O
ubiquitylation O
, O
SUMOylation O
or O
ISGylation S-protein
) O
; O
( O
ii O
) O
virus-host O
cell O
interactions O
, O
including O
virus O
attachment O
, O
entry O
, O
fusion O
, O
egress O
and O
nuclear O
trafficking O
; O
( O
iii O
) O
virulence O
and O
antiviral O
activities O
; O
( O
iv O
) O
virion O
structure O
; O
and O
( O
v O
) O
low-complexity B-protein
regions E-protein
( O
LCRs O
) O
or O
motifs O
enriched O
with O
residues O
( O
Xaa-rich B-DNA
motifs E-DNA
) O
. O
Background O
: O
Patchouli O
alcohol O
( O
PA O
) O
is O
a O
tricyclic O
sesquiterpene O
extracted O
from O
Pogostemonis O
Herba O
, O
which O
is O
a O
traditional O
Chinese O
medicine O
used O
for O
therapy O
of O
inflammatory O
diseases O
. O
Recent O
studies O
have O
shown O
that O
PA O
has O
various O
pharmacological O
activities O
, O
including O
anti-bacterial O
and O
anti-viral O
effects O
. O
Methods O
: O
In O
this O
study O
, O
the O
anti-influenza O
virus O
( O
IAV O
) O
activities O
and O
mechanisms O
were O
investigated O
both O
in O
vitro O
and O
in O
vivo O
. O
The O
inhibitory O
effects O
of O
PA O
against O
IAV O
in O
vitro O
were O
evaluated O
by O
plaque O
assay O
and O
immunofluorescence O
assay O
. O
The O
neuraminidase O
inhibition O
assay O
, O
hemagglutination O
inhibition O
( O
HI O
) O
assay O
, O
and O
western O
blot O
assay O
were O
used O
to O
explore O
the O
anti-viral O
mechanisms O
. O
The O
anti-IAV O
activities O
in O
vivo O
were O
determined O
by O
mice O
pneumonia O
model O
and O
HE O
staining O
. O
The O
results O
showed O
that O
PA O
significantly O
inhibited O
different O
IAV O
strains O
multiplication O
in O
vitro O
, O
and O
may O
block O
IAV O
infection O
through O
inactivating O
virus O
particles O
directly O
and O
interfering O
with O
some O
early O
stages O
after O
virus O
adsorption O
. O
Cellular O
PI3K/Akt O
and O
ERK/MAPK S-protein
signaling O
pathways O
may O
be O
involved O
in O
the O
anti-IAV O
actions O
of O
PA. O
Intranasal O
administration O
of O
PA O
markedly O
improved O
mice O
survival O
and O
attenuated O
pneumonia O
symptoms O
in O
IAV O
infected O
mice O
, O
comparable O
to O
the O
effects O
of O
Oseltamivir O
. O
Conclusions O
: O
Therefore O
, O
Patchouli O
alcohol O
has O
the O
potential O
to O
be O
developed O
into O
a O
novel O
anti-IAV O
agent O
in O
the O
future O
. O
Background O
: O
Antibiotics O
are O
recommended O
for O
severe O
acute O
exacerbation O
of O
chronic O
obstructive O
pulmonary O
disease O
( O
AECOPD O
) O
admitted O
to O
intensive O
care O
units O
( O
ICU O
) O
. O
Serum O
procalcitonin O
( O
PCT O
) O
could O
be O
a O
useful O
tool O
for O
selecting O
patients O
with O
a O
lower O
probability O
of O
developing O
bacterial O
infection O
, O
but O
its O
measurement O
has O
not O
been O
investigated O
in O
this O
population O
. O
We O
conducted O
a O
single O
center O
prospective O
cohort O
study O
in O
consecutive O
COPD O
patients O
admitted O
to O
the O
ICU O
for O
AECOPD O
between O
September O
2005 O
and O
September O
2006 O
. O
Sputum O
samples O
or O
tracheal O
aspirates O
were O
tested O
for O
the O
presence O
of O
bacteria O
and O
viruses O
. O
PCT O
levels O
were O
measured O
at O
the O
time O
of O
admittance O
, O
six O
hours O
, O
and O
24 O
hours O
using O
a O
sensitive O
immunoassay O
. O
: O
Thirty O
nine O
AECOPD O
patients O
were O
included O
, O
31 O
of O
which O
( O
79 O
% O
) O
required O
a O
ventilator O
support O
at O
admission O
. O
The O
median O
[ O
25 O
% O
-75 O
% O
interquartile O
range O
] O
PCT O
level O
, O
assessed O
in O
35/39 O
patients O
, O
was O
: O
0.096 O
μg/ O
L O
[ O
IQR O
, O
0.065 O
to O
0.178 O
] O
at O
the O
time O
of O
admission O
, O
0.113 O
μg/L O
[ O
IQR O
, O
0.074 O
to O
0.548 O
] O
at O
six O
hours O
, O
and O
0.137 O
μg/L O
[ O
IQR O
, O
0.088 O
to O
0.252 O
] O
at O
24 O
hours O
. O
The O
highest O
PCT O
( O
PCTmax O
) O
levels O
were O
less O
than O
0.1 O
μg/L O
in O
14/ O
35 O
( O
40 O
% O
) O
patients O
and O
more O
than O
0.25 O
μg/L O
in O
10/35 O
( O
29 O
% O
) O
patients O
, O
suggesting O
low O
and O
high O
probability O
of O
bacterial O
infection O
, O
respectively O
. O
Five O
species O
of O
bacteria O
and O
nine O
species O
of O
viruses O
were O
detected O
in O
12/ O
39 O
( O
31 O
% O
) O
patients O
. O
Among O
the O
four O
patients O
positive O
for O
Pseudomonas O
aeruginosa O
, O
one O
had O
a O
PCTmax O
less O
than O
0.25 O
μg/L O
and O
three O
had O
a O
PCTmax O
less O
than O
0.1 O
μg/L O
. O
The O
one O
patient O
positive O
for O
Haemophilus O
influenzae O
had O
a O
PCTmax O
more O
than O
0.25 O
μg/L O
. O
The O
presence O
or O
absence O
of O
viruses O
did O
not O
influence O
PCT O
at O
time O
of O
admission O
( O
0.068 O
vs O
0.098 O
μg/L O
respectively O
, O
P O
= O
0.80 O
) O
. O
The O
likelihood O
of O
bacterial O
infection O
is O
low O
among O
COPD O
patients O
admitted O
to O
ICU O
for O
AECOPD O
( O
40 O
% O
with O
PCT O
< O
0.1 O
μg/L O
) O
suggesting O
a O
possible O
inappropriate O
use O
of O
antibiotics O
. O
Further O
studies O
are O
necessary O
to O
assess O
the O
impact O
of O
a O
procalcitonin-based O
therapeutic O
strategy O
in O
critically O
ill O
COPD O
patients O
. O
The O
demyelinating O
canine O
distemper O
virus O
( O
CDV O
) O
-leukoencephalitis O
represents O
a O
translational O
animal O
model O
for O
multiple O
sclerosis O
. O
The O
present O
study O
investigated O
the O
expression O
of O
type B-protein
I I-protein
interferon I-protein
( I-protein
IFN-I I-protein
) I-protein
pathway I-protein
members E-protein
in O
CDV-induced O
cerebellar O
lesions O
to O
gain O
an O
insight O
into O
their O
role O
in O
lesion O
development O
. O
Gene O
expression O
of O
110 O
manually O
selected O
genes O
in O
acute O
, O
subacute O
and O
chronic O
lesions O
was O
analyzed O
using O
pre-existing O
microarray O
data O
. O
Interferon B-protein
regulatory I-protein
factor I-protein
( I-protein
IRF I-protein
) I-protein
3 E-protein
, O
IRF7 S-protein
, O
signal B-protein
transducer I-protein
and I-protein
activator I-protein
of I-protein
transcription I-protein
( I-protein
STAT I-protein
) I-protein
1 E-protein
, O
STAT2 S-protein
, O
MX B-protein
protein E-protein
, O
protein B-protein
kinase I-protein
R E-protein
( O
PKR S-protein
) O
, O
2 B-protein
-5 I-protein
-oligoadenylate I-protein
synthetase I-protein
( I-protein
OAS I-protein
) I-protein
1 E-protein
and O
interferon-stimulated B-protein
gene I-protein
( I-protein
ISG I-protein
) I-protein
15 E-protein
expression O
were O
also O
evaluated O
using O
immunohistochemistry O
. O
Cellular O
origin O
of O
STAT1 S-protein
, O
STAT2 S-protein
, O
MX S-protein
and O
PKR S-protein
were O
determined O
using O
immunofluorescence O
. O
CDV O
infection O
caused O
an O
increased O
expression O
of O
the O
antiviral B-protein
effector I-protein
proteins E-protein
MX S-protein
, O
PKR S-protein
, O
OAS1 S-protein
and O
ISG15 S-protein
, O
which O
probably O
contributed O
to O
a O
restricted O
viral O
replication O
, O
particularly O
in O
neurons O
and O
oligodendrocytes O
. O
This O
increase O
might O
be O
partly O
mediated O
by O
IRF-dependent O
pathways O
due O
to O
the O
lack O
of O
changes O
in O
IFN-I S-protein
levels O
and O
absence O
of O
STAT2 S-protein
in O
astrocytes S-cell_type
. O
Nevertheless O
, O
activated O
microglia/macrophages O
showed O
a O
strong O
expression O
of O
STAT1 S-protein
, O
STAT2 S-protein
and O
MX B-protein
proteins E-protein
in O
later O
stages O
of O
the O
disease O
, O
indicating O
a O
strong O
activation O
of O
the O
IFN-I S-protein
signaling O
cascade O
, O
which O
might O
be O
involved O
in O
the O
aggravation O
of O
bystander O
demyelination O
. O
divided O
into O
acute O
( O
vacuolation O
of O
the O
white O
matter O
and O
mild O
astrogliosis O
) O
, O
subacute O
( O
vacuolation O
and O
demyelination O
with O
mild O
or O
no O
inflammation O
) O
and O
chronic O
changes O
( O
demyelination O
with O
moderate O
to O
severe O
inflammation O
) O
[ O
8 O
] O
. O
The O
demyelinating O
distemper O
leukoencephalitis O
also O
represents O
a O
naturally O
occurring O
animal O
model O
for O
human O
multiple O
sclerosis O
( O
MS O
) O
due O
to O
similar O
histopathological O
findings O
and O
pathogenic O
mechanisms O
[ O
3 O
, O
9 O
, O
10 O
] O
. O
Interferons S-protein
( O
IFNs S-protein
) O
are O
signaling B-protein
proteins E-protein
, O
which O
can O
be O
classified O
into O
three O
major O
types O
based O
on O
their O
specific O
receptor O
binding O
: O
type B-protein
I E-protein
( O
IFNα S-protein
and O
IFNβ S-protein
) O
, O
type B-protein
II E-protein
( O
IFNγ S-protein
) O
and O
type B-protein
III I-protein
( I-protein
IFNλ I-protein
) I-protein
[ I-protein
11 I-protein
, I-protein
12 I-protein
] E-protein
. O
Type B-protein
I I-protein
IFNs E-protein
( O
IFN-I S-protein
) O
play O
an O
important O
role O
in O
the O
innate O
immune O
response O
and O
have O
antiviral O
, O
antiproliferative O
and O
immunomodulatory O
capacities O
, O
which O
are O
already O
used O
in O
the O
therapy O
of O
human O
and O
animal O
disorders O
[ O
13 O
, O
14 O
] O
. O
IFNγ S-protein
is O
primarily O
produced O
in O
later O
stages O
of O
the O
immune O
response O
by O
B B-cell_type
cells E-cell_type
, O
cytotoxic B-cell_type
T I-cell_type
cells E-cell_type
and O
T B-cell_type
helper I-cell_type
( I-cell_type
Th I-cell_type
) I-cell_type
cells E-cell_type
and O
represents O
the O
main O
activator O
of O
macrophages S-cell_type
[ O
15 O
] O
. O
IFNλ O
also O
has O
antiviral O
and O
antiproliferative O
effects O
but O
its O
role O
during O
canine O
distemper O
and O
therapeutic O
potential O
seems O
to O
be O
limited O
[ B-DNA
14 I-DNA
, I-DNA
[ I-DNA
16 I-DNA
] I-DNA
[ I-DNA
17 I-DNA
] I-DNA
[ I-DNA
18 I-DNA
] I-DNA
[ I-DNA
19 I-DNA
] I-DNA
[ I-DNA
20 I-DNA
] E-DNA
. O
While O
in O
human O
medicine O
administering O
IFN-I O
in O
MS O
is O
part O
of O
the O
standard O
therapy O
[ O
21 O
] O
, O
the O
therapeutic O
effect O
of O
IFN-I S-protein
on O
the O
outcome O
of O
a O
CDV O
infection O
in O
dogs O
is O
still O
widely O
undetermined O
[ O
14 O
, O
22 O
] O
. O
The O
IFN-I S-protein
pathway O
is O
initiated O
by O
the O
detection O
of O
typical O
structural O
elements O
of O
infectious O
agents O
( O
pathogen-associated O
molecular O
patterns O
; O
PAMPs O
) O
, O
which O
can O
be O
recognized O
by O
so-called O
pattern B-protein
recognition I-protein
receptors E-protein
( O
PRRs S-protein
) O
[ O
23 O
] O
. O
Single-and B-RNA
double-stranded I-RNA
RNA E-RNA
produced O
during O
viral O
replication O
can O
be O
detected O
by O
toll-like B-protein
receptors E-protein
( O
TLRs S-protein
) O
, O
protein B-protein
kinase I-protein
R E-protein
( O
PKR S-protein
) O
and O
the O
family O
of O
the O
retinoic B-protein
acid-inducible I-protein
gene-I-like I-protein
receptors E-protein
( O
RLRs S-protein
) O
including O
retinoic B-DNA
acid-inducible I-DNA
gene I-DNA
1 E-DNA
( O
RIG1 S-DNA
) O
and O
melanoma B-DNA
differentiation-associated I-DNA
gene I-DNA
5 E-DNA
( O
MDA5 S-protein
) O
, O
which O
are O
bound O
to O
endosomal O
membranes O
or O
localized O
in O
the O
cytoplasm O
[ O
24 O
] O
[ O
25 O
] O
[ O
26 O
] O
. O
After O
binding O
to O
viral B-RNA
RNA E-RNA
, O
these O
receptors O
recruit O
specific O
adapter B-protein
proteins E-protein
like O
Toll/IL-1 B-protein
receptor I-protein
domain E-protein
containing O
adapter-inducing B-protein
IFNβ E-protein
( O
TRIF S-protein
) O
, O
myeloid B-protein
differentiation I-protein
primary I-protein
response I-protein
gene I-protein
88 E-protein
( O
MyD88 S-protein
) O
and O
IFNβ B-protein
promoter I-protein
stimulator E-protein
( O
IPS-1 S-protein
) O
as O
well O
as O
second O
messengers O
to O
activate O
IFN B-protein
regulatory I-protein
factor I-protein
( I-protein
IRF I-protein
) I-protein
3 E-protein
and O
IRF7 S-protein
, O
which O
induce O
the O
transcription O
of O
[ O
27 O
] O
[ O
28 O
] O
[ O
29 O
] O
[ O
30 O
] O
. O
IFN-I S-protein
bind O
in O
an O
autocrine O
or O
paracrine O
fashion O
to O
their O
specific O
receptor O
, O
consisting O
of O
the O
subunits O
IFNAR1 S-protein
and O
IFNAR2 S-protein
, O
to O
trigger O
signaling O
pathways O
that O
inhibit O
viral O
replication O
[ O
31 O
] O
. O
The O
receptor-associated B-protein
kinases E-protein
Janus B-protein
kinase I-protein
1 E-protein
( O
JAK1 S-protein
) O
and O
tyrosine B-protein
kinase I-protein
2 E-protein
( O
TYK2 S-protein
) O
phosphorylate O
the O
transcription B-protein
factors E-protein
, O
signal B-protein
transducer I-protein
and I-protein
activator I-protein
of I-protein
transcription I-protein
( I-protein
STAT I-protein
) I-protein
1 E-protein
and O
STAT2 S-protein
, O
which O
then O
associate O
with O
IRF9 S-protein
to O
form O
a O
heterotrimeric B-protein
complex E-protein
termed O
interferon-stimulated B-protein
gene I-protein
factor I-protein
3 I-protein
( I-protein
ISGF3 I-protein
) I-protein
[ I-protein
32 I-protein
] I-protein
[ I-protein
33 I-protein
] I-protein
[ I-protein
34 I-protein
] I-protein
[ I-protein
35 I-protein
] E-protein
. O
After O
translocation O
into O
the O
nucleus O
, O
ISGF3 S-protein
induces O
the O
transcription O
of O
numerous O
IFN-stimulated B-DNA
genes E-DNA
( O
ISGs S-DNA
) O
, O
which O
have O
an O
IFN-stimulated B-DNA
response I-DNA
element E-DNA
( O
ISRE S-DNA
) O
in O
their O
promoter B-DNA
site I-DNA
[ I-DNA
30 I-DNA
, I-DNA
[ I-DNA
35 I-DNA
] I-DNA
[ I-DNA
36 I-DNA
] I-DNA
[ I-DNA
37 I-DNA
] E-DNA
. O
ISGs S-protein
including O
MX B-protein
proteins E-protein
, O
2 B-protein
-5 I-protein
-oligoadenylate I-protein
synthetase E-protein
( O
OAS S-protein
) O
, O
PKR S-protein
and O
ISG15 S-protein
play O
an O
important O
role O
in O
the O
resistance O
to O
viral O
infections O
due O
to O
their O
inhibitory O
effect O
on O
viral O
transcription O
, O
translation O
and O
release O
[ O
30 O
, O
38 O
, O
39 O
] O
. O
In O
addition O
, O
non-canonical O
aspects O
of O
JAK-STAT S-protein
signaling O
are O
described O
, O
in O
which O
STAT2 B-protein
homodimers E-protein
mediate O
mechanisms O
of O
defense O
against O
pathogens O
that O
impede O
STAT1 S-protein
signaling O
[ O
40 O
, O
41 O
] O
. O
The O
presence O
of O
IFN-I S-protein
in O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
of O
CDV-infected O
dogs O
has O
been O
known O
for O
a O
long O
time O
and O
was O
suggested O
to O
be O
used O
as O
a O
marker O
of O
virus O
persistence O
, O
but O
IFN-I B-protein
CSF E-protein
levels O
are O
generally O
low O
and O
not O
always O
present O
[ O
42 O
, O
43 O
] O
. O
An O
immunohistochemical O
study O
demonstrated O
strong O
expression O
of O
MX B-protein
proteins E-protein
in O
CDV-induced O
brain O
lesions O
[ O
44 O
] O
. O
Moreover O
, O
recent O
studies O
have O
shown O
that O
the O
virulence O
of O
CDV S-protein
depends O
on O
the O
suppression O
of O
the O
IFN-I S-protein
signaling O
pathway O
via O
interference O
with O
MDA5 S-protein
and O
STAT2 S-protein
signaling O
[ O
45 O
] O
. O
Interestingly O
, O
dogs O
exhibit O
a O
relatively O
high O
OAS O
serum O
activity O
compared O
to O
other O
animal O
species O
such O
as O
cats O
, O
rabbits O
and O
guinea O
pigs O
[ O
46 O
] O
. O
However O
, O
ISG O
expression O
has O
hardly O
been O
investigated O
in O
the O
CNS O
of O
CDV-infected O
dogs O
so O
far O
. O
The O
present O
study O
characterized O
the O
expression O
of O
several O
IFN-I B-protein
pathway I-protein
members E-protein
on O
the O
gene O
and O
protein O
level O
in O
order O
to O
contribute O
to O
the O
understanding O
of O
the O
role O
of O
the O
innate O
immune O
response O
in O
the O
initiation O
and O
progression O
of O
CDV-infected O
cerebellar O
lesions O
. O
Background O
: O
Cryopreserved B-cell_line
primary I-cell_line
human I-cell_line
renal I-cell_line
proximal I-cell_line
tubule I-cell_line
epithelial I-cell_line
cells E-cell_line
( O
RPTEC S-cell_line
) O
were O
obtained O
from O
a O
commercial O
supplier O
for O
studies O
of O
Simian O
virus O
40 O
( O
SV40 O
) O
. O
Within O
twelve O
hrs O
after O
cell O
cultures O
were O
initiated O
, O
cytoplasmic O
vacuoles O
appeared O
in O
many O
of O
the O
RPTEC O
. O
The O
RPTEC O
henceforth O
deteriorated O
rapidly O
. O
Since O
SV40 O
induces O
the O
formation O
of O
cytoplasmic O
vacuoles O
, O
this O
batch O
of O
RPTEC O
was O
rejected O
for O
the O
SV40 O
study O
. O
Nevertheless O
, O
we O
sought O
the O
likely O
cause O
( O
s O
) O
of O
the O
deterioration O
of O
the O
RPTEC O
as O
part O
of O
our O
technology O
development O
efforts O
. O
Methods O
: O
Adventitious O
viruses O
in O
the O
RPTEC S-protein
were O
isolated O
and/or O
detected O
and O
identified O
by O
isolation O
in O
various O
indicator O
cell B-cell_line
lines E-cell_line
, O
observation O
of O
cytopathology O
, O
an O
immunoflurorescence O
assay O
, O
electron O
microscopy O
, O
PCR O
, O
and O
sequencing O
. O
Results O
: O
Cytomegalovirus O
( O
CMV O
) O
was O
detected O
in O
some O
RPTEC O
by O
cytology O
, O
an O
immunofluorescence O
assay O
, O
and O
PCR O
. O
Human O
Herpesvirus O
6B O
was O
detected O
by O
PCR O
of O
DNA O
extracted O
from O
the O
RPTEC S-DNA
, O
but O
was O
not O
isolated O
. O
Human O
coronavirus O
NL63 O
was O
isolated O
and O
identified O
by O
RT-PCR O
and O
sequencing O
, O
and O
its O
replication O
in O
a O
fresh O
batch O
of O
RPTEC O
and O
another O
type O
of O
primary B-cell_type
human I-cell_type
kidney I-cell_type
cells E-cell_type
was O
confirmed O
. O
Conclusions O
: O
At O
least O
3 O
different O
adventitious O
viruses O
were O
present O
in O
the O
batch O
of O
contaminated O
RPTEC O
. O
Whereas O
we O
are O
unable O
to O
determine O
whether O
the O
original O
RPTEC O
were O
pre-infected O
prior O
to O
their O
separation O
from O
other O
kidney B-cell_type
cells E-cell_type
, O
or O
had O
gotten O
contaminated O
with O
HCoV-NL63 O
from O
an O
ill O
laboratory O
worker O
during O
their O
preparation O
for O
commercial O
sale O
, O
our O
findings O
are O
a O
reminder O
that O
human-derived O
biologicals O
should O
always O
be O
considered O
as O
potential O
sources O
of O
infectious O
agents O
. O
Importantly O
, O
HCoV-NL63 O
replicates O
to O
high O
titers O
in O
some O
primary B-cell_type
human I-cell_type
kidney I-cell_type
cells E-cell_type
. O
As O
of O
September O
30 O
, O
2015 O
, O
a O
total O
of O
1589 O
laboratory-confirmed O
cases O
of O
infection O
with O
the O
Middle O
East O
respiratory O
syndrome O
coronavirus O
( O
MERS-CoV O
) O
have O
been O
reported O
to O
the O
World O
Health O
Organization O
( O
WHO O
) O
. O
At O
present O
there O
is O
no O
effective O
specific O
therapy O
against O
MERS-CoV O
. O
The O
use O
of O
convalescent O
plasma O
( O
CP O
) O
has O
been O
suggested O
as O
a O
potential O
therapy O
based O
on O
existing O
evidence O
from O
other O
viral O
infections O
. O
We O
aim O
to O
study O
the O
feasibility O
of O
CP S-DNA
therapy O
as O
well O
as O
its O
safety O
and O
clinical O
and O
laboratory O
effects O
in O
critically O
ill O
patients O
with O
MERS-CoV O
infection O
. O
We O
will O
also O
examine O
the O
pharmacokinetics O
of O
the O
MERS-CoV B-protein
antibody E-protein
response O
and O
viral O
load O
over O
the O
course O
of O
MERS-CoV O
infection O
. O
This O
study O
will O
inform O
a O
future O
randomized O
controlled O
trial O
that O
will O
examine O
the O
efficacy O
of O
CP O
therapy O
for O
MERS-CoV O
infection O
. O
In O
the O
CP O
collection O
phase O
, O
potential O
donors O
will O
be O
tested O
by O
the O
enzyme O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
and O
the O
indirect O
fluorescent O
antibody O
( O
IFA O
) O
techniques O
for O
the O
presence O
of O
anti-MERS-CoV B-protein
antibodies E-protein
. O
Subjects O
with O
anti-MERS-CoV O
IFA O
titer O
of O
≥1:160 O
and O
no O
clinical O
or O
laboratory O
evidence O
of O
MERS-CoV O
infection O
will O
be O
screened O
for O
eligibility O
for O
plasma O
donation O
according O
to O
standard O
donation O
criteria O
. O
In O
the O
CP S-DNA
therapy O
phase O
, O
20 O
consecutive O
critically O
ill O
patients O
admitted O
to O
intensive O
care O
unit O
with O
laboratory-confirmed O
MERS-CoV O
infection O
will O
be O
enrolled O
and O
each O
will O
receive O
2 O
units O
of O
CP S-DNA
. O
Post O
enrollment O
, O
patients O
will O
be O
followed O
for O
clinical O
and O
laboratory O
outcomes O
that O
include O
anti-MERS-CoV B-protein
antibodies E-protein
and O
viral O
load O
. O
In O
a O
molecular O
epidemiology O
study O
using O
791 O
fecal O
samples O
collected O
from O
different O
terrestrial O
and O
marine O
mammals O
in O
Hong B-cell_line
Kong I-cell_line
, I-cell_line
genogroup I-cell_line
I I-cell_line
picobirnaviruses E-cell_line
( O
PBVs O
) O
were O
positive O
by O
RT-PCR O
targeting O
the O
partial O
RdRp B-DNA
gene E-DNA
in O
specimens O
from O
five O
cattle O
, O
six O
monkeys O
, O
17 O
horses O
, O
nine O
pigs O
, O
one O
rabbit O
, O
one O
dog O
, O
and O
12 O
California O
sea O
lions O
, O
with O
11 B-DNA
, I-DNA
9 I-DNA
, I-DNA
23 I-DNA
, I-DNA
17 I-DNA
, I-DNA
1 I-DNA
, I-DNA
1 I-DNA
, I-DNA
and I-DNA
15 I-DNA
sequence E-DNA
types O
in O
the O
positive O
specimens O
from O
the O
corresponding O
animals O
, O
respectively O
. O
Phylogenetic O
analysis O
showed O
that O
the O
PBV B-DNA
sequences E-DNA
from O
each O
kind O
of O
animal O
were O
widely O
distributed O
in O
the O
whole O
tree O
with O
high O
diversity O
, O
sharing O
47.4-89.0 O
% O
nucleotide O
identities O
with O
other O
genogroup O
I O
PBV O
strains O
based O
on O
the O
partial O
RdRp B-DNA
gene E-DNA
. O
Nine O
complete O
segment O
1 O
( O
viral O
loads O
1.7 O
× O
10 O
4 O
to O
5.9 O
× O
10 O
6 O
/ml O
) O
and O
15 B-DNA
segment I-DNA
2 E-DNA
( O
viral O
loads O
4.1 O
× O
10 O
3 O
to O
1.3 O
× O
10 O
6 O
/ml O
) O
of O
otarine O
PBVs O
from O
fecal O
samples O
serially O
collected O
from O
California O
sea O
lions O
were O
sequenced O
. O
In O
the O
two O
phylogenetic O
trees O
constructed O
using O
ORF2 S-DNA
and O
ORF3 S-DNA
of O
segment B-DNA
1 E-DNA
, O
the O
nine O
segment B-DNA
1 I-DNA
sequences E-DNA
were O
clustered O
into O
four O
distinct O
clades O
( O
C1-C4 S-DNA
) O
. O
In O
the O
tree O
constructed O
using O
RdRp B-DNA
gene E-DNA
of O
segment B-DNA
2 E-DNA
, O
the O
15 B-DNA
segment I-DNA
2 I-DNA
sequences E-DNA
were O
clustered O
into O
nine O
distinct O
clades O
( O
R1-R9 S-DNA
) O
. O
In O
four O
sea O
lions O
, O
PBVs O
were O
detected O
in O
two O
different O
years O
, O
with O
the O
same O
segment O
1 O
clade O
( O
C3 O
) O
present O
in O
two O
consecutive O
years O
from O
one O
sea O
lion O
and O
different O
clades O
present O
in O
different O
years O
from O
three O
sea O
lions O
. O
A O
high O
diversity O
of O
PBVs O
was O
observed O
in O
a O
variety O
of O
terrestrial O
and O
marine O
mammals O
. O
Multiple O
sequence O
types O
with O
significant O
differences O
, O
representing O
multiple O
strains O
of O
PBV O
, O
were O
present O
in O
the O
majority O
of O
PBV-positive O
samples O
from O
different O
kinds O
of O
animals O
. O
Background O
: O
Guangdong O
Province O
in O
the O
Pearl O
River O
Delta O
of O
Southeast O
China O
is O
among O
the O
areas O
in O
the O
country O
with O
the O
highest O
rates O
of O
avian O
flu O
cases O
. O
In O
order O
to O
control O
the O
outbreak O
of O
human-infected O
H7N9 O
cases O
, O
Guangdong O
launched O
a O
new O
policy O
on O
the O
central O
slaughtering O
of O
live O
poultry O
in O
2015 O
. O
This O
study O
aims O
to O
evaluate O
attitudes O
of O
consumers O
and O
live-poultry O
workers O
toward O
the O
policy O
. O
The O
live-poultry O
workers O
consisted O
of O
two O
sub-groups O
: O
live-poultry O
traders O
and O
poultry O
farm O
workers O
. O
Methods O
: O
Consumers O
and O
live-poultry O
workers O
from O
Guangdong O
were O
enrolled O
by O
stratified O
multi-stage O
random O
sampling O
. O
Online O
and O
field O
surveys O
were O
conducted O
to O
investigate O
participants O
' O
attitudes O
on O
policy O
implementation O
. O
Questionnaires O
were O
developed O
to O
quantify O
participant O
demographics O
, O
to O
collect O
information O
about O
attitudes O
toward O
the O
policy O
, O
and O
to O
identify O
influential O
factors O
of O
policy O
acceptability O
. O
Proportional O
odds O
logistics O
regression O
was O
used O
in O
the O
univariate O
and O
multivariate O
analyses O
. O
A O
total O
of O
1449 O
consumers O
, O
181 O
live-poultry O
traders O
, O
and O
114 O
poultry O
farm O
workers O
completed O
the O
study O
. O
Results O
: O
Policy O
acceptability O
percentages O
among O
consumers O
, O
live-poultry O
traders O
, O
and O
poultry O
farm O
workers O
were O
57 O
. O
1 O
, O
37.9 O
, O
and O
62.6 O
% O
, O
respectively O
. O
Logistics O
regression O
shows O
that O
consumers O
tended O
not O
to O
support O
the O
policy O
if O
they O
were O
males O
, O
if O
they O
were O
concerned O
with O
the O
food O
safety O
of O
chilled O
products O
, O
and O
if O
they O
preferred O
purchasing O
live O
poultry O
. O
Live-poultry O
traders O
tended O
not O
to O
support O
if O
they O
were O
subsidized O
by O
the O
government O
, O
if O
they O
were O
males O
, O
if O
they O
experienced O
a O
drop O
in O
trading O
volume O
, O
and O
if O
they O
were O
unclear O
whether O
avian O
flu O
was O
a O
preventable O
disease O
. O
Finally O
, O
poultry O
farm O
workers O
tended O
not O
to O
support O
if O
they O
experienced O
a O
drop O
in O
trading O
volume O
, O
if O
they O
operated O
a O
poultry O
farm O
on O
a O
small O
to O
medium O
scale O
, O
and O
if O
they O
experienced O
inconvenience O
in O
their O
work O
due O
to O
the O
policy O
. O
The O
study O
reveals O
a O
substantial O
refusal O
or O
slowness O
to O
accept O
the O
policy O
. O
Failure O
to O
accept O
the O
policy O
results O
from O
varying O
reasons O
. O
Among O
consumers O
, O
concern O
about O
food O
safety O
and O
dietary O
preference O
are O
two O
major O
causes O
of O
disapproval O
. O
Policy O
acceptability O
among O
live-poultry O
workers O
diverges O
within O
the O
two O
sub-groups O
. O
While O
a O
large O
percentage O
of O
poultry O
farm O
workers O
accept O
the O
policy O
, O
the O
drop O
in O
trading O
and O
an O
insufficient O
subsidy O
hamper O
acceptance O
by O
live-poultry O
traders O
. O
We O
recommend O
that O
policy-makers O
promote O
health O
education O
and O
alleviate O
the O
policy O
impact O
on O
trading O
with O
a O
reformed O
subsidy O
policy O
to O
increase O
acceptability O
. O
These O
findings O
are O
crucial O
for O
the O
prevention O
of O
human-infected O
H7N9 O
cases O
in O
Guangdong O
. O
Background O
: O
The O
gold O
standard O
for O
respiratory O
virus O
testing O
is O
a O
nasopharyngeal O
( O
NP O
) O
swab O
, O
which O
is O
collected O
by O
a O
healthcare O
worker O
. O
Midturbinate O
( O
MT O
) O
swabs O
are O
an O
alternative O
due O
to O
their O
ease O
of O
collection O
and O
possible O
self-collection O
by O
patients O
. O
The O
objective O
of O
this O
study O
was O
to O
compare O
the O
respiratory O
virus O
isolation O
of O
flocked O
MT O
swabs O
compared O
to O
flocked O
NP O
swabs O
. O
Methods O
: O
Beginning O
in O
October O
2008 O
, O
healthy O
adults O
aged O
18 O
to O
69 O
years O
were O
recruited O
into O
a O
cohort O
and O
followed O
up O
for O
symptoms O
of O
influenza O
. O
They O
were O
asked O
to O
have O
NP O
and O
MT O
swabs O
taken O
as O
soon O
as O
possible O
after O
the O
onset O
of O
a O
fever O
or O
two O
or O
more O
respiratory O
symptoms O
with O
an O
acute O
onset O
. O
The O
swabs O
were O
tested O
for O
viral O
respiratory O
infections O
using O
SeeplexH O
RV12 O
multiplex O
PCR O
detection O
kit O
. O
Seventy O
six O
pairs O
of O
simultaneous O
NP O
and O
MT O
swabs O
were O
collected O
from O
38 O
symptomatic O
subjects O
. O
Twenty O
nine O
( O
38 O
% O
) O
of O
these O
pairs O
were O
positive O
by O
either O
NP O
or O
MT O
swabs O
or O
both O
. O
Sixty O
nine O
( O
91 O
% O
) O
of O
the O
pair O
results O
were O
concordant O
. O
Two O
samples O
( O
3 O
% O
) O
for O
hCV O
OC43/HKU1 O
and O
1 O
sample O
( O
1 O
% O
) O
for O
rhinovirus B-protein
A/B E-protein
were O
positive O
by O
NP O
but O
negative O
by O
MT O
. O
One O
sample O
each O
for O
hCV O
229E/NL63 O
, O
hCV O
OC43/HKU1 O
, O
respiratory O
syncytial O
virus O
A O
, O
and O
influenza O
B O
were O
positive O
by O
MT O
but O
negative O
by O
NP O
. O
Conclusions O
: O
Flocked O
MT O
swabs O
are O
sensitive O
for O
the O
diagnosis O
of O
multiple O
respiratory O
viruses O
. O
Given O
the O
ease O
of O
MT O
collection O
and O
similar O
results O
between O
the O
two O
swabs O
, O
it O
is O
likely O
that O
MT O
swabs O
should O
be O
the O
preferred O
method O
of O
respiratory O
cell O
collection O
for O
outpatient O
studies O
. O
In O
light O
of O
this O
data O
, O
larger O
studies O
should O
be O
performed O
to O
ensure O
that O
this O
still O
holds O
true O
and O
data O
should O
also O
be O
collected O
on O
the O
patient O
preference O
of O
collection O
methods O
. O
Citation O
: O
Larios O
OE O
, O
Coleman O
BL O
, O
Drews O
SJ O
, O
Mazzulli O
T O
, O
Borgundvaag O
B O
, O
et O
al O
. O
( O
2011 O
) O
Self-Collected O
Mid-Turbinate O
Swabs O
for O
the O
Detection O
of O
Respiratory O
Viruses O
in O
Adults O
with O
Acute O
Respiratory O
Illnesses O
. O
PLoS O
ONE O
6 O
( O
6 O
) O
: O
e21335 O
. O
Background O
: O
Phylodynamics O
, O
the O
study O
of O
the O
interaction O
between O
epidemiological O
and O
pathogen O
evolutionary O
processes O
within O
and O
among O
populations O
, O
was O
originally O
defined O
in O
the O
context O
of O
rapidly O
evolving O
viruses O
and O
used O
to O
characterize O
transmission O
dynamics O
. O
The O
concept O
of O
phylodynamics O
has O
evolved O
since O
the O
early O
21 O
st O
century O
, O
extending O
its O
reach O
to O
slower-evolving O
pathogens O
, O
including O
bacteria O
and O
fungi O
, O
and O
to O
the O
identification O
of O
influential O
factors O
in O
disease O
spread O
and O
pathogen O
population O
dynamics O
. O
Results O
: O
The O
phylodynamic O
approach O
has O
now O
become O
a O
fundamental O
building O
block O
for O
the O
development O
of O
comparative O
phylogenetic O
tools O
capable O
of O
incorporating O
epidemiological O
surveillance O
data O
with O
molecular O
sequences O
into O
a O
single O
statistical O
framework O
. O
These O
innovative O
tools O
have O
greatly O
enhanced O
scientific O
investigations O
of O
the O
temporal O
and O
geographical O
origins O
, O
evolutionary O
history O
, O
and O
ecological O
risk O
factors O
associated O
with O
the O
growth O
and O
spread O
of O
viruses O
such O
as O
human O
immunodeficiency O
virus O
( O
HIV O
) O
, O
Zika O
, O
and O
dengue O
and O
bacteria O
such O
as O
Methicillin-resistant O
Staphylococcus O
aureus O
. O
Conclusions O
: O
Capitalizing O
on O
an O
extensive O
review O
of O
the O
literature O
, O
we O
discuss O
the O
evolution O
of O
the O
field O
of O
infectious O
disease O
epidemiology O
and O
recent O
accomplishments O
, O
highlighting O
the O
advancements O
in O
phylodynamics O
, O
as O
well O
as O
the O
challenges O
and O
limitations O
currently O
facing O
researchers O
studying O
emerging O
pathogen O
epidemics O
across O
the O
globe O
. O
The O
influenza B-protein
virus I-protein
surface I-protein
glycoprotein I-protein
hemagglutinin E-protein
( O
HA S-protein
) O
is O
responsible O
for O
viral O
attachment O
to O
sialic B-protein
acid-containing I-protein
host I-protein
cell I-protein
receptors E-protein
and O
it O
facilitates O
the O
initial O
stage O
of O
viral O
infection O
. O
In O
the O
present O
study O
, O
we O
isolated O
an O
RNA O
aptamer O
specific O
to O
the O
glycosylated B-protein
receptor-binding I-protein
domain E-protein
of O
the O
HA B-protein
protein E-protein
( O
gHA1 S-protein
) O
after O
12 O
cycles O
of O
the O
systematic O
evolution O
of O
ligands O
by O
exponential O
enrichment O
procedure O
( O
SELEX O
) O
, O
and O
we O
then O
investigated O
if O
the O
selected O
aptamer O
suppresses O
viral O
infection O
in O
host B-cell_type
cells E-cell_type
. O
Nitrocellulose O
filter O
binding O
and O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
experiments O
revealed O
that O
1 O
RNA O
aptamer O
, O
HA12-16 S-protein
, O
bound O
specifically O
to O
the O
gHA1 B-protein
protein E-protein
. O
Cell O
viability O
assay O
showed O
that O
the O
HA12-16 B-RNA
RNA E-RNA
aptamer O
suppressed O
viral O
infection O
in O
host B-cell_type
cells E-cell_type
by O
enhancing O
cell O
viability O
. O
Immunofluorescence O
microscopic O
analysis O
further O
demonstrated O
that O
the O
HA12-16 B-RNA
RNA E-RNA
aptamer O
suppresses O
viral O
attachment O
to O
host B-cell_type
cells E-cell_type
by O
neutralizing O
the O
receptor-binding O
site O
of O
influenza O
virus O
HA O
. O
These O
results O
indicate O
that O
the O
isolated O
RNA O
aptamer O
can O
be O
developed O
as O
an O
antiviral O
reagent O
against O
influenza O
through O
appropriate O
therapeutic O
formulation O
. O
Lytic O
gammaherpesvirus O
infection O
restricts O
host O
gene O
expression O
by O
promoting O
widespread O
degradation O
of O
cytoplasmic B-RNA
mRNA E-RNA
through O
the O
activity O
of O
the O
viral B-protein
endonuclease I-protein
SOX E-protein
. O
Though O
generally O
assumed O
to O
be O
selective O
for O
cellular B-RNA
transcripts E-RNA
, O
the O
extent O
to O
which O
SOX S-protein
impacts O
viral B-RNA
mRNA E-RNA
stability O
has O
remained O
unknown O
. O
We O
addressed O
this O
issue O
using O
the O
model O
murine O
gammaherpesvirus O
MHV68 O
and O
, O
unexpectedly O
, O
found O
that O
all O
stages O
of O
viral O
gene O
expression O
are O
controlled O
through O
mRNA O
degradation O
. O
Using O
both O
comprehensive O
RNA O
expression O
profiling O
and O
half-life O
studies O
we O
reveal O
that O
the O
levels O
of O
the O
majority O
of O
viral B-RNA
mRNAs E-RNA
but O
not O
noncoding B-RNA
RNAs E-RNA
are O
tempered O
by O
MHV68 B-protein
SOX E-protein
( O
muSOX O
) O
activity O
. O
The O
targeting O
of O
viral B-RNA
mRNA E-RNA
by O
muSOX S-protein
is O
functionally O
significant O
, O
as O
it O
impacts O
intracellular O
viral O
protein O
abundance O
and O
progeny O
virion O
composition O
. O
In O
the O
absence O
of O
muSOX-imposed B-DNA
gene E-DNA
expression O
control O
the O
viral O
particles O
display O
increased O
cell O
surface O
binding O
and O
entry O
as O
well O
as O
enhanced O
immediate O
early O
gene O
expression O
. O
These O
phenotypes O
culminate O
in O
a O
viral O
replication O
defect O
in O
multiple O
cell O
types O
as O
well O
as O
in O
vivo O
, O
highlighting O
the O
importance O
of O
maintaining O
the O
appropriate O
balance O
of O
viral B-RNA
RNA E-RNA
during O
gammaherpesviral O
infection O
. O
This O
is O
the O
first O
example O
of O
a O
virus O
that O
fails O
to O
broadly O
discriminate O
between O
cellular O
and O
viral B-RNA
transcripts E-RNA
during O
host O
shutoff O
and O
instead O
uses O
the O
targeting O
of O
viral O
messages O
to O
fine-tune O
overall O
gene O
expression O
. O
In O
this O
paper O
are O
presented O
mathematical O
predictions O
on O
the O
evolution O
in O
time O
of O
the O
number O
of O
positive O
cases O
in O
Italy O
of O
the O
COVID-19 O
pandemic O
based O
on O
official O
data O
and O
on O
the O
use O
of O
a O
function O
of O
the O
type O
of O
a O
Gauss O
error O
function O
, O
with O
four O
parameters O
, O
as O
a O
cumulative O
distribution O
function O
. O
We O
have O
analyzed O
the O
available O
data O
for O
China O
and O
Italy O
. O
The O
evolution O
in O
time O
of O
the O
number O
of O
cumulative O
diagnosed O
positive O
cases O
of O
COVID-19 O
in O
China O
very O
well O
approximates O
a O
distribution O
of O
the O
type O
of O
the O
error O
function O
, O
that O
is O
, O
the O
integral O
of O
a O
normal O
, O
Gaussian O
distribution O
. O
We O
have O
then O
used O
such O
a O
function O
to O
study O
the O
potential O
evolution O
in O
time O
of O
the O
number O
of O
positive O
cases O
in O
Italy O
by O
performing O
a O
number O
of O
fits O
of O
the O
official O
data O
so O
far O
available O
. O
We O
then O
found O
a O
statistical O
prediction O
for O
the O
day O
in O
which O
the O
peak O
of O
the O
number O
of O
daily O
positive O
cases O
in O
Italy O
occurs O
, O
corresponding O
to O
the O
flex O
of O
the O
fit O
, O
that O
is O
, O
to O
the O
change O
in O
sign O
of O
its O
second O
derivative O
( O
i.e. O
, O
the O
change O
from O
acceleration O
to O
deceleration O
) O
, O
as O
well O
as O
of O
the O
day O
in O
which O
a O
substantial O
attenuation O
of O
such O
number O
of O
daily O
cases O
is O
reached O
. O
We O
have O
also O
analyzed O
the O
predictions O
of O
the O
cumulative O
number O
of O
fatalities O
in O
both O
China O
and O
Italy O
, O
obtaining O
consistent O
results O
. O
We O
have O
then O
performed O
150 O
Monte O
Carlo O
simulations O
to O
have O
a O
more O
robust O
prediction O
of O
the O
day O
of O
the O
above-mentioned O
peak O
and O
of O
the O
day O
of O
the O
substantial O
decrease O
in O
the O
number O
of O
daily O
positive O
cases O
and O
fatalities O
. O
Although O
official O
data O
have O
been O
used O
, O
those O
predictions O
are O
obtained O
with O
a O
heuristic O
approach O
since O
they O
are O
based O
on O
a O
statistical O
approach O
and O
do O
not O
take O
into O
account O
either O
a O
number O
of O
relevant O
issues O
( O
such O
as O
number O
of O
daily O
nasopharyngeal O
swabs O
, O
medical O
, O
social O
distancing O
, O
virological O
and O
epidemiological O
) O
or O
models O
of O
contamination O
diffusion O
. O
Background O
: O
Yokose O
virus O
was O
first O
isolated O
from O
bats O
( O
Miniopterus O
fuliginosus O
) O
collected O
in O
Yokosuka O
, O
Japan O
, O
in O
1971 O
, O
and O
is O
a O
new O
member O
of O
the O
family O
Flaviviridae O
, O
genus O
Flavivirus O
. O
In O
this O
study O
, O
we O
isolated O
a O
Yokose O
virus O
from O
a O
serum O
sample O
of O
Myotis O
daubentonii O
( O
order O
Chiroptera O
, O
family O
Vespertilionidae O
) O
collected O
in O
Yunnan O
province O
, O
China O
in O
2013 O
. O
Methods O
: O
The O
serum O
specimens O
of O
bat O
were O
used O
to O
inoculate O
in O
BHK-21 B-cell_line
and I-cell_line
Vero I-cell_line
E6 I-cell_line
cells E-cell_line
for O
virus O
isolation O
. O
Then O
the O
viral B-DNA
complete I-DNA
genome I-DNA
sequence E-DNA
was O
obtained O
and O
was O
used O
for O
phylogenetic O
analysis O
performed O
by O
BEAST O
software O
package O
. O
Results O
: O
The O
virus O
was O
shown O
to O
have O
cytopathic O
effects O
in O
mammalian B-cell_type
cells E-cell_type
( O
BHK-21 S-cell_line
and O
Vero B-cell_line
E6 E-cell_line
) O
. O
Genome O
sequencing O
indicated O
that O
it O
has O
a O
single O
open B-DNA
reading I-DNA
frame E-DNA
( O
ORF S-DNA
) O
, O
with O
a O
genome O
of O
10,785 O
nucleotides O
in O
total O
. O
Phylogenetic O
analysis O
of O
the O
viral B-DNA
genome E-DNA
suggests O
that O
XYBX1332 S-protein
is O
a O
Yokose O
virus O
( O
YOKV O
) O
of O
the O
genus O
Flavivirus O
. O
Nucleotide O
and O
amino O
acid O
homology O
levels O
of O
the O
ORF S-DNA
of O
XYBX1332 S-DNA
and O
Oita-36 S-protein
, O
the O
original O
strain O
of O
YOKV O
, O
were O
72 O
and O
82 O
% O
, O
respectively O
. O
The O
ORFs S-DNA
of O
XYBX1332 S-DNA
and O
Oita-36 S-DNA
encode O
3422 O
and O
3425 O
amino O
acids O
, O
respectively O
. O
In O
addition O
, O
the O
non-coding B-DNA
regions E-DNA
( O
5′-and B-DNA
3′untranslated I-DNA
regions E-DNA
[ O
UTRs O
] O
) O
of O
these O
two O
strains O
differ O
in O
length O
and O
the O
homology O
of O
the O
5′-and O
3′-UTRs O
was O
81.5 O
and O
78 O
. O
3 O
% O
, O
respectively O
. O
The O
isolation O
of O
YOKV O
( O
XYBX1332 S-DNA
) O
from O
inland O
China O
thousands O
of O
kilometers O
from O
Yokosuka O
, O
Japan O
, O
suggests O
that O
the O
geographical O
distribution O
of O
YOKV O
is O
not O
limited O
to O
the O
islands O
of O
Japan O
and O
that O
it O
can O
also O
exist O
in O
the O
inland O
areas O
of O
Asia O
. O
However O
, O
there O
are O
large O
differences O
between O
the O
Chinese O
and O
Japanese O
YOKV O
strains O
in O
viral B-DNA
genome E-DNA
. O
Norovirus O
infection O
, O
a O
highly O
prevalent O
condition O
associated O
with O
a O
high O
rate O
of O
morbidity O
, O
comprises O
a O
significant O
health O
issue O
. O
Although O
norovirus O
transmission O
mainly O
occurs O
via O
the O
fecal-oral O
and O
vomit-oral O
routes O
, O
airborne O
transmission O
has O
been O
proposed O
in O
recent O
decades O
. O
This O
paper O
re-examines O
a O
previously O
described O
norovirus O
outbreak O
in O
a O
hotel O
restaurant O
wherein O
airborne O
transmission O
was O
originally O
inferred O
. O
Specifically O
, O
the O
original O
evidence O
that O
suggested O
airborne O
transmission O
was O
re-analyzed O
by O
exploring O
an O
alternative O
hypothesis O
: O
could O
this O
outbreak O
instead O
have O
occurred O
via O
fomite O
transmission O
? O
This O
re-analysis O
was O
based O
on O
whether O
fomite O
transmission O
could O
have O
yielded O
similar O
attack O
rate O
distribution O
patterns O
. O
Seven O
representative O
serving O
pathways O
used O
by O
waiters O
were O
considered O
, O
and O
the O
infection O
risk O
distributions O
of O
the O
alternative O
fomite O
transmission O
routes O
were O
predicted O
using O
a O
multi-agent O
model O
. O
These O
distributions O
were O
compared O
to O
the O
reported O
attack O
rate O
distribution O
in O
the O
original O
study O
using O
a O
least O
square O
methods O
approach O
. O
The O
results O
show O
that O
with O
some O
reasonable O
assumptions O
of O
human O
behavior O
patterns O
and O
parameter O
values O
, O
the O
attack O
rate O
distribution O
corresponded O
well O
with O
that O
of O
the O
infection O
risk O
via O
the O
fomite O
route O
. O
This O
finding O
offers O
an O
alternative O
interpretation O
of O
the O
transmission O
routes O
that O
underlay O
this O
particular O
norovirus O
outbreak O
and O
an O
important O
consideration O
in O
the O
development O
of O
infection O
control O
guidelines O
and O
the O
investigation O
of O
similar O
norovirus O
outbreaks O
in O
future O
. O
Influenza O
virus O
infection O
is O
a O
prevalent O
disease O
in O
humans O
. O
Antibodies O
against O
hemagglutinin S-protein
have O
been O
shown O
to O
prevent O
infection O
and O
hence O
hemagglutinin S-protein
is O
the O
major O
constituent O
of O
current O
vaccines O
. O
Antibodies O
directed O
against O
the O
highly O
conserved O
extracellular B-protein
domain E-protein
of O
M2 O
have O
also O
been O
shown O
to O
mediate O
protection O
against O
Influenza O
A O
infection O
in O
various O
animal O
models O
. O
Active O
vaccination O
is O
generally O
considered O
the O
best O
approach O
to O
combat O
viral O
diseases O
. O
However O
, O
passive O
immunization O
is O
an O
attractive O
alternative O
, O
particularly O
in O
acutely O
exposed O
or O
immune O
compromized O
individuals O
, O
young O
children O
and O
the O
elderly O
. O
We O
recently O
described O
a O
novel O
method O
for O
the O
rapid O
isolation O
of O
natural B-protein
human I-protein
antibodies E-protein
by O
mammalian O
cell O
display O
. O
Here O
we O
used O
this O
approach O
to O
isolate O
human B-protein
monoclonal I-protein
antibodies E-protein
directed O
against O
the O
highly O
conserved O
extracellular B-protein
domain E-protein
of O
the O
Influenza B-protein
A I-protein
M2 I-protein
protein E-protein
. O
The O
identified O
antibodies S-protein
bound O
M2 O
peptide O
with O
high O
affinities O
, O
recognized O
native O
cell-surface O
expressed O
M2 O
and O
protected O
mice O
from O
a O
lethal O
influenza O
virus O
challenge O
. O
Moreover O
, O
therapeutic O
treatment O
up O
to O
2 O
days O
after O
infection O
was O
effective O
, O
suggesting O
that O
M2-specific O
monoclonals O
have O
a O
great O
potential O
as O
immunotherapeutic O
agents O
against O
Influenza O
infection O
. O
Bacterial O
pathogens O
can O
exploit O
metabolic O
pathways O
to O
facilitate O
their O
successful O
infection O
cycles O
, O
but O
little O
is O
known O
about O
roles O
of O
d-galactosamine O
( O
GalN O
) O
/ O
N-acetyld-galactosamine O
( O
GalNAc O
) O
catabolism O
pathway O
in O
bacterial O
pathogenesis O
. O
Here O
, O
we O
report O
the O
genomic O
reconstruction O
of O
GalN/GalNAc S-protein
utilization O
pathway O
in O
Streptococci O
and O
the O
diversified O
aga O
regulons O
. O
We O
delineated O
two O
new O
paralogous B-protein
AgaR I-protein
regulators E-protein
for O
the O
GalN/GalNAc S-protein
catabolism O
pathway O
. O
The O
electrophoretic O
mobility O
shift O
assays O
experiment O
demonstrated O
that O
AgaR2 S-protein
( O
AgaR1 S-protein
) O
binds O
the O
predicted O
palindromes O
, O
and O
the O
combined O
in O
vivo O
data O
from O
reverse O
transcription O
quantitative O
polymerase O
chain O
reaction O
and O
RNA-seq S-protein
suggested O
that O
AgaR2 S-protein
( O
not O
AgaR1 S-protein
) O
can O
effectively O
repress O
the O
transcription O
of O
the O
target B-DNA
genes E-DNA
. O
Removal O
of O
agaR2 S-protein
( O
not O
agaR1 S-DNA
) O
from O
Streptococcus O
suis O
05ZYH33 O
augments O
significantly O
the O
abilities O
of O
both O
adherence O
to O
Hep-2 B-cell_line
cells E-cell_line
and O
anti-phagocytosis O
against O
RAW264.7 B-cell_line
macrophage E-cell_line
. O
As O
anticipated O
, O
the O
dysfunction O
in O
AgaR2mediated O
regulation O
of O
S. O
suis O
impairs O
its O
pathogenicity O
in O
experimental O
models O
of O
both O
mice O
and O
piglets O
. O
Our O
finding O
discovered O
two O
novel O
regulators O
specific O
for O
GalN/GalNAc S-protein
catabolism O
and O
assigned O
them O
distinct O
roles O
into O
bacterial O
infections O
. O
To O
the O
best O
of O
our O
knowledge O
, O
it O
might O
represent O
a O
first O
paradigm O
that O
links O
the O
GalN/GalNAc S-protein
catabolism O
pathway O
to O
bacterial O
pathogenesis O
. O
984 O
The O
porcine O
epidemic O
diarrhea O
virus O
( O
PEDV O
) O
is O
an O
important O
swine O
pathogen O
responsible O
for O
severe O
watery O
diarrhea O
, O
particularly O
in O
neonatal O
piglets O
. O
Despite O
extensive O
studies O
performed O
to O
elucidate O
the O
function O
of O
several O
viral B-protein
proteins E-protein
, O
the O
contribution O
of O
an O
accessory B-DNA
protein I-DNA
ORF3 E-DNA
in O
PEDV O
replication O
is O
still O
largely O
unknown O
. O
Here O
, O
we O
constructed O
expression O
plasmids O
as O
well O
as O
recombinant B-protein
PEDV E-protein
carrying O
myc-tagged B-DNA
ORF3 E-DNA
to O
assess O
their O
expression O
and O
subcellular O
localization O
in O
both O
transfected O
and O
infected B-cell_type
cells E-cell_type
. O
In O
PEDV-infected B-cell_line
cells E-cell_line
, O
ORF3 S-DNA
was O
predominantly O
localized O
in O
the O
cytoplasm O
, O
partially O
in O
the O
endoplasmic O
reticulum O
( O
ER S-protein
) O
and O
the O
Golgi O
apparatus O
( O
Golgi O
) O
. O
Interestingly O
, O
ORF3 S-DNA
with O
the O
N-terminal B-protein
Flag I-protein
tag E-protein
was O
also O
detected O
on O
the O
cell O
surface O
concomitant O
with O
the O
spike B-protein
( I-protein
S I-protein
) I-protein
protein E-protein
as O
determined O
by O
flow O
cytometry O
and O
confocal O
microscopy O
. O
ORF3 B-protein
and I-protein
S I-protein
proteins E-protein
were O
also O
co-localized O
at O
perinuclear O
compartments O
and O
in O
the O
vesicle-like O
structures O
in O
transfected O
and O
infected B-cell_type
cells E-cell_type
. O
We O
also O
demonstrated O
that O
both O
full-length O
and O
naturally O
truncated B-protein
ORF3 I-protein
proteins E-protein
could O
interact O
with O
the O
S B-protein
protein E-protein
but O
with O
different O
binding O
affinity O
, O
which O
correlate O
with O
the O
ability O
of O
the O
protein O
to O
regulate O
virus O
replication O
in O
cell O
culture O
. O
Collectively O
, O
our O
results O
underscore O
the O
unprecedented O
role O
of O
the O
ORF3 S-DNA
, O
which O
involves O
the O
interaction O
of O
ORF3 S-DNA
with O
S O
and O
, O
possibly O
, O
other O
structural O
protein O
during O
PEDV O
replication O
. O
Background O
: O
In O
2009 O
, O
China O
launched O
a O
health O
reform O
to O
promote O
the O
equalization O
of O
national O
essential O
public O
health O
services O
package O
( O
NEPHSP O
) O
. O
The O
present O
study O
aimed O
to O
describe O
the O
financing O
strategies O
and O
mechanisms O
to O
improve O
access O
to O
public O
health O
for O
all O
, O
identify O
the O
strengths O
and O
weaknesses O
of O
the O
different O
approaches O
, O
and O
showed O
evidence O
on O
equity O
improvement O
among O
different O
regions O
. O
Methods O
: O
We O
reviewed O
the O
relevant O
literatures O
and O
identified O
208 O
articles O
after O
screening O
and O
quality O
assessment O
and O
conducted O
six O
key O
informants O
' O
interviews O
. O
Secondary O
data O
on O
national O
and O
local O
government O
health O
expenditures O
, O
NEPHSP O
coverage O
and O
health O
indicators O
in O
2003-2014 O
were O
collected O
, O
descriptive O
and O
equity O
analyses O
were O
used O
. O
Results O
: O
Before O
2009 O
, O
the O
government O
subsidy O
to O
primary O
care O
institutions O
( O
PCIs O
) O
were O
mainly O
used O
for O
basic O
construction O
and O
a O
small O
part O
of O
personnel O
expenses O
. O
Since O
2009 O
, O
the O
new O
funds O
for O
NEPHSP O
have O
significantly O
expanded O
service O
coverage O
and O
population O
coverage O
. O
These O
funds O
have O
been O
allocated O
by O
central O
, O
provincial O
, O
municipal O
and O
county O
governments O
at O
different O
proportions O
in O
China O
's O
tax O
distribution O
system O
. O
Due O
to O
the O
fiscal O
transfer O
payment O
, O
the O
Central O
Government O
allocated O
more O
subsides O
to O
less-developed O
western O
regions O
and O
all O
the O
funds O
were O
managed O
in O
a O
specific O
account O
. O
Several O
types O
of O
payment O
methods O
have O
been O
adopted O
including O
capitation O
, O
pay O
for O
performance O
( O
P4P O
) O
, O
pay O
for O
service O
items O
, O
global O
budget O
and O
public O
health O
voucher O
, O
to O
address O
issues O
from O
both O
the O
supply O
and O
demand O
sides O
. O
The O
equalization O
of O
NEPHSP O
did O
well O
through O
the O
establishment O
of O
health O
records O
, O
systematic O
care O
of O
children O
and O
maternal O
women O
, O
etc O
. O
Our O
data O
showed O
that O
the O
gap O
between O
the O
eastern O
, O
central O
and O
western O
regions O
narrowed O
. O
However O
the O
coverage O
for O
migrants O
was O
still O
low O
and O
performance O
was O
needed O
improving O
in O
effectiveness O
of O
managing O
patients O
with O
chronic O
diseases O
. O
Conclusions O
: O
The O
delivery O
of O
essential O
public O
health O
services O
was O
highly O
influenced O
by O
public O
fiscal O
policy O
, O
and O
the O
implementation O
of O
health O
reform O
since O
2009 O
has O
led O
the O
public O
health O
development O
towards O
the O
right O
direction O
. O
However O
China O
still O
needs O
to O
increase O
the O
fiscal O
investments O
to O
expand O
service O
coverage O
as O
well O
as O
promote O
the O
quality O
of O
public O
health O
services O
and O
equality O
among O
regions O
. O
Independent O
scientific O
monitoring O
and O
evaluation O
are O
also O
needed O
. O
Background O
: O
Acute O
diarrhea O
is O
one O
of O
the O
most O
serious O
problems O
in O
global O
public O
health O
that O
causes O
considerable O
morbidity O
and O
mortality O
worldwide O
. O
Human O
caliciviruses O
( O
HuCV O
) O
including O
norovirus O
( O
NoV O
, O
genogroup O
GI O
and O
GII O
) O
and O
sapovirus O
( O
SaV O
) O
, O
is O
a O
leading O
cause O
of O
acute O
sporadic O
diarrhea O
in O
individuals O
across O
all O
age O
groups O
. O
However O
, O
few O
studies O
had O
been O
conducted O
clarifying O
the O
characteristics O
of O
HuCV O
in O
diarrhea O
cases O
across O
all O
age O
groups O
in O
China O
. O
Stool O
specimens O
were O
collected O
from O
1,121 O
diarrhea O
cases O
and O
319 O
healthy O
controls O
in O
outpatient O
departments O
. O
Reverse O
transcription O
polymerase O
chain O
reaction O
( O
RT-PCR O
) O
was O
used O
to O
detect O
NoV B-cell_line
( I-cell_line
GI I-cell_line
, I-cell_line
GII I-cell_line
) E-cell_line
and O
SaV S-protein
. O
Sequencing O
was O
applied O
to O
confirm O
the O
three O
viral O
infections O
and O
phylogenetic O
analysis O
was O
performed O
to O
determine O
their O
genotypes O
. O
A O
structured O
questionnaire O
was O
used O
to O
record O
the O
demographic O
information O
and O
clinical O
symptoms O
of O
subjects O
. O
Results O
: O
HuCV O
was O
detected O
at O
an O
11.0 O
% O
infection O
rate O
in O
1,121 O
diarrhea O
cases O
and O
at O
3.4 O
% O
rate O
in O
319 O
non-diarrhea O
subjects O
( O
p O
< O
0.0001 O
, O
OR O
= O
3.5 O
, O
95 O
% O
CI O
1.8-6.5 O
) O
. O
The O
prevalence O
of O
the O
NoV O
genogroup O
GII O
and O
genotype O
GII.4 O
in O
diarrhea O
cases O
was O
significantly O
higher O
than O
that O
found O
in O
healthy O
controls O
( O
p O
< O
0.0001 O
, O
p O
= O
0.018 O
, O
respectively O
) O
. O
NoV O
GII O
( O
n O
= O
118 O
, O
10.5 O
% O
) O
was O
the O
most O
common O
HuCV O
subtype O
in O
diarrhea O
cases O
, O
followed O
by O
SaV S-protein
( O
n O
= O
3 O
, O
0.3 O
% O
) O
and O
NoV O
GI O
( O
n O
= O
2 O
, O
0.2 O
% O
) O
. O
Of O
118 O
NoV O
GII O
strains O
isolated O
from O
diarrhea O
patients O
. O
GII.4 O
( O
n O
= O
55 O
, O
46.6 O
% O
) O
was O
the O
predominant O
strain O
, O
followed O
by O
GII.3 S-protein
( O
n O
= O
28 O
, O
23.7 O
% O
) O
, O
GII.12 S-protein
( O
n O
= O
25 O
, O
21.2 O
% O
) O
, O
GII.17 S-protein
( O
n O
= O
8 O
, O
6.8 O
% O
) O
, O
and O
GII.5 S-protein
( O
n O
= O
2 O
, O
1.7 O
% O
) O
. O
Of O
the O
55 O
GII.4 O
strains O
, O
the O
GII.4 O
Sydney O
2012 O
variant O
had O
absolutely O
predominant O
prevalence O
( O
n O
= O
52 O
, O
94.5 O
% O
) O
, O
followed O
by O
the O
NoV O
GII.4-2006b O
variant O
( O
n O
= O
3 O
, O
5.5 O
% O
) O
. O
The O
GII.4 O
Orleans O
2009 O
variant O
was O
not O
found O
in O
diarrhea O
cases O
of O
the O
study O
. O
Conclusions O
: O
NoV O
GII O
was O
the O
major O
genogroup O
and O
GII.4 O
was O
the O
most O
predominant O
strain O
detected O
in O
diarrhea O
patients O
. O
The O
GII.17 S-DNA
is O
an O
emergent O
variant O
in O
sporadic O
diarrhea O
and O
might O
become O
the O
predominant O
strain O
in O
diarrhea O
cases O
in O
the O
near O
future O
. O
Rapid O
, O
accurate O
detection O
kits O
need O
to O
be O
developed O
to O
help O
us O
find O
and O
treat O
NoV-associated O
diarrhea O
in O
clinical O
settings O
in O
a O
timely O
manner O
. O
Background O
: O
The O
epidermis O
forms O
a O
critical O
barrier O
that O
is O
maintained O
by O
orchestrated O
programs O
of O
proliferation O
, O
differentiation O
, O
and O
cell O
death O
. O
Gene O
mutations O
that O
disturb O
this O
turnover O
process O
may O
cause O
skin O
diseases O
. O
Human B-protein
GASDERMIN I-protein
A E-protein
( O
GSDMA S-protein
) O
is O
frequently O
silenced O
in O
gastric B-cell_line
cancer I-cell_line
cell I-cell_line
lines E-cell_line
and O
its O
overexpression O
has O
been O
reported O
to O
induce O
apoptosis O
. O
GSDMA S-protein
has O
also O
been O
linked O
with O
airway O
hyperresponsiveness O
in O
genetic O
association O
studies O
. O
The O
function O
of O
GSDMA S-protein
in O
the O
skin O
was O
deduced O
by O
dominant O
mutations O
in O
mouse B-protein
gasdermin I-protein
A3 E-protein
( O
Gsdma3 S-protein
) O
, O
which O
caused O
skin O
inflammation O
and O
hair O
loss O
. O
However O
, O
the O
mechanism O
for O
the O
autosomal O
dominance O
of O
Gsdma3 O
mutations O
and O
the O
mode O
of O
Gsdma3 S-protein
's O
action O
remain O
unanswered O
. O
Results O
: O
We O
demonstrated O
a O
novel O
function O
of O
Gsdma3 S-protein
in O
modulating O
mitochondrial O
oxidative O
stress O
. O
We O
showed O
that O
Gsdma3 S-protein
is O
regulated O
by O
intramolecular O
fold-back O
inhibition O
, O
which O
is O
disrupted O
by O
dominant O
mutations O
in O
the O
C-terminal B-protein
domain E-protein
. O
The O
unmasked O
N-terminal B-protein
domain E-protein
of O
Gsdma3 S-protein
associates O
with O
Hsp90 S-protein
and O
is O
delivered O
to O
mitochondrial O
via O
mitochondrial B-protein
importer I-protein
receptor E-protein
Tom70 S-protein
, O
where O
it O
interacts O
with O
the O
mitochondrial B-protein
chaperone E-protein
Trap1 S-protein
and O
causes O
increased O
production O
of O
mitochondrial O
reactive O
oxygen O
species O
( O
ROS O
) O
, O
dissipation O
of O
mitochondrial O
membrane O
potential O
, O
and O
mitochondrial B-protein
permeability I-protein
transition E-protein
( O
MPT O
) O
. O
Overexpression O
of O
the O
C-terminal B-protein
domain E-protein
of O
Gsdma3 S-protein
as O
well O
as O
pharmacological O
interventions O
of O
mitochondrial O
translocation O
, O
ROS O
production O
, O
and O
MPT O
pore O
opening O
alleviate O
the O
cell O
death O
induced O
by O
Gsdma3 B-protein
mutants E-protein
. O
Our O
results O
indicate O
that O
the O
genetic O
mutations O
in O
the O
C-terminal B-protein
domain E-protein
of O
Gsdma3 S-protein
are O
gain-of-function O
mutations O
which O
unmask O
the O
N-terminal B-protein
functional I-protein
domain E-protein
of O
Gsdma3 S-protein
. O
Gsdma3 S-protein
regulates O
mitochondrial O
oxidative O
stress O
through O
mitochondrial O
targeting O
. O
Since O
mitochondrial O
ROS O
has O
been O
shown O
to O
promote O
epidermal O
differentiation O
, O
we O
hypothesize O
that O
Gsdma3 S-protein
regulates O
context-dependent O
response O
of O
keratinocytes S-cell_type
to O
differentiation O
and O
cell O
death O
signals O
by O
impinging O
on O
mitochondria O
. O
CD8 S-protein
+ O
cytotoxic O
T O
cell O
( O
CTL S-cell_type
) O
responses O
are O
necessary O
for O
the O
lysis O
of O
virally B-cell_type
infected I-cell_type
cells E-cell_type
and O
control O
of O
infection O
. O
CTLs S-cell_type
are O
activated O
when O
their O
TCRs S-protein
bind O
a O
major B-protein
histocompatibility I-protein
complex I-protein
( I-protein
MHC I-protein
) I-protein
-I/peptide I-protein
complex E-protein
on O
the O
surface O
of O
antigen B-cell_type
presenting I-cell_type
cells E-cell_type
such O
as O
macrophages S-cell_type
( O
MΦ O
) O
. O
It O
is O
now O
apparent O
that O
MΦ S-protein
display O
remarkable O
plasticity O
in O
response O
to O
environmental O
signals O
to O
polarize O
into O
classically O
activated O
M O
( O
LPS O
+ O
IFN-γ S-protein
) O
or O
alternatively O
activated O
M O
( O
IL-4 S-protein
) O
. O
However O
, O
little O
is O
known O
about O
how O
MΦ S-protein
activation O
status O
influences O
their O
antigen O
presentation O
function O
to O
CD8 S-protein
+ O
T O
cell O
in O
models O
of O
virus O
infection O
. O
Consequently O
, O
we O
tested O
how O
polarization O
of O
spleen-derived B-protein
( I-protein
Sp I-protein
) I-protein
-MΦ E-protein
impacts O
direct O
presentation O
of O
viral B-protein
antigens E-protein
to O
influence O
effector O
and O
proliferative O
CD8 S-protein
+ O
T-cell O
responses O
. O
We O
show O
that O
M B-protein
( I-protein
IL-4 I-protein
) I-protein
Sp-MΦ E-protein
retain O
MHC-I S-protein
surface O
expression O
and O
the O
ability O
to O
stimulate O
IFN-γ S-protein
production O
by O
CTL S-cell_type
following O
peptide O
stimulation O
and O
lymphocytic O
choriomeningitis O
virus O
infection O
to O
levels O
similar O
to O
M0 O
and O
M O
( O
LPS O
+ O
IFN-γ O
) O
MΦ O
. O
However O
, O
memory B-cell_type
CD8 I-cell_type
+ I-cell_type
T I-cell_type
cells E-cell_type
cultured O
in O
the O
presence O
of O
M B-protein
( I-protein
IL-4 I-protein
) I-protein
MΦ E-protein
underwent O
significantly O
reduced O
proliferation O
and O
produced O
similar O
IFN-γ S-protein
levels O
as O
coculturing O
with O
M0 O
or O
M B-cell_type
( I-cell_type
LPS I-cell_type
+ I-cell_type
IFN-γ I-cell_type
) I-cell_type
cells E-cell_type
. O
Thus O
, O
these O
results O
show O
a O
novel O
ability O
of O
polarized O
MΦ S-protein
to O
regulate O
CD8 S-protein
+ O
T-cell O
proliferation O
and O
effector O
functions O
during O
virus O
infection O
. O
Acute O
respiratory O
infections O
( O
ARIs O
) O
cause O
a O
considerable O
morbidity O
and O
mortality O
worldwide O
especially O
in O
children O
. O
However O
, O
there O
are O
few O
studies O
of O
the O
etiological O
structure O
of O
ARIs S-protein
in O
Russia O
. O
In O
this O
work O
, O
we O
analyzed O
the O
etiology O
of O
ARIs O
in O
children O
( O
0-15 O
years O
old O
) O
admitted O
to O
Novosibirsk O
Children O
's O
Municipal O
Clinical O
Hospital O
in O
2013-2017 O
. O
We O
tested O
nasal O
and O
throat O
swabs O
of O
1560 O
children O
with O
upper O
or O
lower O
respiratory O
infection O
for O
main O
respiratory O
viruses O
( O
influenza O
viruses O
A O
and O
B O
, O
parainfluenza O
virus O
types O
1-4 O
, O
respiratory O
syncytial O
virus O
, O
metapneumovirus O
, O
four O
human O
coronaviruses O
, O
rhinovirus O
, O
adenovirus O
and O
bocavirus O
) O
using O
a O
RT-PCR O
Kit O
. O
Background O
: O
Kawasaki O
disease O
( O
KD O
) O
is O
a O
systemic O
vasculitis O
with O
unknown O
etiology O
mainly O
affecting O
children O
in O
Asian O
countries O
. O
Dendritic B-protein
cell-specific I-protein
intercellular I-protein
adhesion I-protein
molecule-3 I-protein
grabbing I-protein
non-integrin E-protein
( O
DC-SIGN O
, O
CD209 O
) O
in O
humans O
was O
showed O
to O
trigger O
an O
anti-inflammatory O
cascade O
and O
associated O
with O
KD O
susceptibility O
. O
This O
study O
was O
conducted O
to O
investigate O
the O
association O
between O
genetic O
polymorphisms O
of O
CD209 O
and O
the O
risk O
KD O
. O
Methods O
: O
A O
total O
of O
948 O
subjects O
( O
381 O
KD O
and O
567 O
controls O
) O
were O
recruited O
. O
Nine O
tagging O
SNPs B-DNA
( I-DNA
rs8112310 I-DNA
, I-DNA
rs4804800 I-DNA
, I-DNA
rs11465421 I-DNA
, I-DNA
rs1544766 I-DNA
, I-DNA
rs4804801 I-DNA
, I-DNA
rs2287886 I-DNA
, I-DNA
rs735239 I-DNA
, I-DNA
rs735240 I-DNA
, I-DNA
rs4804804 E-DNA
) O
were O
selected O
for O
TaqMan O
allelic O
discrimination O
assay O
. O
Clinical O
phenotypes O
, O
coronary O
artery O
lesions O
( O
CAL O
) O
and O
intravenous O
immunoglobulin S-protein
( O
IVIG S-protein
) O
treatment O
outcomes O
were O
collected O
for O
analysis O
. O
Results O
: O
Significant O
associations O
were O
found O
between O
CD209 B-DNA
polymorphisms E-DNA
( O
rs4804800 O
, O
rs2287886 O
, O
rs735240 O
) O
and O
the O
risk O
of O
KD O
. O
Haplotype O
analysis O
for O
CD209 B-DNA
polymorphisms E-DNA
showed O
that O
A/A/G O
haplotype O
( O
P O
= O
0.0002 O
, O
OR O
= O
1.61 O
) O
and O
G/A/G O
haplotype O
( O
P O
= O
0.0365 O
, O
OR O
= O
1.52 O
) O
had O
higher O
risk O
of O
KD O
as O
compared O
with O
G/G/A O
haplotype O
in O
rs2287886/rs735239/rs735240 O
pairwise O
allele O
analysis O
. O
There O
were O
no O
significant O
association O
in O
KD O
with O
regards O
to O
CAL O
formation O
and O
IVIG S-protein
treatment O
responses O
. O
Conclusion O
: O
CD209 B-DNA
polymorphisms E-DNA
were O
responsible O
for O
the O
susceptibility O
of O
KD O
, O
but O
not O
CAL O
formation O
and O
IVIG S-protein
treatment O
responsiveness O
. O
Background O
: O
Classical O
scrapie O
in O
sheep O
is O
a O
fatal O
neurodegenerative O
disease O
associated O
with O
the O
conversion O
PrP B-protein
C E-protein
to O
PrP O
Sc O
. O
Much O
is O
known O
about O
genetic O
susceptibility O
, O
uptake O
and O
dissemination O
of O
PrP O
Sc O
in O
the O
body O
, O
but O
many O
aspects O
of O
prion O
diseases O
are O
still O
unknown O
. O
Different O
proteomic O
techniques O
have O
been O
used O
during O
the O
last O
decade O
to O
investigate O
differences O
in O
protein O
profiles O
between O
affected O
animals O
and O
healthy O
controls O
. O
We O
have O
investigated O
the O
protein O
profiles O
in O
serum O
of O
sheep O
with O
scrapie O
and O
healthy O
controls O
by O
SELDI-TOF-MS O
and O
LC-MS/MS O
. O
Latent O
Variable O
methods O
such O
as O
Principal O
Component O
Analysis O
, O
Partial O
Least O
Squares-Discriminant O
Analysis O
and O
Target O
Projection O
methods O
were O
used O
to O
describe O
the O
MS O
data O
. O
Results O
: O
The O
serum O
proteomic O
profiles O
showed O
variable O
differences O
between O
the O
groups O
both O
throughout O
the O
incubation O
period O
and O
at O
the O
clinical O
end O
stage O
of O
scrapie O
. O
At O
the O
end O
stage O
, O
the O
target O
projection O
model O
separated O
the O
two O
groups O
with O
a O
sensitivity O
of O
97.8 O
% O
, O
and O
serum B-protein
amyloid I-protein
A E-protein
was O
identified O
as O
one O
of O
the O
protein O
peaks O
that O
differed O
significantly O
between O
the O
groups O
. O
Conclusions O
: O
At O
the O
clinical O
end O
stage O
of O
classical O
scrapie O
, O
ten O
SELDI O
peaks O
significantly O
discriminated O
the O
scrapie O
group O
from O
the O
healthy O
controls O
. O
During O
the O
non-clinical O
incubation O
period O
, O
individual O
SELDI O
peaks O
were O
differently O
expressed O
between O
the O
groups O
at O
different O
time O
points O
. O
Investigations O
of O
differences O
in O
-omic O
profiles O
can O
contribute O
to O
new O
insights O
into O
the O
underlying O
disease O
processes O
and O
pathways O
, O
and O
advance O
our O
understanding O
of O
prion O
diseases O
, O
but O
comparison O
and O
validation O
across O
laboratories O
is O
difficult O
and O
challenging O
. O
Background O
: O
The O
envelope B-protein
glycoprotein E-protein
of O
lymphocytic O
choriomeningitis O
virus O
( O
LCMV O
) O
can O
efficiently O
pseudotype O
lentiviral O
vectors O
. O
Some O
strains O
of O
LCMV O
exploit O
high O
affinity O
interactions O
with O
α-dystroglycan S-protein
( O
α-DG O
) O
to O
bind O
to O
cell O
surfaces O
and O
subsequently O
fuse O
in O
low O
pH O
endosomes O
. O
LCMV O
strains O
with O
low O
α-DG S-protein
affinity O
utilize O
an O
unknown O
receptor O
and O
display O
unique O
tissue O
tropisms O
. O
We O
pseudotyped O
non-primate O
feline O
immunodeficiency O
virus O
( O
FIV O
) O
vectors O
using O
LCMV O
derived O
glycoproteins O
with O
high O
or O
low O
affinity O
to O
α-DG S-protein
and O
evaluated O
their O
properties O
in O
vitro O
and O
in O
vivo O
. O
Methods O
: O
We O
pseudotyped O
FIV O
with O
the O
LCMV B-protein
WE54 I-protein
strain I-protein
envelope I-protein
glycoprotein E-protein
and O
also O
engineered O
a O
point O
mutation O
in O
the O
WE54 B-protein
envelope I-protein
glycoprotein E-protein
( O
L260F S-protein
) O
to O
diminish O
α-DG S-protein
affinity O
and O
direct O
binding O
to O
alternate B-protein
receptors E-protein
. O
We O
hypothesized O
that O
this O
change O
would O
alter O
in O
vivo O
tissue O
tropism O
and O
enhance O
gene O
transfer O
to O
neonatal O
animals O
. O
Results O
: O
In O
mice O
, O
hepatic O
αand O
β-DG S-protein
expression O
was O
greatest O
at O
the O
late O
gestational O
and O
neonatal O
time O
points O
. O
When O
displayed O
on O
the O
surface O
of O
the O
FIV O
lentivirus O
the O
WE54 B-protein
L260F I-protein
mutant I-protein
glycoprotein E-protein
bound O
weakly O
to O
immobilized O
α-DG S-protein
. O
Additionally O
, O
LCMV O
WE54 O
pseudotyped O
FIV O
vector O
transduction O
was O
neutralized O
by O
preincubation O
with O
soluble O
α-DG S-protein
, O
while O
the O
mutant B-DNA
glycoprotein I-DNA
pseudotyped I-DNA
vector E-DNA
was O
not O
. O
In O
vivo O
gene O
transfer O
in O
adult O
mice O
with O
either O
envelope O
yielded O
low O
transduction O
efficiencies O
in O
hepatocytes S-cell_type
following O
intravenous O
delivery O
. O
In O
marked O
contrast O
, O
neonatal O
gene O
transfer O
with O
the O
LCMV O
envelopes O
, O
and O
notably O
with O
the O
FIV-L260F B-DNA
vector E-DNA
, O
conferred O
abundant O
liver O
and O
lower O
level O
cardiomyocyte O
transduction O
as O
detected O
by O
luciferase S-protein
assays O
, O
bioluminescent O
imaging O
, O
and O
β-galactosidase O
staining O
. O
Conclusions O
: O
These O
results O
suggest O
that O
a O
developmentally O
regulated O
receptor O
for O
LCMV S-protein
is O
expressed O
abundantly O
in O
neonatal O
mice O
. O
LCMV O
pseudotyped O
vectors O
may O
have O
applications O
for O
neonatal O
gene O
transfer O
. O
Abbreviations O
: O
Armstrong O
53b O
( O
Arm53b O
) O
; O
baculovirus B-protein
Autographa I-protein
californica I-protein
GP64 I-protein
( I-protein
GP64 I-protein
) E-protein
; O
charge-coupled O
device O
( O
CCD O
) O
; O
dystroglycan S-protein
( O
DG O
) O
; O
feline O
immunodeficiency O
virus O
( O
FIV O
) O
; O
glycoprotein B-protein
precursor E-protein
( O
GP-C S-protein
) O
; O
firefly B-protein
luciferase E-protein
( O
Luc S-protein
) O
; O
lymphocytic O
choriomeningitis O
virus O
( O
LCMV O
) O
; O
nuclear O
targeted O
β-galactosidase O
( O
ntLacZ S-DNA
) O
; O
optical O
density O
( O
OD O
) O
; O
PBS/ O
0.1 O
% O
( O
w/v O
) O
Tween-20 O
( O
PBST S-DNA
) O
; O
relative O
light O
units O
( O
RLU O
) O
; O
Rous O
sarcoma O
virus O
( O
RSV O
) O
; O
transducing O
units O
per O
milliliter O
( O
TU/ O
ml O
) O
; O
vesicular O
stomatitis O
virus O
( O
VSV-G O
) O
; O
wheat B-protein
germ I-protein
agglutinin E-protein
( O
WGA O
) O
; O
50 O
% O
reduction O
in O
binding O
( O
C O
50 O
) O
. O
Background O
Bronchiolitis O
is O
the O
leading O
cause O
of O
hospitalization O
in O
infants O
. O
Biomarkers O
of O
disease O
severity O
might O
help O
in O
clinical O
management O
. O
Objective O
To O
determine O
the O
clinical O
predictiveness O
of O
NW-LDH O
, O
NW-caspase O
3/7 O
, O
and O
NW-LDH/NW-caspase O
3/7 O
ratio O
in O
bronchiolitis O
. O
Methods O
Previously O
healthy O
children O
less O
than O
24 O
months O
of O
age O
with O
bronchiolitis O
were O
recruited O
from O
the O
Texas O
Children O
's O
emergency O
room O
and O
intensive O
care O
unit O
from O
October O
2010 O
to O
April O
2011 O
. O
Demographic O
, O
clinical O
information O
, O
and O
NW O
samples O
were O
obtained O
at O
enrollment O
. O
NW O
samples O
were O
analyzed O
for O
respiratory O
viruses O
, O
caspase B-protein
3/7 E-protein
, O
and O
LDH S-protein
. O
Results O
A O
viral O
pathogen O
was O
detected O
in O
91Á6 O
% O
of O
131 O
children O
, O
with O
the O
most O
common O
being O
respiratory O
syncytial O
virus O
and O
human O
rhinovirus O
. O
A O
single O
infection O
was O
found O
in O
61Á8 O
% O
of O
subjects O
and O
co-infection O
in O
29Á8 O
% O
. O
Children O
admitted O
to O
ICU O
had O
significantly O
higher O
NW-LDH O
than O
children O
sent O
home O
from O
the O
ER S-protein
or O
admitted O
to O
the O
general O
floor O
( O
P O
= O
0Á02 O
) O
. O
Children O
infected O
with O
RSV O
had O
the O
highest O
NW-LDH O
concentration O
( O
P O
= O
0Á03 O
) O
compared O
with O
other O
viral O
infections O
. O
NW-LDH O
and O
NW-caspase O
were O
significantly O
correlated O
( O
r O
= O
0Á77 O
, O
P O
< O
0Á0001 O
) O
. O
The O
univariate O
models O
showed O
NW-LDH O
and O
NW-LDH/NW-caspase O
3/7 O
ratio O
were O
directly O
associated O
with O
hospitalization O
. O
Mutivariate O
regression O
analyses O
suggested O
a O
complex O
interaction O
between O
the O
biomarkers O
, O
demographics O
, O
and O
disposition O
. O
Conclusions O
NW-LDH O
, O
NW-caspase O
3/7 O
and O
NW-LDH/NWcaspase O
3/7 O
ratio O
and O
their O
interactions O
with O
demographic O
factors O
are O
predictive O
of O
bronchiolitis O
severity O
and O
can O
help O
distinguish O
children O
requiring O
ICU-level O
care O
from O
those O
admitted O
to O
the O
general O
floor O
, O
or O
discharged O
home O
from O
the O
emergency O
center O
. O
Keywords O
Bronchiolitis O
, O
caspase O
, O
disease O
severity O
, O
lactate B-protein
dehydrogenase E-protein
. O
Please O
cite O
this O
paper O
as O
: O
Mehta O
et O
al O
. O
( O
2014 O
) O
Lactate B-protein
dehydrogenase E-protein
and O
caspase O
activity O
in O
nasopharyngeal O
secretions O
are O
predictors O
of O
bronchiolitis O
severity O
. O
Background O
: O
Fidelity O
of O
DNA B-protein
polymerases E-protein
can O
be O
influenced O
by O
cation O
co-factors O
. O
Physiologically O
, O
Mg O
2+ O
is O
used O
as O
a O
co-factor O
by O
HIV B-protein
reverse I-protein
transcriptase E-protein
( O
RT O
) O
to O
perform O
catalysis O
; O
however O
, O
alternative O
cations O
including O
Mn O
2+ O
, O
Co O
2 O
+ O
, O
and O
Zn O
2+ O
can O
also O
support O
catalysis O
. O
Although O
Zn O
2+ O
supports O
DNA O
synthesis O
, O
it O
inhibits O
HIV O
RT O
by O
significantly O
modifying O
RT O
catalysis O
. O
Zn O
2+ O
is O
currently O
being O
investigated O
as O
a O
component O
of O
novel O
treatment O
options O
against O
HIV O
and O
we O
wanted O
to O
investigate O
the O
fidelity O
of O
RT O
with O
Zn O
2+ O
. O
Methods O
: O
We O
used O
PCR-based S-protein
and O
plasmid-based O
alpha O
complementation O
assays O
as O
well O
as O
steady-state O
misinsertion O
and O
misincorporation O
assays O
to O
examine O
the O
fidelity O
of O
RT S-protein
with O
Mn O
2+ O
, O
Co O
2+ O
, O
and O
Zn O
2+ O
. O
The O
envelope B-protein
spike I-protein
( I-protein
S I-protein
) I-protein
proteins E-protein
of O
MERS-CoV S-protein
and O
SARS-CoV S-protein
determine O
the O
virus O
host O
tropism O
and O
entry O
into O
host B-cell_type
cells E-cell_type
, O
and O
constitute O
a O
promising O
target O
for O
the O
development O
of O
prophylactics O
and O
therapeutics O
. O
Here O
, O
we O
present O
high-resolution O
structures O
of O
the O
trimeric B-protein
MERS-CoV E-protein
and O
SARS-CoV B-protein
S I-protein
proteins E-protein
in O
its O
pre-fusion O
conformation O
by O
single O
particle O
cryo-electron O
microscopy O
. O
The O
overall O
structures O
resemble O
that O
from O
other O
coronaviruses O
including O
HKU1 S-protein
, O
MHV O
and O
NL63 S-protein
reported O
recently O
, O
with O
the O
exception O
of O
the O
receptor B-protein
binding I-protein
domain E-protein
( O
RBD S-protein
) O
. O
We O
captured O
two O
states O
of O
the O
RBD S-protein
with O
receptor B-protein
binding I-protein
region E-protein
either O
buried O
( O
lying O
state O
) O
or O
exposed O
( O
standing O
state O
) O
, O
demonstrating O
an O
inherently O
flexible O
RBD S-protein
readily O
recognized O
by O
the O
receptor O
. O
Further O
sequence O
conservation O
analysis O
of O
six O
human-infecting O
coronaviruses O
revealed O
that O
the O
fusion O
peptide O
, O
HR1 B-DNA
region E-DNA
and O
the O
central O
helix O
are O
potential O
targets O
for O
eliciting O
broadly O
neutralizing B-protein
antibodies E-protein
. O
Uropathogenic O
E. O
coli O
( O
UPEC O
) O
, O
which O
cause O
urinary O
tract O
infections O
( O
UTI O
) O
, O
utilize O
type O
1 O
pili O
, O
a O
chaperone B-protein
usher I-protein
pathway I-protein
( I-protein
CUP I-protein
) I-protein
pilus E-protein
, O
to O
cause O
UTI S-protein
and O
colonize O
the O
gut O
. O
The O
pilus O
rod O
, O
comprised O
of O
repeating O
FimA B-protein
subunits E-protein
, O
provides O
a O
structural O
scaffold O
for O
displaying O
the O
tip B-protein
adhesin E-protein
, O
FimH S-protein
. O
We O
solved O
the O
4.2 O
Å O
resolution O
structure O
of O
the O
type O
1 O
pilus O
rod O
using O
cryo-electron O
microscopy O
. O
Residues O
forming O
the O
interactive O
surfaces O
that O
determine O
the O
mechanical O
properties O
of O
the O
rod O
were O
maintained O
by O
selection O
based O
on O
a O
global O
alignment O
of O
fimA B-DNA
sequences E-DNA
. O
We O
identified O
mutations O
that O
did O
not O
alter O
pilus O
production O
in O
vitro O
but O
reduced O
the O
force O
required O
to O
unwind O
the O
rod O
. O
UPEC S-protein
expressing O
these O
mutant O
pili O
were O
significantly O
attenuated O
in O
bladder O
infection O
and O
intestinal O
colonization O
in O
mice O
. O
This O
study O
elucidates O
an O
unappreciated O
functional O
role O
for O
the O
molecular O
spring-like O
property O
of O
type O
1 O
pilus O
rods O
in O
host-pathogen O
interactions O
and O
carries O
important O
implications O
for O
other O
pilus-mediated O
diseases O
. O
Modified O
vaccinia O
virus O
Ankara O
( O
MVA O
) O
is O
the O
vector O
of O
choice O
for O
human O
and O
veterinary O
applications O
due O
to O
its O
strong O
safety O
profile O
and O
immunogenicity O
in O
vivo O
. O
The O
use O
of O
MVA O
and O
MVA-vectored O
vaccines O
against O
human O
and O
animal O
diseases O
must O
comply O
with O
regulatory O
requirements O
as O
they O
pertain O
to O
environmental O
risk O
assessment O
, O
particularly O
the O
characterization O
of O
potential O
adverse O
effects O
to O
humans O
, O
animals O
and O
the O
environment O
. O
MVA O
and O
recombinant B-protein
MVA E-protein
are O
widely O
believed O
to O
pose O
low O
or O
negligible O
risk O
to O
ecosystem O
health O
. O
However O
, O
key O
aspects O
of O
MVA O
biology O
require O
further O
research O
in O
order O
to O
provide O
data O
needed O
to O
evaluate O
the O
potential O
risks O
that O
may O
occur O
due O
to O
the O
use O
of O
MVA O
and O
MVA-vectored O
vaccines O
. O
The O
purpose O
of O
this O
paper O
is O
to O
identify O
knowledge O
gaps O
in O
the O
biology O
of O
MVA S-protein
and O
recombinant B-protein
MVA E-protein
that O
are O
of O
relevance O
to O
its O
hazard O
characterization O
and O
discuss O
ongoing O
and O
future O
experiments O
aimed O
at O
providing O
data O
necessary O
to O
fill O
in O
the O
knowledge O
gaps O
. O
In O
addition O
, O
we O
presented O
arguments O
for O
the O
inclusion O
of O
uncertainty O
analysis O
and O
experimental O
investigation O
of O
verifiable O
worst-case O
scenarios O
in O
the O
environmental O
risk O
assessment O
of O
MVA S-protein
and O
recombinant B-protein
MVA E-protein
. O
These O
will O
contribute O
to O
improved O
risk O
assessment O
of O
MVA O
and O
recombinant O
MVA O
vaccines O
. O
Viruses O
2017 O
, O
9 O
, O
318 O
2 O
of O
29 O
adjuvant O
and O
induction O
of O
robust O
cytotoxic B-cell_type
T I-cell_type
lymphocyte E-cell_type
response O
to O
eliminate O
virus-infected B-cell_type
cells E-cell_type
. O
Many O
viruses O
have O
been O
used O
as O
GMVs O
for O
vaccination O
purposes O
, O
the O
major O
ones O
being O
Poxviridae O
( O
Vaccinia O
virus O
; O
VACV O
) O
, O
Retroviridae O
( O
including O
lentivirus O
) O
, O
Adenoviridae O
( O
human O
Adenovirus O
; O
hAdV O
) O
, O
Parvoviridae O
( O
Adeno-associated O
virus O
; O
AAV O
) O
, O
Herpesviridae O
( O
cytomegalovirus O
; O
CMV O
) O
and O
Paramyxoviridae O
( O
sendai O
virus O
; O
SeV O
) O
[ O
1 O
, O
2 O
] O
. O
Each O
has O
unique O
attributes O
and O
associated O
risks O
when O
used O
as O
a O
GM O
virus O
vaccine O
or O
vector O
. O
VACV-based O
vectors O
have O
good O
historical O
precedence O
on O
safety O
in O
that O
VACV O
and O
modified O
vaccinia O
virus O
Ankara O
( O
MVA O
) O
were O
used O
in O
smallpox O
vaccination O
. O
VACV-based O
vectors O
were O
also O
well O
tolerated O
in O
clinical O
trials O
, O
although O
adverse O
effects O
were O
recorded O
in O
some O
studies O
at O
high O
dose O
( O
over O
10 O
8 O
pfu O
) O
of O
MVA O
[ O
3 O
] O
. O
Disadvantages O
of O
vectors O
based O
on O
VACV O
include O
limited O
immunogenicity O
and O
pre-existing O
immunity O
[ O
4 O
] O
. O
Recombinant B-DNA
AdV I-DNA
vectors E-DNA
have O
the O
advantage O
of O
high O
transduction O
efficiency O
, O
a O
high O
level O
of O
transgene O
expression O
, O
broad O
cell O
tropism O
and O
the O
ability O
to O
infect O
both O
dividing B-cell_type
and I-cell_type
non-dividing I-cell_type
cells E-cell_type
[ O
5 O
] O
. O
The O
AdV B-DNA
vectors E-DNA
are O
also O
well O
tolerated O
but O
the O
presence O
of O
pre-existing O
anti-AdV O
immunity O
is O
a O
disadvantage O
associated O
with O
them O
[ O
6 O
] O
[ O
7 O
] O
[ O
8 O
] O
. O
Similar O
to O
AdV O
, O
AAV O
can O
infect O
dividing O
and O
non-dividing B-cell_type
cells E-cell_type
and O
has O
broad O
cell O
tropism O
. O
In O
addition O
, O
AAV O
vectors O
also O
provide O
long-term O
transgene O
expression O
, O
however O
, O
they O
may O
require O
host O
genome O
integration O
for O
viral O
gene O
expression O
[ O
9 O
] O
. O
Retrovirus B-DNA
and I-DNA
AAV I-DNA
vectors E-DNA
provide O
long-term O
gene O
expression O
and O
they O
are O
not O
plagued O
with O
pre-existing O
immunity O
. O
However O
, O
their O
package O
size O
is O
limited O
to O
4.5 O
and O
7.5 O
kilobases O
respectively O
[ O
10 O
] O
and O
retroviruses O
are O
associated O
with O
various O
diseases O
, O
e.g. O
, O
leukemia O
, O
lymphoma O
and O
AIDS O
[ O
11 O
, O
12 O
] O
. O
Vectors O
derived O
from O
SeV O
show O
high O
efficiency O
in O
gene O
transfer O
and O
transduce O
both O
dividing B-cell_type
and I-cell_type
non-dividing I-cell_type
cells E-cell_type
[ O
13 O
] O
. O
SeV O
infects O
human B-cell_type
epithelial I-cell_type
cells E-cell_type
efficiently O
and O
can O
therefore O
be O
administered O
intranasally O
. O
This O
reduces O
the O
influence O
of O
pre-existing O
immunity O
compared O
to O
intramuscular O
administration O
[ O
13 O
] O
. O
These O
advantages/benefits O
of O
the O
various O
GMVs O
are O
being O
exploited O
in O
improving O
virus-based O
GM O
vaccines O
, O
while O
efforts O
are O
underway O
to O
reduce O
their O
limitations O
. O
Canine O
cancer O
rates O
are O
similar O
to O
humans O
, O
though O
the O
therapeutic O
options O
might O
be O
limited O
. O
Inducing O
a O
patient O
's O
own O
immune O
system O
to O
have O
an O
anti-tumor O
response O
is O
an O
attractive O
approach O
to O
cancer O
therapy O
. O
In O
this O
safety O
study O
, O
autologous O
tumor O
vaccines O
produced O
specifically O
for O
each O
canine O
patient O
were O
combined O
with O
Advax™ O
, O
a O
novel O
non-inflammatory O
immunomodulator O
and O
vaccine O
adjuvant O
and O
were O
tested O
for O
safety O
in O
a O
diverse O
range O
of O
patient O
presentations O
alone O
or O
in O
combination O
with O
other O
treatments O
. O
Canine O
patients O
had O
their O
tumor O
biopsied O
, O
debulked O
or O
resected O
and O
the O
tumor B-protein
antigens E-protein
were O
processed O
into O
an O
autologous O
vaccine O
formulated O
with O
Advax™ O
adjuvant O
with O
or O
without O
rhizavidin O
as O
an O
additional O
immune O
stimulant O
. O
Patients O
treated O
early O
in O
the O
trial O
received O
two O
intramuscular O
( O
IM O
) O
doses O
, O
2 O
weeks O
apart O
. O
As O
the O
study O
progressed O
and O
no O
issues O
of O
safety O
were O
observed O
, O
the O
protocol O
was O
changed O
to O
weekly O
vaccinations O
for O
4 O
weeks O
followed O
by O
monthly O
booster O
shots O
. O
Over O
the O
150 O
I.M O
injections O
delivered O
to O
date O
, O
the O
vaccine O
was O
found O
to O
be O
very O
safe O
and O
no O
significant O
adverse O
reactions O
were O
observed O
. O
These O
results O
justify O
ongoing O
development O
and O
future O
controlled O
studies O
of O
this O
autologous O
vaccine O
approach O
. O
In O
the O
field O
of O
host-guest O
chemistry O
, O
some O
of O
the O
most O
widely O
used O
hosts O
are O
probably O
cyclodextrins O
( O
CDs O
) O
. O
As O
CDs O
are O
able O
to O
increase O
the O
water O
solubility O
of O
numerous O
drugs O
by O
inclusion O
into O
their O
hydrophobic O
cavity O
, O
they O
have O
been O
widespread O
used O
to O
develop O
numerous O
pharmaceutical O
formulations O
. O
Nevertheless O
, O
CDs S-DNA
are O
also O
able O
to O
interact O
with O
endogenous O
substances O
that O
originate O
from O
an O
organism O
, O
tissue O
or O
cell O
. O
These O
interactions O
can O
be O
useful O
for O
a O
vast O
array O
of O
topics O
including O
cholesterol O
manipulation O
, O
treatment O
of O
Alzheimer O
's O
disease O
, O
control O
of O
pathogens O
, O
etc O
. O
In O
addition O
, O
the O
use O
of O
natural O
CDs O
offers O
the O
great O
advantage O
of O
avoiding O
or O
reducing O
the O
use O
of O
common O
petroleum-sourced O
drugs O
. O
In O
this O
paper O
, O
the O
general O
features O
and O
applications O
of O
CDs S-DNA
have O
been O
reviewed O
as O
well O
as O
their O
interactions O
with O
isolated O
biomolecules O
leading O
to O
the O
formation O
of O
inclusion O
or O
exclusion O
complexes O
. O
Finally O
, O
some O
potential O
medical O
applications O
are O
highlighted O
throughout O
several O
examples O
. O
2644 O
Tuberculosis O
( O
TB O
) O
, O
an O
infectious O
disease O
caused O
by O
Mycobacterium O
tuberculosis O
( O
Mtb O
) O
, O
kills O
5,000 O
people O
per O
day O
globally O
. O
Rapid O
development O
and O
spread O
of O
various O
multi O
drug-resistant O
strains O
of O
Mtb O
emphasize O
that O
an O
effective O
vaccine O
is O
still O
the O
most O
cost-effectives O
and O
efficient O
way O
of O
controlling O
and O
eradicating O
TB O
. O
Bacillus O
Calmette-Guerin O
( O
BCG O
) O
, O
the O
only O
licensed O
TB O
vaccine O
, O
still O
remains O
the O
most O
widely O
administered O
human O
vaccine O
, O
but O
is O
inefficient O
in O
protecting O
from O
pulmonary O
TB O
in O
adults O
. O
The O
protective O
immunity O
afforded O
by O
BCG O
is O
thought O
to O
wane O
with O
time O
and O
considered O
to O
last O
only O
through O
adolescent O
years O
. O
Heterologous O
boosting O
of O
BCG-primed O
immune O
responses O
using O
a O
subunit O
vaccine O
represents O
a O
promising O
vaccination O
approach O
to O
promote O
strong O
cellular O
responses O
against O
Mtb O
. O
In O
our O
earlier O
studies O
, O
we O
discovered O
lipopeptides O
of O
ESAT-6 B-protein
antigen E-protein
with O
strong O
potential O
as O
a O
subunit O
vaccine O
candidate O
. O
Here O
, O
we O
have O
investigated O
that O
potential O
as O
a O
booster O
to O
BCG O
vaccine O
in O
both O
a O
pre-exposure O
preventive O
vaccine O
and O
a O
post-exposure O
therapeutic O
vaccine O
setting O
. O
Surprisingly O
, O
our O
results O
demonstrated O
that O
boosting O
BCG O
with O
subunit O
vaccine O
shortly O
before O
Mtb O
challenge O
did O
not O
improve O
the O
BCG-primed O
immunity O
, O
whereas O
the O
subunit O
vaccine O
boost O
after O
Mtb O
challenge O
markedly O
improved O
the O
quantity O
and O
quality O
of O
effector O
T O
cell O
responses O
and O
significantly O
reduced O
Mtb O
load O
in O
lungs O
, O
liver O
and O
spleen O
in O
mice O
. O
These O
studies O
suggest O
that O
ESAT-6 B-protein
lipopeptide-based I-protein
subunit E-protein
vaccine O
was O
ineffective O
in O
overcoming O
the O
apparent O
immunomodulation O
induced O
by O
BCG O
vaccine O
in O
Mtb O
uninfected O
mice O
, O
but O
upon O
infection O
, O
the O
subunit O
vaccine O
is O
effective O
in O
re-educating O
the O
protective O
immunity O
against O
Mtb O
infection O
. O
These O
important O
results O
have O
significant O
implications O
in O
the O
design O
and O
investigation O
of O
effective O
vaccine O
strategies O
and O
immunotherapeutic O
approaches O
for O
individuals O
who O
have O
been O
pre-immunized O
with O
BCG O
vaccine O
but O
still O
get O
infected O
with O
Mtb O
. O
IL-35 O
, O
a O
relatively O
newly O
discovered O
cytokine S-protein
belonging O
to O
the O
larger O
IL-12 B-protein
family E-protein
, O
shows O
unique O
anti-inflammatory O
properties O
, O
believed O
to O
be O
associated O
with O
dedicated O
receptors O
and O
signaling O
pathways O
. O
IL-35 S-protein
plays O
a O
pivotal O
role O
in O
the O
development O
and O
the O
function O
of O
both O
regulatory B-cell_type
B I-cell_type
( I-cell_type
Bregs I-cell_type
) I-cell_type
and I-cell_type
T I-cell_type
cells E-cell_type
( O
Tregs O
) O
. O
In O
order O
to O
further O
its O
therapeutic O
potential O
, O
a O
dairy O
Lactococcus O
lactis O
strain O
was O
engineered O
to O
express O
murine B-protein
IL-35 E-protein
( O
LL-IL35 S-protein
) O
, O
and O
this O
recombinant O
strain O
was O
applied O
to O
suppress O
collagen-induced O
arthritis O
( O
CIA O
) O
. O
Oral O
administration O
of O
LL-IL35 S-protein
effectively O
reduced O
the O
incidence O
and O
disease O
severity O
of O
CIA O
. O
When O
administered O
therapeutically O
, O
LL-IL35 O
abruptly O
halted O
CIA O
progression O
with O
no O
increase O
in O
disease O
severity O
by O
reducing O
neutrophil S-cell_type
influx O
into O
the O
joints O
. O
LL-IL35 O
treatment O
reduced O
IFN-γ O
and O
IL-17 O
3.7-and O
8.5-fold O
, O
respectively O
, O
and O
increased O
IL-10 S-protein
production O
compared O
to O
diseased O
mice O
. O
Foxp3 S-protein
+ O
and O
Foxp3 B-cell_line
− I-cell_line
CD39 I-cell_line
+ I-cell_line
CD4 I-cell_line
+ I-cell_line
T I-cell_line
cells E-cell_line
were O
previously O
shown O
to O
be O
the O
Tregs O
responsible O
for O
conferring O
protection O
against O
CIA S-protein
. O
Inquiry O
into O
their O
induction O
revealed O
that O
both O
CCR6 B-cell_line
+ I-cell_line
and I-cell_line
CCR6 I-cell_line
− I-cell_line
Foxp3 I-cell_line
+or− I-cell_line
CD39 I-cell_line
+ I-cell_line
CD4 I-cell_line
+ I-cell_line
T I-cell_line
cells E-cell_line
act O
as O
the O
source O
of O
the O
IL-10 S-protein
induced O
by O
LL-IL35 S-protein
. O
Thus O
, O
this O
study O
demonstrates O
the O
feasibility O
and O
benefits O
of O
engineered O
probiotics O
for O
treating O
autoimmune O
diseases O
. O
Background O
: O
Molecular O
assays O
targeted O
to O
nucleic B-protein
acid I-protein
( I-protein
NA I-protein
) I-protein
markers E-protein
are O
becoming O
increasingly O
important O
to O
medical O
diagnostics O
. O
However O
, O
these O
are O
typically O
confined O
to O
wealthy O
, O
developed O
countries O
; O
or O
, O
to O
the O
national O
reference O
laboratories O
of O
developing-world O
countries O
. O
There O
are O
many O
infectious O
diseases O
that O
are O
endemic O
in O
low-resource O
settings O
( O
LRS O
) O
where O
the O
lack O
of O
simple O
, O
instrument-free O
, O
NA O
diagnostic O
tests O
is O
a O
critical O
barrier O
to O
timely O
treatment O
. O
One O
of O
the O
primary O
barriers O
to O
the O
practicality O
and O
availability O
of O
NA O
assays O
in O
LRS O
has O
been O
the O
complexity O
and O
power O
requirements O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
instrumentation O
( O
another O
is O
sample O
preparation O
) O
. O
Methodology/Principal O
Findings O
: O
In O
this O
article O
, O
we O
investigate O
the O
hypothesis O
that O
an O
electricity-free O
heater O
based O
on O
exothermic O
chemical O
reactions O
and O
engineered O
phase O
change O
materials O
can O
successfully O
incubate O
isothermal O
NA O
amplification O
assays O
. O
We O
assess O
the O
heater O
's O
equivalence O
to O
commercially O
available O
PCR O
instruments O
through O
the O
characterization O
of O
the O
temperature O
profiles O
produced O
, O
and O
a O
minimal O
method O
comparison O
. O
Versions O
of O
the O
prototype O
for O
several O
different O
isothermal O
techniques O
are O
presented O
. O
Conclusions/Significance O
: O
We O
demonstrate O
that O
an O
electricity-free O
heater O
based O
on O
exothermic O
chemical O
reactions O
and O
engineered O
phase O
change O
materials O
can O
successfully O
incubate O
isothermal O
NA O
amplification O
assays O
, O
and O
that O
the O
results O
of O
those O
assays O
are O
not O
significantly O
different O
from O
ones O
incubated O
in O
parallel O
in O
commercially O
available O
PCR O
instruments O
. O
These O
results O
clearly O
suggest O
the O
potential O
of O
the O
non-instrumented O
nucleic O
acid O
amplification O
( O
NINA O
) O
heater O
for O
molecular O
diagnostics O
in O
LRS S-cell_line
. O
When O
combined O
with O
other O
innovations O
in O
development O
that O
eliminate O
power O
requirements O
for O
sample O
preparation O
, O
cold O
reagent O
storage O
, O
and O
readout O
, O
the O
NINA O
heater O
will O
comprise O
part O
of O
a O
kit O
that O
should O
enable O
electricity-free O
NA O
testing O
for O
many O
important O
analytes O
. O
Feline O
leukemia O
virus O
( O
FeLV O
) O
and O
feline O
immunodeficiency O
virus O
( O
FIV O
) O
are O
retroviruses O
with O
global O
impact O
on O
the O
health O
of O
domestic O
cats O
. O
The O
two O
viruses O
differ O
in O
their O
potential O
to O
cause O
disease O
. O
FeLV O
is O
more O
pathogenic O
, O
and O
was O
long O
considered O
to O
be O
responsible O
for O
more O
clinical O
syndromes O
than O
any O
other O
agent O
in O
cats O
. O
FeLV O
can O
cause O
tumors O
( O
mainly O
lymphoma O
) O
, O
bone O
marrow O
suppression O
syndromes O
( O
mainly O
anemia O
) O
, O
and O
lead O
to O
secondary O
infectious O
diseases O
caused O
by O
suppressive O
effects O
of O
the O
virus O
on O
bone O
marrow O
and O
the O
immune O
system O
. O
Today O
, O
FeLV O
is O
less O
commonly O
diagnosed O
than O
in O
the O
previous O
20 O
years O
; O
prevalence O
has O
been O
decreasing O
in O
most O
countries O
. O
However O
, O
FeLV O
importance O
may O
be O
underestimated O
as O
it O
has O
been O
shown O
that O
regressively O
infected O
cats O
( O
that O
are O
negative O
in O
routinely O
used O
FeLV O
tests O
) O
also O
can O
develop O
clinical O
signs O
. O
FIV O
can O
cause O
an O
acquired O
immunodeficiency O
syndrome O
that O
increases O
the O
risk O
of O
opportunistic O
infections O
, O
neurological O
diseases O
, O
and O
tumors O
. O
In O
most O
naturally O
infected O
cats O
, O
however O
, O
FIV O
itself O
does O
not O
cause O
severe O
clinical O
signs O
, O
and O
FIV-infected O
cats O
may O
live O
many O
years O
without O
any O
health O
problems O
. O
This O
article O
provides O
a O
review O
of O
clinical O
syndromes O
in O
progressively O
and O
regressively O
FeLV-infected O
cats O
as O
well O
as O
in O
FIV-infected O
cats O
. O
Frontiers O
in O
Microbiology O
| O
www.frontiersin.org O
Frontiers O
in O
Microbiology O
| O
www.frontiersin.org O
AN O
, O
KK O
and O
GCA O
contributed O
to O
the O
design O
, O
experimentation O
, O
and O
analysis O
of O
the O
study O
, O
drafted O
, O
edited O
, O
improved O
, O
and O
finalized O
the O
manuscript O
. O
Patients O
with O
severe O
viral O
infections O
are O
often O
hospitalized O
in O
intensive O
care O
units O
( O
ICUs O
) O
and O
recent O
studies O
underline O
the O
frequency O
of O
viral O
detection O
in O
ICU O
patients O
. O
Viral O
infections O
in O
the O
ICU O
often O
involve O
the O
respiratory O
or O
the O
central O
nervous O
system O
and O
can O
cause O
significant O
morbidity O
and O
mortality O
especially O
in O
immunocompromised O
patients O
. O
The O
mainstay O
of O
therapy O
of O
viral O
infections O
is O
supportive O
care O
and O
antiviral O
therapy O
when O
available O
. O
Increased O
understanding O
of O
the O
molecular O
mechanisms O
of O
viral O
infection O
has O
provided O
great O
potential O
for O
the O
discovery O
of O
new O
antiviral O
agents O
that O
target B-protein
viral I-protein
proteins E-protein
or O
host O
proteins O
that O
regulate O
immunity O
and O
are O
involved O
in O
the O
viral O
life O
cycle O
. O
These O
novel O
treatments O
need O
to O
be O
further O
validated O
in O
animal O
and O
human O
randomized O
controlled O
studies O
. O
We O
have O
previously O
demonstrated O
that O
3-hydroxyphthalic B-cell_line
anhydride I-cell_line
( I-cell_line
3HP I-cell_line
) I-cell_line
-modified I-cell_line
bovine I-cell_line
beta-lactoglobulin E-cell_line
( O
3HP-β-LG O
) O
is O
highly O
effective O
in O
inhibiting O
entry O
of O
pseudovirus O
( O
PsV O
) O
of O
high-and O
low-risk O
human O
papillomavirus O
( O
HPV O
) O
into O
the O
target O
cell O
. O
Intravaginally O
applied O
3HP-β-LG-containing O
vaginal O
gel O
could O
significantly O
inhibit O
HPV O
infection O
and O
reduce O
viral O
load O
in O
the O
cervical O
region O
. O
However O
, O
we O
still O
do O
not O
understand O
the O
underlying O
molecular O
mechanism O
by O
which O
3HP-β-LG S-protein
is O
able O
to O
inhibit O
HPV O
infection O
. O
Here O
, O
though O
, O
we O
showed O
that O
3HP-β-LG S-protein
did O
not O
inactivate O
HPV O
PsV O
, O
but O
rather O
blocked O
entry O
of O
HPV O
PsV O
into O
the O
target O
cell O
via O
its O
interaction O
with O
virus O
, O
not O
cell O
. O
It O
bound O
to O
the O
positively O
charged O
region O
in O
the O
HPV B-protein
L1 I-protein
protein E-protein
, O
suggesting O
that O
3HP-β-LG S-protein
binds O
to O
HPV B-protein
L1 I-protein
protein E-protein
through O
the O
interaction O
between O
the O
negatively O
charged O
region O
in O
3HP-β-LG S-protein
and O
the O
positively O
charged O
region O
in O
HPV B-protein
L1 I-protein
protein E-protein
, O
thus O
competitively O
blocking O
the O
binding O
of O
HPV O
to O
the O
receptor O
on O
the O
basement O
membrane O
in O
vaginal O
mucosa O
. O
Although O
3HP-modified B-protein
chicken I-protein
ovalbumin E-protein
( O
3HP-OVA S-protein
) O
also O
carries O
high O
net O
negative O
charges O
, O
it O
exhibited O
no O
anti-HPV S-protein
activity O
, O
suggesting O
that O
the O
interaction O
between O
3HP-modified B-protein
protein E-protein
and O
HPV B-protein
L1 I-protein
protein E-protein
relies O
on O
both O
electrostatic O
and O
matchable O
conformation O
of O
the O
binding O
sites O
in O
both O
proteins O
. O
When O
topically O
applied O
, O
3HP-β-LG O
did O
not O
enter O
the O
host O
cell O
or O
blood O
circulation O
. O
These O
findings O
suggest O
that O
3HP-β-LG O
targets O
HPV B-protein
L1 I-protein
protein E-protein
and O
blocks O
HPV O
entry O
into O
the O
host O
cell O
, O
thus O
being O
safe O
and O
effective O
for O
topical O
application O
in O
the O
treatment O
of O
HPV O
infection O
. O
Background O
: O
Respiratory O
tract O
infections O
( O
RTIs O
) O
are O
the O
most O
common O
illness O
in O
children O
, O
and O
rapid O
diagnosis O
is O
required O
for O
the O
optimal O
management O
of O
RTIs O
, O
especially O
severe O
infections O
. O
Methods O
: O
Nasopharyngeal O
swab O
or O
sputum O
specimens O
were O
collected O
from O
children O
aged O
19 O
days O
to O
15 O
years O
who O
were O
admitted O
to O
a O
hospital O
in O
Shanghai O
and O
diagnosed O
with O
RTIs O
. O
The O
specimens O
were O
tested O
with O
the O
FilmArray O
Respiratory O
Panel O
, O
a O
multiplex O
PCR O
assay O
that O
detects O
16 O
viruses O
, O
Mycoplasma O
pneumoniae O
( O
M. O
pneumoniae O
) O
, O
Bordetella O
pertussis O
( O
B. O
pertussis O
) O
and O
Chlamydophila O
pneumoniae O
( O
C. O
pneumoniae O
) O
. O
Results O
: O
Among O
the O
775 O
children O
studied O
, O
626 O
( O
80.8 O
% O
, O
626/775 O
) O
tested O
positive O
for O
at O
least O
one O
organism O
, O
and O
multiple O
organisms O
were O
detected O
in O
198 O
( O
25.5 O
% O
) O
. O
Rhinoviruses/enteroviruses O
( O
25.5 O
% O
, O
198/775 O
) O
were O
detected O
most O
often O
, O
followed O
by O
respiratory O
syncytial O
virus O
( O
19.5 O
% O
, O
151/775 O
) O
, O
parainfluenza O
virus O
3 O
( O
14.8 O
% O
, O
115/775 O
) O
, O
influenza O
A O
or O
B O
( O
10.9 O
% O
) O
, O
adenovirus O
( O
10.8 O
% O
) O
, O
M. O
pneumoniae O
( O
10.6 O
% O
) O
and O
B. O
pertussis O
( O
6.3 O
% O
) O
. O
The O
prevalence O
of O
organisms O
differed O
by O
age O
, O
and O
most O
of O
the O
viruses O
were O
more O
common O
in O
winter O
. O
Of O
the O
140 O
children O
suspected O
of O
having O
pertussis O
, O
35.0 O
% O
( O
49/140 O
) O
tested O
positive O
for O
B. O
pertussis O
. O
Conclusions O
: O
FilmArray O
RP O
allows O
the O
rapid O
simultaneous O
detection O
of O
a O
wide O
number O
of O
respiratory O
organisms O
, O
with O
limited O
hands-on O
time O
, O
in O
Chinese O
pediatric O
patients O
with O
RTIs O
. O
The O
incorporation O
of O
the O
envelope B-protein
glycoprotein I-protein
complex E-protein
( O
Env S-protein
) O
onto O
the O
developing O
particle O
is O
a O
crucial O
step O
in O
the O
HIV-1 O
lifecycle O
. O
The O
long B-protein
cytoplasmic I-protein
tail E-protein
( O
CT O
) O
of O
Env S-protein
is O
required O
for O
the O
incorporation O
of O
Env S-protein
onto O
HIV O
particles O
in O
T B-cell_type
cells E-cell_type
and O
macrophages S-cell_type
. O
Here O
we O
identify O
the O
Rab11a-FIP1C/RCP B-protein
protein E-protein
as O
an O
essential O
cofactor O
for O
HIV-1 O
Env S-protein
incorporation O
onto O
particles O
in O
relevant O
human B-cell_type
cells E-cell_type
. O
Depletion O
of O
FIP1C S-protein
reduced O
Env S-protein
incorporation O
in O
a O
cytoplasmic O
tail-dependent O
manner O
, O
and O
was O
rescued O
by O
replenishment O
of O
FIP1C S-protein
. O
FIP1C S-protein
was O
redistributed O
out O
of O
the O
endosomal B-protein
recycling I-protein
complex E-protein
to O
the O
plasma O
membrane O
by O
wild B-protein
type I-protein
Env I-protein
protein E-protein
but O
not O
by O
CT-truncated O
Env S-protein
. O
Rab14 S-protein
was O
required O
for O
HIV-1 O
Env S-protein
incorporation O
, O
and O
FIP1C B-protein
mutants E-protein
incapable O
of O
binding B-protein
Rab14 E-protein
failed O
to O
rescue O
Env S-protein
incorporation O
. O
Expression O
of O
FIP1C S-protein
and O
Rab14 S-protein
led O
to O
an O
enhancement O
of O
Env S-protein
incorporation O
, O
indicating O
that O
these O
trafficking B-protein
factors E-protein
are O
normally O
limiting O
for O
CT-dependent O
Env S-protein
incorporation O
onto O
particles O
. O
These O
findings O
support O
a O
model O
for O
HIV-1 O
Env S-protein
incorporation O
in O
which O
specific O
targeting O
to O
the O
particle O
assembly O
microdomain O
on O
the O
plasma O
membrane O
is O
mediated O
by O
FIP1C S-protein
and O
Rab14 S-protein
. O
Citation O
: O
Qi O
M O
, O
Williams O
JA O
, O
Chu O
H O
, O
Chen O
X O
, O
Wang O
J-J O
, O
et O
al O
. O
( O
2013 O
) O
Rab11-FIP1C O
and O
Rab14 S-protein
Direct O
Plasma O
Membrane O
Sorting O
and O
Particle O
Incorporation O
of O
the O
HIV-1 B-protein
Envelope I-protein
Glycoprotein I-protein
Complex E-protein
. O
PLoS O
Pathog O
9 O
( O
4 O
) O
: O
e1003278 O
. O
In O
the O
global O
eradication O
program O
for O
poliomyelitis O
, O
the O
laboratory O
diagnosis O
plays O
a O
critical O
role O
by O
isolating O
poliovirus O
( O
PV O
) O
from O
the O
stool O
samples O
of O
acute O
flaccid O
paralysis O
( O
AFP O
) O
cases O
. O
In O
this O
study O
, O
we O
developed O
a O
reverse O
transcription-loop-mediated O
isothermal O
amplification O
( O
RT-LAMP O
) O
system O
for O
a O
rapid O
and O
highly O
sensitive O
detection O
of O
enterovirus O
including O
PV O
to O
identify O
stool O
samples O
positive O
for O
enterovirus O
including O
PV O
. O
A O
primer O
set O
was O
designed O
for O
RT-LAMP O
to O
detect O
enterovirus O
preferably O
those O
with O
PV-like O
5'NTRs O
of O
the O
viral B-DNA
genome E-DNA
. O
The O
sensitivity O
of O
RT-LAMP O
system O
was O
evaluated O
with O
prototype O
strains O
of O
enterovirus O
. O
Detection O
of O
enterovirus O
from O
stool O
extracts O
was O
examined O
by O
using O
RT-LAMP O
system O
. O
We O
detected O
at O
least O
400 O
copies O
of O
the O
viral B-DNA
genomes E-DNA
of O
PV O
( O
Sabin O
) O
strains O
within O
90 O
min O
by O
RT-LAMP O
with O
the O
primer O
set O
. O
This O
RT-LAMP O
system O
showed O
a O
preference O
for O
Human O
enterovirus O
species O
C O
( O
HEV-C O
) O
strains O
including O
PV O
, O
but O
exhibited O
less O
sensitivity O
to O
the O
prototype O
strains O
of O
HEV-A O
and O
HEV-B O
( O
detection O
limits O
of O
7,400 O
to O
28,000 O
copies O
) O
. O
Stool O
extracts O
, O
from O
which O
PV O
, O
HEV-C O
, O
or O
HEV-A O
was O
isolated O
in O
the O
cell O
culture O
system O
, O
were O
mostly O
positive O
by O
RT-LAMP O
method O
( O
positive O
rates O
of O
15/16 O
( O
= O
94 O
% O
) O
, O
13/ O
14 O
( O
= O
93 O
% O
) O
, O
and O
4/4 O
( O
= O
100 O
% O
) O
, O
respectively O
) O
. O
The O
positive O
rate O
of O
this O
RT-LAMP O
system O
for O
stool O
extracts O
from O
which O
HEV-B O
was O
isolated O
was O
lower O
than O
that O
of O
HEV-C O
( O
positive O
rate O
of O
11/21 O
( O
= O
52 O
% O
) O
) O
. O
In O
the O
stool O
samples O
, O
which O
were O
negative O
for O
enterovirus O
isolation O
by O
the O
cell O
culture O
system O
, O
we O
found O
that O
two O
samples O
were O
positive O
for O
RT-LAMP O
( O
positive O
rates O
of O
2/38 O
( O
= O
5.3 O
% O
) O
) O
. O
In O
these O
samples O
, O
enterovirus O
96 O
was O
identified O
by O
sequence O
analysis O
utilizing O
a O
seminested O
PCR O
system O
. O
Conclusions O
: O
RT-LAMP O
system O
developed O
in O
this O
study O
showed O
a O
high O
sensitivity O
comparable O
to O
that O
of O
the O
cell O
culture O
system O
for O
the O
detection O
of O
PV O
, O
HEV-A O
, O
and O
HEV-C O
, O
but O
less O
sensitivity O
to O
HEV-B O
. O
This O
RT-LAMP O
system O
would O
be O
useful O
for O
the O
direct O
detection O
of O
enterovirus O
from O
the O
stool O
extracts O
. O
Purpose O
. O
Irreversible O
electroporation O
( O
IRE S-DNA
) O
has O
been O
demonstrated O
to O
be O
a O
safe O
and O
effective O
method O
for O
locally O
advanced O
pancreatic O
cancer O
( O
LAPC O
) O
. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
immunomodulatory O
effect O
after O
IRE S-DNA
and O
to O
evaluate O
the O
prognostic O
value O
of O
variations O
of O
the O
immune O
parameters O
in O
LAPC O
patients O
after O
IRE S-DNA
. O
Methods O
. O
Peripheral O
blood O
samples O
of O
34 O
patients O
were O
obtained O
preoperatively O
and O
on O
the O
third O
day O
( O
D3 O
) O
and O
seventh O
day O
( O
D7 O
) O
after O
IRE S-DNA
, O
respectively O
. O
The O
phenotypes O
of O
lymphocytes S-cell_type
were O
analyzed O
by O
flow O
cytometry O
, O
and O
dynamic O
changes O
of O
serum O
levels O
of O
cytokines S-protein
, O
complement O
, O
and O
immunoglobulin S-protein
were O
assayed O
by O
enzyme-linked O
immunosorbent O
assay O
. O
Receiver O
operating O
characteristic O
( O
ROC O
) O
curve O
and O
concordance O
index O
( O
C-index O
) O
were O
used O
to O
compare O
the O
survival O
predictive O
ability O
. O
Results O
. O
There O
was O
a O
transitory O
decrease O
followed O
by O
a O
steady O
increase O
for O
CD4 S-protein
+ O
T B-cell_type
cell E-cell_type
, O
CD8 S-protein
+ O
T B-cell_type
cell E-cell_type
, O
NK B-cell_type
cell E-cell_type
, O
IL-2 S-protein
, O
C3 S-protein
, O
C4 S-protein
, O
and O
IgG S-protein
while O
a O
reverse O
trend O
was O
detected O
for O
Treg B-cell_line
cell E-cell_line
, O
IL-6 S-protein
, O
and O
IL10 S-protein
after O
IRE S-DNA
. O
The O
alteration O
of O
CD8 S-protein
+ O
T O
cell O
between O
D3 O
and O
D7 O
was O
identified O
as O
a O
prognostic O
factor O
for O
both O
overall O
survival O
( O
OS O
) O
and O
progression-free O
survival O
( O
PFS O
) O
. O
The O
values O
of O
ROC O
curve O
( O
AUC O
) O
and O
C-indexes O
of O
the O
alteration O
of O
CD8 S-protein
+ O
T O
cell O
for O
OS O
and O
PFS O
were O
0.816 O
and O
0.773 O
and O
0.816 O
and O
0.639 O
, O
respectively O
, O
which O
were O
larger O
than O
those O
of O
other O
immune O
or O
inflammation-based O
indexes O
. O
Conclusions O
. O
This O
study O
presented O
the O
first O
evidence O
of O
IRE-based O
immunomodulatory O
in O
patients O
with O
LAPC O
. O
The O
alteration O
of O
CD8 S-protein
+ O
T O
cell O
between O
D3 O
and O
D7 O
showed O
relatively O
good O
performance O
and O
could O
be O
used O
as O
an O
effective O
tool O
for O
prognostic O
evaluation O
for O
LAPC O
patients O
after O
IRE S-DNA
. O
Background O
: O
'One O
Health O
' O
represents O
a O
call O
for O
health O
researchers O
and O
practitioners O
at O
the O
human O
, O
animal O
and O
environmental O
interfaces O
to O
work O
together O
to O
mitigate O
the O
risks O
of O
emerging O
and O
re-emerging O
infectious O
diseases O
( O
EIDs O
) O
. O
A O
One O
Health O
approach O
emphasizing O
inter-disciplinary O
co-operation O
is O
increasingly O
seen O
as O
necessary O
for O
effective O
EID O
control O
and O
prevention O
. O
There O
are O
, O
however O
, O
socio-political O
, O
ethical O
and O
legal O
challenges O
, O
which O
must O
be O
met O
by O
such O
a O
One O
Health O
approach O
. O
Discussion O
: O
Based O
on O
the O
philosophical O
review O
and O
critical O
analysis O
of O
scholarship O
around O
the O
theory O
and O
practice O
of O
One O
Health O
it O
is O
clear O
that O
EID O
events O
are O
not O
simply O
about O
pathogens O
jumping O
species O
barriers O
; O
they O
are O
comprised O
of O
complex O
and O
contingent O
sets O
of O
relations O
that O
involve O
socioeconomic O
and O
socio-political O
drivers O
and O
consequences O
with O
the O
latter O
extending O
beyond O
the O
impact O
of O
the O
disease O
. O
Therefore O
, O
the O
effectiveness O
of O
policies O
based O
on O
One O
Health O
depends O
on O
their O
implementation O
and O
alignment O
with O
or O
modification O
of O
public O
values O
. O
Summary O
: O
Despite O
its O
strong O
motivating O
rationale O
, O
implementing O
a O
One O
Health O
approach O
in O
an O
integrated O
and O
considered O
manner O
can O
be O
challenging O
, O
especially O
in O
the O
face O
of O
a O
perceived O
crisis O
. O
The O
effective O
control O
and O
prevention O
of O
EIDs O
therefore O
requires O
: O
( O
i O
) O
social O
science O
research O
to O
improve O
understanding O
of O
how O
EID O
threats O
and O
responses O
play O
out O
; O
( O
ii O
) O
the O
development O
of O
an O
analytic O
framework O
that O
catalogues O
case O
experiences O
with O
EIDs O
, O
reflects O
their O
dynamic O
nature O
and O
promotes O
inter-sectoral O
collaboration O
and O
knowledge O
synthesis O
; O
( O
iii O
) O
genuine O
public O
engagement O
processes O
that O
promote O
transparency O
, O
education O
and O
capture O
people O
's O
preferences O
; O
( O
iv O
) O
a O
set O
of O
practical O
principles O
and O
values O
that O
integrate O
ethics O
into O
decision-making O
procedures O
, O
against O
which O
policies O
and O
public O
health O
responses O
can O
be O
assessed O
; O
( O
v O
) O
integration O
of O
the O
analytic O
framework O
and O
the O
statement O
of O
principles O
and O
values O
outlined O
above O
; O
and O
( O
vi O
) O
a O
focus O
on O
genuine O
reform O
rather O
than O
rhetoric O
. O
Background O
: O
Feline O
infectious O
peritonitis O
( O
FIP O
) O
is O
considered O
highly O
fatal O
in O
its O
naturally O
occurring O
form O
, O
although O
up O
to O
36 O
% O
of O
cats O
resist O
disease O
after O
experimental O
infection O
, O
suggesting O
that O
cats O
in O
nature O
may O
also O
resist O
development O
of O
FIP O
in O
the O
face O
of O
infection O
with O
FIP O
virus O
( O
FIPV O
) O
. O
Previous O
experimental O
FIPV O
infection O
studies O
suggested O
a O
role O
for O
cellmediated O
immunity O
in O
resistance O
to O
development O
of O
FIP O
. O
This O
experimental O
FIPV O
infection O
study O
in O
specific O
pathogen O
free O
( O
SPF O
) O
kittens O
describes O
longitudinal O
antiviral O
T O
cell O
responses O
and O
clinical O
outcomes O
ranging O
from O
rapid O
progression O
, O
slow O
progression O
, O
and O
resistance O
to O
disease O
. O
Results O
: O
Differences O
in O
disease O
outcome O
provided O
an O
opportunity O
to O
investigate O
the O
role O
of O
T O
cell O
immunity O
to O
FIP S-protein
determined O
by O
T O
cell O
subset O
proliferation O
after O
stimulation O
with O
different O
viral B-protein
antigens E-protein
. O
Reduced O
total O
white O
blood O
cell O
( O
WBC S-cell_type
) O
, O
lymphocyte S-cell_type
and O
T O
cell O
counts O
in O
blood O
were O
observed O
during O
primary O
acute O
infection O
for O
all O
experimental O
groups O
including O
cats O
that O
survived O
without O
clinical O
FIP O
. O
Antiviral O
T O
cell O
responses O
during O
early O
primary O
infection O
were O
also O
similar O
between O
cats O
that O
developed O
FIP O
and O
cats O
remaining O
healthy O
. O
Recovery O
of O
antiviral O
T O
cell O
responses O
during O
the O
later O
phase O
of O
acute O
infection O
was O
observed O
in O
a O
subset O
of O
cats O
that O
survived O
longer O
or O
resisted O
disease O
compared O
to O
cats O
showing O
rapid O
disease O
progression O
. O
More O
robust O
T O
cell O
responses O
at O
terminal O
time O
points O
were O
observed O
in O
lymph O
nodes O
compared O
to O
blood O
in O
cats O
that O
developed O
FIP O
. O
Cats O
that O
survived O
primary O
infection O
were O
challenged O
a O
second O
time O
to O
pathogenic O
FIPV O
and O
tested O
for O
antiviral O
T O
cell O
responses O
over O
a O
four O
week O
period O
. O
Nine O
of O
ten O
rechallenged O
cats O
did O
not O
develop O
FIP O
or O
T O
cell O
depletion O
and O
all O
cats O
demonstrated O
antiviral O
T O
cell O
responses O
at O
multiple O
time O
points O
after O
rechallenge O
. O
Conclusions O
: O
In O
summary O
, O
definitive O
adaptive O
T O
cell O
responses O
predictive O
of O
disease O
outcome O
were O
not O
detected O
during O
the O
early O
phase O
of O
primary O
FIPV O
infection O
. O
However O
emergence O
of O
antiviral O
T O
cell O
responses O
after O
a O
second O
exposure O
to O
FIPV S-protein
, O
implicated O
cellular O
immunity O
in O
the O
control O
of O
FIPV O
infection O
and O
disease O
progression O
. O
Virus O
host O
interactions O
during O
very O
early O
stages O
of O
FIPV O
infection O
warrant O
further O
investigation O
to O
elucidate O
host O
resistance O
to O
FIP O
. O
Coronaviruses O
infect O
animals O
and O
humans O
causing O
a O
wide O
range O
of O
diseases O
. O
The O
diversity O
of O
coronaviruses O
in O
many O
mammalian O
species O
is O
contributed O
by O
relatively O
high O
mutation O
and O
recombination O
rates O
during O
replication O
. O
This O
dynamic O
nature O
of O
coronaviruses O
may O
facilitate O
cross-species O
transmission O
and O
shifts O
in O
tissue O
or O
cell O
tropism O
in O
a O
host O
, O
resulting O
in O
substantial O
change O
in O
virulence O
. O
Feline O
enteric O
coronavirus O
( O
FECV O
) O
causes O
inapparent O
or O
mild O
enteritis O
in O
cats O
, O
but O
a O
highly O
fatal O
disease O
, O
called O
feline O
infectious O
peritonitis O
( O
FIP O
) O
, O
can O
arise O
through O
mutation O
of O
FECV O
to O
FIP O
virus O
( O
FIPV O
) O
. O
The O
pathogenesis O
of O
FIP S-protein
is O
intimately O
associated O
with O
immune O
responses O
and O
involves O
depletion O
of O
T B-cell_type
cells E-cell_type
, O
features O
shared O
by O
some O
other O
coronaviruses O
like O
Severe O
Acute O
Respiratory O
Syndrome O
Coronavirus O
. O
The O
increasing O
risks O
of O
highly O
virulent O
coronavirus O
infections O
in O
humans O
or O
animals O
call O
for O
effective O
antiviral O
drugs O
, O
but O
no O
such O
measures O
are O
yet O
available O
. O
Previously O
, O
we O
have O
reported O
the O
inhibitors O
that O
target O
3C-like B-protein
protease E-protein
( O
3CLpro O
) O
with O
broad-spectrum O
activity O
against O
important O
human O
and O
animal O
coronaviruses O
. O
Here O
, O
we O
evaluated O
the O
therapeutic O
efficacy O
of O
our O
3CLpro O
inhibitor O
in O
laboratory O
cats O
with O
FIP O
. O
Experimental O
FIP O
is O
100 O
% O
fatal O
once O
certain O
clinical O
and O
laboratory O
signs O
become O
apparent O
. O
We O
found O
that O
antiviral O
treatment O
led O
to O
full O
recovery O
of O
cats O
when O
treatment O
was O
started O
at O
a O
stage O
of O
disease O
that O
would O
be O
otherwise O
fatal O
if O
left O
untreated O
. O
Antiviral O
treatment O
was O
associated O
with O
a O
rapid O
improvement O
in O
fever O
, O
ascites O
, O
lymphopenia O
and O
gross O
signs O
of O
illness O
and O
cats O
returned O
to O
normal O
health O
within O
20 O
days O
or O
less O
of O
treatment O
. O
Significant O
reduction O
in O
viral O
titers O
was O
also O
observed O
in O
cats O
. O
These O
results O
indicate O
that O
continuous O
virus O
replication O
is O
required O
for O
progression O
of O
immune-mediated O
inflammatory O
disease O
of O
FIP O
. O
These O
findings O
may O
provide O
important O
insights O
into O
devising O
therapeutic O
strategies O
and O
selection O
of O
antiviral O
compounds O
for O
further O
development O
for O
important O
coronaviruses O
in O
animals O
and O
humans O
. O
Precise O
dating O
of O
viral O
subtype O
divergence O
enables O
researchers O
to O
correlate O
divergence O
with O
geographic O
and O
demographic O
occurrences O
. O
When O
historical O
data O
are O
absent O
( O
that O
is O
, O
the O
overwhelming O
majority O
) O
, O
viral O
sequence O
sampling O
on O
a O
time O
scale O
commensurate O
with O
the O
rate O
of O
substitution O
permits O
the O
inference O
of O
the O
times O
of O
subtype O
divergence O
. O
Currently O
, O
researchers O
use O
two O
strategies O
to O
approach O
this O
task O
, O
both O
requiring O
strong O
conditions O
on O
the O
molecular O
clock O
assumption O
of O
substitution O
rate O
. O
As O
the O
underlying O
structure O
of O
the O
substitution O
rate O
process O
at O
the O
time O
of O
subtype O
divergence O
is O
not O
understood O
and O
likely O
highly O
variable O
, O
we O
present O
a O
simple O
method O
that O
estimates O
rates O
of O
substitution O
, O
and O
from O
there O
, O
times O
of O
divergence O
, O
without O
use O
of O
an O
assumed O
molecular O
clock O
. O
We O
accomplish O
this O
by O
blending O
estimates O
of O
the O
substitution O
rate O
for O
triplets O
of O
dated O
sequences O
where O
each O
sequence O
draws O
from O
a O
distinct O
viral O
subtype O
, O
providing O
a O
zerothorder O
approximation O
for O
the O
rate O
between O
subtypes O
. O
As O
an O
example O
, O
we O
calculate O
the O
time O
of O
divergence O
for O
three O
genes O
among O
influenza O
subtypes O
A-H3N2 O
and O
B O
using O
subtype O
C O
as O
an O
outgroup O
. O
We O
show O
a O
time O
of O
divergence O
approximately O
100 O
years O
ago O
, O
substantially O
more O
recent O
than O
previous O
estimates O
which O
range O
from O
250 O
to O
3800 O
years O
ago O
. O
Background O
: O
Influenza O
is O
an O
acute O
respiratory O
infectious O
disease O
with O
a O
high O
incidence O
rate O
in O
the O
Chinese O
army O
, O
which O
directly O
disturbs O
military O
training O
and O
affects O
soldiers O
' O
health O
. O
Influenza O
surveillance O
systems O
are O
widely O
used O
around O
the O
world O
and O
play O
an O
important O
role O
in O
influenza O
epidemic O
prevention O
and O
control O
. O
Methods O
: O
As O
a O
theater O
centers O
for O
disease O
prevention O
and O
control O
, O
we O
established O
an O
influenza O
monitoring O
platform O
( O
IMP O
) O
in O
2014 O
to O
strengthen O
the O
monitoring O
of O
influenza-like O
illness O
and O
influenza O
virus O
infection O
. O
In O
this O
study O
, O
we O
introduced O
the O
constitution O
, O
influenza O
virus O
detection O
, O
and O
quality O
control O
for O
an O
IMP S-DNA
. O
The O
monitoring O
effect O
was O
also O
evaluated O
by O
comparing O
the O
monitoring O
data O
with O
data O
from O
national O
influenza O
surveillance O
systems O
. O
The O
experiences O
and O
problems O
associated O
with O
the O
platform O
also O
were O
summarized O
. O
Results O
: O
A O
theater O
IMP O
was O
established O
based O
on O
3 O
levels O
of O
medical O
units O
, O
including O
monitoring O
sites O
, O
testing O
laboratories O
and O
a O
checking O
laboratory O
. O
A O
series O
of O
measures O
were O
taken O
to O
guarantee O
the O
quality O
of O
monitoring O
, O
such O
as O
technical O
training O
, O
a O
unified O
process O
, O
sufficient O
supervision O
and O
timely O
communication O
. O
The O
platform O
has O
run O
smoothly O
for O
3 O
monitoring O
years O
to O
date O
. O
In O
the O
2014-2015 O
and O
2016-2017 O
monitoring O
years O
, O
sample O
amount O
coincided O
with O
that O
obtained O
from O
the O
National O
Influenza O
Surveillance O
program O
. O
In O
the O
2015-2016 O
monitoring O
year O
, O
due O
to O
the O
strict O
prevention O
and O
control O
measures O
, O
an O
influenza O
epidemic O
peak O
was O
avoided O
in O
monitoring O
units O
, O
and O
the O
monitoring O
data O
did O
not O
coincide O
with O
that O
of O
the O
National O
Influenza O
Surveillance O
program O
. O
Several O
problems O
, O
including O
insufficient O
attention O
, O
unreasonable O
administrative O
intervention O
or O
subordination O
relationships O
, O
and O
the O
necessity O
of O
detection O
in O
monitoring O
sites O
were O
still O
observed O
. O
Conclusions O
: O
A O
theater O
IMP O
was O
established O
rationally O
and O
played O
a O
deserved O
role O
in O
the O
prevention O
and O
control O
of O
influenza O
. O
However O
, O
several O
problems O
remain O
to O
be O
solved O
. O
We O
report O
the O
first O
imported O
case O
of O
Rift O
Valley O
fever O
( O
RVF O
) O
in O
China O
. O
The O
patient O
returned O
from O
Angola O
, O
a O
non-epidemic O
country O
, O
with O
an O
infection O
of O
a O
new O
reassortant O
from O
different O
lineages O
of O
Rift O
Valley O
fever O
viruses O
( O
RVFVs O
) O
. O
The O
patient O
developed O
multiorgan O
dysfunction O
and O
gradually O
recovered O
with O
continuous O
renal O
replacement O
therapy O
and O
a O
short O
regimen O
of O
methylprednisolone O
treatment O
. O
The O
disordered O
cytokines S-protein
and O
chemokines S-protein
in O
the O
plasma O
of O
the O
patient O
revealed O
hypercytokinemia O
, O
but O
the O
levels O
of O
protective O
cytokines S-protein
were O
low O
upon O
admission O
and O
fluctuated O
as O
the O
disease O
improved O
. O
Whole-genome O
sequencing O
and O
phylogenetic O
analysis O
revealed O
that O
the O
imported O
strain O
was O
a O
reassortant O
comprising O
the O
L B-DNA
and I-DNA
M I-DNA
genes E-DNA
from O
lineage O
E O
and O
the O
S B-DNA
gene E-DNA
from O
lineage O
A O
. O
This O
case O
highlights O
that O
RVFV O
had O
undergone O
genetic O
reassortment O
, O
which O
could O
potentially O
alter O
its O
biological O
properties O
, O
cause O
large O
outbreaks O
and O
pose O
a O
serious O
threat O
to O
global O
public O
health O
as O
well O
as O
the O
livestock O
breeding O
industry O
. O
The O
state O
of O
antileishmanial O
chemotherapy O
is O
strongly O
compromised O
by O
the O
emergence O
of O
drug-resistant O
Leishmania O
. O
The O
evolution O
of O
drug-resistant O
phenotypes O
has O
been O
linked O
to O
the O
parasites O
' O
intrinsic O
genome O
instability O
, O
with O
frequent O
gene O
and O
chromosome O
amplifications O
causing O
fitness O
gains O
that O
are O
directly O
selected O
by O
environmental O
factors O
, O
including O
the O
presence O
of O
antileishmanial O
drugs O
. O
Thus O
, O
even O
though O
the O
unique O
eukaryotic O
biology O
of O
Leishmania O
and O
its O
dependence O
on O
parasite-specific B-protein
virulence I-protein
factors E-protein
provide O
valid O
opportunities O
for O
chemotherapeutical O
intervention O
, O
all O
strategies O
that O
target O
the O
parasite O
in O
a O
direct O
fashion O
are O
likely O
prone O
to O
select O
for O
resistance O
. O
Here O
, O
we O
review O
the O
current O
state O
of O
antileishmanial O
chemotherapy O
and O
discuss O
the O
limitations O
of O
ongoing O
drug O
discovery O
efforts O
. O
We O
finally O
propose O
new O
strategies O
that O
target O
Leishmania O
viability O
indirectly O
via O
mechanisms O
of O
host-parasite O
interaction O
, O
including O
parasite-released O
ectokinases O
and O
host O
epigenetic O
regulation O
, O
which O
modulate O
host O
cell O
signaling O
and O
transcriptional O
regulation O
, O
respectively O
, O
to O
establish O
permissive O
conditions O
for O
intracellular O
Leishmania O
survival O
. O
Leishmania O
has O
evolved O
mechanisms O
to O
subvert O
both O
innate O
and O
adaptive O
immune O
responses O
that O
cause O
immune O
dysregulation O
and O
the O
pathologies O
characteristic O
of O
CL O
and O
VL O
and O
ultimately O
allow O
parasite O
proliferation O
and O
persistent O
infection O
inside O
the O
mammalian O
host O
[ O
8 O
] O
[ O
9 O
] O
[ O
10 O
] O
. O
Surprisingly O
, O
even O
though O
it O
is O
very O
well O
established O
that O
Leishmania O
reprograms O
its O
host O
cell O
to O
subvert O
the O
immune O
response O
and O
to O
meet O
the O
nutritional O
and O
metabolic O
needs O
for O
intracellular O
parasite O
survival O
and O
proliferation O
[ O
11 O
, O
12 O
] O
, O
there O
is O
only O
little O
effort O
to O
exploit O
these O
crucial O
effects O
of O
the O
parasite O
on O
the O
host O
cell O
for O
antiparasitic O
drug O
discovery O
. O
Here O
, O
we O
review O
the O
current O
literature O
on O
antileishmanial O
therapy O
and O
Leishmania O
host-pathogen O
interaction O
and O
discuss O
novel O
strategies O
to O
target O
host O
cell O
rather O
than O
parasite O
biology O
for O
drug O
discovery-a O
strategy O
that O
likely O
will O
be O
more O
refractory O
to O
the O
emergence O
of O
drug-resistant O
parasites O
. O
Recent O
strategies O
to O
replace O
antimonials O
as O
first-line O
treatment O
to O
circumvent O
their O
limitations O
with O
respect O
to O
toxicity O
[ O
13 O
] O
and O
drug O
resistance O
[ O
14 O
] O
largely O
rely O
on O
repurposing O
of O
existing O
drugs O
[ O
15 O
] O
. O
These O
include O
the O
antifungal O
drug O
amphotericin O
B O
, O
the O
off-patent O
antibiotic O
paromomycin O
, O
the O
oral O
anticancer O
drug O
miltefosine O
, O
and O
the O
antimalarial O
drug O
sitamaquine O
, O
all O
of O
which O
were O
shown O
efficient O
for O
treating O
leishmaniases O
. O
Despite O
the O
success O
of O
this O
repurposing O
strategy O
, O
all O
these O
therapies O
have O
important O
limitations O
: O
( O
1 O
) O
miltefosine O
is O
teratogenic O
, O
can O
provoke O
acute O
gastrointestinal O
side O
effects O
, O
and O
the O
length O
of O
the O
treatment O
( O
several O
weeks O
) O
causes O
poor O
treatment O
compliance O
with O
the O
risk O
of O
relapse O
[ O
16 O
] O
, O
( O
2 O
) O
conventional O
amphotericin O
B O
deoxycholate O
is O
not O
only O
nephrotoxic O
but O
also O
costly O
and O
can O
not O
be O
stored O
at O
high O
temperature O
, O
rendering O
it O
unaffordable O
in O
some O
countries O
[ O
17 O
] O
, O
and O
( O
3 O
) O
paromomycin O
needs O
long O
parenteral O
regimens O
, O
involving O
qualified O
personnel O
and O
hospitalization O
[ O
18 O
] O
. O
In O
addition O
, O
depending O
on O
Leishmania O
species O
and O
geographical O
area O
, O
the O
parasite O
response O
to O
the O
drugs O
can O
vary O
substantially O
, O
with O
, O
for O
example O
, O
a O
cure O
rate O
of O
paromomycin O
treatment O
for O
VL O
ranging O
from O
14.3 O
% O
to O
93.1 O
% O
in O
Sudanese O
and O
Ethiopian O
patients O
, O
respectively O
[ O
19 O
] O
. O
Relapse O
can O
occur O
, O
and O
post-kala-azar O
dermal O
leishmaniasis O
can O
appear O
even O
months O
after O
the O
Fig O
1 O
. O
Different O
aspects O
of O
macrophage-Leishmania O
interaction O
. O
Leishmania O
responds O
to O
the O
intramacrophagic O
environment O
by O
adaptive O
differentiation O
( O
left O
panel O
) O
and O
hijacks O
vital O
macrophage O
functions O
via O
release O
of O
parasite O
ectoproteins O
( O
such O
as O
the O
ectokinase B-protein
casein I-protein
kinase I-protein
1 I-protein
isoform I-protein
2 E-protein
[ O
CK1.2 S-protein
] O
) O
, O
which O
affect O
host O
defense O
mechanisms O
, O
causing O
immune O
subversion O
( O
middle O
panel O
) O
, O
and O
modulate O
host O
metabolic O
pathways O
, O
promoting O
parasite O
growth O
( O
right O
panel O
) O
. O
Background O
: O
Concurrent O
infection O
with O
porcine O
circovirus O
type O
2 O
( O
PCV2 O
) O
and O
porcine O
reproductive O
and O
respiratory O
syndrome O
virus O
( O
PRRSV O
) O
is O
known O
as O
one O
of O
the O
major O
causes O
for O
porcine B-protein
respiratory I-protein
disease I-protein
complex E-protein
( O
PRDC O
) O
. O
Dual O
infection O
with O
PCV2 O
and O
PRRSV O
is O
consistently O
to O
have O
more O
severe O
clinical O
presentations O
and O
pulmonary O
lesions O
than O
infection O
with O
PCV2 O
alone O
or O
PRRSV S-protein
alone O
. O
However O
, O
it O
is O
not O
known O
if O
dual O
infections O
with O
PCV2 O
and O
PRRSV O
in O
different O
infection O
order O
may O
lead O
to O
different O
clinical O
symptoms O
in O
the O
host O
. O
To O
mimic O
the O
possible O
field O
conditions O
, O
swine B-cell_type
alveolar I-cell_type
macrophages E-cell_type
( O
AMs S-cell_type
) O
were O
inoculated O
with O
PCV2 O
and O
PRRSV S-protein
in O
vitro O
simultaneously O
or O
with O
one O
virus O
18 O
h O
earlier O
than O
the O
other O
. O
The O
cell O
viability O
, O
cytopathic O
effects O
, O
antigen-containing O
rates O
, O
phagocytotic O
and O
microbial O
killing O
capabilities O
, O
cytokine B-RNA
profiles I-RNA
( I-RNA
IL-8 I-RNA
, I-RNA
TNF-α I-RNA
, I-RNA
and I-RNA
IFN-α I-RNA
) I-RNA
and I-RNA
FasL I-RNA
transcripts E-RNA
were O
determined O
, O
analyzed O
, O
and O
compared O
to O
prove O
the O
hypothesis O
. O
Results O
: O
A O
marked O
reduction O
in O
PRRSV O
antigen-containing O
rate O
, O
cytopathic O
effect O
, O
and O
TNF-α S-protein
expression O
level O
was O
revealed O
in O
AMs S-cell_line
inoculated O
with O
PCV2 O
and O
PRRSV O
simultaneously O
and O
in O
AMs S-cell_line
inoculated O
with O
PCV2 O
first O
then O
PRRSV O
18 O
h O
later O
, O
but O
not O
in O
AMs O
inoculated O
with O
PRRSV O
first O
then O
PCV2 O
18 O
h O
later O
. O
Transient O
decrease O
in O
phagocytosis O
but O
constant O
reduction O
in O
microbicidal O
capability O
in O
AMs S-cell_type
in O
the O
group O
inoculated O
with O
PCV2 O
alone O
and O
constant O
decrease O
in O
phagocytosis O
and O
microbicidal O
capability O
in O
AMs S-cell_type
in O
all O
PRRSV-inoculated O
groups O
were O
noted O
. O
The O
levels O
of O
IL-8 B-RNA
, I-RNA
TNF-α I-RNA
, I-RNA
IFN-α I-RNA
, I-RNA
and I-RNA
FasL I-RNA
transcripts E-RNA
in O
AMs S-cell_type
in O
all O
groups O
with O
dual O
inoculation O
of O
PCV2 O
and O
PRRSV O
were O
significantly O
increased O
regardless O
of O
the O
infection O
orders O
as O
compared O
with O
infection O
by O
PCV2 O
alone O
or O
PRRSV O
alone O
. O
Conclusions O
: O
Swine O
AMs O
infected O
with O
PCV2 O
first O
then O
PRRSV O
later O
or O
infected O
with O
PCV2 O
and O
PRRSV O
simultaneously O
displayed O
marked O
reduction O
in O
PRRSV O
antigen-containing O
rate O
, O
cytopathic O
effect O
, O
and O
TNF-α S-protein
expression O
level O
. O
The O
different O
inoculation O
orders O
of O
PCV2 O
and O
PRRSV S-protein
in O
AMs S-cell_type
leading O
to O
different O
results O
in O
viral O
antigen O
positivity O
, O
cytopathology O
, O
and O
cytokine S-protein
profile O
may O
explain O
, O
at O
least O
partially O
, O
the O
underlying O
mechanism O
of O
the O
enhanced O
pulmonary O
lesions O
in O
PRDC O
exerted O
by O
dual O
infection O
with O
PCV2 O
and O
PRRSV O
and O
the O
variable O
clinical O
manifestations O
of O
PRDC-affected O
pigs O
in O
the O
field O
. O
Objective O
: O
Cineole O
has O
mucolytic O
, O
bronchodilating O
and O
anti-inflammatory O
properties O
and O
reduces O
the O
exacerbation O
rate O
in O
patients O
suffering O
from O
COPD O
, O
as O
well O
as O
ameliorates O
symptoms O
in O
patients O
suffering O
from O
asthma O
and O
rhinosinusitis O
. O
Based O
on O
these O
effects O
, O
we O
therefore O
postulated O
the O
hypothesis O
that O
patients O
with O
acute O
bronchitis O
would O
also O
benefit O
from O
therapy O
with O
Cineole O
. O
Methods O
: O
As O
part O
of O
a O
double-blind O
, O
placebo-controlled O
, O
multi-center-study O
, O
a O
total O
of O
242 O
patients O
with O
confirmed O
acute O
bronchitis O
was O
randomly O
selected O
to O
participate O
. O
Over O
a O
period O
of O
10 O
days O
, O
all O
patients O
were O
administered O
3 O
x O
200 O
mg O
of O
Cineole O
, O
or O
a O
respective O
placebo O
, O
per O
day O
. O
The O
primary O
outcome O
measure O
was O
a O
Bronchitis O
Sum O
Score O
, O
which O
summarises O
the O
relevant O
symptoms O
of O
acute O
bronchitis O
. O
Results O
: O
After O
4 O
days O
of O
treatment O
it O
was O
notable O
, O
that O
the O
patient O
group O
treated O
with O
Cineole O
, O
showed O
significantly O
more O
improvements O
of O
the O
bronchitis-sum-score O
than O
those O
of O
the O
placebo O
group O
( O
p O
= O
0.0383 O
) O
. O
The O
statistical O
significant O
difference O
of O
the O
individual O
outcome O
measures O
was O
especially O
underlined O
by O
the O
frequency O
of O
cough O
fits O
by O
p O
= O
0.0001 O
after O
4 O
days O
. O
The O
effects O
of O
Cineole O
in O
the O
treatment O
of O
acute O
bronchitis O
were O
clearly O
measurable O
and O
could O
be O
proven O
after O
a O
treatment O
period O
of O
merely O
4 O
days O
. O
This O
study O
corroborates O
the O
fact O
that O
Cineole O
actively O
and O
significantly O
reduces O
cough O
frequency O
after O
four O
days O
. O
Therefore O
it O
has O
been O
shown O
to O
have O
a O
great O
socioeconomic O
impact O
. O
Trial O
registration O
: O
ISRCTN O
: O
ISRCTN37784439 O
Ebola O
and O
marburgviruses O
, O
members O
of O
the O
family O
Filoviridae O
, O
can O
cause O
severe O
hemorrhagic O
fever O
in O
humans O
. O
The O
ongoing O
Ebola O
virus O
( O
EBOV O
) O
disease O
epidemic O
in O
Western O
Africa O
claimed O
more O
than O
11,300 O
lives O
and O
was O
associated O
with O
secondary O
cases O
outside O
Africa O
, O
demonstrating O
that O
filoviruses O
pose O
a O
global O
health O
threat O
. O
Bats O
constitute O
an O
important O
natural O
reservoir O
of O
filoviruses O
, O
including O
viruses O
of O
the O
recently O
identified O
Cuevavirus O
genus O
within O
the O
Filoviridae B-protein
family E-protein
. O
However O
, O
the O
interactions O
of O
filoviruses O
with O
bat B-cell_type
cells E-cell_type
are O
incompletely O
understood O
. O
Here O
, O
we O
investigated O
whether O
filoviruses O
employ O
different O
strategies O
to O
enter O
human B-cell_type
and I-cell_type
bat I-cell_type
cells E-cell_type
. O
For O
this O
, O
we O
examined O
host O
cell O
entry O
driven O
by O
glycoproteins S-protein
( O
GP S-protein
) O
from O
all O
filovirus O
species O
into O
cell B-cell_line
lines E-cell_line
of O
human O
and O
fruit O
bat O
origin O
. O
We O
show O
that O
all O
GPs S-protein
were O
able O
to O
mediate O
entry O
into O
human O
and O
most O
fruit B-cell_line
bat I-cell_line
cell I-cell_line
lines E-cell_line
with O
roughly O
comparable O
efficiency O
. O
In O
contrast O
, O
the O
efficiency O
of O
entry O
into O
the O
cell B-cell_line
line I-cell_line
EidNi/41 E-cell_line
derived O
from O
a O
straw-colored O
fruit O
bat O
varied O
markedly O
between O
the O
GPs S-protein
of O
different O
filovirus O
species O
. O
Furthermore O
, O
inhibition O
studies O
demonstrated O
that O
filoviruses O
employ O
the O
same O
host B-protein
cell I-protein
factors E-protein
for O
entry O
into O
human O
, O
non-human O
primate O
and O
fruit B-cell_line
bat I-cell_line
cell I-cell_line
lines E-cell_line
, O
including O
cysteine B-protein
proteases E-protein
, O
two O
pore B-protein
channels E-protein
and O
NPC1 S-protein
( O
Niemann-Pick B-protein
C1 I-protein
molecule E-protein
) O
. O
Finally O
, O
processing O
of O
GP S-protein
by O
furin S-protein
and O
the O
presence O
of O
the O
mucin-like B-protein
domain E-protein
in O
GP S-protein
were O
dispensable O
for O
entry O
into O
both O
human B-cell_line
and I-cell_line
bat I-cell_line
cell I-cell_line
lines E-cell_line
. O
Collectively O
, O
these O
results O
show O
that O
filoviruses O
rely O
on O
the O
same O
host B-protein
cell I-protein
factors E-protein
for O
entry O
into O
human B-cell_type
and I-cell_type
fruit I-cell_type
bat I-cell_type
cells E-cell_type
, O
although O
the O
efficiency O
of O
the O
usage O
of O
these O
factors O
might O
differ O
between O
filovirus O
species O
. O
The O
innate O
immune O
response O
provides O
the O
first O
line O
of O
defense O
against O
viruses O
and O
other O
pathogens O
by O
responding O
to O
specific O
microbial B-protein
molecules E-protein
. O
Influenza O
A O
virus O
( O
IAV O
) O
produces O
double-stranded B-RNA
RNA E-RNA
as O
an O
intermediate O
during O
the O
replication O
life O
cycle O
, O
which O
activates O
the O
intracellular B-protein
pathogen I-protein
recognition I-protein
receptor E-protein
RIG-I S-protein
and O
induces O
the O
production O
of O
proinflammatory B-protein
cytokines E-protein
and O
antiviral O
interferon S-protein
. O
Understanding O
the O
mechanisms O
that O
regulate O
innate O
immune O
responses O
to O
IAV O
and O
other O
viruses O
is O
of O
key O
importance O
to O
develop O
novel O
therapeutic O
strategies O
. O
Here O
we O
used O
myeloid O
cell O
specific O
A20 O
knockout O
mice O
to O
examine O
the O
role O
of O
the O
ubiquitin-editing B-protein
protein I-protein
A20 E-protein
in O
the O
response O
of O
myeloid B-cell_type
cells E-cell_type
to O
IAV O
infection O
. O
A20 B-cell_line
deficient I-cell_line
macrophages E-cell_line
were O
hyperresponsive O
to O
double O
stranded O
RNA O
and O
IAV O
infection O
, O
as O
illustrated O
by O
enhanced O
NF-kB S-protein
and O
IRF3 S-protein
activation O
, O
concomitant O
with O
increased O
production O
of O
proinflammatory B-protein
cytokines E-protein
, O
chemokines S-protein
and O
type B-protein
I I-protein
interferon E-protein
. O
In O
vivo O
this O
was O
associated O
with O
an O
increased O
number O
of O
alveolar B-cell_type
macrophages E-cell_type
and O
neutrophils S-cell_type
in O
the O
lungs O
of O
IAV O
infected O
mice O
. O
Surprisingly O
, O
myeloid O
cell O
specific O
A20 O
knockout O
mice O
are O
protected O
against O
lethal O
IAV O
infection O
. O
These O
results O
challenge O
the O
general O
belief O
that O
an O
excessive O
host O
proinflammatory O
response O
is O
associated O
with O
IAV-induced O
lethality O
, O
and O
suggest O
that O
under O
certain O
conditions O
inhibition O
of O
A20 O
might O
be O
of O
interest O
in O
the O
management O
of O
IAV O
infections O
. O
Acute O
respiratory O
infections O
are O
a O
major O
cause O
of O
morbidity O
in O
children O
both O
in O
developed O
and O
developing O
countries O
. O
A O
wide O
range O
of O
respiratory O
viruses O
, O
including O
respiratory O
syncytial O
virus O
( O
RSV O
) O
, O
influenza O
A O
and O
B O
viruses O
, O
parainfluenza O
viruses O
( O
PIVs O
) O
, O
adenovirus O
, O
rhinovirus O
( O
HRV O
) O
, O
have O
repeatedly O
been O
detected O
in O
acute O
lower O
respiratory O
tract O
infections O
( O
LRTI O
) O
in O
children O
in O
the O
past O
decades O
. O
However O
, O
in O
the O
last O
ten O
years O
thanks O
to O
progress O
in O
molecular O
technologies O
, O
newly O
discovered O
viruses O
have O
been O
identified O
including O
human O
Metapneumovirus O
( O
hMPV O
) O
, O
coronaviruses B-protein
NL63 E-protein
( O
HcoV-NL63 O
) O
and O
HKU1 O
( O
HcoV-HKU1 O
) O
, O
human O
Bocavirus O
( O
HBoV O
) O
, O
new O
enterovirus O
( O
HEV O
) O
, O
parechovirus O
( O
HpeV O
) O
and O
rhinovirus O
( O
HRV O
) O
strains O
, O
polyomaviruses O
WU O
( O
WUPyV O
) O
and O
KI O
( O
KIPyV O
) O
and O
the O
pandemic O
H1N1v O
influenza O
A O
virus O
. O
These O
discoveries O
have O
heavily O
modified O
previous O
knowledge O
on O
respiratory O
infections O
mainly O
highlighting O
that O
pediatric O
population O
is O
exposed O
to O
a O
variety O
of O
viruses O
with O
similar O
seasonal O
patterns O
. O
In O
this O
context O
establishing O
a O
causal O
link O
between O
a O
newly O
identified O
virus O
and O
the O
disease O
as O
well O
as O
an O
association O
between O
mixed O
infections O
and O
an O
increase O
in O
disease O
severity O
can O
be O
challenging O
. O
This O
review O
will O
present O
an O
overview O
of O
newly O
recognized O
as O
well O
as O
the O
main O
emerging O
respiratory O
viruses O
and O
seek O
to O
focus O
on O
the O
their O
contribution O
to O
infection O
and O
co-infection O
in O
LRTIs O
in O
childhood O
. O
Background O
: O
Many O
commentators O
call O
for O
a O
more O
ethical O
approach O
to O
planning O
for O
influenza O
pandemics O
. O
In O
the O
developed O
world O
, O
some O
pandemic O
preparedness O
plans O
have O
already O
been O
examined O
from O
an O
ethical O
viewpoint O
. O
This O
paper O
assesses O
the O
attention O
given O
to O
ethics O
issues O
by O
the O
Ghana O
National O
Integrated O
Strategic O
Plan O
for O
Pandemic O
Influenza O
( O
NISPPI O
) O
. O
Methods O
: O
We O
critically O
analyzed O
the O
Ghana O
NISPPI O
's O
sensitivity O
to O
ethics O
issues O
to O
determine O
how O
well O
it O
reflects O
ethical O
commitments O
and O
principles O
identified O
in O
our O
review O
of O
global O
pandemic O
preparedness O
literature O
, O
existing O
pandemic O
plans O
, O
and O
relevant O
ethics O
frameworks O
. O
Results O
: O
This O
paper O
reveals O
that O
important O
ethical O
issues O
have O
not O
been O
addressed O
in O
the O
Ghana O
NISPPI O
. O
Several O
important O
ethical O
issues O
are O
unanticipated O
, O
unacknowledged O
, O
and O
unplanned O
for O
. O
These O
include O
guidelines O
on O
allocation O
of O
scarce O
resources O
, O
the O
duties O
of O
healthcare O
workers O
, O
ethics-sensitive O
operational O
guidelines/protocols O
, O
and O
compensation O
programs O
. O
The O
NISPPI O
also O
pays O
scant O
attention O
to O
use O
of O
vaccines O
and O
antivirals O
, O
border O
issues O
and O
cooperation O
with O
neighboring O
countries O
, O
justification O
for O
delineated O
actions O
, O
and O
outbreak O
simulations O
. O
Feedback O
and O
communication O
plans O
are O
nebulous O
, O
while O
leadership O
, O
coordination O
, O
and O
budgeting O
are O
quite O
detailed O
. O
With O
respect O
to O
presentation O
, O
the O
NISPPI O
's O
text O
is O
organized O
around O
five O
thematic O
areas O
. O
While O
each O
area O
implicates O
ethical O
issues O
, O
NISPPI O
treatment O
of O
these O
areas O
consistently O
fails O
to O
address O
them O
. O
Conclusions O
: O
Our O
analysis O
reveals O
a O
lack O
of O
consideration O
of O
ethics O
by O
the O
NISPPI O
. O
We O
contend O
that O
, O
while O
the O
plan O
's O
content O
and O
fundamental O
assumptions O
provide O
support O
for O
implementation O
of O
the O
delineated O
public O
health O
actions O
, O
its O
consideration O
of O
ethical O
issues O
is O
poor O
. O
Deficiencies O
include O
a O
failure O
to O
incorporate O
guidelines O
that O
ensure O
fair O
distribution O
of O
scarce O
resources O
and O
a O
lack O
of O
justification O
for O
delineated O
procedures O
. O
Until O
these O
deficiencies O
are O
recognized O
and O
addressed O
, O
Ghana O
runs O
the O
risk O
of O
rolling O
out O
unjust O
and O
ethically O
indefensible O
actions O
with O
real O
negative O
effects O
in O
the O
event O
of O
a O
pandemic O
. O
Soliciting O
inputs O
from O
the O
public O
and O
consultation O
with O
ethicists O
during O
the O
next O
revision O
of O
the O
NISPPI O
will O
be O
useful O
in O
addressing O
these O
issues O
. O
In O
this O
paper O
, O
a O
susceptible-vaccinated-exposed-infectious-recovered O
( O
SVEIR O
) O
epidemic O
model O
for O
an O
infectious O
disease O
that O
spreads O
in O
the O
host O
population O
through O
horizontal O
transmission O
is O
investigated O
, O
assuming O
that O
the O
horizontal O
transmission O
is O
governed O
by O
an O
unspecified O
function O
f O
( O
S O
, O
I O
) O
. O
The O
role O
that O
temporary O
immunity O
( O
vaccinated-induced O
) O
and O
treatment O
of O
infected O
people O
play O
in O
the O
spread O
of O
disease O
, O
is O
incorporated O
in O
the O
model O
. O
The O
basic O
reproduction O
number O
R O
0 O
is O
found O
, O
under O
certain O
conditions O
on O
the O
incidence O
rate O
and O
treatment O
function O
. O
It O
is O
shown O
that O
the O
model O
exhibits O
two O
equilibria O
, O
namely O
, O
the O
disease-free O
equilibrium O
and O
the O
endemic O
equilibrium O
. O
By O
constructing O
a O
suitable O
Lyapunov O
function O
, O
it O
is O
observed O
that O
the O
global O
asymptotic O
stability O
of O
the O
disease-free O
equilibrium O
depends O
on O
R O
0 O
as O
well O
as O
on O
the O
treatment O
rate O
. O
If O
R O
0 O
> O
1 O
, O
then O
the O
endemic O
equilibrium O
is O
globally O
asymptotically O
stable O
with O
the O
help O
of O
the O
Li O
and O
Muldowney O
geometric O
approach O
applied O
to O
four O
dimensional O
systems O
. O
Numerical O
simulations O
are O
also O
presented O
to O
illustrate O
our O
main O
results O
. O
MSC O
: O
92D25 O
; O
92D30 O
; O
34D23 O
; O
37B25 O
Background O
: O
Patients O
with O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
can O
experience O
'exacerbations O
' O
of O
their O
conditions O
. O
An O
exacerbation O
is O
an O
event O
defined O
in O
terms O
of O
subjective O
descriptors O
or O
symptoms O
, O
namely O
dyspnoea O
, O
cough O
and O
sputum O
that O
worsen O
sufficiently O
to O
warrant O
a O
change O
in O
medical O
management O
. O
There O
is O
a O
need O
for O
reliable O
markers O
that O
reflect O
the O
pathological O
mechanisms O
that O
underlie O
exacerbation O
severity O
and O
that O
can O
be O
used O
as O
a O
surrogate O
to O
assess O
treatment O
effects O
in O
clinical O
studies O
. O
Little O
is O
known O
as O
to O
how O
existing O
study O
variables O
and O
suggested O
markers O
change O
in O
both O
the O
stable O
and O
exacerbation O
phases O
of O
COPD O
. O
In O
an O
attempt O
to O
find O
the O
best O
surrogates O
for O
exacerbations O
, O
we O
have O
reviewed O
the O
literature O
to O
identify O
which O
of O
these O
markers O
change O
in O
a O
consistent O
manner O
with O
the O
severity O
of O
the O
exacerbation O
event O
. O
We O
have O
searched O
standard O
databases O
between O
1966 O
to O
July O
2004 O
using O
major O
keywords O
and O
terms O
. O
Studies O
that O
provided O
demographics O
, O
spirometry O
, O
potential O
markers O
, O
and O
clear O
eligibility O
criteria O
were O
included O
in O
this O
study O
. O
Central O
tendencies O
and O
dispersions O
for O
all O
the O
variables O
and O
markers O
reported O
and O
collected O
by O
us O
were O
first O
tabulated O
according O
to O
sample O
size O
and O
ATS/ERS O
2004 O
Exacerbation O
Severity O
Levels O
I O
to O
III O
criteria O
. O
Due O
to O
the O
possible O
similarity O
of O
patients O
in O
Levels O
II O
and O
III O
, O
the O
data O
was O
also O
redefined O
into O
categories O
of O
exacerbations O
, O
namely O
out-patient O
( O
Level O
I O
) O
and O
in-patient O
( O
Levels O
II O
& O
III O
combined O
) O
. O
For O
both O
approaches O
, O
we O
performed O
a O
fixed O
effect O
meta-analysis O
on O
each O
of O
the O
reported O
variables O
. O
We O
included O
a O
total O
of O
268 O
studies O
reported O
between O
1979 O
to O
July O
2004 O
. O
These O
studies O
investigated O
142,407 O
patients O
with O
COPD O
. O
Arterial O
carbon O
dioxide O
tension O
and O
breathing O
rate O
were O
statistically O
different O
between O
all O
levels O
of O
exacerbation O
severity O
and O
between O
in O
out-and O
in-patient O
settings O
. O
Most O
other O
measures O
showed O
weak O
relationships O
with O
either O
level O
or O
setting O
, O
or O
they O
had O
insufficient O
data O
to O
permit O
meta-analysis O
. O
Arterial O
carbon O
dioxide O
and O
breathing O
rate O
varied O
in O
a O
consistent O
manner O
with O
exacerbation O
severity O
and O
patient O
setting O
. O
Many O
other O
measures O
showed O
weak O
correlations O
that O
should O
be O
further O
explored O
in O
future O
longitudinal O
studies O
or O
assessed O
using O
suggested O
mathematical O
modelling O
techniques O
. O
Bats O
are O
natural O
reservoirs O
of O
coronaviruses O
and O
other O
viruses O
with O
zoonotic O
potential O
. O
Florida O
has O
indigenous O
non-migratory O
populations O
of O
Brazilian O
free-tailed O
bats O
( O
Tadarida O
brasiliensis O
) O
that O
mostly O
roost O
in O
colonies O
in O
artificial O
structures O
. O
Unlike O
their O
counterparts O
in O
Brazil O
and O
Mexico O
, O
the O
viruses O
harbored O
by O
the O
Florida O
bats O
have O
been O
underexplored O
. O
We O
report O
the O
detection O
of O
an O
alphacoronavirus B-DNA
RNA-dependent I-DNA
RNA I-DNA
polymerase I-DNA
( I-DNA
RdRp I-DNA
) I-DNA
gene I-DNA
sequence E-DNA
in O
the O
feces O
of O
two O
of O
19 O
different O
T. O
brasiliensis O
that O
were O
capture/release O
bats O
that O
had O
been O
evaluated O
for O
overall O
health O
. O
The O
RdRp B-DNA
sequence E-DNA
is O
similar O
but O
not O
identical O
to O
previously O
detected O
sequences O
in O
the O
feces O
of O
two O
different O
species O
of O
bats O
( O
T. O
brasiliensis O
and O
Molossus O
molossus O
) O
in O
Brazil O
. O
In O
common O
with O
the O
experience O
of O
others O
doing O
similar O
work O
, O
attempts O
to O
isolate O
the O
virus O
in O
cell O
cultures O
were O
unsuccessful O
. O
We O
surmise O
that O
this O
and O
highly O
related O
alphacoronavirus O
are O
carried O
by O
Brazilian O
free-tailed O
bats O
living O
in O
a O
wide O
eco-spatial B-DNA
region E-DNA
. O
As O
various O
coronaviruses O
( O
CoVs O
) O
that O
affect O
humans O
emerged O
from O
bats O
, O
our O
study O
raises O
the O
question O
whether O
CoVs O
such O
as O
the O
one O
detected O
in O
our O
work O
are O
yet-to-be-detected O
pathogens O
of O
humans O
and O
animals O
other O
than O
bats O
. O
Although O
many O
studies O
provide O
strong O
evidence O
supporting O
the O
development O
of O
HCV O
virus-like O
particle O
( O
VLP O
) O
-based O
vaccines O
, O
the O
fact O
that O
heterologous B-DNA
viral I-DNA
vectors E-DNA
and/or O
multiple O
dosing O
regimes O
are O
required O
to O
induce O
protective O
immunity O
indicates O
that O
it O
is O
necessary O
to O
improve O
their O
immunogenicity O
. O
In O
this O
study O
, O
we O
have O
evaluated O
the O
use O
of O
an O
anionic O
self-adjuvanting O
lipopeptide O
containing O
the O
TLR2 S-protein
agonist O
Pam O
2 O
Cys O
( O
E O
8 O
Pam O
2 O
Cys O
) O
to O
enhance O
the O
immunogenicity O
of O
VLPs O
containing O
the O
HCV B-protein
structural I-protein
proteins E-protein
( O
core O
, O
E1 S-protein
and O
E2 S-protein
) O
of O
genotype O
1a O
. O
While O
co-formulation O
of O
this O
lipopeptide O
with O
VLPs O
only O
resulted O
in O
marginal O
improvements O
in O
dendritic B-cell_type
cell E-cell_type
( O
DC S-cell_type
) O
uptake O
, O
its O
ability O
to O
concomitantly O
induce O
DC S-cell_type
maturation O
at O
very O
small O
doses O
is O
a O
feature O
not O
observed O
using O
VLPs O
alone O
or O
in O
the O
presence O
of O
an O
aluminium O
hydroxide-based O
adjuvant O
( O
Alum O
) O
. O
Dramatically O
improved O
VLP B-protein
and I-protein
E2-specific I-protein
antibody E-protein
responses O
were O
observed O
in O
VLP+E O
8 O
Pam O
2 O
Cys O
vaccinated O
mice O
where O
up O
to O
3 O
doses O
of O
non-adjuvanted O
or O
traditionally O
alum-adjuvanted O
VLPs O
was O
required O
to O
match O
the O
antibody O
titres O
obtained O
with O
a O
single O
dose O
of O
VLPs O
formulated O
with O
this O
lipopeptide O
. O
This O
result O
also O
correlated O
with O
significantly O
higher O
numbers O
of O
specific O
antibody O
secreting O
cells O
that O
was O
detected O
in O
the O
spleens O
of O
VLP+E O
8 O
Pam O
2 O
Cys O
vaccinated O
mice O
and O
greater O
ability O
of O
sera O
from O
these O
mice O
to O
neutralise O
the O
binding O
and O
uptake O
of O
VLPs O
by O
Huh7 B-cell_line
cells E-cell_line
. O
Moreover O
, O
vaccination O
of O
HLA-A2 O
transgenic O
mice O
with O
this O
formulation O
also O
induced O
better O
VLP-specific O
IFN-c-mediated O
responses O
compared O
to O
nonadjuvanted O
VLPs O
but O
comparable O
levels O
to O
that O
achieved O
when O
coadministered O
with O
complete O
freund O
's O
adjuvant O
. O
These O
results O
suggest O
overall O
that O
the O
immunogenicity O
of O
HCV O
VLPs O
can O
be O
significantly O
improved O
by O
the O
addition O
of O
this O
novel O
adjuvant O
by O
targeting O
their O
delivery O
to O
DCs S-cell_type
and O
could O
therefore O
constitute O
a O
viable O
vaccine O
strategy O
for O
the O
treatment O
of O
HCV O
. O
Human O
cytomegalovirus O
( O
HCMV O
) O
is O
a O
ubiquitous O
herpesvirus O
that O
is O
able O
to O
infect O
fibroblastic B-cell_type
, I-cell_type
epithelial I-cell_type
, I-cell_type
endothelial I-cell_type
and I-cell_type
hematopoietic I-cell_type
cells E-cell_type
. O
Over O
the O
past O
ten O
years O
, O
several O
groups O
have O
provided O
direct O
evidence O
that O
dendritic B-cell_type
cells E-cell_type
( O
DCs S-cell_type
) O
fully O
support O
the O
HCMV O
lytic O
cycle O
. O
We O
previously O
demonstrated O
that O
the O
C-type B-protein
lectin I-protein
dendritic I-protein
cell-specific I-protein
intercellular I-protein
adhesion I-protein
molecule-3-grabbing I-protein
non-integrin E-protein
( O
DC-SIGN S-protein
) O
has O
a O
prominent O
role O
in O
the O
docking O
of O
HCMV O
on O
monocyte-derived B-cell_type
DCs E-cell_type
( O
MDDCs S-cell_type
) O
. O
The O
DC-SIGN/HCMV O
interaction O
was O
demonstrated O
to O
be O
a O
crucial O
and O
early O
event O
that O
substantially O
enhanced O
infection O
in O
trans O
, O
i.e. O
, O
from O
one O
CMV-bearing B-cell_line
cell E-cell_line
to O
another O
non-infected O
cell O
( O
or O
trans-infection O
) O
, O
and O
rendered O
susceptible O
cells O
fully O
permissive O
to O
HCMV O
infection O
. O
Nevertheless O
, O
nothing O
is O
yet O
known O
about O
how O
HCMV O
enters O
MDDCs S-protein
. O
In O
this O
study O
, O
we O
demonstrated O
that O
VHL/E O
HCMV O
virions O
( O
an O
endothelio/dendrotropic O
strain O
) O
are O
first O
internalized O
into O
MDDCs S-protein
by O
a O
macropinocytosis-like O
process O
in O
an O
actin-and O
cholesterol-dependent O
, O
but O
pH-independent O
, O
manner O
. O
We O
observed O
the O
accumulation O
of O
virions O
in O
large O
uncoated O
vesicles O
with O
endosomal O
features O
, O
and O
the O
virions O
remained O
as O
intact O
particles O
that O
retained O
infectious O
potential O
for O
several O
hours O
. O
This O
trans-infection O
property O
was O
specific O
to O
MDDCs S-protein
because O
monocytederived B-cell_type
macrophages E-cell_type
or O
monocytes S-cell_type
from O
the O
same O
donor O
were O
unable O
to O
allow O
the O
accumulation O
of O
and O
the O
subsequent O
transmission O
of O
the O
virus O
. O
Together O
, O
these O
data O
allowed O
us O
to O
delineate O
the O
early O
mechanisms O
of O
the O
internalization O
and O
entry O
of O
an O
endothelio/dendrotropic O
HCMV O
strain O
into O
human B-cell_type
MDDCs E-cell_type
and O
to O
propose O
that O
DCs S-cell_type
can O
serve O
as O
a O
`` O
Trojan O
horse O
'' O
to O
convey O
CMV O
from O
entry O
sites O
to O
other O
locations O
that O
may O
favor O
the O
occurrence O
of O
either O
latency O
or O
acute O
infection O
. O
Citation O
: O
Haspot O
F O
, O
Lavault O
A O
, O
Sinzger O
C O
, O
Laib O
Sampaio O
K O
, O
Stierhof O
Y-D O
, O
et O
al O
. O
( O
2012 O
) O
Human O
Cytomegalovirus O
Entry O
into O
Dendritic B-cell_type
Cells E-cell_type
Occurs O
via O
a O
Macropinocytosis-Like O
Pathway O
in O
a O
pH-Independent O
and O
Cholesterol-Dependent O
Manner O
. O
PLoS O
ONE O
7 O
( O
4 O
) O
: O
e34795 O
. O
Background O
: O
Mast B-cell_type
cells E-cell_type
are O
well O
established O
effectors O
of O
IgE-triggered O
allergic O
reactions O
and O
immune O
responses O
to O
parasitic O
infections O
. O
Recent O
studies O
indicate O
that O
mast B-cell_type
cells E-cell_type
may O
play O
roles O
in O
adaptive O
and O
innate O
immunity O
, O
suggesting O
an O
innovative O
view O
of O
the O
regulation O
of O
immune O
responses O
. O
Here O
, O
we O
profiled O
the O
transcriptome O
of O
human B-cell_type
mast I-cell_type
cells E-cell_type
sensitized O
with O
IgE S-protein
alone O
, O
or O
stimulated O
by O
FcεRI S-protein
aggregation O
. O
Results O
: O
Our O
data O
show O
that O
among O
8,793 B-DNA
genes E-DNA
examined O
, O
559 B-DNA
genes E-DNA
are O
differentially O
regulated O
in O
stimulated O
mast B-cell_type
cells E-cell_type
when O
compared O
with O
resting/unstimulated B-cell_type
mast I-cell_type
cells E-cell_type
. O
The O
major O
functional O
categories O
of O
upregulated O
genes O
include O
cytokines S-protein
, O
chemokines S-protein
, O
and O
other O
genes O
involved O
in O
innate O
and O
adaptive O
immune-responses O
. O
We O
observed O
the O
increased O
expression O
of O
over O
63 O
genetranscripts O
following O
IgE-sensitization O
alone O
. O
Our O
data O
was O
validated O
using O
Real-Time-PCR O
; O
ELISA O
and O
western O
blot O
. O
We O
confirmed O
that O
IgE S-protein
alone O
does O
not O
trigger O
mast O
cell-immediate O
responses O
, O
such O
as O
calcium O
signals O
, O
degranulation O
or O
protein-phosphorylation O
. O
This O
report O
represents O
a O
substantial O
advance O
in O
our O
understanding O
of O
the O
genome O
wide O
effects O
triggered O
by O
`` O
passive O
sensitization O
'' O
or O
active O
stimulation O
of O
human B-cell_type
mast I-cell_type
cells E-cell_type
, O
supporting O
mast B-cell_type
cells E-cell_type
' O
potential O
involvement O
in O
a O
wide O
range O
of O
inflammatory O
responses O
. O
Despite O
significant O
advancement O
in O
vaccine O
and O
virus O
research O
, O
influenza O
continues O
to O
be O
a O
major O
public O
health O
concern O
. O
Each O
year O
in O
the O
United O
States O
of O
America O
, O
influenza O
viruses O
are O
responsible O
for O
seasonal O
epidemics O
resulting O
in O
over O
200,000 O
hospitalizations O
and O
30,000-50,000 O
deaths O
. O
Accurate O
and O
early O
diagnosis O
of O
influenza O
viral O
infections O
are O
critical O
for O
rapid O
initiation O
of O
antiviral O
therapy O
to O
reduce O
influenza O
related O
morbidity O
and O
mortality O
both O
during O
seasonal O
epidemics O
and O
pandemics O
. O
Several O
different O
approaches O
are O
currently O
available O
for O
diagnosis O
of O
influenza O
infections O
in O
humans O
. O
These O
include O
viral O
isolation O
in O
cell O
culture O
, O
immunofluorescence O
assays O
, O
nucleic O
acid O
amplification O
tests O
, O
immunochromatography-based O
rapid O
diagnostic O
tests O
, O
etc O
. O
Newer O
diagnostic O
approaches O
are O
being O
developed O
to O
overcome O
the O
limitations O
associated O
with O
some O
of O
the O
conventional O
detection O
methods O
. O
This O
review O
discusses O
diagnostic O
approaches O
currently O
available O
for O
detection O
of O
influenza O
viruses O
in O
humans O
. O
Die O
COVID-19-Epidemie O
wird O
in O
Deutschland O
im O
optimistischen O
Szenario O
mindestens O
bis O
Juli O
2020 O
dauern O
, O
im O
normalen O
Szenario O
bis O
August O
. O
Öffentliche O
Maßnahmen O
wie O
Kontaktverbote O
fl O
achen O
den O
Anstieg O
der O
Zahl O
der O
Erkrankungen O
temporär O
ab O
und O
verlängern O
die O
Dauer O
der O
Epidemie O
. O
In O
der O
Spitze O
sind O
im O
optimistischen O
Szenario O
gleichzeitig O
bis O
zu O
200.000 O
Menschen O
erkrankt O
, O
im O
normalen O
Szenario O
liegen O
die O
Werte O
um O
1 O
Million O
. O
Langfristig O
werden O
im O
normalen O
Szenario O
6 O
% O
der O
Bevölkerung O
( O
gemeldet O
) O
erkrankt O
gewesen O
sein O
. O
The O
alarmin B-DNA
IL-33 E-DNA
has O
been O
described O
to O
be O
upregulated O
in O
human O
and O
murine O
viral O
hepatitis O
. O
However O
, O
the O
role O
of O
endogenous B-protein
IL-33 E-protein
in O
viral O
hepatitis O
remains O
obscure O
. O
We O
aimed O
to O
decipher O
its O
function O
by O
infecting O
IL-33-deficient O
mice O
( O
IL-33 O
KO O
) O
and O
their O
wild-type O
( O
WT O
) O
littermates O
with O
pathogenic O
mouse O
hepatitis O
virus O
( O
L2-MHV3 O
) O
. O
The O
IL-33 O
KO O
mice O
were O
more O
sensitive O
to O
L2-MHV3 O
infection O
exhibiting O
higher O
levels O
of O
AST/ALT S-protein
, O
higher O
tissue O
damage O
, O
significant O
weight O
loss O
, O
and O
earlier O
death O
. O
An O
increased O
depletion O
of O
B B-cell_type
and I-cell_type
T I-cell_type
lymphocytes E-cell_type
, O
NKT B-cell_type
cells E-cell_type
, O
dendritic B-cell_type
cells E-cell_type
, O
and O
macrophages S-cell_type
was O
observed O
48 O
h O
postinfection O
( O
PI O
) O
in O
IL-33 O
KO O
mice O
than O
that O
in O
WT O
mice O
. O
In O
contrast O
, O
a O
massive O
influx O
of O
neutrophils S-cell_type
was O
observed O
in O
IL-33 O
KO O
mice O
at O
48 O
h O
PI O
. O
A O
transcriptomic O
study O
of O
inflammatory B-DNA
and I-DNA
cell-signaling I-DNA
genes E-DNA
revealed O
the O
overexpression O
of O
IL-6 S-protein
, O
TNFα S-protein
, O
and O
several O
chemokines S-protein
involved O
in O
recruitment/activation O
of O
neutrophils S-cell_type
( O
CXCL2 S-protein
, O
CXCL5 S-protein
, O
CCL2 S-protein
, O
and O
CCL6 S-protein
) O
at O
72 O
h O
PI O
in O
IL-33 O
KO O
mice O
. O
However O
, O
the O
IFNγ S-protein
was O
strongly O
induced O
in O
WT O
mice O
with O
less O
profound O
expression O
in O
IL-33 O
KO O
mice O
demonstrating O
that O
endogenous O
IL-33 O
regulated O
IFNγ S-protein
expression O
during O
L2-MHV3 O
hepatitis O
. O
In O
conclusion O
, O
we O
demonstrated O
that O
endogenous B-protein
IL-33 E-protein
had O
multifaceted O
immunoregulatory S-protein
effect O
during O
viral O
hepatitis O
via O
induction O
of O
IFNγ S-protein
, O
survival O
effect O
on O
immune B-cell_type
cells E-cell_type
, O
and O
infiltration O
of O
neutrophils S-cell_type
in O
the O
liver O
. O
A O
variety O
of O
human O
diseases O
are O
associated O
with O
gammaherpesviruses O
, O
including O
neoplasms O
of O
lymphocytes S-cell_type
( O
e.g O
. O
Burkitt O
's O
lymphoma O
) O
and O
endothelial B-cell_type
cells E-cell_type
( O
e.g O
. O
Kaposi O
's O
sarcoma O
) O
. O
Gammaherpesvirus O
infections O
usually O
result O
in O
either O
a O
productive O
lytic O
infection O
, O
characterized O
by O
expression O
of O
all O
viral B-DNA
genes E-DNA
and O
rapid O
cell O
lysis O
, O
or O
latent O
infection O
, O
characterized O
by O
limited O
viral O
gene O
expression O
and O
no O
cell O
lysis O
. O
Here O
, O
we O
report O
characterization O
of O
endothelial O
cell O
infection O
with O
murine B-DNA
gammaherpesvirus I-DNA
68 E-DNA
( O
cHV68 O
) O
, O
a O
virus O
phylogenetically O
related O
and O
biologically O
similar O
to O
the O
human O
gammaherpesviruses O
. O
Endothelial B-cell_type
cells E-cell_type
supported O
cHV68 O
replication O
in O
vitro O
, O
but O
were O
unique O
in O
that O
a O
significant O
proportion O
of O
the O
cells O
escaped O
lysis O
, O
proliferated O
, O
and O
remained O
viable O
in O
culture O
for O
an O
extended O
time O
. O
Upon O
infection O
, O
endothelial B-cell_type
cells E-cell_type
became O
nonadherent O
and O
altered O
in O
size O
, O
complexity O
, O
and O
cell-surface O
protein O
expression O
. O
These O
cells O
were O
uniformly O
infected O
and O
expressed O
the O
lytic O
transcription O
program O
based O
on O
detection O
of O
abundant O
viral B-RNA
gene I-RNA
transcripts E-RNA
, O
GFP S-protein
fluorescence O
from O
the O
viral B-DNA
genome E-DNA
, O
and O
viral O
surface O
protein O
expression O
. O
Additionally O
, O
endothelial B-cell_type
cells E-cell_type
continued O
to O
produce O
new O
infectious O
virions O
as O
late O
as O
30 O
days O
post-infection O
. O
The O
outcome O
of O
this O
long-term O
infection O
was O
promoted O
by O
the O
cHV68 O
v-cyclin O
, O
because O
in O
the O
absence O
of O
the O
v-cyclin O
, O
viability O
was O
significantly O
reduced O
following O
infection O
. O
Importantly O
, O
infected B-cell_type
primary I-cell_type
endothelial I-cell_type
cells E-cell_type
also O
demonstrated O
increased O
viability O
relative O
to O
infected B-cell_type
primary I-cell_type
fibroblasts E-cell_type
, O
and O
this O
increased O
viability O
was O
dependent O
on O
the O
v-cyclin S-protein
. O
Finally O
, O
we O
provide O
evidence O
for O
infection O
of O
endothelial B-cell_type
cells E-cell_type
in O
vivo O
in O
immune-deficient O
mice O
. O
The O
extended O
viability O
and O
virus O
production O
of O
infected B-cell_type
endothelial I-cell_type
cells E-cell_type
indicated O
that O
endothelial B-cell_type
cells E-cell_type
provided O
a O
source O
of O
prolonged O
virus O
production O
and O
identify O
a O
cell-type O
specific O
adaptation O
of O
gammaherpesvirus O
replication O
. O
While O
infected B-cell_type
endothelial I-cell_type
cells E-cell_type
would O
likely O
be O
cleared O
in O
a O
healthy O
individual O
, O
persistently B-cell_type
infected I-cell_type
endothelial I-cell_type
cells E-cell_type
could O
provide O
a O
source O
of O
continued O
virus O
replication O
in O
immune-compromised O
individuals O
, O
a O
context O
in O
which O
gammaherpesvirusassociated O
pathology O
frequently O
occurs O
. O
Here O
, O
we O
present O
the O
calculation O
of O
vaccine O
effectiveness O
( O
VE O
) O
for O
the O
Netherlands O
in O
2014-15 O
and O
2015-16 O
stratified O
for O
particular O
risk O
groups O
, O
namely O
chronic O
conditions O
and O
older O
age O
. O
A O
majority O
of O
emerging O
infectious O
diseases O
are O
of O
zoonotic O
origin O
. O
Metagenomic O
Next-Generation O
Sequencing O
( O
mNGS O
) O
has O
been O
employed O
to O
identify O
uncommon O
and O
novel O
infectious O
etiologies O
and O
characterize O
virus O
diversity O
in O
human O
, O
animal O
, O
and O
environmental O
samples O
. O
Here O
, O
we O
systematically O
reviewed O
studies O
that O
performed O
viral O
mNGS O
in O
common O
livestock O
( O
cattle O
, O
small O
ruminants O
, O
poultry O
, O
and O
pigs O
) O
. O
We O
identified O
2481 O
records O
and O
120 O
records O
were O
ultimately O
included O
after O
a O
first O
and O
second O
screening O
. O
Pigs O
were O
the O
most O
frequently O
studied O
livestock O
and O
the O
virus O
diversity O
found O
in O
samples O
from O
poultry O
was O
the O
highest O
. O
Known O
animal O
viruses O
, O
zoonotic O
viruses O
, O
and O
novel O
viruses O
were O
reported O
in O
available O
literature O
, O
demonstrating O
the O
capacity O
of O
mNGS O
to O
identify O
both O
known O
and O
novel O
viruses O
. O
However O
, O
the O
coverage O
of O
metagenomic O
studies O
was O
patchy O
, O
with O
few O
data O
on O
the O
virome O
of O
small O
ruminants O
and O
respiratory O
virome O
of O
studied O
livestock O
. O
Essential O
metadata O
such O
as O
age O
of O
livestock O
and O
farm O
types O
were O
rarely O
mentioned O
in O
available O
literature O
, O
and O
only O
10.8 O
% O
of O
the O
datasets O
were O
publicly O
available O
. O
Developing O
a O
deeper O
understanding O
of O
livestock O
virome O
is O
crucial O
for O
detection O
of O
potential O
zoonotic O
and O
animal O
pathogens O
and O
One O
Health O
preparedness O
. O
Metagenomic O
studies O
can O
provide O
this O
background O
but O
only O
when O
combined O
with O
essential O
metadata O
and O
following O
the O
`` O
FAIR O
'' O
( O
Findable O
, O
Accessible O
, O
Interoperable O
, O
and O
Reusable O
) O
data O
principles O
. O
Viruses O
2020 O
, O
12 O
, O
107 O
2 O
of O
22 O
flocks O
and O
wild O
birds O
, O
suggesting O
that O
pre-existing O
biosecurity O
measurements O
could O
not O
keep O
up O
with O
the O
rate O
of O
livestock O
intensification O
[ O
16 O
] O
. O
In O
2007-2010 O
, O
a O
large-scale O
Q O
fever O
outbreak O
was O
reported O
in O
the O
Netherlands O
, O
affecting O
more O
than O
3500 O
human O
cases O
and O
resulting O
in O
a O
huge O
economic O
loss O
[ O
17 O
, O
18 O
] O
. O
A O
steep O
increase O
in O
the O
number O
of O
goat O
farms O
most O
likely O
was O
the O
driver O
for O
the O
increased O
prevalence O
of O
Coxiella O
burnetii O
infections O
, O
with O
animal O
abortion O
waves O
that O
had O
gone O
unnoticed O
. O
The O
policy O
of O
voluntary O
reporting O
abortion O
outbreaks O
to O
the O
Animal O
Health O
Service O
hindered O
the O
timely O
detection O
of O
the O
circulation O
of O
Q O
fever O
, O
and O
therefore O
early O
interventions O
. O
These O
examples O
indicate O
that O
zoonotic O
risks O
in O
the O
livestock O
industry O
should O
be O
carefully O
managed O
and O
adapted O
to O
livestock O
intensification O
. O
The O
One O
Health O
approach O
has O
been O
coined O
for O
advocating O
collaboration O
between O
multiple O
stakeholders O
including O
veterinarians O
, O
clinicians O
, O
epidemiologists O
, O
virologists O
, O
microbiologists O
, O
ecologists O
, O
and O
policy O
makers O
to O
prevent O
and O
control O
EIDs O
through O
the O
human-animal-environment O
interface O
[ O
19 O
] O
. O
Surveillance O
of O
livestock O
and O
the O
surrounding O
environment O
is O
a O
hallmark O
of O
early O
detection O
but O
is O
currently O
targeted O
to O
known O
risks O
. O
Advances O
in O
Next-Generation O
Sequencing O
( O
NGS O
) O
technologies O
and O
rapid O
development O
of O
bioinformatics O
and O
computational O
tools O
offer O
new O
opportunities O
for O
EID O
surveillance O
in O
quality O
and O
in O
scale O
. O
Particularly O
, O
metagenomic O
NGS O
( O
mNGS O
) O
allows O
unbiased O
detection O
of O
all O
microbes O
and O
viruses O
in O
a O
sample O
, O
showing O
potential O
for O
timely O
detection O
of O
rare O
or O
novel O
infectious O
etiologies O
, O
as O
well O
as O
for O
surveillance O
of O
foodborne O
and O
waterborne O
viruses O
[ O
20 O
] O
[ O
21 O
] O
[ O
22 O
] O
[ O
23 O
] O
[ O
24 O
] O
[ O
25 O
] O
[ O
26 O
] O
. O
However O
, O
the O
use O
of O
mNGS O
as O
a O
potential O
surveillance O
tool O
requires O
a O
deeper O
understanding O
of O
what O
is O
`` O
normal O
'' O
diversity O
in O
humans O
[ O
27 O
] O
, O
as O
well O
as O
wildlife O
[ O
28,29 O
] O
and O
farm O
animals O
[ O
30 O
] O
. O
Characterizing O
species-specific O
metagenomes O
could O
potentially O
be O
used O
to O
provide O
a O
surveillance O
baseline O
for O
early O
detection O
and O
for O
tracking O
of O
movements O
of O
pathogens O
across O
different O
hosts O
, O
and O
has O
been O
promoted O
by O
projects O
like O
the O
global O
virome O
project O
[ O
31 O
] O
. O
However O
, O
for O
such O
applications O
, O
detailed O
background O
is O
needed O
regarding O
coverage O
, O
representativeness O
, O
and O
biases O
in O
the O
study O
designs O
. O
Here O
, O
we O
conduct O
a O
systematic O
review O
to O
identify O
available O
literature O
that O
performed O
viral B-DNA
mNGS E-DNA
in O
common O
farm O
animals O
including O
cattle O
, O
small O
ruminants O
( O
goats O
and O
sheep O
) O
, O
poultry O
, O
and O
pigs O
. O
We O
reviewed O
the O
data O
and O
metadata O
availability O
and O
quality O
of O
these O
studies O
. O
We O
further O
summarized O
reported O
viromes O
of O
common O
farm O
animals O
in O
order O
to O
translate O
these O
efforts O
as O
background O
virus O
diversity O
profiles O
of O
common O
farm O
animals O
to O
guide O
preparedness O
of O
diseases O
at O
the O
livestock-human O
interface O
. O
M.A.A O
. O
) O
; O
Mobarak.Mraheil O
@ O
mikrobio.med.uni-giessen.de O
( O
M.A.M O
. O
) O
† O
These O
authors O
contributed O
equally O
to O
this O
work O
. O
Abstract O
: O
Vaccination O
is O
the O
most O
functional O
medical O
intervention O
to O
prophylactically O
control O
severe O
diseases O
caused O
by O
human-to-human O
or O
animal-to-human O
transmissible O
viral O
pathogens O
. O
Annually O
, O
seasonal O
influenza O
epidemics O
attack O
human O
populations O
leading O
to O
290-650 O
thousand O
deaths/year O
worldwide O
. O
Recently O
, O
a O
novel O
Middle O
East O
Respiratory O
Syndrome O
Coronavirus O
emerged O
. O
Together O
, O
those O
two O
viruses O
present O
a O
significant O
public O
health O
burden O
in O
areas O
where O
they O
circulate O
. O
Herein O
, O
we O
generated O
a O
bacterial O
outer O
membrane O
vesicles O
( O
OMVs O
) O
-based O
vaccine O
presenting O
the O
antigenic O
stable O
chimeric B-protein
fusion I-protein
protein E-protein
of O
the O
H1-type B-protein
haemagglutinin E-protein
( O
HA S-protein
) O
of O
the O
pandemic O
influenza O
A O
virus O
( O
H1N1 O
) O
strain O
from O
2009 O
( O
H1N1pdm09 O
) O
and O
the O
receptor B-protein
binding I-protein
domain E-protein
( O
RBD S-protein
) O
of O
the O
Middle O
East O
Respiratory O
Syndrome O
Coronavirus O
( O
MERS-CoV O
) O
( O
OMVs-H1/RBD O
) O
. O
Our O
results O
showed O
that O
the O
chimeric B-protein
antigen E-protein
could O
induce O
specific O
neutralizing O
antibodies O
against O
both O
strains O
leading O
to O
protection O
of O
immunized O
mice O
against O
H1N1pdm09 S-protein
and O
efficient O
neutralization O
of O
MERS-CoV S-protein
. O
This O
study O
demonstrate O
that O
OMVs-based O
vaccines O
presenting O
viral B-protein
antigens E-protein
provide O
a O
safe O
and O
reliable O
approach O
to O
protect O
against O
two O
different O
viral O
infections O
. O
Both O
environmental O
factors O
and O
genetic O
factors O
are O
involved O
in O
the O
pathogenesis O
of O
autism O
spectrum O
disorders O
( O
ASDs O
) O
. O
Epigenetics O
, O
an O
essential O
mechanism O
for O
gene O
regulation O
based O
on O
chemical O
modifications O
of O
DNA O
and O
histone B-protein
proteins E-protein
, O
is O
also O
involved O
in O
congenital O
ASDs O
. O
It O
was O
recently O
demonstrated O
that O
environmental O
factors O
, O
such O
as O
endocrine O
disrupting O
chemicals O
and O
mental O
stress O
in O
early O
life O
, O
can O
change O
epigenetic O
status O
and O
gene O
expression O
, O
and O
can O
cause O
ASDs O
. O
Moreover O
, O
environmentally O
induced O
epigenetic O
changes O
are O
not O
erased O
during O
gametogenesis O
and O
are O
transmitted O
to O
subsequent O
generations O
, O
leading O
to O
changes O
in O
behavior O
phenotypes O
. O
However O
, O
epigenetics O
has O
a O
reversible O
nature O
since O
it O
is O
based O
on O
the O
addition O
or O
removal O
of O
chemical O
residues O
, O
and O
thus O
the O
original O
epigenetic O
status O
may O
be O
restored O
. O
Indeed O
, O
several O
antidepressants O
and O
anticonvulsants O
used O
for O
mental O
disorders O
including O
ASDs O
restore O
the O
epigenetic O
state O
and O
gene O
expression O
. O
Therefore O
, O
further O
epigenetic O
understanding O
of O
ASDs O
is O
important O
for O
the O
development O
of O
new O
drugs O
that O
take O
advantages O
of O
epigenetic O
reversibility O
. O
Background O
: O
Years O
of O
advocacy O
for O
the O
neglected O
tropical O
diseases O
( O
NTDs O
) O
have O
focused O
the O
world O
's O
attention O
on O
these O
diseases O
of O
the O
poor O
, O
resulting O
most O
recently O
in O
the O
2012 O
`` O
London O
Declaration O
'' O
and O
the O
recent O
World O
Health O
Assembly O
Resolution O
WHA66.12 O
on O
NTDs O
in O
May O
2013 O
. O
Control O
of O
the O
endemic O
neglected O
zoonotic O
diseases O
( O
NZDs O
) O
would O
benefit O
from O
a O
similar O
campaign O
, O
which O
needs O
the O
support O
of O
a O
global O
community O
. O
Mesenchymal B-cell_type
stromal I-cell_type
cells E-cell_type
( O
MSC O
) O
for O
cellular O
therapy O
in O
European O
Union O
are O
classified O
as O
advanced O
therapy O
medicinal O
products O
( O
ATMPs O
) O
, O
and O
their O
production O
must O
fulfill O
the O
requirements O
of O
Good O
Manufacturing O
Practice O
( O
GMP O
) O
rules O
. O
Despite O
their O
classification O
as O
medicinal O
products O
is O
already O
well O
recognized O
, O
there O
is O
still O
a O
lack O
of O
information O
and O
indications O
to O
validate O
methods O
and O
to O
adapt O
the O
noncompendial O
and O
compendial O
methods O
to O
these O
peculiar O
biological O
products O
with O
intrinsic O
characteristics O
that O
differentiate O
them O
from O
classic O
synthetic O
or O
biologic O
drugs O
. O
In O
the O
present O
paper O
, O
we O
present O
the O
results O
of O
the O
validation O
studies O
performed O
in O
the O
context O
of O
MSC O
development O
as O
ATMPs O
for O
clinical O
experimental O
use O
. O
Specifically O
, O
we O
describe O
the O
validation O
policies O
followed O
for O
sterility O
testing O
, O
endotoxins O
, O
adventitious O
viruses O
, O
cell O
count O
, O
and O
immunophenotyping O
. O
Our O
work O
demonstrates O
that O
it O
is O
possible O
to O
fully O
validate O
analytical O
methods O
also O
for O
ATMPs O
and O
that O
a O
risk-based O
approach O
can O
fill O
the O
gap O
between O
the O
prescription O
of O
the O
available O
guidelines O
shaped O
on O
traditional O
medicinal O
products O
and O
the O
peculiar O
characteristics O
of O
these O
novel O
and O
extremely O
promising O
new O
drugs O
. O
Background O
: O
Based O
on O
clinical O
representation O
of O
disease O
symptoms O
multiple O
sclerosis O
( O
MScl O
) O
patients O
can O
be O
divided O
into O
two O
major O
subtypes O
; O
relapsing O
remitting O
( O
RR O
) O
MScl O
( O
85-90 O
% O
) O
and O
primary O
progressive O
( O
PP O
) O
MScl O
( O
10-15 O
% O
) O
. O
Proteomics O
analysis O
of O
cerebrospinal O
fluid O
( O
CSF O
) O
has O
detected O
a O
number O
of O
proteins O
that O
were O
elevated O
in O
MScl O
patients O
. O
Here O
we O
specifically O
aimed O
to O
differentiate O
between O
the O
PP O
and O
RR O
subtypes O
of O
MScl S-protein
by O
comparing O
CSF B-protein
proteins E-protein
. O
Methodology/Principal O
Findings O
: O
CSF O
samples O
( O
n O
= O
31 O
) O
were O
handled O
according O
to O
the O
same O
protocol O
for O
quantitative O
mass O
spectrometry O
measurements O
we O
reported O
previously O
. O
In O
the O
comparison O
of O
PP O
MScl O
versus O
RR O
MScl O
we O
observed O
a O
number O
of O
differentially O
abundant O
proteins O
, O
such O
as O
protein B-protein
jagged-1 E-protein
and O
vitamin B-protein
D-binding I-protein
protein E-protein
. O
Protein B-protein
jagged-1 E-protein
was O
over O
three O
times O
less O
abundant O
in O
PP B-protein
MScl E-protein
compared O
to O
RR B-protein
MScl E-protein
. O
Vitamin B-protein
D-binding I-protein
protein E-protein
was O
only O
detected O
in O
the O
RR O
MScl O
samples O
. O
These O
two O
proteins O
were O
validated O
by O
independent O
techniques O
( O
western O
blot O
and O
ELISA O
) O
as O
differentially O
abundant O
in O
the O
comparison O
between O
both O
MScl O
types O
. O
Background O
: O
The O
recent O
Ebola O
Virus O
Disease O
( O
EVD O
) O
epidemic O
that O
hit O
some O
countries O
in O
West O
Africa O
underscores O
the O
need O
to O
train O
front O
line O
high-risk O
health O
workers O
on O
disease O
prevention O
skills O
. O
Although O
Ghana O
did O
not O
record O
( O
and O
is O
yet O
to O
) O
any O
case O
, O
and O
several O
health O
workers O
have O
received O
numerous O
training O
schemes O
, O
there O
is O
no O
record O
of O
any O
study O
that O
assessed O
preparedness O
of O
healthcare O
workers O
( O
HCWS O
) O
regarding O
EVD O
and O
any O
emergency O
prone O
disease O
in O
Ghana O
. O
We O
therefore O
conducted O
a O
hospital O
based O
cross O
sectional O
study O
involving O
101 O
HCWs O
from O
two O
facilities O
in O
Kumasi O
, O
Ghana O
to O
assess O
the O
level O
of O
preparedness O
of O
HCWs O
to O
respond O
to O
any O
possible O
EVD O
. O
Methods O
: O
We O
administered O
a O
face-to-face O
questionnaire O
using O
an O
adapted O
WHO O
( O
2015 O
) O
and O
CDC O
( O
2014 O
) O
Checklist O
for O
Ebola O
Preparedness O
and O
assessed O
overall O
knowledge O
gaps O
, O
and O
preparedness O
of O
the O
Ghanaian O
HCWs O
in O
selected O
health O
facilities O
of O
the O
Ashanti B-DNA
Region E-DNA
of O
Ghana O
from O
October O
to O
December O
2015 O
. O
Results O
: O
A O
total O
92 O
( O
91.09 O
% O
) O
HCWs O
indicated O
they O
were O
not O
adequately O
trained O
to O
handle O
an O
EVD O
suspected O
case O
. O
Only O
25.74 O
% O
( O
n O
= O
26 O
) O
considered O
their O
facilities O
sufficiently O
equipped O
to O
handle O
and O
manage O
EVD O
patients O
. O
When O
asked O
which O
disinfectant O
to O
use O
after O
attending O
to O
and O
caring O
for O
a O
suspected O
patient O
with O
EVD O
, O
only O
8.91 O
% O
( O
n O
= O
9 O
) O
could O
correctly O
identify O
the O
right O
disinfectant O
( O
χ O
2 O
= O
28.52 O
, O
p O
= O
0.001 O
) O
. O
Conclusion O
: O
Our O
study O
demonstrates O
poor O
knowledge O
and O
ill O
preparedness O
and O
unwillingness O
of O
many O
HCWs O
to O
attend O
to O
EVD O
. O
Beyond O
knowledge O
acquisition O
, O
there O
is O
the O
need O
for O
more O
training O
from O
time O
to O
time O
to O
fully O
prepare O
HCWs O
to O
handle O
any O
possible O
EVD O
case O
. O
Background O
: O
Acute O
respiratory O
infection O
( O
ARI O
) O
is O
a O
leading O
cause O
of O
morbidity O
and O
mortality O
in O
children O
worldwide O
. O
This O
study O
aimed O
to O
determine O
the O
viral O
and O
atypical O
bacterial O
causes O
of O
different O
severities O
and O
clinical O
manifestations O
of O
ARI O
in O
preschool O
children O
from O
low-income O
families O
in O
North-East O
Brazil O
. O
Methods O
: O
Clinical/demographic O
data O
and O
nasopharyngeal O
aspirates O
( O
NPA O
) O
were O
prospectively O
collected O
from O
children O
,5 O
years O
presenting O
with O
ARI O
over O
one O
year O
to O
a O
paediatric O
A O
& O
E O
department O
. O
Disease O
severity O
was O
grouped O
according O
to O
presence O
of O
lower O
respiratory O
tract O
signs O
, O
need O
for O
hospital O
admission O
and O
need O
for O
oxygen O
. O
Clinical O
manifestation O
of O
ARI O
was O
based O
on O
discharge O
diagnosis O
from O
hospital O
with O
four O
conditions O
predominating O
: O
bronchiolitis O
, O
pneumonia O
, O
episodic O
viral O
wheeze/asthma O
and O
upper O
respiratory O
tract O
infection O
. O
Multiplex O
PCR O
was O
used O
to O
detect O
17 O
common O
respiratory O
viral O
and O
atypical O
bacterial O
pathogens O
in O
NPA O
. O
Findings O
: O
407 O
children O
with O
a O
median O
age O
of O
eight O
months O
were O
recruited O
. O
Pathogens O
were O
detected O
in O
85 O
? O
5 O
% O
samples O
with O
co-infection O
being O
particularly O
common O
( O
39 O
? O
5 O
% O
) O
. O
Respiratory O
Syncytial O
Virus O
( O
RSV O
; O
37 O
% O
) O
, O
Adenoviruses O
( O
AdV O
; O
25 O
% O
) O
, O
Rhinoviruses O
( O
hRV O
; O
19 O
% O
) O
, O
Bocavirus O
( O
hBoV O
; O
19 O
% O
) O
, O
human O
Meta-pneumovirus O
( O
hMPV O
; O
10 O
% O
) O
and O
Mycoplasma O
pneumoniae O
( O
Mpp O
; O
10 O
% O
) O
were O
most O
prevalent O
. O
Detection O
and O
co-infection O
rates O
were O
similar O
in O
all O
severities O
and O
clinical O
manifestations O
of O
ARI O
apart O
from O
RSV O
, O
which O
was O
associated O
with O
more O
severe O
disease O
and O
specifically O
more O
severe O
cases O
of O
bronchiolitis O
, O
and O
Mpp O
, O
which O
was O
associated O
with O
more O
severe O
cases O
of O
pneumonia O
. O
Mpp O
was O
detected O
in O
17 O
% O
of O
children O
admitted O
to O
hospital O
with O
pneumonia O
. O
Interpretation O
: O
This O
study O
underlines O
the O
importance O
of O
viral O
and O
atypical O
bacterial O
pathogens O
in O
ARI O
in O
pre-school O
children O
and O
highlights O
the O
complex O
epidemiology O
of O
these O
pathogens O
in O
this O
age O
group O
. O
Generally O
, O
viruses O
and O
atypical O
bacteria O
were O
detected O
in O
all O
severities O
and O
clinical O
manifestations O
of O
ARI O
but O
RSV O
and O
Mpp O
were O
associated O
with O
more O
severe O
cases O
of O
bronchiolitis O
and O
pneumonia O
respectively O
. O
Introduction O
: O
Healthcare O
workers O
( O
HCW O
) O
are O
exposed O
to O
infectious O
agents O
. O
Disease O
surveillance O
is O
therefore O
needed O
in O
order O
to O
foster O
prevention O
. O
The O
data O
of O
the O
compensation O
board O
that O
covers O
HCWs O
of O
non-governmental O
healthcare O
providers O
in O
Germany O
was O
analysed O
for O
a O
five-year O
period O
. O
For O
hepatitis O
B O
virus O
( O
HBV O
) O
and O
hepatitis O
C O
virus O
( O
HCV O
) O
infections O
, O
the O
period O
analysed O
was O
extended O
to O
the O
last O
15 O
years O
. O
The O
annual O
rate O
of O
occupational O
infectious O
diseases O
( O
OIDs O
) O
per O
100,000 O
employees O
was O
calculated O
. O
For O
needlestick O
injuries O
( O
NSI O
) O
a O
rate O
per O
1,000 O
employees O
was O
calculated O
. O
Results O
: O
Within O
the O
five O
years O
from O
2005 O
to O
2009 O
a O
total O
of O
384 O
HCV O
infections O
were O
recognised O
as O
OIDs O
( O
1.5/100,000 O
employees O
) O
. O
Active O
TB O
was O
the O
second O
most O
frequent O
cause O
of O
an O
OID O
. O
While O
the O
numbers O
of O
HBV O
and O
HCV O
infections O
decreased O
, O
the O
numbers O
for O
active O
TB O
did O
not O
follow O
a O
clear O
pattern O
. O
Needlestick O
injuries O
( O
NSIs O
) O
were O
reported O
especially O
often O
at O
hospitals O
( O
29.9/1,000 O
versus O
7.4/1,000 O
employees O
for O
all O
other O
HCWs O
) O
. O
Conclusion O
: O
Although O
they O
are O
declining O
, O
HCV O
infections O
remain O
frequent O
in O
HCWs O
, O
as O
do O
NSIs O
. O
Whether O
the O
reinforcement O
of O
the O
recommendations O
for O
the O
use O
of O
safety O
devices O
in O
Germany O
will O
prevent O
NSIs O
and O
therefore O
HCV O
infections O
should O
be O
closely O
observed O
. O
Pre-existing O
immunity O
to O
human O
adenovirus O
serotype O
5 O
( O
Ad5 O
) O
is O
common O
in O
the O
general O
population O
. O
Bypassing O
pre-existing O
immunity O
could O
maximize O
Ad5 O
vaccine O
efficacy O
. O
Vaccination O
by O
the O
intramuscular O
( O
I.M O
. O
) O
, O
nasal O
( O
I.N O
. O
) O
or O
oral O
( O
P.O O
. O
) O
route O
with O
Ad5 O
expressing O
Ebola B-protein
Zaire I-protein
glycoprotein E-protein
( O
Ad5-ZGP S-protein
) O
fully O
protected O
naïve O
mice O
against O
lethal O
challenge O
with O
Ebola O
. O
In O
the O
presence O
of O
pre-existing O
immunity O
, O
only O
mice O
vaccinated O
I.N O
. O
survived O
. O
The O
frequency O
of O
IFN-c+ B-cell_type
CD8+ I-cell_type
T I-cell_type
cells E-cell_type
was O
reduced O
by O
80 O
% O
and O
by O
15 O
% O
in O
animals O
vaccinated O
by O
the O
I.M O
. O
and O
P.O O
. O
routes O
respectively O
. O
Neutralizing B-protein
antibodies E-protein
could O
not O
be O
detected O
in O
serum O
from O
either O
treatment O
group O
. O
Pre-existing O
immunity O
did O
not O
compromise O
the O
frequency O
of O
IFN-c+ B-cell_type
CD8+ I-cell_type
T I-cell_type
cells E-cell_type
( O
3.961 O
% O
naïve O
vs. O
3.661 O
% O
pre-existing O
immunity O
, O
PEI O
) O
nor O
anti-Ebola B-protein
neutralizing I-protein
antibody E-protein
( O
NAB O
, O
40610 O
reciprocal O
dilution O
, O
both O
groups O
) O
. O
The O
number O
of O
INF-c+ B-cell_type
CD8+ I-cell_type
cells E-cell_type
detected O
in O
bronchioalveolar O
lavage O
fluid O
( O
BAL O
) O
after O
I.N O
. O
immunization O
was O
not O
compromised O
by O
pre-existing O
immunity O
to O
Ad5 O
( O
146614 O
, O
naïve O
vs. O
120616 O
SFC/million O
MNCs O
, O
PEI O
) O
. O
However O
, O
pre-existing O
immunity O
reduced O
NAB O
levels O
in O
BAL O
by O
,25 O
% O
in O
this O
group O
. O
To O
improve O
the O
immune O
response O
after O
oral O
vaccination O
, O
the O
Ad5-based O
vaccine O
was O
PEGylated O
. O
Mice O
given O
the O
modified O
vaccine O
did O
not O
survive O
challenge O
and O
had O
reduced O
levels O
of O
IFN-c+ B-cell_type
CD8+ I-cell_type
T I-cell_type
cells E-cell_type
10 O
days O
after O
administration O
( O
0.360.3 O
% O
PEG O
vs. O
1.760.5 O
% O
unmodified O
) O
. O
PEGylation O
did O
increase O
NAB O
levels O
2-fold O
. O
These O
results O
provide O
some O
insight O
about O
the O
degree O
of O
T B-cell_type
and I-cell_type
B I-cell_type
cell E-cell_type
mediated O
immunity O
necessary O
for O
protection O
against O
Ebola O
virus O
and O
suggest O
that O
modification O
of O
the O
virus O
capsid O
can O
influence O
the O
type O
of O
immune O
response O
elicited O
by O
an O
Ad5-based O
vaccine O
. O
Zika O
virus O
( O
ZIKV O
) O
infection O
is O
currently O
one O
of O
the O
major O
concerns O
in O
human O
public O
health O
due O
to O
its O
association O
with O
neurological O
disorders O
. O
Intensive O
effort O
has O
been O
implemented O
for O
the O
treatment O
of O
ZIKV O
, O
however O
there O
are O
not O
currently O
approved O
vaccines O
or O
antivirals O
available O
to O
combat O
ZIKV O
infection O
. O
In O
this O
sense O
, O
the O
identification O
of O
virulence B-protein
factors E-protein
associated O
with O
changes O
in O
ZIKV O
virulence O
could O
help O
to O
develop O
safe O
and O
effective O
countermeasures O
to O
treat O
ZIKV O
or O
to O
prevent O
future O
outbreaks O
. O
Here O
, O
we O
have O
compared O
the O
virulence O
of O
two O
related O
ZIKV O
strains O
from O
the O
recent O
outbreak O
in O
Brazil O
( O
2015 O
) O
, O
Rio O
Grande O
do O
Norte O
Natal O
( O
RGN O
) O
and O
Paraiba O
. O
In O
spite O
of O
both O
viruses O
being O
identified O
in O
the O
same O
period O
of O
time O
and O
region O
, O
significant O
differences O
in O
virulence O
and O
replication O
were O
observed O
using O
a O
validated O
mouse O
model O
of O
ZIKV O
infection O
. O
While O
ZIKV-RGN S-protein
has O
a O
50 O
% O
mouse O
lethal O
dose O
( O
MLD O
50 O
) O
of O
~10 O
5 O
focus O
forming O
units O
( O
FFUs O
) O
, O
ZIKV-Paraiba O
infection O
resulted O
in O
100 O
% O
of O
lethality O
with O
less O
than O
10 O
FFUs S-DNA
. O
Combining O
deep-sequencing O
analysis O
and O
our O
previously O
described O
infectious O
ZIKV-RGN B-DNA
cDNA I-DNA
clone E-DNA
, O
we O
identified O
a O
natural O
polymorphism O
in O
the O
non-structural B-protein
protein I-protein
2 I-protein
A E-protein
( O
NS2A S-protein
) O
that O
increase O
the O
virulence O
of O
ZIKV S-protein
. O
Moreover O
, O
results O
demonstrate O
that O
the O
single O
amino O
acid O
alanine O
to O
valine O
substitution O
at O
position O
117 O
( O
A117V O
) O
in O
the O
NS2A S-protein
was O
sufficient O
to O
convert O
the O
attenuated O
rZIKV-RGN S-protein
in O
a O
virulent O
Paraiba-like O
virus O
( O
MLD O
50 O
< O
10 O
FFU O
) O
. O
The O
mechanism O
of O
action O
was O
also O
evaluated O
and O
data O
indicate O
that O
substitution O
A117V B-protein
in I-protein
ZIKV I-protein
NS2A I-protein
protein E-protein
reduces O
host O
innate O
immune O
responses O
and O
viralinduced O
apoptosis O
in O
vitro O
. O
Therefore O
, O
amino O
acid O
substitution O
A117V O
in O
ZIKV O
NS2A O
could O
be O
used O
as O
a O
genetic O
risk-assessment O
marker O
for O
future O
ZIKV O
outbreaks O
. O
Zika O
virus O
( O
ZIKV O
) O
is O
an O
emerging O
mosquito-borne O
flavivirus O
, O
which O
became O
a O
global O
public O
concern O
due O
to O
its O
association O
with O
an O
increase O
in O
congenital O
microcephaly O
cases O
in O
Brazil O
in O
2015 O
1 O
. O
ZIKV O
was O
first O
isolated O
in O
1947 O
from O
a O
sentinel O
rhesus O
monkey O
in O
the O
Zika O
forest O
of O
Uganda O
2 O
. O
ZIKV O
infection O
in O
humans O
was O
first O
described O
during O
a O
jaundice O
epidemic O
in O
Nigeria O
in O
1954 O
3 O
and O
only O
sporadic O
cases O
of O
ZIKV O
infection O
in O
humans O
have O
been O
reported O
in O
Africa O
and O
Asia O
over O
the O
last O
century O
4-8 O
. O
It O
was O
not O
until O
2007 O
, O
when O
ZIKV O
caused O
the O
first O
outbreak O
on O
Yap O
Island O
in O
the O
Federated O
States O
of O
Micronesia O
with O
almost O
75 O
% O
of O
the O
population O
showing O
signs O
of O
infection O
9 O
. O
ZIKV O
was O
historically O
associated O
with O
a O
mild O
febrile O
illness O
, O
which O
is O
similar O
to O
that O
caused O
by O
other O
mosquito-borne O
diseases O
of O
public O
relevance O
such O
as O
Dengue O
virus O
( O
DENV O
) O
, O
Yellow O
fever O
virus O
( O
YFV O
) O
or O
Chikungunya O
virus O
( O
CHIKV O
) O
10 O
. O
The O
similarity O
of O
the O
clinical O
signs O
of O
ZIKV O
disease O
with O
those O
of O
DENV O
or O
CHIKV O
has O
interfered O
with O
ZIKV O
diagnosis O
and O
most O
probably O
underestimated O
the O
number O
of O
cases O
of O
ZIKV O
infections O
11 O
. O
However O
, O
ZIKV O
has O
become O
a O
major O
human O
health O
concern O
due O
to O
its O
association O
with O
severe O
neurological O
complications O
, O
including O
an O
increased O
risk O
of O
Guillain-Barré O
syndrome O
in O
adults O
during O
the O
large O
outbreak O
in O
French O
Polynesia O
in O
2013-2014 O
12,13 O
and O
a O
dramatic O
increase O
in O
severe O
congenital O
malformations O
, O
including O
fetal O
microcephaly O
in O
neonates O
during O
the O
massive O
epidemic O
that O
emerged O
in O
Brazil O
in O
2015 O
[ O
14 O
] O
[ O
15 O
] O
[ O
16 O
] O
[ O
17 O
] O
[ O
18 O
] O
[ O
19 O
] O
. O
Since O
then O
, O
millions O
of O
infected O
individuals O
have O
been O
reported O
in O
South O
and O
Central O
America O
, O
the O
Caribbean O
and O
the O
South O
of O
United O
States O
20-22 O
. O
ZIKV O
is O
primarily O
transmitted O
through O
the O
bite O
of O
an O
infected O
Aedes O
spp O
. O
mosquito O
( O
Aedes O
aegypti O
and O
Aedes O
albopictus O
) O
6,23-25 O
. O
However O
, O
non-vector O
ZIKV O
transmission O
has O
been O
reported O
to O
occur O
by O
vertical O
transmission O
from O
mother O
to O
child O
14 O
, O
26 O
, O
27 O
and O
by O
sexual O
transmission O
25,28-30 O
. O
In O
addition O
, O
ZIKV B-RNA
RNA E-RNA
has O
been O
detected O
in O
body O
fluids O
including O
blood O
, O
urine O
, O
semen O
, O
saliva O
and O
breast O
milk O
, O
increasing O
the O
risk O
of O
a O
human O
to O
human O
transmission O
via O
direct O
contact O
with O
body O
fluids O
from O
infected O
people O
31,32 O
. O
ZIKV O
is O
a O
positive O
single-stranded O
RNA O
virus O
with O
a O
genome O
of O
about O
10.8 O
kb O
that O
contains O
a O
cap O
structure O
at O
the O
5′-end S-DNA
and O
a O
single B-DNA
open I-DNA
reading I-DNA
frame E-DNA
( O
ORF S-DNA
) O
flanked O
by O
two O
5′ B-DNA
and I-DNA
3′ I-DNA
untranslated I-DNA
regions I-DNA
( I-DNA
UTRs I-DNA
) I-DNA
33,34 E-DNA
. O
The O
ORF S-DNA
encodes O
a O
single O
polyprotein O
of O
approximately O
3,424 O
amino O
acids O
that O
is O
co-and O
post-translationally O
processed O
by O
viral B-protein
and I-protein
cellular I-protein
proteases E-protein
to O
produce O
three O
structural B-protein
proteins E-protein
, O
capsid B-protein
( I-protein
C I-protein
) E-protein
, O
pre-membrane S-protein
( O
prM S-protein
) O
and O
envelope B-protein
( I-protein
E I-protein
) I-protein
, I-protein
and I-protein
seven I-protein
non-structural I-protein
( I-protein
NS I-protein
) I-protein
proteins E-protein
( O
NS1 B-RNA
, I-RNA
NS2A I-RNA
, I-RNA
NS2B I-RNA
, I-RNA
NS3 I-RNA
, I-RNA
NS4A I-RNA
, I-RNA
NS4B I-RNA
and I-RNA
NS5 I-RNA
) I-RNA
33,34 E-RNA
. O
Phylogenetic O
analyses O
of O
ZIKV B-DNA
genomes E-DNA
have O
identified O
two O
major O
genetic O
lineages O
, O
African O
and O
Asian O
35 O
. O
ZIKV O
strains O
from O
the O
recent O
epidemic O
in O
the O
Americas O
are O
phylogenetically O
related O
to O
the O
Asian O
lineage O
36,37 O
. O
The O
molecular O
determinants O
of O
ZIKV S-protein
evolution O
, O
spread O
, O
virulence O
, O
and O
disease O
have O
not O
been O
totally O
established O
. O
It O
has O
been O
postulated O
that O
ZIKV B-DNA
genome E-DNA
changes O
may O
have O
evolved O
to O
modify O
tissue O
tropism O
, O
becoming O
more O
neurotrophic O
8,38-41 O
, O
and/or O
more O
efficiently O
transmitted O
to O
humans O
8,32,42-44 O
, O
but O
the O
virulence B-protein
factors E-protein
associated O
with O
ZIKV O
pathogenesis O
remain O
unknown O
. O
During O
the O
last O
years O
, O
extensive O
efforts O
have O
been O
made O
to O
develop O
in O
vitro O
and O
in O
vivo O
approaches O
to O
study O
ZIKV O
infection O
and O
pathogenesis O
, O
including O
reverse O
genetic O
systems O
34 O
and O
suitable O
animal O
models O
of O
infection O
45 O
. O
In O
this O
sense O
, O
the O
emergence O
of O
ZIKV O
has O
promoted O
the O
rapid O
development O
of O
numerous O
reverse O
genetic O
approaches O
34 O
, O
which O
constitute O
an O
essential O
tool O
for O
research O
to O
generate O
recombinant O
viruses O
containing O
specific O
substitutions O
to O
evaluate O
their O
contribution O
in O
viral O
replication O
or O
transcription O
, O
pathogenicity O
, O
virus-host O
interaction O
, O
viral O
tropism O
and O
transmissibility O
[ O
46 O
] O
[ O
47 O
] O
[ O
48 O
] O
. O
Recently O
, O
we O
have O
developed O
a O
reverse O
genetic O
approach O
based O
on O
the O
use O
of O
a O
bacterial B-DNA
artificial I-DNA
chromosome E-DNA
( O
BAC S-DNA
) O
to O
assemble O
the O
full-length B-DNA
cDNA E-DNA
of O
the O
viral O
genome O
of O
ZIKV O
Rio O
Grande O
do O
Norte O
Natal O
( O
RGN O
) O
strain O
( O
Brazil O
, O
2015 O
) O
49 O
. O
On O
the O
other O
hand O
, O
animal O
models O
are O
essential O
to O
understand O
the O
biology O
and O
pathogenesis O
of O
ZIKV O
. O
It O
is O
known O
that O
infection O
of O
immunocompetent O
mice O
results O
in O
little O
to O
no O
virus O
production O
, O
and O
infected O
mice O
do O
not O
develop O
disease O
50 O
. O
However O
, O
mice O
with O
deficiencies O
in O
the O
interferon S-protein
( O
IFN S-protein
) O
signaling O
pathway O
display O
enhanced O
susceptibility O
to O
infection O
by O
ZIKV O
and O
other O
flaviviruses O
, O
and O
they O
recapitulate O
many O
of O
the O
symptoms O
associated O
with O
infections O
in O
humans O
45,51-54 O
. O
Therefore O
, O
these O
animal O
models O
are O
currently O
used O
to O
study O
ZIKV O
infection O
in O
vivo O
, O
including O
the O
development O
of O
new O
therapeutic O
approaches O
to O
combat O
and/or O
prevent O
ZIKV O
infections O
24 O
, O
45 O
, O
50 O
, O
52 O
, O
55 O
. O
In O
the O
present O
study O
, O
we O
have O
analyzed O
the O
virulence O
of O
ZIKV-RGN O
and O
Paraiba O
, O
two O
viral O
strains O
that O
have O
been O
identified O
from O
the O
recent O
outbreak O
in O
Brazil O
in O
2015 O
. O
Using O
the O
validated O
type-I B-protein
IFN I-protein
receptor E-protein
deficient O
( O
IFNAR−/− O
) O
A129 O
mice O
model O
of O
ZIKV O
infection O
, O
we O
have O
observed O
that O
ZIKV-Paraiba S-protein
is O
more O
virulent O
and O
replicates O
to O
higher O
levels O
compared O
to O
rZIKV-RGN S-protein
. O
Combining O
deep-sequencing O
analysis O
and O
reverse O
genetic O
systems O
, O
we O
have O
identified O
a O
single O
amino O
acid O
polymorphism O
at O
position B-DNA
117 E-DNA
in O
the O
viral B-protein
protein E-protein
NS2A S-protein
responsible O
for O
the O
differences O
in O
virulence O
between O
both O
ZIKV O
strains O
. O
This O
polymorphism O
( O
A117V S-DNA
) O
in O
ZIKV B-DNA
NS2A E-DNA
affects O
host O
innate O
immune O
responses O
and O
viral-induced O
apoptosis O
, O
and O
, O
therefore O
, O
represents O
an O
important O
viral O
genetic O
marker O
for O
risk-assessment O
to O
prevent O
future O
ZIKV O
outbreaks O
. O
( O
2019 O
) O
9:19968 O
| O
https O
: O
//doi.www.nature.com/scientificreports O
www.nature.com/scientificreports/ O
was O
removed O
, O
and O
the O
cell O
monolayers O
were O
overlaid O
with O
100 O
μl O
of O
viral O
growth O
media O
containing O
1 O
% O
microcrystalline O
cellulose O
( O
Avicel O
, O
Sigma-Aldrich O
) O
. O
After O
36 O
hpi O
, O
cells O
were O
fixed O
with O
4 O
% O
formaldehyde O
for O
1 O
h O
at O
room O
temperature O
and O
the O
overlays O
removed O
. O
Cells O
were O
then O
permeabilized O
with O
0.5 O
% O
Triton O
X-100 O
in O
PBS O
for O
15 O
min O
at O
room O
temperature O
, O
blocked O
with O
2.5 O
% O
bovine B-protein
serum I-protein
albumin E-protein
( O
BSA S-protein
) O
in O
PBS O
, O
and O
used O
for O
immunofluorescence O
with O
the O
pan-flavivirus B-protein
E I-protein
protein I-protein
monoclonal I-protein
antibody I-protein
( I-protein
mAb I-protein
) I-protein
4G2 E-protein
( O
BEI S-protein
resources O
; O
NR-50327 O
) O
and O
a O
secondary B-protein
AlexaFluor488-conjugated I-protein
goat I-protein
anti-mouse E-protein
IgG S-protein
( O
Invitrogen S-protein
) O
. O
Viral O
titers O
were O
expressed O
as O
FFU/ml S-protein
, O
determined O
by O
the O
average O
number O
of O
E-positive O
foci O
at O
the O
highest O
dilutions O
in O
triplicates O
. O
Plaque O
assay O
and O
immunostaining O
. O
Subconfluent O
monolayers O
of O
Vero B-cell_line
cells E-cell_line
( O
6-well O
plate O
format O
, O
1 O
× O
10 O
6 O
cells/well O
) O
were O
infected O
with O
0.5 O
ml O
of O
viruses O
for O
90 O
min O
at O
37 O
°C O
. O
Then O
, O
2 O
ml O
of O
viral O
growth O
media O
supplemented O
with O
0.6 O
% O
Agar O
Noble O
( O
Difco O
) O
and O
1 O
% O
DEAE-Dextran S-protein
( O
Sigma-Aldrich O
) O
was O
added O
to O
each O
well O
. O
After O
3 O
days O
of O
incubation O
at O
37 O
°C O
, O
cells O
were O
fixed O
with O
4 O
% O
formaldehyde O
for O
1 O
h O
and O
the O
overlays O
removed O
. O
Cells O
were O
then O
permeabilized O
with O
0.5 O
% O
Triton O
X-100 O
in O
PBS O
for O
15 O
min O
at O
room O
temperature O
and O
prepared O
for O
immunostaining O
using O
the O
pan-flavivirus B-protein
E I-protein
protein I-protein
mAb I-protein
4G2 E-protein
. O
Viral O
plaques O
were O
visualized O
using O
Vectastin O
ABC O
kit O
and O
DAB O
HRP O
substrate O
( O
Vector O
Laboratories O
Inc. O
) O
, O
following O
the O
manufacturer O
's O
instructions O
. O
Scientific O
RepoRtS O
| O
( O
2019 O
) O
9:19968 O
| O
https O
: O
//doi.org/10.1038/s41598-019-56291-4 O
www.nature.com/scientificreports O
www.nature.com/scientificreports/ O
Statistical O
analysis O
. O
For O
quantitative O
analyses O
, O
a O
two-tailed O
, O
unpaired O
Student O
t O
test O
was O
used O
to O
analyze O
differences O
in O
mean O
values O
between O
groups O
. O
All O
results O
were O
expressed O
as O
mean O
+/− O
standard O
deviations O
( O
SD O
) O
of O
the O
means O
. O
P O
values O
of O
< O
0.05 O
were O
considered O
significant O
. O
The O
initial O
interaction O
between O
viral B-protein
attachment I-protein
proteins E-protein
and O
the O
host O
cell O
is O
a O
critical O
determinant O
for O
the O
susceptibility O
of O
a O
host O
for O
a O
particular O
virus O
. O
To O
increase O
our O
understanding O
of O
avian O
pathogens O
and O
the O
susceptibility O
of O
poultry O
species O
, O
we O
developed O
novel O
avian O
tissue O
microarrays O
( O
TMAs O
) O
. O
Tissue O
binding O
profiles O
of O
avian B-protein
viral I-protein
attachment I-protein
proteins E-protein
were O
studied O
by O
performing O
histochemistry O
on O
multi-species O
TMA O
, O
comprising O
of O
selected O
tissues O
from O
ten O
avian O
species O
, O
and O
single-species B-protein
TMAs E-protein
, O
grouping O
organ O
systems O
of O
each O
species O
together O
. O
The O
attachment O
pattern O
of O
the O
hemagglutinin B-protein
protein E-protein
was O
in O
line O
with O
the O
reported O
tropism O
of O
influenza O
virus O
H5N1 O
, O
confirming O
the O
validity O
of O
TMAs S-protein
in O
profiling O
the O
initial O
virus-host O
interaction O
. O
The O
previously O
believed O
chicken-specific B-protein
coronavirus I-protein
( I-protein
CoV I-protein
) I-protein
M41 I-protein
spike I-protein
( I-protein
S1 I-protein
) I-protein
protein E-protein
displayed O
a O
broad O
attachment O
pattern O
to O
respiratory O
tissues O
of O
various O
avian O
species O
, O
albeit O
with O
lower O
affinity O
than O
hemagglutinin S-protein
, O
suggesting O
that O
other O
avian O
species O
might O
be O
susceptible O
for O
chicken B-protein
CoV E-protein
. O
When O
comparing O
tissue-specific O
binding O
patterns O
of O
various O
avian B-protein
coronaviral I-protein
S1 I-protein
proteins E-protein
on O
the O
single-species B-protein
TMAs E-protein
, O
chicken B-protein
and I-protein
partridge I-protein
CoV I-protein
S1 E-protein
had O
predominant O
affinity O
for O
the O
trachea O
, O
while O
pigeon B-protein
CoV I-protein
S1 E-protein
showed O
marked O
preference O
for O
lung O
of O
their O
respective O
hosts O
. O
Binding O
of O
all O
coronaviral B-protein
S1 I-protein
proteins E-protein
was O
dependent O
on O
sialic O
acids O
; O
however O
, O
while O
chicken B-protein
CoV I-protein
S1 E-protein
preferred O
sialic O
acids O
type O
I O
lactosamine O
( O
Gal O
( O
1-3 O
) O
GlcNAc O
) O
over O
type B-protein
II I-protein
( I-protein
Gal I-protein
( I-protein
1-4 I-protein
) I-protein
GlcNAc E-protein
) O
, O
the O
fine O
glycan O
specificities O
of O
pigeon O
and O
partridge O
CoVs O
were O
different O
, O
as O
chicken B-protein
CoV I-protein
S1-specific I-protein
sialylglycopolymers E-protein
could O
not O
block O
their O
binding O
to O
tissues O
. O
Taken O
together O
, O
TMAs S-protein
provide O
a O
novel O
platform O
in O
the O
field O
of O
infectious O
diseases O
to O
allow O
identification O
of O
binding O
specificities O
of O
viral B-protein
attachment I-protein
proteins E-protein
and O
are O
helpful O
to O
gain O
insight O
into O
the O
susceptibility O
of O
host O
and O
organ O
for O
avian O
pathogens O
. O
In O
the O
model O
fungus O
Podospora O
anserina O
, O
the O
PaYIP3 B-DNA
gene E-DNA
encoding O
the O
orthologue O
of O
the O
Saccharomyces B-protein
cerevisiae I-protein
YIP3 I-protein
Rab-GDI I-protein
complex I-protein
dissociation I-protein
factor E-protein
expresses O
two O
polypeptides O
, O
one O
of O
which O
, O
the O
long O
form O
, O
is O
produced O
through O
a O
programmed O
translation O
frameshift O
. O
Inactivation O
of O
PaYIP3 S-protein
results O
in O
slightly O
delayed O
growth O
associated O
with O
modification O
in O
repartition O
of O
fruiting O
body O
on O
the O
thallus O
, O
along O
with O
reduced O
ascospore O
production O
on O
wood O
. O
Long O
and O
short O
forms O
of O
PaYIP3 S-protein
are O
expressed O
in O
the O
mycelium O
, O
while O
only O
the O
short O
form O
appears O
expressed O
in O
the O
maturing O
fruiting O
body O
( O
perithecium O
) O
. O
The O
frameshift O
has O
been O
conserved O
over O
the O
evolution O
of O
the O
Pezizomycotina O
, O
lasting O
for O
over O
400 O
million O
years O
, O
suggesting O
that O
it O
has O
an O
important O
role O
in O
the O
wild O
. O
Coronavirus O
disease O
( O
COVID-19 O
) O
in O
a O
paucisymptomatic O
patient O
: O
epidemiological O
and O
clinical O
challenge O
in O
settings O
with O
limited O
community O
transmission O
, O
Background O
: O
Intravenous O
( O
IV O
) O
zanamivir O
could O
be O
a O
suitable O
alternative O
for O
the O
treatment O
of O
severe O
influenza O
A O
( O
H1N1 O
) O
pdm09 O
infection O
in O
patients O
who O
are O
unable O
to O
take O
oral O
or O
inhaled O
medication O
, O
for O
example O
, O
those O
on O
mechanical O
ventilation O
and O
extracorporeal O
membrane O
oxygenation O
( O
ECMO O
) O
. O
However O
, O
data O
on O
the O
clinical O
outcomes O
of O
such O
patients O
is O
limited O
. O
Case O
presentation O
: O
We O
report O
the O
clinical O
outcomes O
of O
four O
patients O
who O
were O
admitted O
at O
the O
intensive O
care O
unit O
during O
the O
2017-2018 O
influenza O
season O
with O
severe O
sepsis O
( O
SOFA O
score O
> O
11 O
) O
and O
acute O
respiratory O
distress O
syndrome O
requiring O
ECMO O
and O
mechanical O
ventilation O
. O
Two O
patients O
were O
immune-compromised O
. O
The O
A O
( O
H1N1 O
) O
pdm09 O
genome O
was O
confirmed O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
on O
nasopharyngeal O
specimen O
swabs O
prior O
to O
administration O
of O
IV O
zanamivir O
at O
a O
dose O
of O
600 O
mg O
twice O
daily O
. O
Weekly O
qualitative O
PCR O
analysis O
was O
done O
to O
monitor O
viral O
clearance O
, O
with O
zanamivir O
treatment O
being O
discontinued O
upon O
receipt O
of O
negative O
results O
. O
In O
addition O
, O
the O
patients O
were O
managed O
for O
concomitant O
multidrug-resistant O
bacterial O
infections O
, O
with O
infection O
resolution O
confirmed O
with O
blood O
cultures O
. O
The O
median O
time O
for O
zanamivir O
treatment O
was O
10 O
days O
( O
IQR O
10-17 O
) O
. O
The O
clinical O
outcome O
was O
favourable O
with O
all O
four O
patients O
surviving O
and O
improving O
clinically O
. O
All O
four O
patients O
achieved O
viral O
clearance O
of O
A O
( O
H1N1 O
) O
pdm09 O
genome O
, O
and O
resolution O
of O
multidrug-resistant O
bacterial O
infections O
. O
Conclusions O
: O
IV O
zanamivir O
could O
be O
a O
good O
therapeutic O
option O
in O
patients O
with O
severe O
influenza O
A O
( O
H1N1 O
) O
pdm09 O
infection O
who O
are O
unable O
to O
take O
oral O
or O
aerosolised O
antiviral O
medication O
. O
We O
recommend O
prospective O
randomized O
control O
trials O
to O
support O
this O
hypothesis O
. O
Chlamydiae O
may O
exist O
at O
the O
site O
of O
infection O
in O
an O
alternative O
replicative O
form O
, O
called O
the O
aberrant O
body O
( O
AB O
) O
. O
ABs S-protein
are O
produced O
during O
a O
viable O
but O
non-infectious O
developmental O
state O
termed O
`` O
persistence O
'' O
or O
`` O
chlamydial O
stress O
. O
'' O
As O
persistent/stressed O
chlamydiae O
: O
( O
i O
) O
may O
contribute O
to O
chronic O
inflammation O
observed O
in O
diseases O
like O
trachoma O
; O
and O
( O
ii O
) O
are O
more O
resistant O
to O
current O
anti-chlamydial O
drugs O
of O
choice O
, O
it O
is O
critical O
to O
better O
understand O
this O
developmental O
stage O
. O
We O
previously O
demonstrated O
that O
porcine O
epidemic O
diarrhea O
virus O
( O
PEDV O
) O
co-infection O
induced O
Chlamydia O
pecorum O
persistence/stress O
in O
culture O
. O
One O
critical O
characteristic O
of O
persistence/stress O
is O
that O
the O
chlamydiae O
remain O
viable O
and O
can O
reenter O
the O
normal O
developmental O
cycle O
when O
the O
stressor O
is O
removed O
. O
Thus O
, O
we O
hypothesized O
that O
PEDV-induced O
persistence O
would O
be O
reversible O
if O
viral O
replication O
was O
inhibited O
. O
Therefore O
, O
we O
performed O
time O
course O
experiments O
in O
which O
Vero B-cell_line
cells E-cell_line
were O
C. O
pecorum/PEDV O
infected O
in O
the O
presence O
of O
cycloheximide O
( O
CHX O
) O
, O
which O
inhibits O
viral O
but O
not O
chlamydial O
protein O
synthesis O
. O
CHX-exposure O
inhibited O
PEDV O
replication O
, O
but O
did O
not O
inhibit O
induction O
of O
C. O
pecorum O
persistence O
at O
24 O
h O
post-PEDV O
infection O
, O
as O
indicated O
by O
AB O
formation O
and O
reduced O
production O
of O
infectious B-protein
EBs E-protein
. O
Interestingly O
, O
production O
of O
infectious O
EBs O
resumed O
when O
CHX-exposed B-cell_line
, I-cell_line
co-infected I-cell_line
cells E-cell_line
were O
incubated O
48-72 O
h O
post-PEDV O
co-infection O
. O
These O
data O
demonstrate O
that O
PEDV O
co-infection-induced O
chlamydial O
persistence/stress O
is O
reversible O
and O
suggest O
that O
this O
induction O
( O
i O
) O
does O
not O
require O
viral O
replication O
in O
host B-cell_type
cells E-cell_type
; O
and O
( O
ii O
) O
does O
not O
require O
de O
novo O
host O
or O
viral O
protein O
synthesis O
. O
These O
data O
also O
suggest O
that O
viral O
binding O
and/or O
entry O
may O
be O
required O
for O
this O
effect O
. O
Because O
the O
PEDV B-protein
host I-protein
cell I-protein
receptor E-protein
( O
CD13 S-protein
or O
aminopeptidase B-protein
N E-protein
) O
stimulates O
cellular O
signaling O
pathways O
in O
the O
absence O
of O
PEDV O
infection O
, O
we O
suspect O
that O
PEDV O
co-infection O
might O
alter O
CD13 S-protein
function O
and O
induce O
the O
chlamydiae O
to O
enter O
the O
persistent O
state O
. O
Fast O
point-of-use O
detection O
of O
, O
for O
example O
, O
early-stage O
zoonoses O
, O
e.g. O
, O
Q-fever O
, O
bovine O
tuberculosis O
, O
or O
the O
Covid-19 O
coronavirus O
, O
is O
beneficial O
for O
both O
humans O
and O
animal O
husbandry O
as O
it O
can O
save O
lives O
and O
livestock O
. O
The O
latter O
prevents O
farmers O
from O
going O
bankrupt O
after O
a O
zoonoses O
outbreak O
. O
This O
paper O
describes O
the O
development O
of O
a O
fabrication O
process O
and O
the O
proof-of-principle O
of O
a O
disposable O
DNA O
amplification O
chip O
with O
an O
integrated O
heater O
. O
Based O
on O
the O
analysis O
of O
the O
milling O
process O
, O
metal O
adhesion O
studies O
, O
and O
COMSOL O
MultiPhysics O
heat O
transfer O
simulations O
, O
the O
first O
batch O
of O
chips O
has O
been O
fabricated O
and O
successful O
multiple O
displacement O
amplification O
reactions O
are O
performed O
inside O
these O
chips O
. O
This O
research O
is O
the O
first O
step O
towards O
the O
development O
of O
an O
early-stage O
zoonoses O
detection O
device O
. O
Tests O
with O
real O
zoonoses O
and O
DNA O
specific O
amplification O
reactions O
still O
need O
to O
be O
done O
. O
Background O
: O
Advances O
in O
molecular O
diagnostics O
have O
implicated O
newly-discovered O
respiratory O
viruses O
in O
the O
pathogenesis O
of O
pneumonia O
. O
We O
aimed O
to O
determine O
the O
prevalence O
and O
clinical O
characteristics O
of O
human O
bocavirus O
( O
hBoV O
) O
, O
human O
rhinovirus O
( O
hRV O
) O
, O
polyomavirus-WU O
( O
WUPyV O
) O
and O
-KI O
( O
KIPyV O
) O
and O
human O
coronaviruses O
( O
CoV O
) O
-OC43 O
, O
-NL63 O
, O
-HKU1 O
and O
-229E O
among O
children O
hospitalized O
with O
lower O
respiratory O
tract O
infections O
( O
LRTI O
) O
. O
Methods O
: O
Multiplex O
real-time O
reverse-transcriptase O
polymerase O
chain O
reaction O
was O
undertaken O
on O
archived O
nasopharyngeal O
aspirates O
from O
HIV-infected O
and O
-uninfected O
children O
( O
,2 O
years O
age O
) O
hospitalized O
for O
LRTI O
, O
who O
had O
been O
previously O
investigated O
for O
respiratory O
syncytial O
virus O
, O
human O
metapneumovirus O
, O
parainfluenza O
I-III O
, O
adenovirus B-protein
and I-protein
influenza I-protein
A/B E-protein
. O
Results O
: O
At O
least O
one O
of O
these O
viruses O
were O
identified O
in O
274 O
( O
53.0 O
% O
) O
of O
517 O
and O
in O
509 O
( O
54.0 O
% O
) O
of O
943 O
LRTI-episodes O
in O
HIVinfected O
and O
-uninfected O
children O
, O
respectively O
. O
Human O
rhinovirus O
was O
the O
most O
prevalent O
in O
HIV-infected O
( O
31.7 O
% O
) O
anduninfected O
children O
( O
32.0 O
% O
) O
, O
followed O
by O
CoV-OC43 O
( O
12.2 O
% O
) O
and O
hBoV O
( O
9.5 O
% O
) O
in O
HIV-infected O
; O
and O
by O
hBoV O
( O
13.3 O
% O
) O
and O
WUPyV O
( O
11.9 O
% O
) O
in O
HIV-uninfected O
children O
. O
Polyomavirus-KI O
( O
8.9 O
% O
vs. O
4.8 O
% O
; O
p O
= O
0.002 O
) O
and O
CoV-OC43 O
( O
12.2 O
% O
vs. O
3.6 O
% O
; O
p O
, O
0.001 O
) O
were O
more O
prevalent O
in O
HIV-infected O
than O
-uninfected O
children O
. O
Combined O
with O
previously-tested O
viruses O
, O
respiratory O
viruses O
were O
identified O
in O
60.9 O
% O
of O
HIV-infected O
and O
78.3 O
% O
of O
HIV-uninfected O
children O
. O
The O
newly O
tested O
viruses O
were O
detected O
at O
high O
frequency O
in O
association O
with O
other O
respiratory O
viruses O
, O
including O
previously-investigated O
viruses O
( O
22.8 O
% O
in O
HIV-infected O
and O
28.5 O
% O
in O
HIV-uninfected O
children O
) O
. O
We O
established O
that O
combined O
with O
previously-investigated O
viruses O
, O
at O
least O
one O
respiratory O
virus O
was O
identified O
in O
the O
majority O
of O
HIV-infected O
and O
HIV-uninfected O
children O
hospitalized O
for O
LRTI O
. O
The O
high O
frequency O
of O
viral O
coinfections O
illustrates O
the O
complexities O
in O
attributing O
causality O
to O
specific O
viruses O
in O
the O
aetiology O
of O
LRTI O
and O
may O
indicate O
a O
synergetic O
role O
of O
viral O
co-infections O
in O
the O
pathogenesis O
of O
childhood O
LRTI S-protein
. O
Serum B-protein
albumin E-protein
is O
one O
of O
the O
most O
widely O
studied O
proteins O
. O
It O
is O
the O
most O
abundant O
protein O
in O
plasma O
with O
a O
typical O
concentration O
of O
5 O
g/100 O
mL O
and O
the O
principal O
transporter O
of O
fatty O
acids O
in O
plasma O
. O
While O
the O
crystal O
structures O
of O
human B-protein
serum I-protein
albumin E-protein
( O
HSA S-protein
) O
free O
and O
in O
complex O
with O
fatty O
acids O
, O
hemin O
, O
and O
local O
anesthetics O
have O
been O
characterized O
, O
no O
crystallographic O
models O
are O
available O
on O
bovine B-protein
serum I-protein
albumin E-protein
( O
BSA S-protein
) O
, O
presumably O
because O
of O
the O
poor O
diffraction O
power O
of O
existing O
hexagonal O
BSA S-protein
crystals O
. O
Here O
, O
the O
crystallization O
and O
diffraction O
data O
of O
a O
new O
BSA B-protein
crystal I-protein
form E-protein
, O
obtained O
by O
the O
hanging O
drop O
method O
using O
MPEG B-protein
5K E-protein
as O
precipitating O
agent O
, O
are O
presented O
. O
The O
crystals O
belong O
to O
space O
group O
C2 O
, O
with O
unit-cell O
parameters O
a O
= O
216.45 O
Å O
, O
b O
= O
44.72 O
Å O
, O
c O
= O
140.18 O
Å O
, O
β O
= O
114.5° O
. O
Dehydration O
was O
found O
to O
increase O
the O
diffraction O
limit O
of O
BSA S-protein
crystals O
from O
~8 O
Å O
to O
3.2 O
Å O
, O
probably O
by O
improving O
the O
packing O
of O
protein B-protein
molecules E-protein
in O
the O
crystal O
lattice O
. O
These O
results O
, O
together O
with O
a O
survey O
of O
more O
than O
60 O
successful O
cases O
of O
protein O
crystal O
dehydration O
, O
confirm O
that O
it O
can O
be O
a O
useful O
procedure O
to O
be O
used O
in O
initial O
screening O
as O
a O
method O
of O
improving O
the O
diffraction O
limits O
of O
existing O
crystals O
. O
Int O
. O
J. O
Mol O
. O
Sci O
. O
2012 O
, O
13 O
3783 O
Background O
: O
Iron O
is O
an O
essential O
nutrient O
, O
and O
iron O
supplementation O
has O
been O
shown O
to O
reduce O
the O
incidence O
of O
abomasal O
bloat O
in O
lambs O
. O
Additionally O
, O
iron O
deficiency O
is O
linked O
to O
pica O
, O
which O
may O
increase O
uptake O
of O
Eimeria O
oocysts O
. O
Coccidiosis O
in O
sheep O
, O
caused O
by O
Eimeria O
spp. O
, O
is O
an O
important O
infection O
, O
leading O
to O
reduced O
welfare O
and O
economic O
losses O
. O
The O
aims O
of O
our O
study O
were O
to O
investigate O
: O
( O
1 O
) O
the O
use O
of O
iron O
supplementation O
in O
Norwegian O
sheep O
flocks O
using O
a O
questionnaire O
survey O
, O
and O
( O
2 O
) O
whether O
iron O
supplementation O
reduced O
excretion O
of O
Eimeria O
oocysts O
and O
increased O
the O
growth O
rates O
of O
young O
lambs O
. O
A O
questionnaire O
regarding O
the O
use O
of O
iron O
supplementation O
, O
sent O
to O
all O
members O
of O
the O
Norwegian O
Sheep O
Recording O
System O
( O
n O
= O
4993 O
) O
, O
showed O
that O
152/1823 O
farmers O
iron-supplemented O
lambs O
, O
either O
orally O
( O
56.7 O
% O
) O
or O
by O
injection O
( O
43.3 O
% O
) O
. O
The O
main O
purpose O
of O
supplementation O
was O
to O
prevent O
abomasal O
bloat O
( O
38.4 O
% O
) O
, O
coccidiosis O
( O
9.3 O
% O
) O
, O
or O
both O
( O
27.8 O
% O
) O
. O
In O
the O
field O
study O
, O
102 O
twin O
lambs O
from O
five O
flocks O
were O
included O
: O
one O
twin O
( O
treated O
) O
received O
600 O
mg O
of O
gleptoferron O
subcutaneously O
within O
3 O
days O
of O
birth O
, O
whereas O
the O
control O
was O
given O
saline O
. O
McMaster O
analysis O
of O
individual O
faecal O
samples O
obtained O
at O
weekly O
intervals O
( O
n O
= O
4 O
per O
lamb O
, O
starting O
at O
turnout O
) O
showed O
no O
significant O
difference O
in O
oocyst O
excretion O
between O
treatment O
groups O
at O
any O
sampling O
, O
except O
for O
one O
flock O
14 O
days O
after O
turnout O
. O
Mean O
growth O
rates O
, O
measured O
at O
iron O
injection O
, O
21 O
days O
after O
turnout O
, O
and O
in O
the O
autumn O
, O
differed O
significantly O
between O
treated O
and O
untreated O
lambs O
from O
iron O
injection O
to O
21 O
days O
after O
turnout O
, O
however O
, O
no O
difference O
in O
growth O
rates O
was O
observed O
in O
the O
overall O
period O
from O
iron O
injection O
to O
autumn O
. O
Blood O
analysis O
suggested O
that O
the O
controls O
were O
at O
risk O
of O
developing O
iron O
deficiency O
anaemia O
during O
the O
housed O
period O
, O
but O
signs O
of O
anaemia O
were O
not O
observed O
. O
Conclusion O
: O
Iron O
supplementation O
of O
lambs O
was O
used O
by O
8.3 O
% O
of O
the O
farmers O
responding O
to O
the O
questionnaire O
, O
mainly O
with O
the O
intention O
to O
prevent O
abomasal O
bloat O
, O
coccidiosis O
, O
or O
both O
. O
The O
field O
trial O
results O
indicate O
that O
iron O
supplementation O
of O
young O
lambs O
do O
not O
reduce O
oocyst O
excretion O
and O
only O
induced O
a O
transitory O
increase O
in O
weight O
gain O
. O
However O
further O
studies O
, O
including O
more O
flocks O
and O
possibly O
repeated O
iron O
injections O
, O
would O
provide O
more O
definitive O
information O
. O
Purpose O
: O
Malignant O
melanoma O
's O
( O
MM O
) O
incidence O
is O
rising O
faster O
than O
that O
of O
any O
other O
cancer O
in O
the O
US O
and O
the O
overall O
survival O
at O
5 O
years O
is O
less O
than O
10 O
% O
. O
B B-protein
cell I-protein
associated I-protein
protein I-protein
31 E-protein
( O
BAP31 S-protein
) O
is O
overexpressed O
in O
most O
MMs O
and O
might O
be O
a O
promising O
target O
for O
immunotherapy O
of O
this O
disease O
. O
Experimental O
design O
: O
Firstly O
, O
we O
investigated O
the O
expression O
profiles O
of O
human B-protein
BAP31 E-protein
( O
hBAP31 S-protein
) O
and O
mouse B-protein
BAP31 E-protein
( O
mBAP31 S-DNA
) O
in O
human O
and O
mouse O
normal O
tissues O
, O
respectively O
. O
The O
expression O
level O
of O
hBAP31 S-protein
in O
human B-cell_line
MMs I-cell_line
and I-cell_line
mBAP31 I-cell_line
in I-cell_line
B16 I-cell_line
melanoma I-cell_line
cells E-cell_line
was O
also O
analyzed O
. O
Then O
we O
constructed O
novel O
mBAP31 S-protein
DNA O
vaccines O
and O
tested O
there O
ability O
to O
stimulate O
mBAP31-specific O
immune O
responses O
and O
antitumor O
immunity O
in O
B16 O
melanoma-bearing O
mice O
. O
Results O
: O
For O
the O
first O
time O
, O
we O
found O
that O
protein O
expression O
of O
hBAP31 S-protein
were O
dramatically O
upregulated O
in O
human O
MMs O
when O
compared O
with O
human O
normal O
tissues O
. O
Predominant O
protein O
expression O
of O
mBAP31 S-protein
was O
found O
in O
mouse B-cell_line
B16 I-cell_line
melanoma I-cell_line
cells E-cell_line
but O
not O
in O
mouse O
important O
organs O
. O
When O
mice O
were O
immunized O
with O
mBAP31 S-protein
DNA O
vaccines O
, O
strong O
cellular O
response O
to O
mBAP31 S-protein
was O
observed O
in O
the O
vaccinated O
mice O
. O
CTLs S-cell_type
isolated O
from O
immunized O
mice O
could O
effectively O
kill O
mBAP31-positive B-cell_line
target I-cell_line
mouse I-cell_line
B16 I-cell_line
melanoma I-cell_line
tumor I-cell_line
cells E-cell_line
in O
vitro O
and O
vaccination O
with O
mBAP31 O
DNA O
vaccines O
had O
potent O
anti-tumor O
activity O
in O
therapeutic O
model O
using O
B16 B-cell_line
melanoma I-cell_line
cells E-cell_line
. O
Conclusions O
: O
These O
are O
the O
first O
data O
supporting O
a O
vaccine O
targeting O
BAP31 S-protein
that O
is O
capable O
of O
inducing O
effective O
immunity O
against O
BAP31-expressing O
MMs O
and O
will O
be O
applicable O
to O
human O
MMs O
and O
hBAP31 O
DNA O
vaccine O
warrants O
investigation O
in O
human O
clinical O
trials O
. O
Arabian O
peninsula O
and O
sporadic O
cases O
in O
Europe O
and O
Asia O
. O
This O
study O
was O
conducted O
to O
evaluate O
the O
genetic O
analysis O
of O
this O
virus O
in O
human O
and O
camel O
at O
the O
first O
time O
in O
Iraq O
. O
Two O
hundred O
samples O
were O
collected O
from O
camels O
and O
human O
who O
suffering O
from O
respiratory O
symptoms O
, O
these O
samples O
treated O
with O
RNA O
extraction O
kit O
then O
amplification O
the O
genetic O
material O
by O
PCR O
which O
give O
5 O
% O
positive O
results O
. O
The O
amplicon O
then O
sequenced O
, O
registration O
in O
gene O
bank O
of O
NCBI S-DNA
for O
getting O
accession O
numbers O
. O
The O
local O
strains O
give O
close O
relationship O
with O
neighbor O
countries O
as O
Saudi O
Arabia O
and O
Jordan O
strains O
when O
using O
MEGA O
analysis O
software O
. O
Carnero O
have O
contributed O
equally O
to O
this O
work O
. O
Many O
long B-RNA
non-coding I-RNA
RNAs E-RNA
( O
lncRNAs S-DNA
) O
are O
expressed O
in O
cells O
but O
only O
a O
few O
have O
been O
well O
characterized O
. O
In O
these O
cases O
, O
lncRNAs S-protein
have O
been O
shown O
to O
be O
key O
regulators O
of O
several O
cellular O
processes O
. O
Therefore O
, O
there O
is O
a O
great O
need O
to O
understand O
the O
function O
of O
more O
lncRNAs S-protein
and O
their O
regulation O
in O
response O
to O
stimuli O
. O
Interferon S-protein
( O
IFN S-protein
) O
is O
a O
key O
molecule O
in O
the O
cellular O
antiviral O
response O
. O
IFN S-protein
binding O
to O
its O
receptor O
activates O
transcription O
of O
several O
IFN-stimulated B-DNA
genes E-DNA
( O
ISGs S-DNA
) O
that O
function O
as O
potent O
antivirals O
. O
In O
addition O
, O
several O
ISGs S-protein
are O
positive O
or O
negative O
regulators O
of O
the O
IFN S-protein
pathway O
. O
This O
is O
essential O
to O
ensure O
a O
strong O
antiviral O
response O
and O
a O
later O
return O
of O
the O
cell O
to O
homeostasis O
. O
As O
the O
ISGs S-DNA
described O
to O
date O
are O
coding O
genes O
, O
we O
sought O
to O
determine O
whether O
IFN S-protein
also O
regulates O
the O
expression O
of O
long B-protein
non-coding I-protein
ISGs E-protein
. O
To O
this O
aim O
, O
we O
used O
RNA O
sequencing O
to O
analyze O
the O
transcriptome O
of O
control O
and O
HuH7 B-cell_line
cells E-cell_line
treated O
with O
IFNα2 S-protein
. O
The O
results O
show O
that O
IFN-treatment S-protein
regulates O
the O
expression O
of O
several O
unknown O
non-coding B-RNA
transcripts E-RNA
. O
We O
have O
validated O
two O
lncRNAs S-protein
upregulated O
after O
treatment O
with O
different O
doses O
of O
type B-protein
I I-protein
IFNα2 E-protein
in O
different O
cells O
or O
with O
type B-protein
III I-protein
IFNλ E-protein
. O
These O
lncRNAs S-protein
were O
also O
induced O
by O
influenza O
and O
vesicular O
stomatitis O
virus O
mutants O
unable O
to O
block O
the O
IFN S-protein
response O
, O
but O
not O
by O
several O
wild-type B-DNA
lytic I-DNA
viruses I-DNA
tested.These I-DNA
lncRNA I-DNA
genes E-DNA
were O
named O
lncISG15 S-protein
and O
lncBST2 S-protein
as O
they O
are O
located O
close O
to O
ISGs B-DNA
ISG15 E-DNA
and O
BST2 S-DNA
, O
respectively O
. O
Interestingly O
, O
inhibition O
experiments O
showed O
that O
lncBST2 S-protein
is O
a O
positive O
regulator O
of O
BST2 S-protein
. O
Therefore O
lncBST2 S-protein
has O
been O
renamed O
BISPR S-protein
, O
from O
BST2 B-protein
IFN-stimulated I-protein
positive I-protein
regulator E-protein
. O
Our O
results O
may O
have O
therapeutic O
implications O
as O
lncBST2/BISPR S-protein
, O
but O
also O
lncISG15 S-protein
and O
their O
coding O
neighbors O
, O
are O
increased O
in O
cells O
infected O
with O
hepatitis O
C O
virus O
and O
in O
the O
liver O
of O
infected O
patients O
. O
These O
results O
allow O
us O
to O
hypothesize O
that O
several O
lncRNAs S-protein
could O
be O
activated O
by O
IFN S-protein
to O
control O
the O
potency O
of O
the O
antiviral O
IFN S-protein
response O
. O
Citation O
: O
Barriocanal O
M O
, O
Carnero O
E O
, O
Segura O
V O
and O
Fortes O
P O
( O
2015 O
) O
Long B-DNA
non-coding I-DNA
RNA I-DNA
BST2/BISPR E-DNA
is O
induced O
by O
IFN S-protein
and O
regulates O
the O
expression O
of O
the O
antiviral B-protein
factor I-protein
tetherin E-protein
. O
Front O
. O
Immunol O
. O
5:655 O
. O
On O
17 O
September O
2015 O
, O
Buliisa O
District O
Health O
Office O
reported O
multiple O
deaths O
due O
to O
haemorrhage O
to O
the O
Uganda O
Ministry O
of O
Health O
. O
We O
conducted O
an O
investigation O
to O
verify O
the O
existence O
of O
an O
outbreak O
and O
to O
identify O
the O
disease O
nature O
, O
mode O
of O
transmission O
and O
risk O
factors O
. O
Methods O
: O
We O
defined O
a O
suspected O
case O
as O
onset O
of O
hematemesis O
between O
1 O
June O
2015 O
and O
15 O
October O
2015 O
in O
a O
resident O
of O
Hoima O
, O
Buliisa O
or O
neighbouring O
districts O
. O
We O
identified O
cases O
by O
reviewing O
medical O
records O
and O
actively O
searching O
in O
the O
community O
. O
We O
interviewed O
casepatients O
and O
health-care O
workers O
and O
performed O
descriptive O
epidemiology O
to O
generate O
hypotheses O
on O
possible O
exposures O
. O
In O
a O
case-control O
study O
we O
compared O
exposures O
between O
21 O
cases O
and O
81 O
controls O
, O
matched O
by O
age O
( O
± O
10 O
years O
) O
, O
sex O
and O
village O
of O
residence O
. O
We O
collected O
22 O
biological O
specimens O
from O
19 O
case-patients O
to O
test O
for O
Viral O
Haemorrhagic O
Fevers O
( O
VHF O
) O
. O
We O
analysed O
the O
data O
using O
the O
Mantel-Haenszel O
method O
to O
account O
for O
the O
matched O
study O
design O
. O
Results O
: O
We O
identified O
56 O
cases O
with O
onset O
from O
June O
to O
October O
( O
attack O
rate O
15/100,000 O
in O
Buliisa O
District O
and O
5.2/100,000 O
in O
Hoima O
District O
) O
. O
The O
age-specific O
attack O
rate O
was O
highest O
in O
persons O
aged O
31-60 O
years O
( O
15/100,000 O
in O
Hoima O
and O
47/100,000 O
in O
Buliisa O
) O
; O
no O
persons O
below O
15 O
years O
of O
age O
had O
the O
illness O
. O
In O
the O
case-control O
study O
, O
42 O
% O
( O
5/12 O
) O
of O
cases O
vs. O
0.0 O
% O
( O
0/77 O
) O
of O
controls O
had O
liver O
disease O
( O
ORM-H O
= O
∞ O
; O
95 O
% O
CI O
= O
3.7-∞ O
) O
; O
71 O
% O
( O
10/14 O
) O
of O
cases O
vs. O
35 O
% O
( O
28/81 O
) O
of O
controls O
had O
ulcer O
disease O
( O
ORM-H O
= O
13 O
; O
95 O
% O
CI O
= O
1.6-98 O
) O
; O
27 O
% O
( O
3/11 O
) O
of O
cases O
vs. O
14 O
% O
( O
11/81 O
) O
of O
controls O
used O
indomethacin O
prior O
to O
disease O
onset O
( O
ORM-H O
= O
6.0 O
; O
95 O
% O
CI O
= O
1.0-36 O
) O
. O
None O
of O
the O
blood O
samples O
were O
positive O
for O
any O
of O
the O
VHFs O
. O
Conclusion O
: O
This O
reported O
cluster O
of O
hematemesis O
illness O
was O
due O
to O
predisposing O
conditions O
and O
use O
of O
Non-Steroidal O
Anti-inflammatory O
Drugs O
( O
NSAID O
) O
. O
Health O
education O
should O
be O
conducted O
on O
the O
danger O
of O
NSAIDs O
misuse O
, O
especially O
in O
persons O
with O
predisposing O
conditions O
. O
Human O
coronaviruses O
( O
HCoV O
) O
OC43 O
, O
229E O
, O
NL63 O
, O
and O
HKU1 O
are O
common O
respiratory O
viruses O
which O
cause O
various O
respiratory O
diseases O
, O
including O
pneumonia O
. O
There O
is O
a O
paucity O
of O
evidence O
on O
the O
epidemiology O
and O
clinical O
manifestations O
of O
these O
four O
HCoV O
strains O
worldwide O
. O
We O
collected O
11,399 O
throat O
swabs O
from O
hospitalized O
children O
with O
acute O
respiratory O
tract O
infection O
from O
These O
were O
tested O
for O
four O
strains O
of O
HCoV O
infection O
using O
real-time O
polymerase O
chain O
reaction O
( O
PCR O
) O
. O
HCoV-positive O
patients O
were O
then O
tested O
for O
11 O
other O
respiratory O
pathogens O
. O
4.3 O
% O
( O
489/11399 O
) O
of O
patients O
were O
positive O
for O
HCoV O
, O
of O
which O
3.0 O
% O
were O
positive O
for O
OC43 O
( O
346/11399 O
) O
, O
0.6 O
% O
for O
229E O
( O
65/11399 O
) O
, O
0.5 O
% O
for O
NL63 O
( O
60/ O
11399 O
) O
, O
and O
0.3 O
% O
for O
HKU1 O
( O
38/11399 O
) O
. O
Patients O
aged O
7-12 O
months O
had O
the O
highest O
prevalence O
of O
HCoV O
and O
OC43 O
when O
compared O
with O
other O
age O
groups O
( O
p O
< O
0.001 O
) O
. O
The O
peak O
seasons O
of O
infection O
varied O
depending O
on O
the O
HCoV O
strain O
. O
Patients O
infected O
with O
a O
single O
strain O
of O
HCoV O
infection O
were O
less O
likely O
to O
present O
fever O
( O
≥ O
38°C O
) O
( O
p O
= O
0.014 O
) O
and O
more O
likely O
to O
present O
pulmonary O
rales O
( O
p O
= O
0.043 O
) O
than O
those O
co-infected O
with O
more O
than O
one O
HCoV O
strain O
or O
other O
respiratory O
pathogens O
. O
There O
were O
also O
significant O
differences O
in O
the O
prevalence O
of O
certain O
symptoms O
, O
including O
coughing O
( O
p O
= O
0.032 O
) O
, O
pneumonia O
( O
p O
= O
0.026 O
) O
, O
and O
abnormal O
pulmonary O
rales O
( O
p O
= O
0.002 O
) O
according O
to O
the O
strain O
of O
HCoV O
detected O
. O
This O
retrospective O
study O
of O
the O
prevalence O
of O
four O
HCoV O
strains O
and O
clinical O
signs O
among O
a O
large O
population O
of O
pediatric O
patients O
in O
a O
subtropical O
region O
of O
China O
provides O
further O
insight O
into O
the O
epidemiology O
and O
clinical O
features O
of O
HCoV O
. O
Human O
respiratory O
syncytial O
virus O
( O
hRSV O
) O
and O
human O
metapneumovirus O
( O
hMPV O
) O
, O
two O
members O
of O
the O
Pneumoviridae O
family O
, O
account O
for O
the O
majority O
of O
severe O
lower O
respiratory O
tract O
infections O
worldwide O
in O
very O
young O
children O
. O
They O
are O
also O
a O
frequent O
cause O
of O
morbidity O
and O
mortality O
in O
the O
elderly O
and O
immunocompromised O
adults O
. O
High O
levels O
of O
neutralizing B-protein
antibodies E-protein
, O
mostly O
directed O
against O
the O
viral B-protein
fusion I-protein
( I-protein
F I-protein
) I-protein
glycoprotein E-protein
, O
correlate O
with O
protection O
against O
either O
hRSV S-protein
or O
hMPV S-protein
. O
However O
, O
no O
cross-neutralization O
is O
observed O
in O
polyclonal O
antibody O
responses O
raised O
after O
virus O
infection O
or O
immunization O
with O
purified B-protein
F I-protein
proteins E-protein
. O
Based O
on O
crystal O
structures O
of O
hRSV B-protein
F E-protein
and O
hMPV B-protein
F E-protein
, O
we O
designed O
chimeric B-protein
F I-protein
proteins E-protein
in O
which O
certain O
residues O
of O
well-characterized O
antigenic O
sites O
were O
swapped O
between O
the O
two O
antigens S-protein
. O
The O
antigenic O
changes O
were O
monitored O
by O
ELISA O
with O
virus-specific B-protein
monoclonal I-protein
antibodies E-protein
. O
Inoculation O
of O
mice O
with O
these O
chimeras O
induced O
polyclonal O
cross-neutralizing O
antibody O
responses O
, O
and O
mice O
were O
protected O
against O
challenge O
with O
the O
virus O
used O
for O
grafting O
of O
the O
heterologous B-DNA
antigenic I-DNA
site E-DNA
. O
These O
results O
provide O
a O
proof O
of O
principle O
for O
chimeric B-protein
fusion I-protein
proteins E-protein
as O
single O
immunogens O
that O
can O
induce O
cross-neutralizing B-protein
antibody E-protein
and O
protective O
responses O
against O
more O
than O
one O
human O
pneumovirus O
. O
Background O
: O
In O
the O
healthy O
central O
nervous O
system O
( O
CNS O
) O
, O
microglia S-cell_type
are O
found O
in O
a O
homeostatic O
state O
and O
peripheral B-cell_type
macrophages E-cell_type
are O
absent O
from O
the O
brain O
. O
Microglia S-cell_type
play O
key O
roles O
in O
maintaining O
CNS O
homeostasis O
and O
acting O
as O
first O
responders O
to O
infection O
and O
inflammation O
, O
and O
peripheral B-cell_type
macrophages E-cell_type
infiltrate O
the O
CNS O
during O
neuroinflammation O
. O
Due O
to O
their O
distinct O
origins O
and O
functions O
, O
discrimination O
between O
these O
cell O
populations O
is O
essential O
to O
the O
comprehension O
of O
neuroinflammatory O
disorders O
. O
Studies O
comparing O
the O
gene O
profiles O
of O
microglia S-cell_type
and O
peripheral B-cell_type
macrophages E-cell_type
, O
or O
macrophages S-cell_type
in O
vitro-derived O
from O
bone O
marrow O
, O
under O
non-infectious O
conditions O
of O
the O
CNS O
, O
have O
revealed O
valuable O
microglial-specific B-DNA
genes E-DNA
. O
However O
, O
studies O
comparing O
gene O
profiles O
between O
CNS-infiltrating B-cell_type
macrophages E-cell_type
and O
microglia S-cell_type
, O
when O
both O
are O
isolated O
from O
the O
CNS O
during O
viral-induced O
neuroinflammation O
, O
are O
lacking O
. O
Methods O
: O
We O
isolated O
, O
via O
flow O
cytometry O
, O
microglia S-cell_type
and O
infiltrating O
macrophages S-cell_type
from O
the O
brains O
of O
Theiler O
's O
murine O
encephalomyelitis O
virus-infected O
C57BL/6 O
J O
mice O
and O
used O
RNA-Seq S-protein
, O
followed O
by O
validation O
with O
qPCR S-protein
, O
to O
examine O
the O
differential O
transcriptional O
profiles O
of O
these O
cells O
. O
We O
utilized O
primary O
literature O
defining O
subcellular O
localization O
to O
determine O
whether O
or O
not O
particular O
proteins O
extracted O
from O
the O
transcriptional O
profiles O
were O
expressed O
at O
the O
cell O
surface O
. O
The O
surface O
expression O
and O
cellular O
specificity O
of O
triggering O
receptor O
expressed O
on O
myeloid B-protein
cells I-protein
1 I-protein
( I-protein
TREM-1 I-protein
) I-protein
protein E-protein
were O
examined O
via O
flow O
cytometry O
. O
We O
also O
examined O
the O
immune O
response O
gene O
profile O
within O
the O
transcriptional O
profiles O
of O
these O
isolated O
microglia S-cell_type
and O
infiltrating O
macrophages S-cell_type
. O
We O
have O
identified O
and O
validated O
new O
microglial-and B-DNA
macrophage-specific I-DNA
genes E-DNA
, O
encoding O
cell B-protein
surface I-protein
proteins E-protein
, O
expressed O
at O
the O
peak O
of O
neuroinflammation O
. O
TREM-1 B-protein
protein E-protein
was O
confirmed O
to O
be O
expressed O
by O
infiltrating O
macrophages S-cell_type
, O
not O
microglia S-cell_type
, O
at O
the O
peak O
of O
neuroinflammation O
. O
We O
also O
identified O
both O
unique O
and O
redundant O
immune O
functions O
, O
through O
examination O
of O
the O
immune O
response O
gene O
profiles O
, O
of O
microglia S-cell_type
and O
infiltrating O
macrophages S-cell_type
during O
neurotropic O
viral O
infection O
. O
The O
differential O
expression O
of O
cell B-DNA
surface-specific I-DNA
genes E-DNA
during O
neuroinflammation O
can O
potentially O
be O
used O
to O
discriminate O
between O
microglia S-cell_type
and O
macrophages S-cell_type
as O
well O
as O
provide O
a O
resource O
that O
can O
be O
further O
utilized O
to O
target O
and O
manipulate O
specific O
cell O
responses O
during O
neuroinflammation O
. O
The O
objective O
of O
the O
study O
is O
to O
develop O
an O
Alignment-free O
tool O
for O
sequence O
clustering O
. O
To O
illustrate O
the O
effectiveness O
of O
our O
method O
we O
compared O
the O
distance O
matrices O
and O
the O
phylogenetic O
trees O
generated O
by O
our O
method O
with O
the O
other O
freely O
available O
recent O
alignmentfree O
tools O
[ O
1 O
] O
. O
The O
clustering O
efficiency O
of O
our O
tool O
can O
be O
noticed O
across O
all O
the O
benchmark O
datasets O
. O
The O
phylogenetic O
trees O
generated O
by O
our O
method O
and O
the O
other O
freely O
available O
recent O
methods O
shows O
superiority O
of O
our O
method O
over O
the O
other O
methods O
in O
terms O
of O
sequence O
clustering O
. O
The O
consistency O
can O
also O
be O
seen O
from O
the O
statistical O
analysis O
such O
as O
AUC O
( O
area O
under O
the O
ROC O
) O
values O
calculated O
from O
ROC O
( O
Receiver O
operating O
characteristic O
) O
curves O
. O
AUC O
values O
are O
often O
used O
to O
explain O
the O
accuracy O
of O
models O
and O
not O
to O
compare O
them O
. O
Accuracy O
classification O
of O
AUC O
is O
summarised O
in O
Table O
1 O
, O
which O
is O
given O
below O
. O
AUC O
≥ O
0.9 O
high O
accuracy O
0.7 O
≤ O
AUC O
< O
0.9 O
moderate O
accuracy O
0.5 O
≤ O
AUC O
< O
0.7 O
Low O
accuracy O
Table O
1 O
: O
Accuracy O
classification O
of O
AUC B-DNA
[ I-DNA
2 I-DNA
, I-DNA
3 I-DNA
, I-DNA
4 I-DNA
, I-DNA
5 I-DNA
, I-DNA
6 I-DNA
] E-DNA
. O
A O
low O
AUC O
value O
does O
not O
necessarily O
imply O
a O
bad O
or O
poor O
model O
; O
rather O
it O
simply O
suggests O
that O
, O
besides O
the O
accounted O
predictors O
, O
other O
factors O
also O
exercise O
influence O
on O
the O
response O
variable O
. O
It O
is O
evident O
from O
the O
ROC O
plots O
below O
that O
our O
method O
's O
performance O
is O
in O
good O
agreement O
with O
other O
methods O
. O
The O
phylogenetic O
tree O
is O
generated O
by O
a O
distance O
matrix O
using O
PHYLIP O
package O
[ O
7 O
] O
which O
is O
equal O
to O
( O
1-similarity O
matrix O
) O
from O
equation O
( O
12 O
) O
in O
our O
manuscript O
. O
We O
used O
similarity O
matrix O
for O
ROC O
analysis O
. O
We O
follow O
sonego O
et O
al O
. O
's O
method O
[ O
8 O
] O
for O
calculating O
the O
ROC S-DNA
. O
In O
the O
similarity O
matrix O
, O
we O
put O
positive O
sign O
, O
if O
the O
two O
sequences O
belong O
to O
same O
class O
( O
i.e. O
, O
genus O
level O
classification O
, O
phylum O
level O
classification O
, O
family O
level O
classification O
, O
etc. O
, O
) O
otherwise O
we O
put O
negative O
sign O
. O
We O
plotted O
the O
ROC O
curve O
by O
changing O
the O
decision O
threshold O
in O
either O
strictly O
increasing O
or O
strictly O
decreasing O
pattern O
lies O
between O
the O
minimum O
and O
maximum O
values O
of O
the O
similarity O
matrix O
. O
We O
plotted O
the O
FPR S-DNA
( O
false O
positive O
rate O
) O
on O
Xaxis O
and O
TPR S-DNA
( O
true O
positive O
rate O
) O
on O
Y-axis O
. O
Every O
point O
in O
the O
ROC O
curve O
corresponds O
to O
a O
discrete O
classifier O
that O
can O
be O
calculated O
using O
a O
decision O
threshold O
( O
Figure O
3 O
in O
[ O
8 O
] O
) O
. O
After O
plotting O
ROC O
curve O
, O
we O
calculated O
the O
area O
under O
the O
ROC O
curve O
( O
AUC O
) O
. O
Phylogenetic O
tree O
on O
11 O
AMF B-DNA
sequences E-DNA
. O
Figure O
1 O
: O
Our O
method O
. O
Unclassified O
1 B-DNA
Uncultured I-DNA
Glomeromycota I-DNA
Sp I-DNA
11 I-DNA
Rhizophagus I-DNA
clarus I-DNA
4 I-DNA
Rhizophagus I-DNA
intraradices I-DNA
Cluster E-DNA
( O
a O
) O
10 O
Glomus O
spp O
16 O
Glomus O
sp O
18 O
Glomus O
sp O
14 O
Glomus O
Sp O
Cluster O
( O
b O
) O
Clade O
C O
12 O
Gigaspora O
margarita O
13 O
Gigaspora O
gigantea O
cluster O
( O
c O
) O
Cluster O
( O
d O
) O
15 O
Rhizophagus O
intraradices O
Clade O
D O
Clade O
A O
Unclassified O
, O
Clade O
B O
17 O
Glomeromycota O
sp O
0.0100 O
Figure O
2 O
: O
CV O
method O
using O
string O
length O
3 O
. O
Figure O
3 O
: O
FFP O
method O
using O
string O
length O
7 O
. O
In O
a O
large-scale O
epidemic O
outbreak O
, O
there O
can O
be O
many O
high-risk O
individuals O
to O
be O
transferred O
for O
medical O
isolation O
in O
epidemic O
areas O
. O
Typically O
, O
the O
individuals O
are O
scattered O
across O
different O
locations O
, O
and O
available O
quarantine O
vehicles O
are O
limited O
. O
Therefore O
, O
it O
is O
challenging O
to O
efficiently O
schedule O
the O
vehicles O
to O
transfer O
the O
individuals O
to O
isolated O
regions O
to O
control O
the O
spread O
of O
the O
epidemic O
. O
In O
this O
paper O
, O
we O
formulate O
such O
a O
quarantine O
vehicle O
scheduling O
problem O
for O
high-risk O
individual O
transfer O
, O
which O
is O
more O
difficult O
than O
most O
well-known O
vehicle O
routing O
problems O
. O
To O
efficiently O
solve O
this O
problem O
, O
we O
propose O
a O
hybrid O
algorithm O
based O
on O
the O
water O
wave O
optimization O
( O
WWO O
) O
metaheuristic O
and O
neighborhood O
search O
. O
The O
metaheuristic O
uses O
a O
small O
population O
to O
rapidly O
explore O
the O
solution O
space O
, O
and O
the O
neighborhood O
search O
uses O
a O
gradual O
strategy O
to O
improve O
the O
solution O
accuracy O
. O
Computational O
results O
demonstrate O
that O
the O
proposed O
algorithm O
significantly O
outperforms O
several O
existing O
algorithms O
and O
obtains O
high-quality O
solutions O
on O
real-world O
problem O
instances O
for O
high-risk O
individual O
transfer O
in O
Hangzhou O
, O
China O
, O
during O
the O
peak O
period O
of O
the O
novel O
coronavirus O
pneumonia O
. O
Since O
the O
first O
case O
was O
diagnosed O
on O
May O
20 O
, O
2015 O
, O
there O
were O
186 O
confirmed O
cases O
of O
Middle O
East O
Respiratory O
Syndrome O
( O
MERS O
) O
until O
the O
end O
of O
outbreak O
in O
South O
Korea O
. O
Although O
medical O
institutions O
were O
the O
most O
identifiable O
sources O
of O
MERS O
transmission O
in O
South O
Korea O
, O
similar O
to O
other O
countries O
, O
in-depth O
epidemiological O
investigation O
was O
required O
for O
some O
confirmed O
cases O
with O
indefinite O
contact O
history O
or O
hospital O
visit O
records O
. O
The O
subject O
of O
epidemiological O
investigation O
in O
the O
present O
study O
was O
a O
35 O
year-old O
male O
patient O
diagnosed O
with O
MERS O
( O
# O
119 O
) O
who O
lived O
in O
Asan-city O
and O
worked O
in O
Pyeongtaek-city O
. O
Various O
potential O
sources O
of O
transmission O
were O
carefully O
investigated O
. O
While O
he O
could O
have O
been O
exposed O
to O
MERS O
through O
a O
friend O
from O
Saudi O
Arabia O
or O
confirmed O
MERS O
cases O
in O
his O
workplace O
, O
neighboring O
areas O
, O
and O
medical O
institutions O
, O
as O
well O
as O
contacts O
in O
his O
home O
, O
the O
chances O
of O
transmission O
were O
low O
; O
however O
, O
the O
potential O
for O
transmission O
through O
his O
local O
community O
could O
not O
be O
excluded O
. O
Practically O
, O
it O
was O
difficult O
to O
determine O
the O
modes O
of O
transmission O
for O
all O
outbreak O
cases O
in O
communicable O
disease O
that O
occurred O
in O
this O
short O
period O
of O
time O
. O
The O
investigation O
to O
identify O
the O
mode O
of O
transmission O
in O
this O
case O
was O
ultimately O
unsuccessful O
. O
However O
, O
the O
various O
data O
collected O
and O
analyzed O
to O
reveal O
modes O
of O
transmission O
provided O
detailed O
information O
that O
could O
not O
be O
collected O
using O
only O
interview O
surveys O
. O
Objective O
: O
This O
paper O
describes O
the O
physical O
structure O
and O
environmental O
contamination O
in O
selected O
hospital O
wards O
in O
three O
government O
hospitals O
in O
Bangladesh O
. O
The O
qualitative O
research O
team O
conducted O
48 O
hours O
of O
observation O
in O
six O
wards O
from O
three O
Bangladeshi O
tertiary O
hospitals O
in O
2007 O
. O
They O
recorded O
environmental O
contamination O
with O
body O
secretions O
and O
excretions O
and O
medical O
waste O
and O
observed O
ward O
occupant O
handwashing O
and O
use O
of O
personal O
protective O
equipment O
. O
They O
recorded O
number O
of O
persons O
, O
number O
of O
open O
doors O
and O
windows O
, O
and O
use O
of O
fans O
. O
They O
measured O
the O
ward O
area O
and O
informally O
observed O
waste O
disposal O
outside O
the O
wards O
. O
They O
conducted O
nine O
focus O
group O
discussions O
with O
doctors O
, O
nurses O
and O
support O
staff O
. O
Results O
: O
A O
median O
of O
3.7 O
persons O
were O
present O
per O
10 O
m O
2 O
of O
floor O
space O
in O
the O
wards O
. O
A O
median O
of O
4.9 O
uncovered O
coughs O
or O
sneezes O
were O
recorded O
per O
10 O
m O
2 O
per O
hour O
per O
ward O
. O
Floors O
in O
the O
wards O
were O
soiled O
with O
saliva O
, O
spit O
, O
mucous O
, O
vomitus O
, O
feces O
and O
blood O
125 O
times O
in O
48 O
hours O
. O
Only O
two O
of O
the O
12 O
patient O
handwashing O
stations O
had O
running O
water O
and O
none O
had O
soap O
. O
No O
disinfection O
was O
observed O
before O
or O
after O
using O
medical O
instruments O
. O
Used O
medical O
supplies O
were O
often O
discarded O
in O
open O
containers O
under O
the O
beds O
. O
Handwashing O
with O
soap O
was O
observed O
in O
only O
32 O
of O
3,373 O
handwashing O
opportunities O
noted O
during O
48 O
hours O
. O
Mosquitoes O
and O
feral O
cats O
were O
commonly O
observed O
in O
the O
wards O
. O
The O
physical O
structure O
and O
environment O
of O
our O
study O
hospitals O
are O
conducive O
to O
the O
spread O
of O
infection O
to O
people O
in O
the O
wards O
. O
Low-cost O
interventions O
on O
hand O
hygiene O
and O
cleaning O
procedures O
for O
rooms O
and O
medical O
equipment O
should O
be O
developed O
and O
evaluated O
for O
their O
practicality O
and O
effectiveness O
. O
Citation O
: O
Rimi O
NA O
, O
Sultana O
R O
, O
Luby O
SP O
, O
Islam O
MS O
, O
Uddin O
M O
, O
et O
al O
. O
( O
2014 O
) O
Infrastructure O
and O
Contamination O
of O
the O
Physical O
Environment O
in O
Three O
Bangladeshi O
Hospitals O
: O
Putting O
Infection O
Control O
into O
Context O
. O
PLoS O
ONE O
9 O
( O
2 O
) O
: O
e89085 O
. O
Sialic O
acids O
( O
SAs O
) O
linked O
to O
galactose O
( O
Gal O
) O
in O
a2,3and O
a2,6-configurations O
are O
the O
receptors O
for O
avian O
and O
human O
influenza O
viruses O
, O
respectively O
. O
We O
demonstrate O
that O
chicken B-cell_type
tracheal I-cell_type
ciliated I-cell_type
cells E-cell_type
express O
a2,3-linked B-protein
SA E-protein
, O
while O
goblet B-cell_type
cells E-cell_type
mainly O
express O
a2,6-linked B-protein
SA E-protein
. O
In O
addition O
, O
the O
plant O
lectin S-protein
MAL-II S-protein
, O
but O
not O
MAA/MAL-I S-protein
, O
is O
bound O
to O
the O
surface O
of O
goblet B-cell_type
cells E-cell_type
, O
suggesting O
that O
SA2,3-linked B-protein
oligosaccharides E-protein
with O
Galb1-3GalNAc B-protein
subterminal I-protein
residues E-protein
are O
specifically O
present O
on O
the O
goblet B-cell_type
cells E-cell_type
. O
Moreover O
, O
both O
a2,3and B-cell_line
a2,6-linked I-cell_line
SAs E-cell_line
are O
detected O
on O
single B-cell_type
tracheal I-cell_type
basal I-cell_type
cells E-cell_type
. O
At O
a O
low O
multiplicity O
of O
infection O
( O
MOI O
) O
avian O
influenza O
virus O
H6N1 O
is O
exclusively O
detected O
in O
the O
ciliated B-cell_type
cells E-cell_type
, O
suggesting O
that O
the O
ciliated B-cell_type
cell E-cell_type
is O
the O
major O
target O
cell O
of O
the O
H6N1 O
virus O
. O
At O
a O
MOI O
of O
1 O
, O
ciliated B-cell_type
, I-cell_type
goblet I-cell_type
and I-cell_type
basal I-cell_type
cells E-cell_type
are O
all O
permissive O
to O
the O
AIV O
infection O
. O
This O
result O
clearly O
elucidates O
the O
receptor O
distribution O
for O
the O
avian O
influenza O
virus O
among O
chicken B-cell_type
tracheal I-cell_type
epithelial I-cell_type
cells E-cell_type
and O
illustrates O
a O
primary O
cell O
model O
for O
evaluating O
the O
cell O
tropisms O
of O
respiratory O
viruses O
in O
poultry O
. O
Models O
of O
infectious O
disease O
spread O
that O
incorporate O
contact O
heterogeneity O
through O
contact O
networks O
are O
an O
important O
tool O
for O
epidemiologists O
studying O
disease O
dynamics O
and O
assessing O
intervention O
strategies O
. O
One O
of O
the O
challenges O
of O
contact O
network O
epidemiology O
has O
been O
the O
difficulty O
of O
collecting O
individual O
and O
population-level O
data O
needed O
to O
develop O
an O
accurate O
representation O
of O
the O
underlying O
host O
population O
's O
contact O
structure O
. O
In O
this O
study O
, O
we O
evaluate O
the O
utility O
of O
common O
epidemiological O
measures O
( O
R O
0 O
, O
epidemic O
peak O
size O
, O
duration O
and O
final O
size O
) O
for O
inferring O
the O
degree O
of O
heterogeneity O
in O
a O
population O
's O
unobserved O
contact O
structure O
through O
a O
Bayesian O
approach O
. O
We O
test O
the O
method O
using O
ground O
truth O
data O
and O
find O
that O
some O
of O
these O
epidemiological O
metrics O
are O
effective O
at O
classifying O
contact O
heterogeneity O
. O
The O
classification O
is O
also O
consistent O
across O
pathogen O
transmission O
probabilities O
, O
and O
so O
can O
be O
applied O
even O
when O
this O
characteristic O
is O
unknown O
. O
In O
particular O
, O
the O
reproductive O
number O
, O
R O
0 O
, O
turns O
out O
to O
be O
a O
poor O
classifier O
of O
the O
degree O
heterogeneity O
, O
while O
, O
unexpectedly O
, O
final O
epidemic O
size O
is O
a O
powerful O
predictor O
of O
network O
structure O
across O
the O
range O
of O
heterogeneity O
. O
We O
also O
evaluate O
our O
framework O
on O
empirical O
epidemiological O
data O
from O
past O
and O
recent O
outbreaks O
to O
demonstrate O
its O
application O
in O
practice O
and O
to O
gather O
insights O
about O
the O
relevance O
of O
particular O
contact O
structures O
for O
both O
specific O
systems O
and O
general O
classes O
of O
infectious O
disease O
. O
We O
thus O
introduce O
a O
simple O
approach O
that O
can O
shed O
light O
on O
the O
unobserved O
connectivity O
of O
a O
host O
population O
given O
epidemic O
data O
. O
Our O
study O
has O
the O
potential O
to O
inform O
future O
data-collection O
efforts O
and O
study O
design O
by O
driving O
our O
understanding O
of O
germane O
epidemic O
measures O
, O
and O
highlights O
a O
general O
inferential O
approach O
to O
learning O
about O
host O
contact O
structure O
in O
contemporary O
or O
historic O
populations O
of O
humans O
and O
animals O
. O
The O
RNA O
interference O
( O
RNAi O
) O
pathway O
is O
a O
potent O
antiviral O
defense O
mechanism O
in O
plants O
and O
invertebrates O
, O
in O
response O
to O
which O
viruses O
evolved O
suppressors O
of O
RNAi S-DNA
. O
In O
mammals O
, O
the O
first O
line O
of O
defense O
is O
mediated O
by O
the O
type B-protein
I I-protein
interferon I-protein
system E-protein
( O
IFN S-protein
) O
; O
however O
, O
the O
degree O
to O
which O
RNAi O
contributes O
to O
antiviral O
defense O
is O
still O
not O
completely O
understood O
. O
Recent O
work O
suggests O
that O
antiviral O
RNAi O
is O
active O
in O
undifferentiated B-cell_type
stem I-cell_type
cells E-cell_type
and O
that O
antiviral O
RNAi O
can O
be O
uncovered O
in O
differentiated B-cell_type
cells E-cell_type
in O
which O
the O
IFN S-protein
system O
is O
inactive O
or O
in O
infections O
with O
viruses O
lacking O
putative O
viral O
suppressors O
of O
RNAi O
. O
In O
this O
review O
, O
we O
describe O
the O
mechanism O
of O
RNAi O
and O
its O
antiviral O
functions O
in O
insects O
and O
mammals O
. O
We O
draw O
parallels O
and O
highlight O
differences O
between O
( O
antiviral O
) O
RNAi O
in O
these O
classes O
of O
animals O
and O
discuss O
open O
questions O
for O
future O
research O
. O
Figure O
1 O
. O
The O
small O
interfering O
RNA O
( O
siRNA S-protein
) O
pathway O
in O
Drosophila O
melanogaster O
. O
Double-stranded B-RNA
93 I-RNA
RNA I-RNA
precursors E-RNA
of O
different O
sources O
are O
processed O
by O
Dicer-2 S-protein
into O
short O
interfering O
RNAs S-RNA
of O
~21 B-RNA
nt E-RNA
in O
94 O
size O
. O
The O
siRNA B-DNA
duplex E-DNA
is O
loaded O
into O
an O
Argonaute2 O
containing O
RISC B-protein
complex E-protein
, O
where O
one O
strand O
95 O
( O
passenger O
) O
is O
degraded O
, O
and O
the O
guide O
strand O
is O
retained O
. O
The O
guide O
strand O
mediates O
target O
RNA O
96 O
recognition O
through O
Watson-Crick O
base O
pairing O
, O
followed O
by O
target O
cleavage O
( O
slicing O
) O
by O
Argonaute S-protein
. O
97 O
Loqs-PD S-protein
is O
required O
for O
endo-siRNA S-protein
biogenesis O
, O
but O
dispensable O
for O
viral B-protein
siRNA I-protein
( I-protein
vsiRNA I-protein
) I-protein
98 E-protein
biogenesis O
. O
99 O
Viruses O
2019 O
, O
11 O
, O
x O
FOR O
PEER O
REVIEW O
4 O
of O
32 O
100 O
Figure O
2 O
. O
Dicer O
proteins O
process O
double-stranded B-RNA
RNA E-RNA
( O
dsRNA O
) O
into O
small O
interfering O
RNA O
( O
siRNA S-protein
) O
. O
101 O
( O
A O
) O
Schematic O
representation O
of O
the O
domain O
organization O
of O
human B-protein
Dicer I-protein
protein E-protein
[ O
40 O
] O
. O
RIIIa S-protein
, O
RNase-102 O
IIIa O
; O
RIIIb S-protein
, O
RNase-IIIb B-protein
( I-protein
B I-protein
) I-protein
Cryo-EM E-protein
structure O
of O
human B-protein
Dicer E-protein
. O
Protein O
domains O
are O
colored O
in O
103 O
accordance O
to O
the O
scheme O
in O
A O
. O
The O
structure O
was O
determined O
by O
Liu O
et O
al O
. O
[ O
41 O
] O
, O
and O
the O
published O
104 O
PDB O
file O
( O
5ZAM O
) O
was O
edited O
in O
Yasara O
View O
[ O
42 O
] O
. O
Drosophila B-DNA
Dicer-2 E-DNA
has O
a O
similar O
domain O
structure O
105 O
and O
L-shaped B-protein
Cryo-EM I-protein
structure E-protein
as O
human O
Dicer O
[ O
40 O
] O
. O
( O
C O
) O
Schematic O
representation O
of O
the O
recognition O
106 O
and O
cleavage O
of O
dsRNA O
with O
a O
3 O
' O
overhang O
and O
dsRNA S-DNA
with O
blunt O
termini O
by O
Drosophila O
Dicer-2 O
, O
107 O
proposed O
by O
Sinha S-protein
and O
colleagues O
[ O
40 O
] O
. O
Substrates O
with O
a O
3 B-DNA
' I-DNA
overhang E-DNA
were O
proposed O
to O
bind O
the O
PAZ-108 B-DNA
Platform I-DNA
domains E-DNA
( O
referred O
to O
as O
PAZ S-protein
in O
panel O
A O
) O
via O
the O
3 B-DNA
' I-DNA
terminal I-DNA
overhang E-DNA
. O
Blunt-ended B-DNA
termini I-DNA
109 E-DNA
bind O
to O
the O
helicase B-protein
domain E-protein
and O
the O
dsRNA O
threads O
through O
this O
domain O
, O
after O
which O
cleavage O
occurs O
110 O
by O
the O
two O
RNaseIII B-protein
domains E-protein
. O
The O
latter O
mode O
results O
in O
processive O
, O
ATP-dependent O
cleavage O
of O
111 O
dsRNA O
and O
may O
contribute O
to O
efficient O
production O
of O
vsiRNAs S-protein
for O
antiviral O
defense O
. O
112 O
Figure O
2 O
. O
Dicer O
proteins O
process O
double-stranded B-RNA
RNA E-RNA
( O
dsRNA O
) O
into O
small O
interfering O
RNA B-protein
( I-protein
siRNA I-protein
) E-protein
. O
( O
A O
) O
Schematic O
representation O
of O
the O
domain O
organization O
of O
human B-protein
Dicer I-protein
protein E-protein
[ O
40 O
] O
. O
RIIIa S-protein
, O
RNase-IIIa S-protein
; O
RIIIb S-protein
, O
RNase-IIIb B-protein
( I-protein
B I-protein
) I-protein
Cryo-EM E-protein
structure O
of O
human B-protein
Dicer E-protein
. O
Protein O
domains O
are O
colored O
in O
accordance O
to O
the O
scheme O
in O
A O
. O
The O
structure O
was O
determined O
by O
Liu O
et O
al O
. O
[ O
41 O
] O
, O
and O
the O
published O
PDB O
file O
( O
5ZAM O
) O
was O
edited O
in O
Yasara O
View O
[ O
42 O
] O
. O
Drosophila B-DNA
Dicer-2 E-DNA
has O
a O
similar O
domain O
structure O
and O
L-shaped B-protein
Cryo-EM I-protein
structure E-protein
as O
human O
Dicer O
[ O
40 O
] O
. O
( O
C O
) O
Schematic O
representation O
of O
the O
recognition O
and O
cleavage O
of O
dsRNA O
with O
a O
3 O
' O
overhang O
and O
dsRNA S-DNA
with O
blunt O
termini O
by O
Drosophila B-DNA
Dicer-2 E-DNA
, O
proposed O
by O
Sinha S-protein
and O
colleagues O
[ O
40 O
] O
. O
Substrates O
with O
a O
3 O
' O
overhang O
were O
proposed O
to O
bind O
the O
PAZ-Platform B-protein
domains E-protein
( O
referred O
to O
as O
PAZ S-protein
in O
panel O
A O
) O
via O
the O
3 B-DNA
' I-DNA
terminal I-DNA
overhang E-DNA
. O
Blunt-ended B-protein
termini E-protein
bind O
to O
the O
helicase B-protein
domain E-protein
and O
the O
dsRNA O
threads O
through O
this O
domain O
, O
after O
which O
cleavage O
occurs O
by O
the O
two O
RNaseIII B-protein
domains E-protein
. O
The O
latter O
mode O
results O
in O
processive O
, O
ATP-dependent O
cleavage O
of O
dsRNA O
and O
may O
contribute O
to O
efficient O
production O
of O
vsiRNAs S-protein
for O
antiviral O
defense O
. O
Viruses O
2019 O
, O
11 O
, O
x O
FOR O
PEER O
REVIEW O
7 O
of O
32 O
189 O
Figure O
4 O
. O
The O
RNA O
interference O
( O
RNAi O
) O
pathway O
in O
mammals O
. O
A O
single O
Dicer O
protein O
processes O
long O
190 O
dsRNA O
into O
siRNAs B-DNA
and I-DNA
pre-miRNAs I-DNA
into I-DNA
miRNA I-DNA
duplexes E-DNA
. O
These O
small B-RNA
RNAs E-RNA
are O
loaded O
into O
an O
191 O
Argonaute O
containing O
RISC B-protein
complex E-protein
, O
from O
which O
one O
of O
the O
strands O
is O
eliminated O
and O
degraded O
. O
The O
192 O
other O
strand O
, O
referred O
to O
as O
guide O
strand O
( O
for O
siRNAs O
) O
or O
the O
mature O
miRNA S-protein
( O
for O
miRNAs S-protein
) O
, O
is O
retained O
193 O
and O
used O
to O
guide O
Argonaute B-RNA
onto I-RNA
target I-RNA
RNAs E-RNA
, O
resulting O
in O
cleavage O
( O
siRNA S-protein
) O
or O
translational O
194 O
inhibition O
or O
target O
RNA O
destabilization O
( O
miRNA S-protein
) O
. O
The O
scheme O
shows O
the O
cytoplasmic O
stage O
of O
the O
195 O
miRNA S-protein
pathway O
; O
the O
nuclear O
stage O
( O
pri-miRNA O
transcription O
, O
processing O
, O
and O
pre-miRNA B-protein
nuclear I-protein
196 I-protein
export E-protein
) O
is O
not O
shown O
. O
197 O
The O
miRISC B-protein
complex E-protein
is O
guided O
by O
the O
miRNA S-protein
to O
target O
sites O
typically O
located O
in O
the O
3 O
' O
UTRs O
of O
198 B-RNA
mRNAs E-RNA
[ O
77 O
] O
. O
Target O
recognition O
is O
initiated O
by O
a O
short O
nucleotide O
stretch O
at O
the O
5 B-DNA
' I-DNA
end E-DNA
of O
the O
miRNA B-DNA
199 I-DNA
( I-DNA
position I-DNA
2-8 E-DNA
) O
, O
the O
so-called O
seed O
sequence O
, O
accompanied O
with O
various O
degree O
of O
base O
pairing O
at O
the O
200 O
3 O
' O
end O
[ O
77,95-97 O
] O
. O
Mechanisms O
for O
miRNA-mediated B-DNA
gene E-DNA
silencing O
include O
translational O
repression O
, O
201 O
de-adenylation O
, O
and O
enhancement O
of O
mRNA O
decay O
[ O
77,98,99 O
] O
. O
The O
majority O
of O
mRNAs S-RNA
is O
estimated O
202 O
to O
be O
regulated O
by O
miRNAs O
[ O
100 O
] O
, O
and O
post-transcriptional O
regulation O
by O
miRNAs S-protein
is O
thus O
implicated O
203 O
in O
almost O
all O
cell O
biological O
processes O
. O
Although O
miRNA-mediated B-DNA
gene E-DNA
regulation O
seems O
to O
be O
the O
dominant O
function O
of O
mammalian B-DNA
205 I-DNA
RNAi E-DNA
, O
early O
evidence O
has O
already O
indicated O
that O
the O
siRNA S-protein
pathway O
is O
functional O
in O
mammals O
. O
Transfection O
of O
synthetic O
siRNAs O
or O
expression O
of O
short-hairpin B-RNA
RNAs E-RNA
( O
shRNAs S-DNA
) O
with O
207 O
complementarity O
to O
a O
gene O
of O
interest O
was O
found O
to O
induce O
robust O
and O
sequence-specific O
RNAi O
, O
208 O
without O
activation O
of O
the O
interferon S-protein
response O
as O
siRNAs O
are O
too O
short O
to O
be O
detected O
by O
dsRNA O
209 O
sensors O
( O
discussed O
in O
Section O
3.1 O
) O
[ O
25 O
, O
101 O
] O
. O
Moreover O
, O
long B-DNA
dsRNA E-DNA
was O
reported O
to O
be O
functional O
in O
We O
report O
the O
first O
complete O
genome O
sequence O
of O
a O
feline O
astrovirus O
( O
FAstV O
) O
, O
FAstV2 O
strain O
1637F O
, O
identified O
from O
a O
domestic O
cat O
. O
The O
genome O
is O
6,779 O
nucleotides O
( O
nt O
) O
in O
length O
and O
consists O
of O
three O
overlapping B-DNA
open I-DNA
reading I-DNA
frames E-DNA
( O
ORF1a-ORF1b-ORF2 S-DNA
) O
. O
Sequence O
analysis O
suggests O
that O
FAstV2 S-protein
represents O
a O
new O
FAstV B-DNA
genotype E-DNA
that O
is O
closely O
related O
to O
human O
astroviruses O
. O
The O
dynamics O
of O
infectious O
diseases O
spread O
via O
direct O
person-to-person O
transmission O
( O
such O
as O
influenza O
, O
smallpox O
, O
HIV/AIDS O
, O
etc O
. O
) O
depends O
on O
the O
underlying O
host O
contact O
network O
. O
Human O
contact O
networks O
exhibit O
strong O
community O
structure O
. O
Understanding O
how O
such O
community O
structure O
affects O
epidemics O
may O
provide O
insights O
for O
preventing O
the O
spread O
of O
disease O
between O
communities O
by O
changing O
the O
structure O
of O
the O
contact O
network O
through O
pharmaceutical O
or O
non-pharmaceutical O
interventions O
. O
We O
use O
empirical O
and O
simulated O
networks O
to O
investigate O
the O
spread O
of O
disease O
in O
networks O
with O
community O
structure O
. O
We O
find O
that O
community O
structure O
has O
a O
major O
impact O
on O
disease O
dynamics O
, O
and O
we O
show O
that O
in O
networks O
with O
strong O
community O
structure O
, O
immunization O
interventions O
targeted O
at O
individuals O
bridging O
communities O
are O
more O
effective O
than O
those O
simply O
targeting O
highly O
connected O
individuals O
. O
Because O
the O
structure O
of O
relevant O
contact O
networks O
is O
generally O
not O
known O
, O
and O
vaccine O
supply O
is O
often O
limited O
, O
there O
is O
great O
need O
for O
efficient O
vaccination O
algorithms O
that O
do O
not O
require O
full O
knowledge O
of O
the O
network O
. O
We O
developed O
an O
algorithm O
that O
acts O
only O
on O
locally O
available O
network O
information O
and O
is O
able O
to O
quickly O
identify O
targets O
for O
successful O
immunization O
intervention O
. O
The O
algorithm O
generally O
outperforms O
existing O
algorithms O
when O
vaccine O
supply O
is O
limited O
, O
particularly O
in O
networks O
with O
strong O
community O
structure O
. O
Understanding O
the O
spread O
of O
infectious O
diseases O
and O
designing O
optimal O
control O
strategies O
is O
a O
major O
goal O
of O
public O
health O
. O
Social O
networks O
show O
marked O
patterns O
of O
community O
structure O
, O
and O
our O
results O
, O
based O
on O
empirical O
and O
simulated O
data O
, O
demonstrate O
that O
community O
structure O
strongly O
affects O
disease O
dynamics O
. O
These O
results O
have O
implications O
for O
the O
design O
of O
control O
strategies O
. O
Citation O
: O
Salathé O
M O
, O
Jones O
JH O
( O
2010 O
) O
Dynamics O
and O
Control O
of O
Diseases O
in O
Networks O
with O
Community O
Structure O
. O
PLoS O
Comput O
Biol O
6 O
( O
4 O
) O
: O
e1000736 O
. O
Background O
. O
Sputum O
examination O
can O
be O
useful O
in O
diagnosing O
the O
cause O
of O
pneumonia O
in O
adults O
but O
is O
less O
well O
established O
in O
children O
. O
We O
sought O
to O
assess O
the O
diagnostic O
utility O
of O
polymerase O
chain O
reaction O
( O
PCR O
) O
for O
detection O
of O
respiratory O
viruses O
and O
bacteria O
in O
induced O
sputum O
( O
IS O
) O
specimens O
from O
children O
hospitalized O
with O
severe O
or O
very O
severe O
pneumonia O
. O
Methods O
. O
Among O
children O
aged O
1-59 O
months O
, O
we O
compared O
organism O
detection O
by O
multiplex O
PCR O
in O
IS O
and O
nasopharyngeal/ O
oropharyngeal O
( O
NP/OP O
) O
specimens O
. O
To O
assess O
whether O
organism O
presence O
or O
density O
in O
IS O
specimens O
was O
associated O
with O
chest O
radiographic O
evidence O
of O
pneumonia O
( O
radiographic O
pneumonia O
) O
, O
we O
compared O
prevalence O
and O
density O
in O
IS O
specimens O
from O
children O
with O
radiographic O
pneumonia O
and O
children O
with O
suspected O
pneumonia O
but O
without O
chest O
radiographic O
changes O
or O
clinical O
or O
laboratory O
findings O
suggestive O
of O
pneumonia O
( O
nonpneumonia O
group O
) O
. O
Results O
. O
Among O
4232 O
cases O
with O
World O
Health O
Organization-defined O
severe O
or O
very O
severe O
pneumonia O
, O
we O
identified O
1935 O
( O
45.7 O
% O
) O
with O
radiographic O
pneumonia O
and O
573 O
( O
13.5 O
% O
) O
with O
nonpneumonia O
. O
The O
organism O
detection O
yield O
was O
marginally O
improved O
with O
IS O
specimens O
( O
96.2 O
% O
vs O
92.4 O
% O
for O
NP/OP O
specimens O
for O
all O
viruses O
combined O
[ O
P O
= O
.41 O
] O
; O
96.9 O
% O
vs O
93.3 O
% O
for O
all O
bacteria O
combined O
[ O
P O
= O
.01 O
] O
) O
. O
After O
accounting O
for O
presence O
in O
NP/OP O
specimens O
, O
no O
organism O
was O
detected O
more O
frequently O
in O
the O
IS O
specimens O
from O
the O
radiographic O
pneumonia O
compared O
with O
the O
nonpneumonia O
cases O
. O
Among O
high-quality O
IS O
specimens O
, O
there O
were O
no O
statistically O
significant O
differences O
in O
organism O
density O
, O
except O
with O
cytomegalovirus O
, O
for O
which O
there O
was O
a O
higher O
quantity O
in O
the O
IS O
specimens O
from O
cases O
with O
radiographic O
pneumonia O
compared O
with O
the O
nonpneumonia O
cases O
( O
median O
cycle O
threshold O
value O
, O
27.9 O
vs O
28.5 O
, O
respectively O
; O
P O
= O
.01 O
) O
. O
Conclusions O
. O
Using O
advanced O
molecular O
methods O
with O
IS O
specimens O
provided O
little O
additional O
diagnostic O
information O
beyond O
that O
obtained O
with O
NP/OP O
swab O
specimens O
. O
Korea O
failed O
in O
its O
risk O
communication O
during O
the O
early O
stage O
of O
the O
Middle O
East O
Respiratory O
Syndrome O
( O
MERS O
) O
outbreak O
; O
consequently O
, O
it O
faced O
difficulties O
in O
managing O
MERS O
, O
while O
disease-related O
worry O
increased O
. O
Disease-related O
worry O
can O
help O
disease O
prevention O
and O
management O
, O
but O
can O
also O
have O
a O
detrimental O
effect O
. O
This O
study O
measured O
the O
overall O
level O
of O
disease-related O
worry O
during O
the O
MERS O
outbreak O
period O
in O
Korea O
and O
the O
influencing O
factors O
and O
levels O
of O
disease-related O
worry O
during O
key O
outbreak O
periods O
. O
The O
cross-sectional O
survey O
included O
1,000 O
adults O
who O
resided O
in O
Korea O
. O
An O
ordinal O
logistic O
regression O
was O
performed O
for O
the O
overall O
level O
of O
MERS-related O
worry O
, O
and O
influencing O
factors O
of O
worry O
were O
analyzed O
. O
A O
reliability O
test O
was O
performed O
on O
the O
levels O
of O
MERS-related O
worry O
during O
key O
outbreak O
periods O
. O
The O
overall O
level O
of O
MERS-related O
worry O
was O
2.44 O
. O
Multivariate O
analysis O
revealed O
that O
women O
and O
respondents O
w O
very O
poor O
subjective O
health O
status O
had O
higher O
levels O
of O
worry O
. O
Respondents O
with O
very O
high O
stress O
in O
daily O
life O
had O
higher O
levels O
of O
worry O
than O
those O
who O
reported O
having O
little O
stress O
. O
The O
reliability O
test O
results O
on O
MERS-related O
worry O
scores O
during O
key O
outbreak O
periods O
showed O
consistent O
scores O
during O
each O
period O
. O
Level O
of O
worry O
increased O
in O
cases O
having O
higher O
perceived O
susceptibility O
and O
greater O
trust O
in O
informal O
information O
, O
while O
initial O
stage O
of O
outbreak O
was O
closely O
associated O
with O
that O
at O
later O
stages O
. O
These O
findings O
suggest O
the O
importance O
of O
managing O
the O
level O
of O
worry O
by O
providing O
timely O
and O
accurate O
disease-related O
information O
during O
the O
initial O
stage O
of O
disease O
outbreak O
. O
Background O
: O
Influenza O
is O
a O
major O
cause O
of O
respiratory O
illness O
in O
young O
children O
. O
Assessing O
the O
impact O
of O
infection O
on O
children O
and O
the O
community O
is O
required O
to O
guide O
immunisation O
policies O
. O
Objectives O
: O
To O
describe O
the O
impact O
of O
laboratory-proven O
influenza O
in O
young O
children O
and O
to O
compare O
its O
impact O
with O
that O
of O
other O
respiratory O
viruses O
on O
the O
child O
, O
their O
family O
and O
the O
health O
care O
system O
. O
Methods O
: O
Preschool O
children O
presenting O
for O
care O
or O
admission O
to O
a O
tertiary O
paediatric O
hospital O
during O
the O
2008-2014 O
influenza O
seasons O
were O
tested O
for O
respiratory O
virus O
by O
polymerase O
chain O
reaction O
and O
culture O
. O
Parental O
surveys O
were O
used O
to O
determine O
the O
impact O
of O
infection O
on O
illness O
duration O
, O
medication O
use O
, O
absenteeism O
and O
health O
service O
utilisation O
. O
Multivariate O
regression O
analyses O
were O
used O
to O
assess O
the O
impact O
of O
influenza O
and O
to O
evaluate O
the O
association O
between O
influenza O
status O
and O
outcomes O
. O
Results O
: O
Among O
1191 O
children O
assessed O
, O
238 O
had O
influenza O
. O
Among O
children O
with O
influenza O
, O
87.8 O
% O
were O
administered O
antipyretics O
and O
40.9 O
% O
antibiotics O
. O
28.6 O
% O
had O
secondary O
complications O
. O
65.4 O
% O
of O
children O
missed O
school/day O
care O
, O
and O
53.4 O
% O
of O
parents O
missed O
work O
. O
When O
influenza O
and O
other O
viruses O
were O
compared O
, O
significant O
| O
19 O
WILLIS O
et O
aL O
. O
Ubiquitin-specific B-protein
protease I-protein
2 E-protein
( O
USP2 S-protein
) O
belongs O
to O
the O
family O
of O
deubiquitinases O
that O
can O
rescue O
protein O
targets O
from O
proteasomal O
degradation O
by O
reversing O
their O
ubiquitination O
. O
In O
various O
cancers O
, O
including O
prostate O
cancer O
and O
ovarian O
carcinoma O
, O
upregulation O
of O
USP2 S-protein
leads O
to O
an O
increase O
in O
the O
levels O
of O
deubiquitinated B-protein
substrates E-protein
such O
as O
fatty B-protein
acid I-protein
synthase E-protein
, O
MDM2 S-protein
, O
cyclin B-protein
D1 E-protein
and O
Aurora-A S-protein
. O
USP2 S-protein
thus O
plays O
a O
critical O
role O
in O
tumor B-cell_type
cells E-cell_type
' O
survival O
and O
therefore O
represents O
a O
therapeutic O
target O
. O
Here O
a O
leukemia O
drug O
, O
6-thioguanine O
, O
was O
found O
to O
be O
a O
potent O
inhibitor O
of O
USP2 S-protein
. O
Enzyme-kinetic O
and O
X-ray O
crystallographic O
data O
suggest O
that O
6-thioguanine O
displays O
a O
noncompetitive O
and O
slow-binding O
inhibitory O
mechanism O
against O
USP2 S-protein
. O
Our O
study O
provides O
a O
clear O
rationale O
for O
the O
clinical O
evaluation O
of O
6-thioguanine O
for O
USP2-upregulated O
cancers O
. O
Ubiquitination O
, O
a O
kind O
of O
post-translational O
modification O
, O
as O
well O
as O
deubiquitination O
, O
which O
together O
comprise O
the O
ubiquitination O
system O
, O
can O
regulate O
not O
only O
the O
turnover O
of O
cellular B-protein
proteins E-protein
but O
also O
, O
through O
various O
modes O
of O
mono-or O
polyubiquitination O
, O
receptor O
trafficking O
, O
DNA O
repair O
, O
cell-cycle O
progression O
, O
immune O
response O
, O
autophagy O
and O
apoptosis O
1 O
. O
This O
versatility O
has O
raised O
interest O
in O
pinpointing O
components O
of O
the O
ubiquitin S-protein
system O
as O
prime O
candidates O
for O
drug O
targets O
2 O
. O
Among O
them O
, O
the O
pursuit O
of O
deubiquitinases O
( O
DUBs O
) O
as O
pharmaceutical O
targets O
is O
still O
in O
its O
infancy O
in O
that O
few O
inhibitors O
have O
entered O
clinical O
trials O
, O
albeit O
some O
broad-spectrum O
inhibitors O
have O
been O
patented O
and O
highly O
selective O
inhibitors O
have O
been O
developed O
3-6 O
. O
The O
human B-DNA
genome E-DNA
encodes O
about O
80-90 O
DUBs O
, O
of O
which O
the O
largest O
of O
the O
five O
DUB B-protein
families E-protein
is O
the O
ubiquitin-specific B-protein
proteases I-protein
( I-protein
USPs I-protein
) I-protein
7 E-protein
. O
One O
of O
these O
, O
USP2 S-protein
, O
is O
able O
to O
remove O
ubiquitin S-protein
from O
a O
range O
of O
protein O
substrates O
such O
as O
fatty B-protein
acid I-protein
synthase I-protein
8 E-protein
, O
MDM2 B-protein
9 E-protein
, O
cyclin B-protein
D1 I-protein
10 E-protein
and O
Aurora-A B-DNA
11 E-DNA
. O
Fatty B-protein
acid I-protein
synthase E-protein
has O
been O
reported O
to O
be O
highly O
expressed O
in O
a O
variety O
of O
cancers O
, O
including O
cancers O
of O
the O
prostate O
, O
ovary O
, O
lung O
, O
colon O
, O
and O
breast O
12 O
, O
while O
MDM2 S-protein
, O
cyclin B-protein
D1 E-protein
and O
Aurora-A S-protein
play O
critical O
roles O
in O
p53 S-protein
regulation O
, O
cell O
cycle O
progression O
and O
mitotic O
events O
, O
respectively O
9,10,13 O
. O
All O
of O
these O
studies O
suggest O
that O
the O
inhibition O
of O
USP2 S-protein
may O
be O
a O
good O
therapeutic O
approach O
against O
cancers O
. O
In O
2016 O
, O
Davis O
et O
al O
. O
6 O
reported O
that O
a O
small O
molecule O
, O
ML364 S-protein
, O
can O
induce O
cell O
cycle O
arrest O
and O
inhibit O
the O
growth O
of O
colorectal B-cell_line
and I-cell_line
mantle I-cell_line
cell I-cell_line
lymphoma I-cell_line
cell I-cell_line
lines E-cell_line
via O
USP2 S-protein
inhibition O
, O
albeit O
it O
is O
still O
not O
a O
clinical O
drug O
. O
In O
the O
present O
study O
, O
6-thioguanine O
( O
6TG O
) O
, O
an O
old O
drug O
still O
clinically O
used O
to O
treat O
leukemia O
, O
rheumatoid O
arthritis O
and O
bowel O
disease O
14 O
, O
was O
identified O
as O
a O
potent O
USP2 S-protein
inhibitor O
. O
Further O
studies O
using O
enzyme O
kinetics O
and O
X-ray O
crystallography O
to O
delineate O
its O
direct O
binding O
to O
USP2 S-protein
were O
performed O
. O
Our O
findings O
support O
earlier O
results O
suggesting O
that O
6TG O
has O
a O
broad O
spectrum O
of O
activity O
[ B-DNA
15 I-DNA
] I-DNA
[ I-DNA
16 I-DNA
] I-DNA
[ I-DNA
17 I-DNA
] E-DNA
, O
and O
have O
implications O
with O
respect O
to O
the O
need O
for O
direct O
clinical O
evaluation O
of O
its O
use O
against O
USP2-upregulated O
cancers O
. O
Identification O
of O
inhibitors O
of O
human B-protein
USP2 E-protein
. O
According O
to O
previous O
studies O
involving O
molecular O
docking O
experiments O
, O
the O
anti-leukemia O
and O
immunosuppressant O
drugs O
6MP O
and O
6TG O
, O
which O
act O
as O
inhibitors O
of O
SARS B-protein
and I-protein
MERS I-protein
coronavirus I-protein
papain-like I-protein
proteases E-protein
( O
PLpros S-protein
) O
, O
may O
also O
be O
able O
to O
bind O
to O
the O
active O
site O
of O
human B-protein
USP2 E-protein
as O
both O
kinds O
of O
enzymes S-protein
share O
the O
palm-thumb-fingers B-protein
structural I-protein
scaffold I-protein
and I-protein
conserved I-protein
catalytic I-protein
triad I-protein
Cys-His-Asp/Asn I-protein
17-20 E-protein
. O
To O
validate O
the O
simulation O
results O
, O
the O
deubiquitination O
activity O
of O
the O
recombinant B-protein
human I-protein
USP2 I-protein
catalytic I-protein
domain E-protein
( O
residues O
258-605 O
) O
was O
measured O
in O
the O
presence O
of O
various O
concentrations O
of O
6MP O
or O
6TG O
Published O
: O
xx O
xx O
xxxx O
OPEN O
www.nature.com/scientificreports/ O
2 O
Scientific O
RepoRts O
| O
( O
2018 O
) O
8:3102 O
| O
Background O
: O
Lower O
respiratory O
tract O
infections O
( O
LRTI O
) O
are O
responsible O
for O
a O
considerable O
number O
of O
deaths O
among O
children O
, O
particularly O
in O
developing O
countries O
. O
In O
Egypt O
and O
the O
Middle B-DNA
East I-DNA
region E-DNA
, O
there O
is O
a O
lack O
of O
data O
regarding O
the O
viral O
causes O
of O
LRTI S-protein
. O
In O
this O
study O
, O
we O
aimed O
to O
identify O
the O
relative O
prevalence O
of O
various O
respiratory O
viruses O
that O
contribute O
to O
LRTIs S-protein
in O
young O
children O
. O
Although O
, O
nucleic O
acid-based O
methods O
have O
gained O
importance O
as O
a O
sensitive O
tool O
to O
determine O
the O
viral O
infections O
, O
their O
use O
is O
limited O
because O
of O
their O
prohibitive O
cost O
in O
low-income O
countries O
. O
Therefore O
, O
we O
applied O
three O
different O
laboratory O
methods O
, O
and O
presented O
the O
different O
virus O
prevalence O
patterns O
detected O
by O
each O
method O
. O
Methods O
: O
We O
collected O
nasopharyngeal O
aspirate O
samples O
, O
demographic O
data O
and O
, O
clinical O
data O
from O
450 O
children O
under O
five O
years O
of O
age O
who O
presented O
with O
LRTI O
at O
Abou O
El O
Reesh O
hospital O
in O
Cairo O
during O
a O
one-year O
period O
. O
To O
identify O
the O
viral O
causes O
of O
the O
LRTI S-DNA
we O
used O
direct O
fluorescence O
assay O
, O
real-time O
reverse-transcriptase O
polymerase O
chain O
reaction O
( O
rt-RT-PCR O
) O
, O
and O
shell O
vial O
culture O
. O
We O
tested O
for O
eight O
major O
respiratory O
viruses O
. O
Results O
: O
Two O
hundred O
sixty-nine O
patients O
( O
59.9 O
% O
) O
had O
a O
viral O
infection O
, O
among O
which O
10.8 O
% O
had O
a O
co-infection O
with O
two O
or O
more O
viruses O
. O
By O
all O
three O
methods O
, O
respiratory O
syncytial O
virus O
( O
RSV O
) O
was O
the O
most O
predominant O
, O
and O
parainfluenza O
virus O
type O
2 O
( O
HPIV-2 O
) O
, O
influenza O
B O
virus O
( O
FLUBV O
) O
were O
the O
least O
predominant O
. O
Other O
viral O
prevalence O
patterns O
differed O
according O
to O
the O
detection O
method O
used O
. O
The O
distribution O
of O
various O
viruses O
among O
different O
age O
groups O
and O
seasonal O
distribution O
of O
the O
viruses O
were O
also O
determined O
. O
Conclusions O
: O
RSV O
and O
human O
adenovirus O
were O
the O
most O
common O
respiratory O
viruses O
detected O
by O
rt-RT-PCR O
. O
Co-infections O
were O
found O
to O
be O
frequent O
among O
children O
and O
the O
vast O
majority O
of O
co-infections O
were O
detected O
by O
nucleic O
acid-based O
detection O
assays O
. O
Andes O
virus O
( O
ANDV O
) O
is O
associated O
with O
a O
lethal O
vascular O
leak O
syndrome O
in O
humans O
termed O
hantavirus O
pulmonary O
syndrome O
( O
HPS O
) O
. O
The O
mechanism O
for O
the O
massive O
vascular O
leakage O
associated O
with O
HPS O
is O
poorly O
understood O
; O
however O
, O
dysregulation O
of O
components O
of O
the O
immune O
response O
is O
often O
suggested O
as O
a O
possible O
cause O
. O
Alveolar B-cell_type
macrophages E-cell_type
are O
found O
in O
the O
alveoli O
of O
the O
lung O
and O
represent O
the O
first O
line O
of O
defense O
to O
many O
airborne O
pathogens O
. O
To O
determine O
whether O
alveolar B-cell_type
macrophages E-cell_type
play O
a O
role O
in O
HPS O
pathogenesis O
, O
alveolar B-cell_type
macrophages E-cell_type
were O
depleted O
in O
an O
adult O
rodent O
model O
of O
HPS O
that O
closely O
resembles O
human O
HPS O
. O
Syrian O
hamsters O
were O
treated O
, O
intratracheally O
, O
with O
clodronate-encapsulated O
liposomes O
or O
control O
liposomes O
and O
were O
then O
challenged O
with O
ANDV O
. O
Treatment O
with O
clodronate-encapsulated O
liposomes O
resulted O
in O
significant O
reduction O
in O
alveolar B-cell_type
macrophages E-cell_type
, O
but O
depletion O
did O
not O
prevent O
pathogenesis O
or O
prolong O
disease O
. O
Depletion O
also O
did O
not O
significantly O
reduce O
the O
amount O
of O
virus O
in O
the O
lung O
of O
ANDV-infected O
hamsters O
but O
altered O
neutrophil O
recruitment O
, O
MIP-1␣ S-protein
and O
MIP-2 B-protein
chemokine E-protein
expression O
, O
and O
vascular B-protein
endothelial I-protein
growth I-protein
factor E-protein
( O
VEGF S-protein
) O
levels O
in O
hamster O
bronchoalveolar O
lavage O
( O
BAL O
) O
fluid O
early O
after O
intranasal O
challenge O
. O
These O
data O
demonstrate O
that O
alveolar B-cell_type
macrophages E-cell_type
may O
play O
a O
limited O
protective O
role O
early O
after O
exposure O
to O
aerosolized O
ANDV O
but O
do O
not O
directly O
contribute O
to O
hantavirus O
disease O
pathogenesis O
in O
the O
hamster O
model O
of O
HPS O
. O
Hantaviruses O
continue O
to O
cause O
disease O
worldwide O
for O
which O
there O
are O
no O
FDA-licensed O
vaccines O
, O
effective O
postexposure O
prophylactics O
, O
or O
therapeutics O
. O
Much O
of O
this O
can O
be O
attributed O
to O
a O
poor O
understanding O
of O
the O
mechanism O
of O
hantavirus O
disease O
pathogenesis O
. O
Hantavirus O
disease O
has O
long O
been O
considered O
an O
immune-mediated O
disease O
; O
however O
, O
by O
directly O
manipulating O
the O
Syrian O
hamster O
model O
, O
we O
continue O
to O
eliminate O
individual O
immune O
cell O
types O
. O
As O
the O
most O
numerous O
immune B-cell_type
cells E-cell_type
present O
in O
the O
respiratory O
tract O
, O
alveolar B-cell_type
macrophages E-cell_type
are O
poised O
to O
defend O
against O
hantavirus O
infection O
, O
but O
those O
antiviral O
responses O
may O
also O
contribute O
to O
hantavirus O
disease O
. O
Here O
, O
we O
demonstrate O
that O
, O
like O
in O
our O
prior O
T O
and O
B O
cell O
studies O
, O
alveolar B-cell_type
macrophages E-cell_type
neither O
prevent O
hantavirus O
infection O
nor O
cause O
hantavirus O
disease O
. O
While O
these O
studies O
reflect O
pathogenesis O
in O
the O
hamster O
model O
, O
they O
should O
help O
us O
rule O
out O
specific O
cell O
types O
and O
prompt O
us O
to O
consider O
other O
potential O
mechanisms O
of O
disease O
in O
an O
effort O
to O
improve O
the O
outcome O
of O
human O
HPS O
. O
Background O
: O
Pneumonia O
remains O
a O
leading O
cause O
of O
child O
death O
in O
developing O
countries O
. O
The O
viruses O
in O
severe O
pneumonia O
remain O
poorly O
defined O
. O
. O
Patients O
aged O
8 O
days O
to O
13 O
years O
old O
who O
were O
admitted O
to O
the O
Department O
of O
Pediatrics O
with O
severe O
pneumonia O
were O
enrolled O
for O
the O
study O
. O
Upon O
admission O
, O
polymerase O
chain O
reaction O
was O
performed O
using O
nasopharyngeal O
swabs O
and O
blood O
cultures O
to O
detect O
respiratory O
viruses O
and O
bacteria O
, O
respectively O
. O
Result O
: O
Among O
the O
819 O
patients O
enrolled O
, O
at O
least O
one O
virus O
was O
detected O
in O
501 O
cases O
( O
61.2 O
% O
) O
. O
In O
addition O
, O
423 O
cases O
were O
positive O
for O
a O
single O
virus O
while O
bacteria O
were O
detected O
in O
the O
blood O
culture O
sample O
of O
31 O
cases O
. O
The O
most O
commonly O
detected O
viruses O
were O
human O
rhinoviruses O
( O
n O
= O
189 O
) O
, O
including O
types O
A O
( O
n O
= O
103 O
) O
, O
B O
( O
n O
= O
17 O
) O
, O
and O
C O
( O
n O
= O
69 O
) O
, O
and O
respiratory O
syncytial O
virus O
( O
RSV O
) O
( O
n O
= O
165 O
) O
. O
Novel O
viruses O
such O
as O
human O
metapneumovirus O
, O
human O
coronavirus O
NL63 O
, O
human O
bocavirus O
, O
and O
human O
polyomaviruses O
WU O
and O
KI O
were O
also O
detected O
. O
There O
were O
70 O
deaths O
, O
and O
one O
or O
more O
viruses O
were O
detected O
in O
35 O
( O
50 O
% O
) O
of O
these O
cases O
. O
Positivity O
only O
for O
influenza O
A O
virus O
( O
OR O
= O
4.3 O
, O
95 O
% O
CI O
= O
1.3-14.6 O
) O
was O
significantly O
associated O
with O
fatal O
outcome O
. O
From O
the O
blood O
culture O
, O
Burkholderia O
cepacia O
group O
( O
n O
= O
9 O
) O
, O
Streptococcus O
pneumoniae O
( O
n O
= O
4 O
) O
, O
Staphylococcus O
aureus O
( O
n O
= O
4 O
) O
, O
Haemophilus O
influenzae O
( O
n O
= O
1 O
) O
, O
and O
Salmonella O
C1 O
( O
n O
= O
1 O
) O
were O
also O
isolated O
. O
Conclusion O
: O
Viruses O
were O
commonly O
detected O
in O
children O
with O
severe O
pneumonia O
in O
the O
Philippines O
. O
Hence O
, O
viral O
etiologies O
should O
be O
considered O
while O
developing O
better O
effective O
strategies O
to O
reduce O
child O
pneumonia-related O
deaths O
in O
developing O
countries O
. O
Tollip O
plays O
an O
important O
role O
in O
the O
interleukin-1 B-protein
receptor I-protein
IL-1R E-protein
and O
Toll S-protein
pathways O
. O
As O
a O
modulator O
of O
the O
immune O
pathway O
, O
it O
indirectly O
controls O
the O
amount O
of O
antimicrobial O
peptides O
. O
This O
could O
indicate O
a O
vital O
step O
in O
maintaining O
animal O
immune O
systems O
and O
preventing O
infection O
. O
Evolutionary O
questions O
are O
crucial O
to O
understanding O
the O
conservation O
and O
functioning O
of O
the O
biochemical O
pathways O
like O
the O
Tollip-mediated O
one O
. O
Through O
an O
analysis O
of O
36 O
sequences O
of O
the O
Tollip B-protein
protein E-protein
from O
different O
animal O
taxa O
, O
downloaded O
from O
Kyoto O
Encyclopedia O
of O
Genes B-DNA
and I-DNA
Genomes I-DNA
( I-DNA
KEGG I-DNA
) I-DNA
databank E-DNA
, O
we O
inferred O
diverse O
evolutionary O
parameters O
, O
such O
as O
molecular O
selection O
and O
structure O
conservation O
, O
by O
analyzing O
residue O
by O
residue O
, O
beyond O
the O
canonical O
parameters O
to O
this O
type O
of O
study O
, O
as O
maximum O
likelihood O
trees O
. O
We O
found O
that O
Tollip O
presented O
different O
trends O
in O
its O
evolving O
history O
. O
In O
primates O
, O
the O
protein O
is O
becoming O
more O
unstable O
, O
just O
the O
opposite O
is O
observed O
in O
the O
arthropod O
group O
. O
The O
most O
interesting O
finding O
was O
the O
concentration O
of O
positively O
selected O
residues O
at O
amino O
terminal O
ends O
. O
Some O
observed O
topological O
incongruences O
in O
maximum O
likelihood O
trees O
of O
complete O
and O
curated O
Tollip O
data O
sets O
could O
be O
explained O
through O
horizontal O
transfers O
, O
evidenced O
by O
recombination O
detection O
. O
These O
results O
suggest O
that O
there O
is O
more O
to O
be O
researched O
and O
understood O
about O
this O
protein O
. O
Exacerbations O
of O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
are O
important O
events O
that O
carry O
significant O
consequences O
for O
patients O
. O
Some O
patients O
experience O
frequent O
exacerbations O
, O
and O
are O
now O
recognized O
as O
a O
distinct O
clinical O
subgroup O
, O
the O
'frequent O
exacerbator O
' O
phenotype O
. O
This O
is O
relatively O
stable O
over O
time O
, O
occurs O
across O
disease O
severity O
, O
and O
is O
associated O
with O
poorer O
health O
outcomes O
. O
These O
patients O
are O
therefore O
a O
priority O
for O
research O
and O
treatment O
. O
The O
pathophysiology O
underlying O
the O
frequent O
exacerbator O
phenotype O
is O
complex O
, O
with O
increased O
airway O
and O
systemic O
inflammation O
, O
dynamic O
lung O
hyperinflation O
, O
changes O
in O
lower O
airway O
bacterial O
colonization O
and O
a O
possible O
increased O
susceptibility O
to O
viral O
infection O
. O
Frequent O
exacerbators O
are O
also O
at O
increased O
risk O
from O
comorbid O
extrapulmonary O
diseases O
including O
cardiovascular O
disease O
, O
gastroesophageal O
reflux O
, O
depression O
, O
osteoporosis O
and O
cognitive O
impairment O
. O
Overall O
these O
patients O
have O
poorer O
health O
status O
, O
accelerated O
forced O
expiratory O
volume O
over O
1 O
s O
( O
FEV1 O
) O
decline O
, O
worsened O
quality O
of O
life O
, O
and O
increased O
hospital O
admissions O
and O
mortality O
, O
contributing O
to O
increased O
exacerbation O
susceptibility O
and O
perpetuation O
of O
the O
frequent O
exacerbator O
phenotype O
. O
This O
review O
article O
sets O
out O
the O
definition O
and O
importance O
of O
the O
frequent O
exacerbator O
phenotype O
, O
with O
a O
detailed O
examination O
of O
its O
pathophysiology O
, O
impact O
and O
interaction O
with O
other O
comorbidities O
. O
Background O
: O
Absenteeism O
due O
to O
communicable O
illness O
is O
a O
major O
problem O
encountered O
by O
North O
American O
elementary O
school O
children O
. O
Although O
handwashing O
is O
a O
proven O
infection O
control O
measure O
, O
barriers O
exist O
in O
the O
school O
environment O
, O
which O
hinder O
compliance O
to O
this O
routine O
. O
Currently O
, O
alternative O
hand O
hygiene O
techniques O
are O
being O
considered O
, O
and O
one O
such O
technique O
is O
the O
use O
of O
antimicrobial O
rinse-free O
hand O
sanitizers O
. O
A O
systematic O
review O
was O
conducted O
to O
examine O
the O
effectiveness O
of O
antimicrobial O
rinsefree O
hand O
sanitizer O
interventions O
in O
the O
elementary O
school O
setting O
. O
MEDLINE O
, O
EMBASE O
, O
Biological O
Abstract O
, O
CINAHL O
, O
HealthSTAR O
and O
Cochrane O
Controlled O
Trials O
Register O
were O
searched O
for O
both O
randomized O
and O
non-randomized O
controlled O
trials O
. O
Absenteeism O
due O
to O
communicable O
illness O
was O
the O
primary O
outcome O
variable O
. O
Results O
: O
Six O
eligible O
studies O
, O
two O
of O
which O
were O
randomized O
, O
were O
identified O
( O
5 O
published O
studies O
, O
1 O
published O
abstract O
) O
. O
The O
quality O
of O
reporting O
was O
low O
. O
Due O
to O
a O
large O
amount O
of O
heterogeneity O
and O
low O
quality O
of O
reporting O
, O
no O
pooled O
estimates O
were O
calculated O
. O
There O
was O
a O
significant O
difference O
reported O
in O
favor O
of O
the O
intervention O
in O
all O
5 O
published O
studies O
. O
The O
available O
evidence O
for O
the O
effectiveness O
of O
antimicrobial O
rinse-free O
hand O
sanitizer O
in O
the O
school O
environment O
is O
of O
low O
quality O
. O
The O
results O
suggest O
that O
the O
strength O
of O
the O
benefit O
should O
be O
interpreted O
with O
caution O
. O
Given O
the O
potential O
to O
reduce O
student O
absenteeism O
, O
teacher O
absenteeism O
, O
school O
operating O
costs O
, O
healthcare O
costs O
and O
parental O
absenteeism O
, O
a O
well-designed O
and O
analyzed O
trial O
is O
needed O
to O
optimize O
this O
hand O
hygiene O
technique O
. O
The O
ability O
to O
detect O
nanoscale O
objects O
is O
particular O
crucial O
for O
a O
wide O
range O
of O
applications O
, O
such O
as O
environmental O
protection O
, O
early-stage O
disease O
diagnosis O
and O
drug O
discovery O
. O
Photonic O
crystal O
nanobeam O
cavity O
( O
PCNC O
) O
sensors O
have O
attracted O
great O
attention O
due O
to O
high-quality B-protein
factors E-protein
and O
small-mode O
volumes O
( O
Q/V O
) O
and O
good O
on-chip O
integrability O
with O
optical O
waveguides/circuits O
. O
In O
this O
review O
, O
we O
focus O
on O
nanoscale O
optical O
sensing O
based O
on O
PCNC O
sensors O
, O
including O
ultrahigh O
figure O
of O
merit O
( O
FOM O
) O
sensing O
, O
single O
nanoparticle O
trapping O
, O
label-free B-protein
molecule E-protein
detection O
and O
an O
integrated O
sensor O
array O
for O
multiplexed O
sensing O
. O
We O
believe O
that O
the O
PCNC O
sensors O
featuring O
ultracompact O
footprint O
, O
high O
monolithic O
integration O
capability O
, O
fast O
response O
and O
ultrahigh O
sensitivity O
sensing O
ability O
, O
etc. O
, O
will O
provide O
a O
promising O
platform O
for O
further O
developing O
lab-on-a-chip O
devices O
for O
biosensing O
and O
other O
functionalities O
. O
Micromachines O
2020 O
, O
11 O
, O
72 O
2 O
of O
20 O
microcavities O
confine O
the O
light O
in O
a O
small O
volume O
, O
leading O
to O
significant O
enhancement O
of O
light-matter O
interaction O
, O
resulting O
in O
ultra-high O
sensitivity O
( O
S O
) O
and O
a O
low O
detection O
limit O
. O
When O
subject O
to O
slight O
environmental O
changes O
, O
the O
spectral O
properties O
change O
can O
be O
obtained O
, O
e.g. O
, O
resonator O
wavelength O
shift O
[ O
20 O
] O
[ O
21 O
] O
[ O
22 O
] O
and O
mode O
broadening O
[ O
23 O
] O
. O
The O
main O
types O
of O
optical O
microcavities O
include O
whispering O
gallery O
mode O
( O
WGM O
) O
cavities O
, O
Fabry-Perot O
( O
F-P O
) O
cavities O
and O
photonic O
crystal O
( O
PhC O
) O
cavities O
[ O
24 O
] O
. O
Among O
these O
, O
PhC O
cavities O
have O
been O
investigated O
as O
advantageous O
platforms O
due O
to O
their O
ultra-high O
Q/V O
enabling O
the O
enhancement O
of O
lightmatter O
interactions O
. O
Particularly O
, O
compared O
with O
two-dimensional O
( O
2D O
) O
PhC O
cavities O
, O
one-dimensional O
photonic O
crystal O
nanobeam O
cavities O
( O
1D-PCNCs O
) O
attract O
great O
attention O
for O
their O
ultra-sensitive O
optical O
sensing O
and O
lab-on-a-chip O
applications O
, O
owing O
to O
their O
ultra-compact O
size O
, O
ultra-small O
mode O
volume O
, O
high O
integrability O
with O
bus-waveguide O
and O
excellent O
complementary O
metal-oxide-semiconductor O
( O
CMOS O
) O
compatible O
properties O
[ B-DNA
25 I-DNA
] I-DNA
[ I-DNA
26 I-DNA
] I-DNA
[ I-DNA
27 I-DNA
] I-DNA
[ I-DNA
28 I-DNA
] I-DNA
[ I-DNA
29 I-DNA
] I-DNA
[ I-DNA
30 I-DNA
] I-DNA
[ I-DNA
31 I-DNA
] I-DNA
[ I-DNA
32 I-DNA
] I-DNA
[ I-DNA
33 I-DNA
] E-DNA
. O
In O
this O
review O
, O
we O
will O
focus O
on O
nanoscale O
optical O
sensing O
based O
on O
1D-PCNCs O
. O
The O
structure O
of O
the O
review O
is O
organized O
as O
follows O
. O
A O
comprehensive O
overview O
about O
basic O
properties O
and O
sensing O
mechanisms O
of O
1D-PCNCs O
sensors O
is O
discussed O
in O
Section O
2 O
. O
In O
Section O
3 O
, O
firstly O
, O
we O
introduce O
the O
efforts O
to O
pursue O
ultra-high O
figure O
of O
merit O
( O
FOM O
) O
in O
refractive O
index O
( O
RI O
) O
sensing O
based O
on O
1D-PCNCs O
. O
Secondly O
, O
we O
outline O
the O
applications O
of O
1D-PCNC O
sensors O
on O
single O
nanoparticle O
and O
label-free B-protein
molecule E-protein
( O
viruses O
, O
proteins O
and O
DNAs O
) O
detection O
. O
Thirdly O
, O
a O
monolithic O
integrated O
1D-PCNC O
sensor O
array O
for O
multiplexed O
sensing O
is O
introduced O
explicitly O
. O
In O
addition O
, O
we O
present O
other O
sensing O
applications O
of O
1D-PCNC O
sensors O
such O
as O
temperature O
sensing O
and O
optomechanical O
sensing O
, O
etc O
. O
Next O
, O
we O
review O
the O
nanofabrication O
and O
coupling O
techniques O
in O
the O
development O
of O
1D-PCNC O
sensors O
in O
Section O
4 O
. O
Finally O
, O
we O
draw O
a O
brief O
conclusion O
. O
Figure O
2 O
. O
( O
a O
) O
Schematic O
of O
photonic O
circuits O
. O
The O
green B-cell_line
lines E-cell_line
, O
red O
boxes O
and O
black O
boxes O
represent O
waveguides O
, O
PCNCs O
and O
grating O
couplers O
, O
respectively O
. O
( O
b O
) O
Resonance O
shift O
measured O
in O
real O
time O
with O
different O
concentration O
of O
carcinoembryonic B-protein
antigen E-protein
( O
CEA S-protein
) O
. O
Reproduced O
with O
permission O
[ O
81 O
] O
. O
Arabia O
. O
Using O
parametric O
and O
nonparametric O
methods O
, O
we O
estimated O
a O
mean O
incubation O
period O
of O
6.9 O
days O
( O
95 O
% O
credibility O
interval O
: O
6.3-7.5 O
) O
for O
cases O
in O
South O
Korea O
and O
5.0 O
days O
( O
95 O
% O
credibility O
interval O
: O
4.0-6.6 O
) O
among O
cases O
in O
Saudi O
Arabia O
. O
In O
a O
log-linear O
regression O
model O
, O
the O
mean O
incubation O
period O
was O
1.42 O
times O
longer O
( O
95 O
% O
credibility O
interval O
: O
1.18-1.71 O
) O
among O
cases O
in O
South O
Korea O
compared O
to O
Saudi O
Arabia O
. O
The O
variation O
that O
we O
identified O
in O
the O
incubation O
period O
distribution O
between O
locations O
could O
be O
associated O
with O
differences O
in O
ascertainment O
or O
reporting O
of O
exposure O
dates O
and O
illness O
onset O
dates O
, O
differences O
in O
the O
source O
or O
mode O
of O
infection O
, O
or O
environmental O
differences O
. O
Background O
: O
Despite O
the O
development O
of O
various O
systems O
to O
generate O
live O
recombinant O
Salmonella O
Typhimurium O
vaccine O
strains O
, O
little O
work O
has O
been O
performed O
to O
systematically O
evaluate O
and O
compare O
their O
relative O
immunogenicity O
. O
Such O
information O
would O
provide O
invaluable O
guidance O
for O
the O
future O
rational O
design O
of O
live O
recombinant O
Salmonella O
oral O
vaccines O
. O
Interferon-induced B-protein
transmembrane I-protein
proteins E-protein
( O
IFITMs S-protein
) O
can O
inhibit O
the O
cellular O
entry O
of O
several O
enveloped O
viruses O
, O
including O
simian O
immunodeficiency O
virus O
( O
SIV O
) O
. O
The O
blockade O
of O
SIV O
by O
IFITMs S-protein
is O
isolate O
specific O
, O
raising O
the O
question O
of O
which O
parameters O
impact O
sensitivity O
to O
IFITM S-protein
. O
We O
show O
that O
the O
virion O
context O
in O
which O
SIV-Env S-protein
is O
presented O
and O
the O
efficiency O
of O
virion O
incorporation O
determine O
Env S-protein
susceptibility O
to O
inhibition O
by O
IFITMs S-protein
. O
Thus O
, O
determinants O
other O
than O
the O
nature O
of O
the O
envelope B-protein
protein E-protein
can O
impact O
the O
IFITM S-protein
sensitivity O
of O
viral O
entry O
. O
IMPORTANCE O
The O
host B-protein
cell-encoded I-protein
IFITM I-protein
proteins E-protein
can O
block O
viral O
entry O
and O
are O
an O
important O
component O
of O
the O
innate O
defenses O
against O
viral O
infection O
. O
However O
, O
the O
determinants O
controlling O
whether O
a O
virus O
is O
susceptible O
to O
blockade O
by O
IFITM B-protein
proteins E-protein
are O
incompletely O
understood O
. O
Our O
study O
shows O
that O
the O
amount O
of O
envelope B-protein
proteins E-protein
incorporated O
into O
virions O
as O
well O
as O
the O
nature O
of O
the O
virion O
particle O
itself O
can O
impact O
the O
sensitivity O
of O
viral O
entry O
to O
IFITMs S-protein
. O
These O
results O
show O
for O
the O
first O
time O
that O
determinants O
other O
than O
the O
viral B-protein
envelope I-protein
protein E-protein
can O
impact O
sensitivity O
to O
IFITM S-protein
and O
have O
implications O
for O
the O
interpretation O
of O
previously O
published O
data O
on O
inhibition O
of O
viruses O
by O
IFITM B-protein
proteins E-protein
. O
Moreover O
, O
our O
findings O
might O
help O
to O
define O
the O
mechanism O
underlying O
the O
antiviral O
activity O
of O
IFITM B-protein
proteins E-protein
. O
Citation O
Wrensch O
F O
, O
Hoffmann O
M O
, O
Gärtner O
S O
, O
Nehlmeier O
I O
, O
Winkler O
M O
, O
Pöhlmann O
S. O
2017 O
. O
Virion O
background O
and O
efficiency O
of O
virion O
incorporation O
determine O
susceptibility O
of O
simian O
immunodeficiency O
virus O
Env-driven O
viral O
entry O
to O
inhibition O
by O
IFITM B-protein
proteins E-protein
. O
J O
Virol O
91 O
: O
e01488-16 O
. O
https O
: O
//doi O
. O
Human O
papillomavirus O
( O
HPV O
) O
infection O
is O
the O
most O
common O
viral O
infection O
of O
the O
reproductive O
tract O
, O
with O
virtually O
all O
cases O
of O
cervical O
cancer O
being O
attributable O
to O
infection O
by O
oncogenic B-protein
HPVs E-protein
. O
However O
, O
the O
exact O
mechanism O
and O
receptors O
used O
by O
HPV O
to O
infect O
epithelial B-cell_type
cells E-cell_type
are O
controversial O
. O
The O
current O
entry O
model O
suggests O
that O
HPV O
initially O
attaches O
to O
heparan B-protein
sulfate I-protein
proteoglycans E-protein
( O
HSPGs S-protein
) O
at O
the O
cell O
surface O
, O
followed O
by O
conformational O
changes O
, O
cleavage O
by O
furin B-protein
convertase E-protein
, O
and O
subsequent O
transfer O
of O
the O
virus O
to O
an O
as-yet-unidentified B-protein
high-affinity I-protein
receptor E-protein
. O
In O
line O
with O
this O
model O
, O
we O
established O
an O
in O
vitro O
infection O
system O
using O
the O
HSPGdeficient B-cell_line
cell I-cell_line
line I-cell_line
pgsD677 E-cell_line
together O
with O
HPV16 B-protein
pseudovirions E-protein
( O
HPV16-PsVs O
) O
. O
While O
pgsD677 B-cell_line
cells E-cell_line
were O
nonpermissive O
for O
untreated O
HPV16-PsVs S-protein
, O
furin S-protein
cleavage O
of O
the O
particles O
led O
to O
a O
substantial O
increase O
in O
infection O
. O
Biochemical O
pulldown O
assays O
followed O
by O
mass O
spectrometry O
analysis O
showed O
that O
furin-precleaved B-protein
HPV16-PsVs E-protein
specifically O
interacted O
with O
surface-expressed B-protein
vimentin E-protein
on O
pgsD677 B-cell_line
cells E-cell_line
. O
We O
further O
demonstrated O
that O
both O
furin-precleaved B-protein
and I-protein
uncleaved I-protein
HPV16-PsVs E-protein
colocalized O
with O
surface-expressed B-protein
vimentin E-protein
on O
pgsD677 B-cell_line
, I-cell_line
HeLa I-cell_line
, I-cell_line
HaCaT I-cell_line
, I-cell_line
and I-cell_line
NIKS I-cell_line
cells E-cell_line
, O
while O
binding O
of O
incoming O
viral O
particles O
to O
soluble O
vimentin B-protein
protein E-protein
before O
infection O
led O
to O
a O
substantial O
decrease O
in O
viral O
uptake O
. O
Interestingly O
, O
decreasing O
cell B-protein
surface I-protein
vimentin E-protein
by O
small O
interfering O
RNA O
( O
siRNA S-protein
) O
knockdown O
in O
HeLa S-cell_line
and O
NIKS B-cell_line
cells E-cell_line
significantly O
increased O
HPV16-PsV O
infectious O
internalization O
, O
while O
overexpression O
of O
vimentin S-protein
had O
the O
opposite O
effect O
. O
The O
identification O
of O
vimentin S-protein
as O
an O
HPV B-protein
restriction I-protein
factor E-protein
enhances O
our O
understanding O
of O
the O
initial O
steps O
of O
HPV-host O
interaction O
and O
may O
lay O
the O
basis O
for O
the O
design O
of O
novel O
antiviral O
drugs O
preventing O
HPV O
internalization O
into O
epithelial B-cell_type
cells E-cell_type
. O
IMPORTANCE O
Despite O
HPV O
being O
a O
highly O
prevalent O
sexually O
transmitted O
virus O
causing O
significant O
disease O
burden O
worldwide O
, O
particularly O
cancer O
of O
the O
cervix O
, O
cell O
surface O
events O
preceding O
oncogenic O
HPV O
internalization O
are O
poorly O
understood O
. O
We O
herein O
describe O
the O
identification O
of O
surface-expressed B-protein
vimentin E-protein
as O
a O
novel O
molecule O
not O
previously O
implicated O
in O
the O
infectious O
internalization O
of O
HPV16 S-protein
. O
Contrary O
to O
our O
expectations O
, O
vimentin S-protein
was O
found O
to O
act O
not O
as O
a O
receptor O
but O
rather O
as O
a O
restriction B-protein
factor E-protein
dampening O
the O
initial O
steps O
of O
HPV16 O
infection O
. O
These O
results O
importantly O
contribute O
to O
our O
current O
understanding O
of O
the O
molecular O
events O
during O
the O
infectious O
internalization O
of O
HPV16 S-protein
and O
open O
a O
new O
direction O
in O
the O
development O
of O
alternative O
drugs O
to O
prevent O
HPV O
infection O
. O
Citation O
Schäfer O
G O
, O
Graham O
LM O
, O
Lang O
DM O
, O
Blumenthal O
MJ O
, O
Bergant O
Marušič O
M O
, O
Katz O
AA O
. O
2017 O
. O
Vimentin S-protein
modulates O
infectious O
internalization O
of O
human O
papillomavirus O
16 O
pseudovirions O
. O
J O
Virol O
91 O
: O
e00307-17 O
. O
https O
: O
//doi O
. O
Over O
the O
past O
few O
decades O
, O
global O
metapopulation O
epidemic O
simulations O
built O
with O
worldwide O
air-transportation O
data O
have O
been O
the O
main O
tool O
for O
studying O
how O
epidemics O
spread O
from O
the O
origin O
to O
other O
parts O
of O
the O
world O
( O
e.g. O
, O
for O
pandemic O
influenza O
, O
SARS O
, O
and O
Ebola O
) O
. O
However O
, O
it O
remains O
unclear O
how O
disease O
epidemiology O
and O
the O
air-transportation O
network O
structure O
determine O
epidemic O
arrivals O
for O
different O
populations O
around O
the O
globe O
. O
Here O
, O
we O
fill O
this O
knowledge O
gap O
by O
developing O
and O
validating O
an O
analytical O
framework O
that O
requires O
only O
basic O
analytics O
from O
stochastic O
processes O
. O
We O
apply O
this O
framework O
retrospectively O
to O
the O
2009 O
influenza O
pandemic O
and O
2014 O
Ebola O
epidemic O
to O
show O
that O
key O
epidemic O
parameters O
could O
be O
robustly O
estimated O
in O
real-time O
from O
public O
data O
on O
local O
and O
global O
spread O
at O
very O
low O
computational O
cost O
. O
Our O
framework O
not O
only O
elucidates O
the O
dynamics O
underlying O
global O
spread O
of O
epidemics O
but O
also O
advances O
our O
capability O
in O
nowcasting O
and O
forecasting O
epidemics O
. O
Human O
coronaviruses O
( O
HCoVs O
) O
are O
known O
respiratory O
pathogens O
associated O
with O
a O
range O
of O
respiratory O
outcomes O
. O
In O
the O
past O
14 O
years O
, O
the O
onset O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
( O
SARS-CoV O
) O
and O
Middle O
East O
respiratory O
syndrome O
coronavirus O
( O
MERS-CoV O
) O
have O
thrust O
HCoVs O
into O
spotlight O
of O
the O
research O
community O
due O
to O
their O
high O
pathogenicity O
in O
humans O
. O
The O
study O
of O
HCoV-host O
interactions O
has O
contributed O
extensively O
to O
our O
understanding O
of O
HCoV O
pathogenesis O
. O
In O
this O
review O
, O
we O
discuss O
some O
of O
the O
recent O
findings O
of O
host B-protein
cell I-protein
factors E-protein
that O
might O
be O
exploited O
by O
HCoVs S-protein
to O
facilitate O
their O
own O
replication O
cycle O
. O
We O
also O
discuss O
various O
cellular O
processes O
, O
such O
as O
apoptosis O
, O
innate O
immunity O
, O
ER S-protein
stress O
response O
, O
mitogen-activated B-protein
protein I-protein
kinase E-protein
( O
MAPK S-protein
) O
pathway O
and O
nuclear B-protein
factor I-protein
kappa I-protein
B E-protein
( O
NF-κB S-protein
) O
pathway O
that O
may O
be O
modulated O
by O
HCoVs S-protein
. O
Diseases O
2016 O
, O
4 O
, O
26 O
2 O
of O
28 O
but O
with O
a O
much O
higher O
mortality O
rate O
of O
about O
35 O
% O
[ O
17 O
] O
. O
Unlike O
SARS-CoV S-protein
, O
which O
exhibits O
super-spreader O
events O
, O
transmission O
of O
MERS-CoV O
is O
geographically O
limited O
[ O
12 O
] O
. O
In O
fact O
, O
reported O
cases O
of O
MERS-CoV O
often O
stem O
from O
outbreaks O
within O
the O
Middle O
Eastern O
countries O
or O
recent O
travel O
to O
the O
region O
[ O
18 O
, O
19 O
] O
. O
CoVs O
are O
a O
group O
of O
large O
enveloped O
RNA O
viruses O
under O
the O
Coronaviridae B-DNA
family E-DNA
. O
Together O
with O
Artierivirdae O
and O
Roniviridae O
, O
Coronaviridae O
is O
classified O
under O
the O
Nidovirale O
order O
[ O
20 O
] O
. O
As O
proposed O
by O
the O
International O
Committee O
for O
Taxonomy O
of O
Viruses O
, O
CoVs O
are O
further O
categorized O
into O
four O
main O
genera O
, O
Alpha- O
, O
Beta- O
, O
Gammaand O
Deltacoronaviruses O
based O
on O
sequence O
comparisons O
of O
entire B-DNA
viral I-DNA
genomes E-DNA
[ O
21 O
, O
22 O
] O
. O
These O
CoVs O
can O
infect O
a O
wide O
variety O
of O
hosts O
, O
including O
avian O
, O
swine O
and O
humans O
. O
HCoVs O
are O
identified O
to O
be O
either O
in O
the O
Alphaor O
Betacoronavirus O
genera O
, O
including O
Alphacoronaviruses O
, O
HCoV-229E O
and O
HCoV-NL63 O
, O
and O
Betacoronaviruses O
, O
HCoV-HKU1 O
, O
SARS-CoV O
, O
MERS-CoV O
and O
HCoV-OC43 O
( O
Table O
1 O
) O
. O
Under O
the O
electron O
microscope O
, O
the O
CoV O
virions O
appear O
to O
be O
roughly O
spherical O
or O
moderately O
pleomorphic O
, O
with O
distinct O
`` O
club-like O
'' O
projections O
formed O
by O
the O
spike B-protein
( I-protein
S I-protein
) I-protein
protein E-protein
[ O
23 O
, O
24 O
] O
. O
Within O
the O
virion O
interior O
lies O
a O
helically O
symmetrical O
nucleocapsid O
that O
encloses O
a O
single-stranded O
and O
positive O
sense O
RNA B-DNA
viral I-DNA
genome E-DNA
of O
an O
extraordinarily O
large O
size O
of O
about O
26 O
to O
32 O
kilobases O
[ O
20 O
] O
. O
The O
positive O
sense O
viral B-RNA
genomic I-RNA
RNA E-RNA
acts O
as O
a O
messenger B-RNA
RNA E-RNA
( O
mRNA S-RNA
) O
, O
comprising O
a O
5 B-protein
1 I-protein
terminal I-protein
cap I-protein
structure E-protein
and O
a O
3 B-DNA
1 I-DNA
poly I-DNA
A I-DNA
tail E-DNA
. O
This O
genomic B-RNA
RNA E-RNA
acts O
in O
three O
capacities O
during O
the O
viral O
life O
cycle O
: O
( O
1 O
) O
as O
an O
initial O
RNA O
of O
the O
infectious O
cycle O
; O
( O
2 O
) O
as O
a O
template O
for O
replication O
and O
transcription O
; O
and O
( O
3 O
) O
as O
a O
substrate O
for O
packaging O
into O
the O
progeny O
virus O
. O
The O
replicase-transcriptase O
is O
the O
only O
protein O
translated O
from O
the O
genome O
, O
while O
the O
viral O
products O
of O
all O
downstream B-DNA
open I-DNA
reading I-DNA
frames E-DNA
are O
derived O
from O
subgenomic B-RNA
mRNAs E-RNA
. O
In O
all O
CoVs S-DNA
, O
the O
replicase B-DNA
gene E-DNA
makes O
up O
approximately O
5 O
1 O
two-thirds O
of O
the O
genome O
and O
is O
comprised O
of O
two O
overlapping B-DNA
open I-DNA
reading I-DNA
frames E-DNA
( O
ORFs S-DNA
) O
, O
ORF1a S-DNA
and O
ORF1b S-DNA
, O
which O
encodes O
16 B-protein
non-structural I-protein
proteins E-protein
. O
The O
final O
one-third O
of O
the O
CoV B-RNA
genomic I-RNA
RNA E-RNA
encodes O
CoV S-DNA
canonical O
set O
of O
four O
structural B-DNA
protein I-DNA
genes E-DNA
, O
in O
the O
order O
of O
spike O
( O
S O
) O
, O
envelope B-protein
( I-protein
E I-protein
) I-protein
, I-protein
membrane I-protein
( I-protein
M I-protein
) I-protein
and I-protein
nucleocapsid I-protein
( I-protein
N I-protein
) E-protein
. O
In O
addition O
, O
several O
accessory O
ORFs S-DNA
are O
also O
interspersed O
along O
the O
structural B-DNA
protein I-DNA
genes E-DNA
and O
the O
number O
and O
location O
varies O
among O
CoV O
species O
[ O
25 O
] O
( O
Figure O
1 O
) O
. O
Diseases O
2016 O
, O
4 O
, O
26 O
2 O
of O
27 O
SARS-CoV O
but O
with O
a O
much O
higher O
mortality O
rate O
of O
about O
35 O
% O
[ O
17 O
] O
. O
Unlike O
SARS-CoV S-protein
, O
which O
exhibits O
super-spreader O
events O
, O
transmission O
of O
MERS-CoV O
is O
geographically O
limited O
[ O
12 O
] O
. O
In O
fact O
, O
reported O
cases O
of O
MERS-CoV O
often O
stem O
from O
outbreaks O
within O
the O
Middle O
Eastern O
countries O
or O
recent O
travel O
to O
the O
region O
[ O
18,19 O
] O
. O
CoVs O
are O
a O
group O
of O
large O
enveloped O
RNA O
viruses O
under O
the O
Coronaviridae B-DNA
family E-DNA
. O
Together O
with O
Artierivirdae O
and O
Roniviridae O
, O
Coronaviridae O
is O
classified O
under O
the O
Nidovirale O
order O
[ O
20 O
] O
. O
As O
proposed O
by O
the O
International O
Committee O
for O
Taxonomy O
of O
Viruses O
, O
CoVs O
are O
further O
categorized O
into O
four O
main O
genera O
, O
Alpha- O
, O
Beta- O
, O
Gamma-and O
Deltacoronaviruses O
based O
on O
sequence O
comparisons O
of O
entire B-DNA
viral I-DNA
genomes E-DNA
[ O
21 O
, O
22 O
] O
. O
These O
CoVs O
can O
infect O
a O
wide O
variety O
of O
hosts O
, O
including O
avian O
, O
swine O
and O
humans O
. O
HCoVs O
are O
identified O
to O
be O
either O
in O
the O
Alpha-or O
Betacoronavirus O
genera O
, O
including O
Alphacoronaviruses O
, O
HCoV-229E O
and O
HCoV-NL63 O
, O
and O
Betacoronaviruses O
, O
HCoV-HKU1 O
, O
SARS-CoV O
, O
MERS-CoV O
and O
HCoV-OC43 O
( O
Table O
1 O
) O
. O
Under O
the O
electron O
microscope O
, O
the O
CoV O
virions O
appear O
to O
be O
roughly O
spherical O
or O
moderately O
pleomorphic O
, O
with O
distinct O
`` O
club-like O
'' O
projections O
formed O
by O
the O
spike B-protein
( I-protein
S I-protein
) I-protein
protein E-protein
[ O
23 O
, O
24 O
] O
. O
Within O
the O
virion O
interior O
lies O
a O
helically O
symmetrical O
nucleocapsid O
that O
encloses O
a O
single-stranded O
and O
positive O
sense O
RNA B-DNA
viral I-DNA
genome E-DNA
of O
an O
extraordinarily O
large O
size O
of O
about O
26 O
to O
32 O
kilobases O
[ O
20 O
] O
. O
The O
positive O
sense O
viral B-RNA
genomic I-RNA
RNA E-RNA
acts O
as O
a O
messenger B-RNA
RNA E-RNA
( O
mRNA S-RNA
) O
, O
comprising O
a O
5′ B-protein
terminal I-protein
cap I-protein
structure E-protein
and O
a O
3′ B-DNA
poly I-DNA
A I-DNA
tail E-DNA
. O
This O
genomic B-RNA
RNA E-RNA
acts O
in O
three O
capacities O
during O
the O
viral O
life O
cycle O
: O
( O
1 O
) O
as O
an O
initial O
RNA O
of O
the O
infectious O
cycle O
; O
( O
2 O
) O
as O
a O
template O
for O
replication O
and O
transcription O
; O
and O
( O
3 O
) O
as O
a O
substrate O
for O
packaging O
into O
the O
progeny O
virus O
. O
The O
replicase-transcriptase O
is O
the O
only O
protein O
translated O
from O
the O
genome O
, O
while O
the O
viral O
products O
of O
all O
downstream B-DNA
open I-DNA
reading I-DNA
frames E-DNA
are O
derived O
from O
subgenomic B-RNA
mRNAs E-RNA
. O
In O
all O
CoVs S-DNA
, O
the O
replicase B-DNA
gene E-DNA
makes O
up O
approximately O
5′ O
twothirds O
of O
the O
genome O
and O
is O
comprised O
of O
two O
overlapping B-DNA
open I-DNA
reading I-DNA
frames E-DNA
( O
ORFs S-DNA
) O
, O
ORF1a S-DNA
and O
ORF1b S-DNA
, O
which O
encodes O
16 B-protein
non-structural I-protein
proteins E-protein
. O
The O
final O
one-third O
of O
the O
CoV B-RNA
genomic I-RNA
RNA E-RNA
encodes O
CoV S-DNA
canonical O
set O
of O
four O
structural B-DNA
protein I-DNA
genes E-DNA
, O
in O
the O
order O
of O
spike O
( O
S O
) O
, O
envelope B-protein
( I-protein
E I-protein
) I-protein
, I-protein
membrane I-protein
( I-protein
M I-protein
) I-protein
and I-protein
nucleocapsid I-protein
( I-protein
N I-protein
) E-protein
. O
In O
addition O
, O
several O
accessory O
ORFs S-DNA
are O
also O
interspersed O
along O
the O
structural B-DNA
protein I-DNA
genes E-DNA
and O
the O
number O
and O
location O
varies O
among O
CoV O
species O
[ O
25 O
] O
( O
Figure O
1 O
) O
. O
Innate O
recognition O
of O
virus B-protein
proteins E-protein
is O
an O
important O
component O
of O
the O
immune O
response O
to O
viral O
pathogens O
. O
A O
component O
of O
this O
immune O
recognition O
is O
the O
family O
of O
lectins S-protein
; O
pattern B-protein
recognition I-protein
receptors E-protein
( O
PRRs S-protein
) O
that O
recognise O
viral O
pathogen-associated O
molecular O
patterns O
( O
PAMPs O
) O
including O
viral B-protein
glycoproteins E-protein
. O
In O
this O
review O
we O
discuss O
the O
contribution O
of O
soluble B-protein
and I-protein
membrane-associated I-protein
PRRs E-protein
to O
immunity O
against O
virus O
pathogens O
, O
and O
the O
potential O
role O
of O
these O
molecules O
in O
facilitating O
virus O
replication O
. O
These O
processes O
are O
illustrated O
with O
examples O
of O
viruses O
including O
human O
immunodeficiency O
virus O
( O
HIV O
) O
, O
hepatitis O
C O
virus O
( O
HCV O
) O
and O
Ebola O
virus O
( O
EBOV O
) O
. O
We O
focus O
on O
the O
structure O
, O
function O
and O
genetics O
of O
the O
well-characterised B-protein
C-type I-protein
lectin I-protein
mannose-binding I-protein
lectin E-protein
, O
the O
ficolins S-protein
, O
and O
the O
membrane-bound B-protein
CD209 I-protein
proteins E-protein
expressed O
on O
dendritic B-cell_type
cells E-cell_type
. O
The O
potential O
for O
lectin-based O
antiviral O
therapies O
is O
also O
discussed O
. O
2230 O
the O
primitive O
immune O
system O
depended O
on O
lectin-protease-mediated O
opsonophagocytosis O
[ O
2 O
] O
. O
Lectins S-protein
differ O
in O
tissue O
expression O
, O
ligand O
affinities O
, O
structure O
and O
function O
, O
and O
are O
classified O
by O
the O
phylogeny O
and O
primary O
and O
tertiary O
amino O
acid O
structures O
of O
their O
carbohydrate-recognition B-protein
domains E-protein
( O
CRD O
) O
. O
However O
there O
are O
several O
inconsistencies O
in O
this O
classification O
system O
( O
reviewed O
in O
[ O
3 O
] O
) O
. O
Glycosylation O
is O
a O
form O
of O
post-translational O
modification O
in O
which O
glycans-monosaccharides O
or O
oligosaccharides-are O
glycosidically O
bonded O
to O
an O
organic B-protein
molecule E-protein
( O
reviewed O
in O
[ O
4 O
] O
) O
. O
This O
modification O
plays O
an O
essential O
role O
in O
the O
expression O
and O
function O
of O
many O
proteins O
in O
eukaryotes O
and O
prokaryote B-cell_type
cells E-cell_type
, O
with O
roles O
in O
, O
for O
example O
, O
inter-compound O
interaction O
and O
pathogenic O
immune O
evasion O
. O
Eukaryotic O
and O
viral O
glycosylation O
occurs O
in O
the O
host O
cell O
endoplasmic O
reticulum O
( O
ER S-protein
) O
and O
Golgi O
apparatus O
. O
Lectin-glycan O
interactions O
are O
generally O
achieved O
by O
hydrogen O
bonding O
and O
Van O
der O
Waals O
forces O
, O
and O
often O
depend O
on O
cations O
and O
multivalent O
interactions O
between O
multiple O
CRDs S-protein
and O
multiple O
, O
clustered O
target O
glycans O
in O
order O
to O
achieve O
sufficient O
affinities O
for O
lectin S-protein
activity O
[ O
3 O
] O
. O
The O
roles O
of O
human B-protein
lectins E-protein
include O
protein O
modulation O
, O
cell O
growth O
and O
homeostasis O
[ O
4 O
] O
. O
As O
glycoproteins S-protein
are O
found O
on O
the O
surfaces O
of O
several O
pathogens O
to O
a O
diverse O
and O
widespread O
degree O
, O
some O
lectins O
act O
as O
pattern-recognition B-protein
receptors E-protein
( O
PRRs S-protein
) O
, O
recognising O
pathogen-associated O
molecular O
patterns O
( O
PAMPs O
) O
-including O
glycans O
and O
nucleic O
acid-related O
to O
invading O
microorganisms O
and O
malignant B-cell_type
, I-cell_type
apoptotic I-cell_type
or I-cell_type
dead I-cell_type
host I-cell_type
cells E-cell_type
. O
This O
can O
lead O
to O
the O
induction O
of O
an O
immune O
response O
against O
the O
invading O
pathogen O
. O
However O
, O
the O
relationship O
between O
lectins S-protein
and O
viruses O
is O
complex O
. O
In O
addition O
to O
immune O
evasion O
, O
glycosylation O
is O
essential O
for O
protein O
expression O
, O
assembly O
and O
entry O
steps O
in O
virus O
replication O
cycles O
[ O
5 O
] O
, O
and O
many O
viruses O
have O
evolved O
mechanisms O
to O
exploit O
lectins S-protein
to O
enhance O
infection O
. O
This O
review O
focuses O
on O
human B-protein
lectins E-protein
and O
their O
roles O
during O
viral O
infections O
, O
concentrating O
on O
the O
well-described B-protein
lectins I-protein
mannose-binding I-protein
lectin E-protein
( O
MBL S-protein
) O
, O
ficolins S-protein
and O
dendritic B-protein
cell-specific I-protein
ICAM-3 I-protein
grabbing I-protein
non-integrin E-protein
( O
DC-SIGN S-protein
) O
. O
It O
highlights O
the O
different O
effects O
of O
lectins S-protein
on O
viral O
infections O
and O
the O
consequences O
of O
genetic O
variation O
in O
lectin B-DNA
genes E-DNA
on O
susceptibility O
to O
virus O
infections O
. O
Complement O
contributes O
towards O
the O
initial O
defence O
against O
viral O
infections O
through O
a O
sequential O
protein O
activation O
cascade O
( O
reviewed O
in O
[ O
6 O
] O
) O
. O
There O
are O
three O
known O
complement O
activation O
pathways O
. O
Each O
pathway O
converges O
at O
the O
formation O
of O
C3 B-protein
convertase E-protein
, O
which O
activates O
downstream B-protein
complement I-protein
factors E-protein
to O
constitute O
the O
membrane B-protein
attack I-protein
complex E-protein
( O
MAC S-protein
) O
. O
The O
MAC O
subsequently O
forms O
pores O
in O
the O
lipid O
membranes O
of O
pathogens O
and O
infected B-cell_type
cells E-cell_type
, O
causing O
osmotic O
lysis O
. O
Parallel O
to O
the O
cascade O
, O
some O
complement B-protein
cleavage I-protein
products E-protein
mediate O
inflammation O
and O
opsonise O
pathogens O
, O
attracting O
phagocytes S-cell_type
, O
encouraging O
antigen O
aggregation O
and O
preventing O
viral O
entry O
. O
To O
avoid O
potentially O
damaging O
, O
excessive O
complement O
activity O
, O
stringent O
regulation O
mechanisms O
have O
evolved O
, O
including O
complement B-protein
factor E-protein
cleavage O
and O
endocytotic O
shedding O
of O
MACs S-cell_type
. O
The O
alternate O
and O
classical O
complement O
pathways O
are O
triggered O
by O
foreign B-protein
surface I-protein
molecules E-protein
and O
antigen B-protein
: I-protein
antibody I-protein
complexes E-protein
, O
respectively O
. O
The O
lectin S-protein
pathway O
involves O
the O
binding O
of O
microbial B-protein
surface I-protein
carbohydrate I-protein
moieties E-protein
to O
serum B-protein
lectins E-protein
, O
which O
activates O
lectin-bound B-protein
MBL-associated I-protein
serine I-protein
proteases E-protein
( O
MASPs S-protein
) O
and O
proteins O
( O
MAPs O
) O
( O
Figure O
1 O
) O
. O
Immunological O
checkpoints O
, O
such O
as O
the O
inhibitory B-protein
CD200 I-protein
receptor E-protein
( O
CD200R S-protein
) O
, O
play O
a O
dual O
role O
in O
balancing O
the O
immune O
system O
during O
microbial O
infection O
. O
On O
the O
one O
hand O
these O
inhibitory O
signals O
prevent O
excessive O
immune O
mediated O
pathology O
but O
on O
the O
other O
hand O
they O
may O
impair O
clearance O
of O
the O
pathogen O
. O
We O
studied O
the O
influence O
of O
the O
inhibitory O
CD200-CD200R S-protein
axis O
on O
clearance O
and O
pathology O
in O
two O
different O
virus O
infection O
models O
. O
We O
find O
that O
lack O
of O
CD200R S-protein
signaling O
strongly O
enhances O
type B-protein
I I-protein
interferon E-protein
( O
IFN S-protein
) O
production O
and O
viral O
clearance O
and O
improves O
the O
outcome O
of O
mouse O
hepatitis O
corona O
virus O
( O
MHV O
) O
infection O
, O
particularly O
in O
female O
mice O
. O
MHV O
clearance O
is O
known O
to O
be O
dependent O
on O
Toll B-protein
like I-protein
receptor I-protein
7 E-protein
( O
TLR7 S-protein
) O
-mediated O
type B-protein
I I-protein
IFN E-protein
production O
and O
sex O
differences O
in O
TLR7 S-protein
responses O
previously O
have O
been O
reported O
for O
humans O
. O
We O
therefore O
hypothesize O
that O
CD200R S-protein
ligation O
suppresses O
TLR7 S-protein
responses O
and O
that O
release O
of O
this O
inhibition O
enlarges O
sex O
differences O
in O
TLR7 S-protein
signaling O
. O
This O
hypothesis O
is O
supported O
by O
our O
findings O
that O
in O
vivo O
administration O
of O
synthetic O
TLR7 B-protein
ligand E-protein
leads O
to O
enhanced O
type B-protein
I I-protein
IFN E-protein
production O
, O
particularly O
in O
female O
Cd200 O
2/2 O
mice O
and O
that O
CD200R S-protein
ligation O
inhibits O
TLR7 S-protein
signaling O
in O
vitro O
. O
In O
influenza O
A O
virus O
infection O
we O
show O
that O
viral O
clearance O
is O
determined O
by O
sex O
but O
not O
by O
CD200R S-protein
signaling O
. O
However O
, O
absence O
of O
CD200R S-protein
in O
influenza O
A O
virus O
infection O
results O
in O
enhanced O
lung O
neutrophil O
influx O
and O
pathology O
in O
females O
. O
Thus O
, O
CD200-CD200R S-protein
and O
sex O
are O
host O
factors O
that O
together O
determine O
the O
outcome O
of O
viral O
infection O
. O
Our O
data O
predict O
a O
sex O
bias O
in O
both O
beneficial O
and O
pathological O
immune O
responses O
to O
virus O
infection O
upon O
therapeutic O
targeting O
of O
CD200-CD200R S-protein
. O
Positive-strand O
RNA O
viruses O
, O
a O
large O
group O
including O
human O
pathogens O
such O
as O
SARS-coronavirus S-protein
( O
SARS-CoV O
) O
, O
replicate O
in O
the O
cytoplasm O
of O
infected B-cell_type
host I-cell_type
cells E-cell_type
. O
Their O
replication B-protein
complexes E-protein
are O
commonly O
associated O
with O
modified O
host O
cell O
membranes O
. O
Membrane O
structures O
supporting O
viral B-RNA
RNA E-RNA
synthesis O
range O
from O
distinct O
spherular O
membrane O
invaginations O
to O
more O
elaborate O
webs O
of O
packed O
membranes O
and O
vesicles O
. O
Generally O
, O
their O
ultrastructure O
, O
morphogenesis O
, O
and O
exact O
role O
in O
viral O
replication O
remain O
to O
be O
defined O
. O
Poorly O
characterized O
double-membrane O
vesicles O
( O
DMVs O
) O
were O
previously O
implicated O
in O
SARS-CoV B-RNA
RNA E-RNA
synthesis O
. O
We O
have O
now O
applied O
electron O
tomography O
of O
cryofixed B-cell_type
infected I-cell_type
cells E-cell_type
for O
the O
three-dimensional O
imaging O
of O
coronavirus-induced O
membrane O
alterations O
at O
high O
resolution O
. O
Our O
analysis O
defines O
a O
unique O
reticulovesicular O
network O
of O
modified O
endoplasmic O
reticulum O
that O
integrates O
convoluted O
membranes O
, O
numerous O
interconnected O
DMVs S-protein
( O
diameter O
200-300 O
nm O
) O
, O
and O
`` O
vesicle O
packets O
'' O
apparently O
arising O
from O
DMV O
merger O
. O
The O
convoluted O
membranes O
were O
most O
abundantly O
immunolabeled O
for O
viral B-protein
replicase I-protein
subunits E-protein
. O
However O
, O
double-stranded B-RNA
RNA E-RNA
, O
presumably O
revealing O
the O
site O
of O
viral B-RNA
RNA E-RNA
synthesis O
, O
mainly O
localized O
to O
the O
DMV O
interior O
. O
Since O
we O
could O
not O
discern O
a O
connection O
between O
DMV O
interior O
and O
cytosol O
, O
our O
analysis O
raises O
several O
questions O
about O
the O
mechanism O
of O
DMV O
formation O
and O
the O
actual O
site O
of O
SARS-CoV B-RNA
RNA E-RNA
synthesis O
. O
Our O
data O
document O
the O
extensive O
virusinduced O
reorganization O
of O
host O
cell O
membranes O
into O
a O
network O
that O
is O
used O
to O
organize O
viral O
replication O
and O
possibly O
hide O
replicating O
RNA O
from O
antiviral O
defense O
mechanisms O
. O
Together O
with O
biochemical O
studies O
of O
the O
viral B-protein
enzyme I-protein
complex E-protein
, O
our O
ultrastructural O
description O
of O
this O
`` O
replication O
network O
'' O
will O
aid O
to O
further O
dissect O
the O
early O
stages O
of O
the O
coronavirus O
life O
cycle O
and O
its O
virus-host O
interactions O
. O
Citation O
: O
Knoops O
K O
, O
Kikkert O
M O
, O
van O
den O
Worm O
SHE O
, O
Zevenhoven-Dobbe O
JC O
, O
van O
der O
Meer O
Y O
, O
et O
al O
. O
( O
2008 O
) O
SARS-coronavirus O
replication O
is O
supported O
by O
a O
reticulovesicular O
network O
of O
modified O
endoplasmic O
reticulum O
. O
PLoS O
Biol O
6 O
( O
9 O
) O
: O
e226 O
. O
Background O
: O
In O
Plasmodium O
falciparum O
malaria O
endemic O
areas O
placental O
malaria O
( O
PM O
) O
is O
an O
important O
complication O
of O
malaria O
. O
The O
recurrence O
of O
malaria O
in O
primigravidae O
women O
irrespective O
of O
acquired O
protection O
during O
childhood O
is O
caused O
by O
the O
interaction O
between O
the O
parasite-expressed B-protein
VAR2CSA I-protein
antigen E-protein
and O
chondroitin O
sulfate O
A O
( O
CSA O
) O
in O
the O
placental O
intervillous O
space O
and O
lack O
of O
protective B-protein
antibodies E-protein
. O
PM O
impairs O
fetal O
development O
mainly O
by O
excessive O
inflammation O
processes O
. O
After O
infections O
during O
pregnancy O
women O
acquire O
immunity O
to O
PM O
conferred O
by O
antibodies S-protein
against O
VAR2CSA S-protein
. O
Ideally O
, O
a O
vaccine O
against O
PM O
will O
induce O
antibody-mediated O
immune O
responses O
that O
block O
the O
adhesion O
of O
infected B-cell_type
erythrocytes E-cell_type
( O
IE O
) O
in O
the O
placenta O
. O
Principal O
Findings O
: O
We O
have O
previously O
shown O
that O
antibodies S-protein
raised O
in O
rat O
against O
individual O
domains O
of O
VAR2CSA S-protein
can O
block O
IE O
binding O
to O
CSA O
. O
In O
this O
study O
we O
have O
immunized O
mice O
, O
rats O
and O
rabbits O
with O
each O
individual O
domain O
and O
the O
fulllength B-protein
protein E-protein
corresponding O
to O
the O
FCR3 B-protein
VAR2CSA I-protein
variant E-protein
. O
We O
found O
there O
is O
an O
inherently O
higher O
immunogenicity O
of O
Cterminal B-protein
domains E-protein
compared O
to O
N-terminally B-protein
located I-protein
domains E-protein
. O
This O
was O
irrespective O
of O
whether O
antibodies S-protein
were O
induced O
against O
single O
domains O
or O
the O
full-length B-protein
protein E-protein
. O
Species-specific O
antibody O
responses O
were O
also O
found O
, O
these O
were O
mainly O
directed O
against O
single O
domains O
and O
not O
the O
full-length B-protein
VAR2CSA I-protein
protein E-protein
. O
Genetic O
material O
in O
plants O
is O
distributed O
into O
nucleus O
, O
plastids O
and O
mitochondria O
. O
Plastid O
has O
a O
central O
role O
of O
carrying O
out O
photosynthesis O
in O
plant B-cell_type
cells E-cell_type
. O
Plastid O
transformation O
is O
becoming O
more O
popular O
and O
an O
alternative O
to O
nuclear O
gene O
transformation O
because O
of O
various O
advantages O
like O
high O
protein O
levels O
, O
the O
feasibility O
of O
expressing O
multiple O
proteins O
from O
polycistronic B-RNA
mRNAs E-RNA
, O
and O
gene O
containment O
through O
the O
lack O
of O
pollen O
transmission O
. O
Recently O
, O
much O
progress O
in O
plastid O
engineering O
has O
been O
made O
. O
In O
addition O
to O
model O
plant O
tobacco O
, O
many O
transplastomic O
crop O
plants O
have O
been O
generated O
which O
possess O
higher O
resistance O
to O
biotic O
and O
abiotic O
stresses O
and O
molecular O
pharming O
. O
In O
this O
mini O
review O
, O
we O
will O
discuss O
the O
features O
of O
the O
plastid B-DNA
DNA E-DNA
and O
advantages O
of O
plastid O
transformation O
. O
We O
will O
also O
present O
some O
examples O
of O
transplastomic O
plants O
developed O
so O
far O
through O
plastid O
engineering O
, O
and O
the O
various O
applications O
of O
plastid O
transformation O
. O
Maintenance O
of O
epigenetic O
modifiers O
is O
of O
utmost O
importance O
to O
preserve O
the O
epigenome O
and O
consequently O
appropriate O
cellular O
functioning O
. O
Here O
, O
we O
analyzed O
Polycomb B-protein
group I-protein
protein I-protein
( I-protein
PcG I-protein
) I-protein
complex E-protein
integrity O
in O
response O
to O
heat O
shock O
( O
HS O
) O
. O
Upon O
HS O
, O
various O
Polycomb B-protein
Repressive I-protein
Complex I-protein
( I-protein
PRC I-protein
) I-protein
1 E-protein
and O
PRC2 B-protein
subunits E-protein
, O
including O
CBX B-protein
proteins E-protein
, O
but O
also O
other O
chromatin B-protein
regulators E-protein
, O
are O
found O
to O
accumulate O
in O
the O
nucleolus O
. O
In O
parallel O
, O
binding O
of O
PRC1/2 S-protein
to O
target O
genes O
is O
strongly O
reduced O
, O
coinciding O
with O
a O
dramatic O
loss O
of O
H2AK119ub B-protein
and I-protein
H3K27me3 I-protein
marks I-protein
. I-protein
Nucleolar-accumulated I-protein
CBX I-protein
proteins E-protein
are O
immobile O
, O
but O
remarkably O
both O
CBX B-protein
protein E-protein
accumulation O
and O
loss O
of O
PRC1/2 S-protein
epigenetic O
marks O
are O
reversible O
. O
This O
post-heat O
shock O
recovery O
of O
pan-nuclear B-protein
CBX I-protein
protein E-protein
localization O
and O
reinstallation O
of O
epigenetic O
marks O
is O
HSP70 S-protein
dependent O
. O
Our O
findings O
demonstrate O
that O
the O
nucleolus O
is O
an O
essential O
protein O
quality O
control O
center O
, O
which O
is O
indispensable O
for O
recovery O
of O
epigenetic O
regulators O
and O
maintenance O
of O
the O
epigenome O
after O
heat O
shock O
. O
The O
1st O
Workshop O
of O
the O
Canadian O
Society O
for O
Virology O
( O
CSV2016 O
) O
was O
a O
Special O
Workshop O
of O
the O
35th O
Annual O
Meeting O
for O
the O
American O
Society O
for O
Virology O
, O
held O
on O
18 O
June O
2016 O
on O
the O
beautiful O
Virginia O
Tech O
campus O
in O
Blacksburg O
, O
Virginia O
. O
The O
workshop O
provided O
a O
forum O
for O
discussion O
of O
recent O
advances O
in O
the O
field O
, O
in O
an O
informal O
setting O
conducive O
to O
interaction O
with O
colleagues O
. O
CSV2016 O
featured O
two O
internationally-renowned O
Canadian O
keynote O
speakers O
who O
discussed O
translational O
virology O
research O
; O
American O
Society O
for O
Virology O
President O
Grant O
McFadden O
( O
then O
from O
University O
of O
Florida O
, O
now O
relocated O
to O
Arizona O
State O
University O
) O
who O
presented O
his O
studies O
of O
oncolytic O
poxviruses O
, O
while O
Matthew O
Miller O
( O
McMaster O
University O
) O
reviewed O
the O
prospects O
for O
a O
universal O
influenza O
vaccine O
. O
The O
workshop O
also O
featured O
a O
variety O
of O
trainee O
oral O
and O
poster O
presentations O
, O
and O
a O
panel O
discussion O
on O
the O
topic O
of O
the O
future O
of O
the O
CSV O
and O
virus O
research O
in O
Canada O
. O
Ensuring O
the O
virological O
safety O
of O
biologicals O
is O
challenging O
due O
to O
the O
risk O
of O
viral O
contamination O
of O
raw O
materials O
and O
cell O
banks O
, O
and O
exposure O
during O
in-process O
handling O
to O
known O
and/or O
emerging O
viral O
pathogens O
. O
Viruses O
may O
contaminate O
raw O
materials O
and O
biologicals O
intended O
for O
human O
or O
veterinary O
use O
and O
remain O
undetected O
until O
appropriate O
testing O
measures O
are O
employed O
. O
The O
outbreak O
and O
expansive O
spread O
of O
the O
mosquito-borne O
flavivirus O
Zika O
virus O
( O
ZIKV O
) O
poses O
challenges O
to O
screening O
human-and O
animal O
-derived O
products O
used O
in O
the O
manufacture O
of O
biologicals O
. O
Here O
, O
we O
report O
the O
results O
of O
an O
in O
vitro O
study O
where O
detector B-cell_line
cell I-cell_line
lines E-cell_line
were O
challenged O
with O
African O
and O
Asian O
lineages O
of O
ZIKV S-cell_line
. O
We O
demonstrate O
that O
this O
pathogen O
is O
robustly O
detectable O
by O
in O
vitro O
assay O
, O
thereby O
providing O
assurance O
of O
detection O
of O
ZIKV S-protein
, O
and O
in O
turn O
underpinning O
the O
robustness O
of O
in O
vitro O
virology O
assays O
in O
safety O
testing O
of O
biologicals O
. O
Despite O
environmental O
, O
social O
and O
ecological O
dependencies O
, O
emergence O
of O
zoonotic O
viruses O
in O
human O
populations O
is O
clearly O
also O
affected O
by O
genetic O
factors O
which O
determine O
cross-species O
transmission O
potential O
. O
RNA O
viruses O
pose O
an O
interesting O
case O
study O
given O
their O
mutation O
rates O
are O
orders O
of O
magnitude O
higher O
than O
any O
other O
pathogen O
-as O
reflected O
by O
the O
recent O
emergence O
of O
SARS O
and O
Influenza O
for O
example O
. O
Here O
, O
we O
show O
how O
feature O
selection O
techniques O
can O
be O
used O
to O
reliably O
classify O
viral O
sequences O
by O
host O
species O
, O
and O
to O
identify O
the O
crucial O
minority O
of O
host-specific B-DNA
sites E-DNA
in O
pathogen O
genomic O
data O
. O
The O
variability O
in O
alleles O
at O
those O
sites O
can O
be O
translated O
into O
prediction O
probabilities O
that O
a O
particular O
pathogen O
isolate O
is O
adapted O
to O
a O
given O
host O
. O
We O
illustrate O
the O
power O
of O
these O
methods O
by O
: O
1 O
) O
identifying O
the O
sites O
explaining O
SARS O
coronavirus O
differences O
between O
human O
, O
bat O
and O
palm O
civet O
samples O
; O
2 O
) O
showing O
how O
cross O
species O
jumps O
of O
rabies O
virus O
among O
bat O
populations O
can O
be O
readily O
identified O
; O
and O
3 O
) O
de O
novo O
identification O
of O
likely O
functional O
influenza B-protein
host I-protein
discriminant I-protein
markers E-protein
. O
Interferon-inducible B-protein
transmembrane I-protein
protein I-protein
3 E-protein
( O
IFITM3 S-protein
) O
is O
an O
effector B-protein
protein E-protein
of O
the O
innate O
immune O
system O
. O
It O
confers O
potent O
, O
cell-intrinsic O
resistance O
to O
infection O
by O
diverse O
enveloped O
viruses O
both O
in O
vitro O
and O
in O
vivo O
, O
including O
influenza O
viruses O
, O
West O
Nile O
virus O
, O
and O
dengue O
virus O
. O
IFITM3 S-protein
prevents O
cytosolic O
entry O
of O
these O
viruses O
by O
blocking O
complete O
virus O
envelope O
fusion O
with O
cell O
endosome O
membranes O
. O
Although O
the O
IFITM B-DNA
locus E-DNA
, O
which O
includes O
IFITM1 B-protein
, I-protein
-2 I-protein
, I-protein
-3 I-protein
, I-protein
and I-protein
-5 E-protein
, O
is O
present O
in O
mammalian O
species O
, O
this O
locus O
has O
not O
been O
unambiguously O
identified O
or O
functionally O
characterized O
in O
avian O
species O
. O
Here O
, O
we O
show O
that O
the O
IFITM B-DNA
locus E-DNA
exists O
in O
chickens O
and O
is O
syntenic O
with O
the O
IFITM B-DNA
locus E-DNA
in O
mammals O
. O
IFITM2 B-protein
and I-protein
-3 E-protein
are O
constitutively O
expressed O
in O
all O
tissues O
examined O
, O
whereas O
IFITM1 S-protein
is O
only O
expressed O
in O
the O
bursa O
of O
Fabricius O
, O
gastrointestinal O
tract O
, O
cecal O
tonsil O
, O
and O
trachea O
. O
Despite O
being O
highly O
divergent O
at O
the O
amino O
acid O
level O
, O
IFITM3 B-protein
proteins E-protein
of O
birds O
and O
mammals O
can O
restrict O
replication O
of O
viruses O
that O
are O
able O
to O
infect O
different O
host O
species O
, O
suggesting O
IFITM B-protein
proteins E-protein
may O
provide O
a O
crucial O
barrier O
for O
zoonotic O
infections O
. O
The O
chicken B-protein
IFITM3 I-protein
protein E-protein
restricts O
cell O
infection O
by O
influenza O
A O
viruses O
and O
lyssaviruses O
to O
a O
similar O
level O
as O
its O
human O
orthologue O
. O
Furthermore O
, O
we O
show O
that O
chicken B-protein
IFITM3 E-protein
is O
functional O
in O
chicken B-cell_type
cells E-cell_type
and O
that O
knockdown O
of O
constitutive O
expression O
in O
chicken B-cell_type
fibroblasts E-cell_type
results O
in O
enhanced O
infection O
by O
influenza O
A O
virus O
. O
Chicken O
Considering O
the O
high O
morbidity O
of O
hepatitis O
B O
in O
China O
, O
many O
epidemiological O
studies O
based O
on O
classic O
medical O
statistical O
analysis O
have O
been O
started O
but O
lack O
spatial O
information O
. O
However O
, O
spatial O
information O
such O
as O
the O
spatial O
distribution O
, O
autocorrelation O
and O
risk O
factors O
of O
the O
disease O
is O
of O
great O
help O
in O
studying O
patients O
with O
hepatitis O
B O
. O
This O
study O
examined O
2851 O
cases O
of O
hepatitis O
B O
that O
were O
hospitalized O
in O
Shenzhen O
in O
2010 O
and O
studied O
the O
spatial O
distribution O
, O
risk O
factors O
and O
spatial O
access O
to O
health O
services O
using O
spatial O
interpolation O
, O
Pearson O
correlation O
analysis O
and O
the O
improved O
two-step O
floating O
catchment O
area O
method O
. O
The O
results O
showed O
that O
the O
spatial O
distribution O
of O
hepatitis O
B O
, O
along O
with O
risk O
factors O
as O
well O
as O
spatial O
access O
to O
the O
regional O
medical O
resources O
, O
was O
uneven O
and O
mainly O
concentrated O
in O
the O
south O
and O
southwest O
of O
Shenzhen O
in O
2010 O
. O
In O
addition O
, O
the O
distribution O
characteristics O
of O
hepatitis O
B O
revealed O
a O
positive O
correlation O
between O
four O
types O
of O
service O
establishments O
and O
risk O
factors O
for O
the O
disease O
. O
The O
Pearson O
correlation O
coefficients O
are O
0.566 O
, O
0.515 O
, O
0.626 O
, O
0.538 O
corresponding O
to O
bath O
centres O
, O
beauty O
OPEN O
ACCESS O
salons O
, O
massage O
parlours O
and O
pedicure O
parlours O
( O
p O
< O
0.05 O
) O
. O
Additionally O
, O
the O
allocation O
of O
medical O
resources O
for O
hepatitis O
B O
is O
adequate O
, O
as O
most O
patients O
could O
be O
treated O
at O
nearby O
hospitals O
. O
The O
hepatitis O
B O
virus O
( O
HBV O
) O
is O
one O
of O
the O
most O
common O
viral O
infections O
in O
the O
world O
, O
leading O
to O
many O
deaths O
each O
year O
from O
associated O
liver O
diseases O
[ O
1 O
, O
2 O
] O
. O
HBV O
is O
also O
an O
important O
public O
health O
issue O
in O
China O
[ O
2 O
] O
, O
as O
national O
surveys O
conducted O
since O
the O
1970s O
have O
repeatedly O
showed O
high O
morbidity O
from O
HBV O
infections O
in O
the O
general O
population O
[ O
3 O
, O
4 O
] O
. O
To O
address O
this O
challenge O
, O
many O
scholars O
now O
to O
study O
the O
disease O
using O
different O
approaches O
( O
e.g. O
, O
pathology O
, O
immunology O
and O
epidemiology O
) O
, O
but O
none O
of O
these O
approaches O
incorporate O
spatial O
information O
[ O
5 O
] O
. O
With O
the O
development O
of O
Geographic O
Information O
System O
( O
GIS O
) O
technology O
and O
its O
applications O
in O
epidemiology O
[ O
6 O
] O
, O
it O
has O
become O
clear O
the O
spatial O
information O
has O
great O
value O
in O
Epidemiology O
. O
Spatial O
epidemiology O
is O
a O
branch O
of O
epidemiology O
that O
uses O
spatial O
information O
to O
extend O
the O
analysis O
of O
disease O
distribution O
and O
risk O
factors O
. O
This O
information O
serves O
as O
a O
powerful O
analytical O
tool O
for O
epidemiological O
studies O
and O
will O
likely O
show O
greater O
significance O
in O
the O
future O
[ O
7 O
] O
. O
Our O
team O
have O
done O
some O
works O
on O
spatial O
epidemiology O
[ O
8-10 O
] O
. O
Using O
geographic O
information O
systems O
and O
spatial O
analysis O
technology O
, O
spatial O
epidemiology O
attempts O
to O
describe O
and O
analyze O
human O
diseases O
, O
including O
the O
spatial O
distribution O
characteristics O
of O
health O
and O
hygiene O
events O
as O
well O
as O
the O
regularity O
of O
changes O
and O
developments O
. O
Spatial O
epidemiology O
also O
explores O
the O
decisive O
elements O
that O
can O
impact O
public O
health O
and O
provides O
strategies O
and O
measures O
for O
disease O
prevention O
and O
cure O
and O
health O
promotion O
and O
hygiene O
services O
[ O
7 O
, O
11 O
] O
. O
Research O
on O
this O
subject O
mainly O
utilizes O
four O
elements O
: O
disease O
mapping O
, O
risk O
assessment O
in O
relation O
to O
a O
point O
or O
line O
source O
, O
disease O
clustering O
analysis O
and O
geographical O
correlation O
studies O
[ O
11 O
] O
. O
Disease O
mapping O
is O
the O
most O
important O
tool O
in O
spatial O
epidemiology O
and O
is O
used O
to O
describe O
and O
evaluate O
disease O
area O
distribution O
[ O
7 O
] O
. O
The O
most O
typical O
example O
of O
disease O
mapping O
is O
the O
epidemiological O
investigation O
of O
a O
cholera O
outbreak O
caused O
by O
street O
water O
pollution O
in O
London O
in O
1854 O
[ O
12 O
, O
13 O
] O
. O
The O
assessment O
of O
risk O
factors O
is O
similar O
to O
geographical O
correlation O
studies O
in O
that O
they O
both O
focus O
on O
studying O
cause O
of O
geographical O
phenomenon O
. O
Moreover O
, O
analysis O
of O
disease O
clustering O
uses O
statistical O
methods O
to O
identify O
disease O
spatial O
aggregation O
, O
thus O
providing O
corresponding O
methods O
to O
search O
for O
etiologic O
clues O
[ O
7 O
, O
14 O
, O
15 O
] O
. O
Among O
the O
four O
study O
elements O
, O
disease O
mapping O
and O
disease O
clustering O
analysis O
are O
relatively O
mature O
, O
and O
typical O
methods O
and O
models O
, O
such O
as O
spatial O
interpolation O
and O
spatial O
scan O
statistics O
are O
commonly O
used O
[ B-DNA
16 I-DNA
] I-DNA
[ I-DNA
17 I-DNA
] I-DNA
[ I-DNA
18 I-DNA
] E-DNA
. O
However O
, O
exploring O
the O
risk O
factors O
for O
disease O
is O
complex O
and O
difficult O
, O
especially O
for O
diseases O
in O
which O
it O
is O
difficult O
to O
obtain O
patient O
exposure O
information O
, O
and O
data O
involving O
patients O
' O
privacy O
[ O
7 O
] O
; O
this O
challenge O
represents O
a O
weak O
link O
in O
epidemiological O
studies O
. O
Compared O
with O
other O
infectious O
diseases O
such O
as O
schistosomiasis O
[ O
19 O
, O
20 O
] O
, O
most O
respiratory O
system O
diseases O
[ O
21 O
] O
and O
cardiovascular O
diseases O
[ O
8 O
] O
, O
the O
spatial O
risk O
factors O
for O
hepatitis O
B O
are O
less O
obvious O
, O
and O
there O
have O
been O
few O
studies O
on O
this O
aspect O
. O
In O
view O
of O
this O
problem O
, O
this O
study O
sought O
to O
explore O
the O
spatial O
risk O
factors O
for O
hepatitis O
B O
and O
to O
discover O
the O
relationship O
between O
these O
risk O
factors O
and O
hepatitis O
B O
morbidity O
. O
Multipartitism O
counts O
amongst O
the O
weirdest O
lifestyles O
found O
in O
the O
virosphere O
. O
Multipartite O
viruses O
have O
genomes O
segmented O
in O
pieces O
enclosed O
in O
different O
capsids O
that O
are O
independently O
transmitted O
. O
Since O
all O
segments O
have O
to O
meet O
in O
the O
host O
for O
complementation O
and O
completion O
of O
the O
viral O
cycle O
, O
multipartite O
viruses O
are O
bound O
to O
fight O
the O
loss O
of O
genomic O
information O
. O
While O
this O
is O
an O
obvious O
disadvantage O
of O
this O
strategy O
, O
no O
consensus O
on O
its O
actual O
advantages O
has O
been O
reached O
. O
In O
this O
review O
we O
present O
an O
exhaustive O
summary O
of O
all O
multipartite O
viruses O
described O
to O
date O
. O
Based O
on O
evidence O
, O
we O
discuss O
possible O
mechanistic O
and O
evolutionary O
origins O
of O
different O
groups O
, O
as O
well O
as O
their O
mutual O
relationships O
. O
We O
argue O
that O
the O
ubiquitous O
interactions O
of O
viruses O
with O
other O
unrelated O
viruses O
and O
with O
subviral B-DNA
elements E-DNA
might O
be O
regarded O
as O
a O
plausible O
first O
step O
towards O
multipartitism O
. O
In O
agreement O
with O
the O
view O
of O
the O
Virosphere O
as O
a O
deeply O
entangled O
network O
of O
gene O
sharing O
, O
we O
contend O
that O
the O
power O
of O
multipartitism O
relies O
on O
its O
dynamical O
and O
opportunistic O
nature O
, O
because O
it O
enables O
immediate O
adaptive O
responses O
to O
environmental O
changes O
. O
As O
such O
, O
perhaps O
the O
reasons O
for O
its O
success O
should O
be O
shought O
in O
multipartitism O
itself O
as O
an O
adaptive O
mechanism O
, O
to O
which O
its O
evolutionarily B-protein
short-lived I-protein
products E-protein
( O
that O
is O
, O
the O
extant O
ensemble O
of O
multipartite B-protein
viral I-protein
species E-protein
) O
are O
subordinated O
. O
We O
close O
by O
discussing O
how O
our O
understanding O
of O
multipartitism O
would O
improve O
by O
using O
concepts O
and O
tools O
from O
systems O
biology O
. O
Background O
: O
Nosocomial O
infection O
of O
health-care O
workers O
( O
HCWs O
) O
during O
outbreaks O
of O
respiratory O
infections O
( O
e.g O
. O
Influenza O
A O
H1N1 O
( O
2009 O
) O
) O
is O
a O
significant O
concern O
for O
public O
health O
policy O
makers O
. O
World O
Health O
Organization O
( O
WHO O
) O
-defined O
'aerosol O
generating O
procedures O
' O
( O
AGPs O
) O
are O
thought O
to O
increase O
the O
risk O
of O
aerosol O
transmission O
to O
HCWs O
, O
but O
there O
are O
presently O
insufficient O
data O
to O
quantify O
risk O
accurately O
or O
establish O
a O
hierarchy O
of O
risk-prone O
procedures O
. O
Methodology/Principal O
Findings O
: O
This O
study O
measured O
the O
amount O
of O
H1N1 B-RNA
( I-RNA
2009 I-RNA
) I-RNA
RNA E-RNA
in O
aerosols O
in O
the O
vicinity O
of O
H1N1 O
positive O
patients O
undergoing O
AGPs O
to O
help O
quantify O
the O
potential O
risk O
of O
transmission O
to O
HCWs O
. O
There O
were O
99 O
sampling O
occasions O
( O
windows O
) O
producing O
a O
total O
of O
198 O
May O
stages O
for O
analysis O
in O
the O
size O
ranges O
0.86-7.3 O
mm O
. O
Considering O
stages O
2 O
( O
4-7.3 O
mm O
) O
and O
3 O
( O
0.86-4 O
mm O
) O
as O
comprising O
one O
sample O
, O
viral B-RNA
RNA E-RNA
was O
detected O
in O
14 O
( O
14.1 O
% O
) O
air O
samples O
from O
10 O
( O
25.6 O
% O
) O
patients O
. O
Twenty O
three O
air O
samples O
were O
collected O
while O
potential O
AGPs O
were O
being O
performed O
of O
which O
6 O
( O
26.1 O
% O
) O
contained O
viral B-RNA
RNA E-RNA
; O
in O
contrast O
, O
76 O
May O
samples O
were O
collected O
when O
no O
WHO O
2009 O
defined O
AGP O
was O
being O
performed O
of O
which O
8 O
( O
10.5 O
% O
) O
contained O
viral B-RNA
RNA E-RNA
( O
unadjusted O
OR O
= O
2.84 O
( O
95 O
% O
CI O
1.11-7.24 O
) O
adjusted O
OR O
= O
4.31 O
( O
0.83-22.5 O
) O
) O
. O
Conclusions/Significance O
: O
With O
our O
small O
sample O
size O
we O
found O
that O
AGPs O
do O
not O
significantly O
increase O
the O
probability O
of O
sampling O
an O
H1N1 O
( O
2009 O
) O
positive O
aerosol O
( O
OR O
( O
95 O
% O
CI O
) O
= O
4.31 O
( O
0.83-22.5 O
) O
. O
Although O
the O
probability O
of O
detecting O
positive O
H1N1 O
( O
2009 O
) O
positive O
aerosols O
when O
performing O
various O
AGPs O
on O
intensive O
care O
patients O
above O
the O
baseline O
rate O
( O
i.e O
. O
in O
the O
absence O
of O
AGPs O
) O
did O
not O
reach O
significance O
, O
there O
was O
a O
trend O
towards O
hierarchy O
of O
AGPs O
, O
placing O
bronchoscopy O
and O
respiratory O
and O
airway O
suctioning O
above O
baseline O
( O
background O
) O
values O
. O
Further O
, O
larger O
studies O
are O
required O
but O
these O
preliminary O
findings O
may O
be O
of O
benefit O
to O
infection O
control O
teams O
. O
Background O
: O
The O
spike O
proteins O
of O
coronaviruses O
associate O
with O
cellular B-protein
molecules E-protein
to O
mediate O
infection O
of O
their O
target B-cell_type
cells E-cell_type
. O
The O
characterization O
of O
cellular B-protein
proteins E-protein
required O
for O
virus O
infection O
is O
essential O
for O
understanding O
viral O
life O
cycles O
and O
may O
provide O
cellular O
targets O
for O
antiviral O
therapies O
. O
Results O
: O
We O
identified O
Neural B-protein
Cell I-protein
Adhesion I-protein
Molecule E-protein
( O
NCAM O
) O
as O
a O
novel O
interacting O
partner O
of O
the O
PHE-CoV B-protein
S I-protein
protein E-protein
. O
A O
T7 O
phage O
display O
cDNA B-DNA
library E-DNA
from O
N2a B-cell_line
cells E-cell_line
was O
constructed O
, O
and O
the O
library O
was O
screened O
with O
the O
soluble O
PHE-CoV B-protein
S I-protein
glycoproteins E-protein
. O
We O
used O
a O
coimmunoprecipitation O
assay O
to O
show O
that O
only O
the O
NCAM O
was O
a O
binding B-protein
partner I-protein
of I-protein
spike I-protein
protein E-protein
. O
We O
found O
that O
a O
soluble O
form O
of O
anti-NCAM B-protein
antibody E-protein
blocked O
association O
of O
the O
PHE-CoV S-protein
with O
N2a B-cell_line
cells E-cell_line
. O
Furthermore O
, O
double-stranded B-protein
siRNA E-protein
targeted O
against O
NCAM O
inhibited O
PHE-CoV O
infection O
. O
Conclusions O
: O
A O
novel O
interaction O
was O
identified O
between O
NCAM B-protein
and I-protein
spike I-protein
protein E-protein
and O
this O
association O
is O
critical O
during O
PHE-CoV O
infection O
. O
Asthma O
is O
a O
chronic O
respiratory O
disease O
characterized O
by O
reversible O
airway O
obstruction O
and O
airway O
hyperresponsiveness O
to O
non-specific O
bronchoconstriction O
agonists O
as O
the O
primary O
underlying O
pathophysiology O
. O
The O
worldwide O
incidence O
of O
asthma O
has O
increased O
dramatically O
in O
the O
last O
40 O
years O
. O
According O
to O
World O
Health O
Organization O
( O
WHO O
) O
estimates O
, O
over O
300 O
million O
children O
and O
adults O
worldwide O
currently O
suffer O
from O
this O
incurable O
disease O
and O
255,000 O
die O
from O
the O
disease O
each O
year O
. O
It O
is O
now O
well O
accepted O
that O
asthma O
is O
a O
heterogeneous O
syndrome O
and O
many O
clinical O
subtypes O
have O
been O
described O
. O
Viral O
infections O
such O
as O
respiratory O
syncytial O
virus O
( O
RSV O
) O
and O
human O
rhinovirus O
( O
hRV O
) O
have O
been O
implicated O
in O
asthma O
exacerbation O
in O
children O
because O
of O
their O
ability O
to O
cause O
severe O
airway O
inflammation O
and O
wheezing O
. O
Infections O
with O
atypical O
bacteria O
also O
appear O
to O
play O
a O
role O
in O
the O
induction O
and O
exacerbation O
of O
asthma O
in O
both O
children O
and O
adults O
. O
Recent O
studies O
confirm O
the O
existence O
of O
an O
infectious O
asthma O
etiology O
mediated O
by O
Chlamydia O
pneumoniae O
( O
CP O
) O
and O
possibly O
by O
other O
viral O
, O
bacterial O
and O
fungal O
microbes O
. O
It O
is O
also O
likely O
that O
early-life O
infections O
with O
microbes O
such O
as O
CP S-DNA
could O
lead O
to O
alterations O
in O
the O
lung O
microbiome O
that O
significantly O
affect O
asthma O
risk O
and O
treatment O
outcomes O
. O
These O
infectious O
microbes O
may O
exacerbate O
the O
symptoms O
of O
established O
chronic O
asthma O
and O
may O
even O
contribute O
to O
the O
initial O
development O
of O
the O
clinical O
onset O
of O
the O
disease O
. O
It O
is O
now O
becoming O
more O
widely O
accepted O
that O
patterns O
of O
airway O
inflammation O
differ O
based O
on O
the O
trigger O
responsible O
for O
asthma O
initiation O
and O
exacerbation O
. O
Therefore O
, O
a O
better O
understanding O
of O
asthma O
subtypes O
is O
now O
being O
explored O
more O
aggressively O
, O
not O
only O
to O
decipher O
pathophysiologic O
mechanisms O
but O
also O
to O
select O
treatment O
and O
guide O
prognoses O
. O
This O
review O
will O
explore O
infection-mediated O
asthma O
with O
special O
emphasis O
on O
the O
protean O
manifestations O
of O
CP O
lung O
infection O
, O
clinical O
characteristics O
of O
infection-mediated O
asthma O
, O
mechanisms O
involved O
and O
antibiotic O
treatment O
outcomes O
. O
Regulation O
of O
proteolysis O
plays O
a O
critical O
role O
in O
a O
myriad O
of O
important O
cellular O
processes O
. O
The O
key O
to O
better O
understanding O
the O
mechanisms O
that O
control O
this O
process O
is O
to O
identify O
the O
specific O
substrates O
that O
each O
protease O
targets O
. O
To O
address O
this O
, O
we O
have O
developed O
iProt-Sub S-protein
, O
a O
powerful O
bioinformatics O
tool O
for O
the O
accurate O
prediction O
of O
protease-specific O
substrates O
and O
their O
cleavage O
sites O
. O
Importantly O
, O
iProt-Sub S-protein
represents O
a O
significantly O
advanced O
version O
of O
its O
successful O
predecessor O
, O
PROSPER O
. O
It O
provides O
optimized O
cleavage O
site O
prediction O
models O
with O
better O
prediction O
performance O
and O
coverage O
for O
more O
species-specific O
proteases O
( O
4 O
major O
protease O
families O
and O
38 O
different O
proteases S-protein
) O
. O
iProt-Sub S-protein
integrates O
heterogeneous O
Jiangning O
Song O
received O
his O
BEng O
and O
DEng O
degrees O
from O
Jiangnan O
University O
, O
China O
. O
He O
is O
affiliated O
with O
the O
Advisory O
Professor O
of O
several O
Universities O
. O
His O
research O
interests O
are O
in O
computational O
biology O
and O
biomedicine O
, O
protein O
structure O
prediction O
, O
low-frequency O
internal O
motion O
of O
protein/DNA B-protein
molecules E-protein
and O
its O
biological O
functions O
, O
diffusion-controlled O
reactions O
of O
enzymes S-protein
, O
as O
well O
as O
graphic O
rules O
in O
enzyme O
kinetics O
and O
other O
biological O
systems O
. O
sequence O
and O
structural O
features O
and O
uses O
a O
two-step O
feature O
selection O
procedure O
to O
further O
remove O
redundant O
and O
irrelevant O
features O
in O
an O
effort O
to O
improve O
the O
cleavage O
site O
prediction O
accuracy O
. O
Features O
used O
by O
iProt-Sub S-protein
are O
encoded O
by O
11 O
different O
sequence O
encoding O
schemes O
, O
including O
local O
amino O
acid O
sequence O
profile O
, O
secondary O
structure O
, O
solvent O
accessibility O
and O
native O
disorder O
, O
which O
will O
allow O
a O
more O
accurate O
representation O
of O
the O
protease O
specificity O
of O
approximately O
38 O
proteases O
and O
training O
of O
the O
prediction O
models O
. O
Benchmarking O
experiments O
using O
cross-validation O
and O
independent O
tests O
showed O
that O
iProt-Sub S-protein
is O
able O
to O
achieve O
a O
better O
performance O
than O
several O
existing O
generic O
tools O
. O
We O
anticipate O
that O
iProt-Sub S-protein
will O
be O
a O
powerful O
tool O
for O
proteome-wide O
prediction O
of O
protease-specific O
substrates O
and O
their O
cleavage O
sites O
, O
and O
will O
facilitate O
hypothesis-driven O
functional O
interrogation O
of O
protease-specific O
substrate O
cleavage O
and O
proteolytic O
events O
. O
Interferon-inducible B-protein
transmembrane I-protein
( I-protein
IFITM I-protein
) I-protein
proteins E-protein
restrict O
the O
entry O
processes O
of O
several O
pathogenic O
viruses O
, O
including O
the O
flaviviruses O
West O
Nile O
virus O
and O
dengue O
virus O
( O
DENV O
) O
. O
DENV O
infects O
cells O
directly O
or O
via O
antibody-dependent O
enhancement O
( O
ADE O
) O
in O
Fc-receptor-bearing B-cell_line
cells E-cell_line
, O
a O
process O
thought O
to O
contribute O
to O
severe O
disease O
in O
a O
secondary O
infection O
. O
Here O
we O
investigated O
whether O
ADE-mediated O
DENV O
infection O
bypasses O
IFITM-mediated O
restriction O
or O
whether O
IFITM B-protein
proteins E-protein
can O
be O
protective O
in O
a O
secondary O
infection O
. O
We O
observed O
that O
IFITM B-protein
proteins E-protein
restricted O
ADE-mediated O
and O
direct O
infection O
with O
comparable O
efficiencies O
in O
a O
myelogenous B-cell_line
leukemia I-cell_line
cell I-cell_line
line E-cell_line
. O
Our O
data O
suggest O
that O
IFITM B-protein
proteins E-protein
can O
contribute O
to O
control O
of O
secondary O
DENV O
infections O
. O
Since O
their O
discovery O
as O
a O
tool O
for O
gene O
transfer O
, O
vectors O
derived O
from O
the O
adeno-associated O
virus O
( O
AAV O
) O
have O
been O
used O
for O
gene O
therapy O
applications O
and O
attracted O
scientist O
to O
this O
field O
for O
their O
exceptional O
properties O
of O
efficiency O
of O
in O
vivo O
gene O
transfer O
and O
the O
level O
and O
duration O
of O
transgene O
expression O
. O
For O
many O
years O
, O
AAVs O
have O
been O
considered O
as O
low O
immunogenic O
vectors O
due O
to O
their O
ability O
to O
induce O
long-term O
expression O
of O
non-selfproteins O
in O
contrast O
to O
what O
has O
been O
observed O
with O
other O
viral O
vectors O
, O
such O
as O
adenovirus O
, O
for O
which O
strong O
immune O
responses O
against O
the O
same O
transgene O
products O
were O
documented O
. O
The O
perceived O
low O
immunogenicity O
likely O
explains O
why O
the O
use O
of O
AAV O
vectors O
for O
vaccination O
was O
not O
seriously O
considered O
before O
the O
early O
2000s O
. O
Indeed O
, O
while O
analyses O
conducted O
using O
a O
variety O
of O
transgenes O
and O
animal O
species O
slowly O
changed O
the O
vision O
of O
immunological O
properties O
of O
AAVs O
, O
an O
increasing O
number O
of O
studies O
were O
also O
performed O
in O
the O
field O
of O
vaccination O
. O
Even O
if O
the O
comparison O
with O
other O
modes O
of O
vaccination O
was O
not O
systemically O
performed O
, O
the O
analyses O
conducted O
so O
far O
in O
the O
field O
of O
active O
immunotherapy O
strongly O
suggest O
that O
AAVs O
possess O
some O
interesting O
features O
to O
be O
used O
as O
tools O
to O
produce O
an O
efficient O
and O
sustained O
antibody O
response O
. O
In O
addition O
, O
recent O
studies O
also O
highlighted O
the O
potential O
of O
AAVs O
for O
passive O
immunotherapy O
. O
This O
review O
summarizes O
the O
main O
studies O
conducted O
to O
evaluate O
the O
potential O
of O
AAV O
vectors O
for O
vaccination O
against O
infectious O
agents O
and O
discusses O
their O
advantages O
and O
drawbacks O
. O
Altogether O
, O
the O
variety O
of O
studies O
conducted O
in O
this O
field O
contributes O
to O
the O
understanding O
of O
the O
immunological O
properties O
of O
this O
versatile O
virus O
and O
to O
the O
definition O
of O
its O
possible O
future O
applications O
. O
Growing O
experimental O
evidence O
indicates O
that O
, O
in O
addition O
to O
the O
physical O
virion O
components O
, O
the O
non-structural B-protein
proteins E-protein
of O
hepatitis O
C O
virus O
( O
HCV O
) O
are O
intimately O
involved O
in O
orchestrating O
morphogenesis O
. O
Since O
it O
is O
dispensable O
for O
HCV O
RNA O
replication O
, O
the O
non-structural B-protein
viral I-protein
protein I-protein
NS2 E-protein
is O
suggested O
to O
play O
a O
central O
role O
in O
HCV O
particle O
assembly O
. O
However O
, O
despite O
genetic O
evidences O
, O
we O
have O
almost O
no O
understanding O
about O
NS2 S-protein
protein-protein O
interactions O
and O
their O
role O
in O
the O
production O
of O
infectious O
particles O
. O
Here O
, O
we O
used O
co-immunoprecipitation O
and/or O
fluorescence O
resonance O
energy O
transfer O
with O
fluorescence O
lifetime O
imaging O
microscopy O
analyses O
to O
study O
the O
interactions O
between O
NS2 S-protein
and O
the O
viroporin B-protein
p7 E-protein
and O
the O
HCV B-protein
glycoprotein I-protein
E2 E-protein
. O
In O
addition O
, O
we O
used O
alanine O
scanning O
insertion O
mutagenesis O
as O
well O
as O
other O
mutations O
in O
the O
context O
of O
an O
infectious O
virus O
to O
investigate O
the O
functional O
role O
of O
NS2 S-protein
in O
HCV O
assembly O
. O
Finally O
, O
the O
subcellular O
localization O
of O
NS2 S-protein
and O
several O
mutants O
was O
analyzed O
by O
confocal O
microscopy O
. O
Our O
data O
demonstrate O
molecular O
interactions O
between O
NS2 S-protein
and O
p7 S-protein
and O
E2 S-protein
. O
Furthermore O
, O
we O
show O
that O
, O
in O
the O
context O
of O
an O
infectious O
virus O
, O
NS2 S-protein
accumulates O
over O
time O
in O
endoplasmic O
reticulum-derived O
dotted O
structures O
and O
colocalizes O
with O
both O
the O
envelope B-protein
glycoproteins E-protein
and O
components O
of O
the O
replication B-protein
complex E-protein
in O
close O
proximity O
to O
the O
HCV B-protein
core I-protein
protein E-protein
and O
lipid O
droplets O
, O
a O
location O
that O
has O
been O
shown O
to O
be O
essential O
for O
virus O
assembly O
. O
We O
show O
that O
NS2 B-protein
transmembrane I-protein
region E-protein
is O
crucial O
for O
both O
E2 S-protein
interaction O
and O
subcellular O
localization O
. O
Moreover O
, O
specific O
mutations O
in O
core O
, O
envelope B-protein
proteins E-protein
, O
p7 S-protein
and O
NS5A S-protein
reported O
to O
abolish O
viral O
assembly O
changed O
the O
subcellular O
localization O
of O
NS2 B-protein
protein E-protein
. O
Together O
, O
these O
observations O
indicate O
that O
NS2 B-protein
protein E-protein
attracts O
the O
envelope B-protein
proteins E-protein
at O
the O
assembly O
site O
and O
it O
crosstalks O
with O
non-structural B-protein
proteins E-protein
for O
virus O
assembly O
. O
Background O
: O
Pandemic O
influenza O
A O
( O
H1N1 O
) O
virus O
emerged O
in O
North O
America O
in O
April O
2009 O
and O
spread O
globally O
. O
We O
describe O
the O
epidemiology O
and O
public O
health O
response O
to O
the O
first O
known O
outbreak O
of O
2009 O
H1N1 O
in O
a O
train O
, O
which O
occurred O
in O
June O
2009 O
in O
China O
. O
Methods O
: O
After O
2 O
provinces O
provided O
initial O
reports O
of O
2009 O
H1N1 O
infection O
in O
2 O
persons O
who O
had O
travelled O
on O
the O
same O
train O
, O
we O
conducted O
a O
retrospective O
epidemiologic O
investigation O
to O
collect O
information O
from O
the O
passengers O
, O
crew O
members O
, O
contacts O
, O
and O
health O
care O
providers O
. O
We O
explored O
the O
source O
of O
infection O
and O
possible O
routes O
of O
transmission O
in O
the O
train O
. O
All O
cases O
were O
confirmed O
by O
real-time O
reverse O
transcription O
polymerase O
chain O
reaction O
testing O
. O
Results O
: O
Train O
# O
1223 O
traveled O
40 O
hours O
, O
made O
28 O
stops O
in O
4 O
Chinese O
provinces O
, O
and O
boarded O
2555 O
passengers O
, O
who O
logged O
a O
total O
of O
59 O
144 O
person-hours O
of O
travel O
time O
. O
Nineteen O
confirmed O
2009 O
H1N1 O
cases O
were O
identified O
. O
Of O
these O
, O
13 O
were O
infected O
and O
developed O
symptoms O
on O
the O
train O
and O
6 O
occurred O
among O
contacts O
who O
developed O
illness O
during O
medical O
monitoring O
. O
In O
addition O
, O
3 O
asymptomatic O
cases O
were O
identified O
based O
on O
RT-PCR O
testing O
of O
respiratory O
swabs O
from O
contacts O
. O
The O
attack O
rate O
among O
contacts O
of O
confirmed O
cases O
in O
the O
same O
car O
was O
higher O
than O
that O
among O
contacts O
in O
other O
cars O
( O
3.15 O
% O
vs. O
0 O
% O
, O
P O
< O
0.001 O
) O
. O
Attack O
rates O
increased O
with O
exposure O
time O
. O
Conclusions O
: O
Close O
contact O
and O
long O
exposure O
may O
have O
contributed O
to O
the O
transmission O
of O
2009 O
H1N1 O
virus O
in O
the O
train O
. O
Trains O
may O
have O
played O
an O
important O
role O
in O
the O
2009 O
influenza O
pandemic O
. O
In O
recent O
years O
, O
many O
studies O
have O
shown O
that O
recombinant O
adenovirus O
live O
vector-based O
vaccines O
are O
a O
promising O
novel O
vaccine O
candidate O
against O
virus O
infection O
. O
erefore O
, O
in O
this O
study O
, O
a O
new O
type O
of O
recombinant O
adenovirus O
expressing O
the O
spike B-protein
( I-protein
S I-protein
) I-protein
protein E-protein
of O
porcine O
epidemic O
diarrhea O
virus O
( O
PEDV O
) O
, O
rAd-PEDV-S O
, O
was O
generated O
, O
and O
its O
characteristics O
were O
determined O
. O
en O
, O
its O
efficacy O
as O
a O
vaccine O
candidate O
was O
evaluated O
in O
4-week-old O
pigs O
. O
e O
results O
showed O
that O
the O
S B-protein
protein E-protein
could O
be O
well O
expressed O
at O
a O
high O
level O
in O
rAd-PEDV-S-infected B-cell_line
cells E-cell_line
and O
that O
the O
viral O
titers O
could O
reach O
10 O
11 O
PFU/mL O
. O
Further O
animal O
experimental O
results O
showed O
that O
rAd-PEDV-S O
elicited O
a O
significant O
PEDV-specific O
humoral O
immune O
response O
after O
vaccination O
( O
P O
< O
0.05 O
) O
. O
In O
addition O
, O
rAd-PEDV-S O
provided O
partial O
protection O
for O
pigs O
against O
the O
highly O
virulent O
PEDV O
challenge O
. O
e O
results O
presented O
in O
this O
study O
indicate O
that O
the O
adenovirus O
vector O
can O
be O
used O
as O
a O
vaccine O
delivery O
vector O
for O
the O
development O
of O
a O
PEDV O
vaccine O
and O
is O
a O
promising O
novel O
vaccine O
candidate O
for O
future O
prevention O
and O
control O
of O
porcine O
epidemic O
diarrhea O
( O
PED O
) O
, O
but O
its O
efficacy O
still O
needs O
to O
be O
improved O
in O
the O
future O
. O
Background O
: O
The O
four O
types O
of O
human O
parainfluenza O
viruses O
( O
PIV O
) O
are O
important O
causes O
of O
community-acquired O
pneumonia O
, O
particularly O
in O
children O
; O
however O
, O
limited O
information O
exists O
about O
the O
incidence O
of O
PIV O
in O
critically O
ill O
patients O
. O
The O
aim O
of O
this O
study O
is O
to O
describe O
the O
spectrum O
, O
incidence O
and O
clinical O
features O
of O
PIV-associated O
infections O
diagnosed O
during O
the O
hospital O
stay O
of O
patients O
admitted O
to O
pediatric O
intensive O
care O
unit O
( O
PICU O
) O
and O
intensive O
care O
unit O
( O
ICU O
) O
of O
5 O
medical O
centers O
across O
Kuwait O
. O
Methods O
: O
This O
was O
a O
population-based O
, O
retrospective O
study O
from O
2013 O
to O
2015 O
. O
Specimens O
were O
analyzed O
by O
molecular O
methods O
. O
This O
analysis O
was O
performed O
using O
the O
database O
of O
Virology O
Unit O
, O
Mubarak O
Al-Kabeer O
Hospital O
. O
Data O
from O
1510 O
admitted O
patients O
with O
suspected O
respiratory O
viral O
infections O
was O
extracted O
. O
Results O
: O
The O
database O
contained O
a O
total O
of O
39 O
( O
2.6 O
% O
) O
patients O
infected O
with O
PIV O
( O
53.8 O
% O
male O
and O
46.2 O
% O
females O
) O
and O
20 O
( O
51.3 O
% O
) O
were O
under O
1 O
year O
of O
age O
. O
The O
most O
frequently O
isolated O
type O
was O
type O
3 O
( O
28 O
, O
71.8 O
% O
) O
followed O
by O
type O
1 O
( O
9 O
, O
23.1 O
% O
) O
. O
At O
admission O
the O
most O
common O
clinical O
diagnosis O
was O
pneumonia O
in O
12 O
patients O
( O
30.8 O
% O
, O
p O
< O
0.05 O
) O
followed O
by O
bronchiolitis O
in O
10 O
patients O
( O
25.6 O
% O
) O
. O
Conclusion O
: O
PIV O
plays O
an O
important O
yet O
unrecognized O
role O
in O
the O
outcomes O
of O
PIUC O
and O
ICU O
patients O
. O
Our O
results O
contribute O
to O
the O
limited O
epidemiologic O
data O
of O
PIV O
in O
PIUC O
and O
ICU O
in O
this O
region O
. O
Background O
: O
Influenza O
is O
a O
zoonotic O
disease O
that O
infects O
millions O
of O
people O
each O
year O
resulting O
in O
hundreds O
of O
thousands O
of O
deaths O
, O
and O
in O
turn O
devastating O
pandemics O
. O
Influenza O
is O
caused O
by O
influenza O
viruses O
, O
including O
influenza O
A O
virus O
( O
IAV O
) O
. O
There O
are O
many O
subtypes O
of O
IAV O
but O
only O
a O
few O
seem O
to O
be O
able O
to O
adapt O
to O
humans O
and O
to O
cause O
disease O
. O
In O
2013 O
, O
an O
H7N9 O
IAV O
subtype O
emerged O
in O
China O
that O
does O
not O
cause O
clinical O
symptoms O
in O
its O
chicken O
host O
but O
leads O
to O
severe O
infections O
when O
transmitted O
into O
humans O
. O
Since O
2013 O
, O
there O
have O
been O
six O
epidemic O
waves O
of O
H7N9 O
with O
1567 O
laboratory-confirmed O
human O
infections O
and O
615 O
deaths O
. O
Pathogenicity O
of O
IAV S-protein
is O
complex O
, O
but O
a O
crucial O
feature O
contributing O
to O
virulence O
is O
the O
activation O
of O
the O
hemagglutinin B-protein
( I-protein
HA I-protein
) I-protein
fusion I-protein
protein E-protein
by O
host B-protein
proteases E-protein
that O
triggers O
membrane O
fusion O
and O
leads O
to O
subsequent O
virus O
propagation O
. O
: O
293T B-cell_line
, I-cell_line
VERO I-cell_line
, I-cell_line
and I-cell_line
MDCK I-cell_line
cells E-cell_line
were O
used O
to O
conduct O
Western O
blot O
analysis O
, O
immunofluorescence O
assays O
, O
and O
pseudoparticle O
and O
live O
virus O
infections O
, O
and O
to O
evaluate O
H7N9 O
HA O
cleavage-activation O
. O
Results/Conclusions O
: O
We O
show O
that O
human B-protein
matriptase/ST I-protein
14 E-protein
is O
able O
to O
cleave O
H7N9 B-protein
HA E-protein
. O
Cleavage O
of O
H7N9 B-protein
HA E-protein
expressed O
in O
cell O
culture O
results O
in O
fusogenic O
HA O
and O
syncytia O
formation O
. O
In O
infection O
studies O
with O
viral O
pseudoparticles O
carrying O
matriptase/ O
ST O
14-activated O
H7N9 O
HA O
, O
we O
observed O
a O
high O
infectivity O
of O
cells O
. O
Finally O
, O
human B-protein
matriptase/ST I-protein
14 E-protein
also O
activated O
H7N9 O
live O
virus O
which O
resulted O
in O
high O
infectivity O
. O
Our O
data O
demonstrate O
that O
human B-protein
matriptase/ST I-protein
14 E-protein
is O
a O
likely O
candidate O
protease O
to O
promote O
H7N9 O
infections O
in O
humans O
. O
Middle O
East O
respiratory O
syndrome O
coronavirus O
( O
MERS-CoV O
) O
induces O
severe O
aggravating O
respiratory O
failure O
in O
infected O
patients O
, O
frequently O
resulting O
in O
mechanical O
ventilation O
. O
As O
limited O
therapeutic O
antibody O
is O
accumulated O
in O
lung O
tissue O
following O
systemic O
administration O
, O
inhalation O
is O
newly O
recognized O
as O
an O
alternative O
, O
possibly O
better O
, O
route O
of O
therapeutic O
antibody O
for O
pulmonary O
diseases O
. O
The O
nebulization O
process O
, O
however O
, O
generates O
diverse O
physiological O
stresses O
, O
and O
thus O
, O
the O
therapeutic O
antibody O
must O
be O
resistant O
to O
these O
stresses O
, O
remain O
stable O
, O
and O
form O
minimal O
aggregates O
. O
We O
first O
isolated O
a O
MERS-CoV B-protein
neutralizing I-protein
antibody E-protein
that O
is O
reactive O
to O
the O
receptor-binding B-protein
domain E-protein
( O
RBD S-protein
) O
of O
spike B-protein
( I-protein
S I-protein
) I-protein
glycoprotein E-protein
. O
To O
increase O
stability O
, O
we O
introduced O
mutations O
into O
the O
complementarity-determining B-DNA
regions E-DNA
( O
CDRs S-DNA
) O
of O
the O
antibody O
. O
In O
the O
HCDRs S-DNA
( O
excluding O
HCDR3 S-DNA
) O
in O
this O
clone O
, O
two O
hydrophobic O
residues O
were O
replaced O
with O
Glu O
, O
two O
residues O
were O
replaced O
with O
Asp O
, O
and O
four O
residues O
were O
replaced O
with O
positively B-protein
charged I-protein
amino I-protein
acids E-protein
. O
In O
LCDRs S-protein
, O
only O
two O
Leu O
residues O
were O
replaced O
with O
Val O
. O
These O
modifications O
successfully O
generated O
a O
clone O
with O
significantly O
greater O
stability O
and O
equivalent O
reactivity O
and O
neutralizing O
activity O
following O
nebulization O
compared O
to O
the O
original O
clone O
. O
In O
summary O
, O
we O
generated O
a O
MERS-CoV B-protein
neutralizing I-protein
human I-protein
antibody E-protein
that O
is O
reactive O
to O
recombinant B-protein
MERS-CoV I-protein
S I-protein
RBD I-protein
protein E-protein
for O
delivery O
via O
a O
pulmonary O
route O
by O
introducing O
stabilizing O
mutations O
into O
five O
CDRs S-protein
. O
Nonstructural B-protein
protein I-protein
5A E-protein
( O
NS5A S-protein
) O
of O
hepatitis O
C O
virus O
( O
HCV O
) O
serves O
dual O
functions O
in O
viral O
RNA O
replication O
and O
virus O
assembly O
. O
Here O
, O
we O
demonstrate O
that O
HCV B-protein
replication I-protein
complex E-protein
along O
with O
NS5A S-protein
and O
Core B-protein
protein E-protein
was O
transported O
to O
the O
lipid O
droplet O
( O
LD O
) O
through O
microtubules S-protein
, O
and O
NS5A-Core B-protein
complexes E-protein
were O
then O
transported O
from O
LD O
through O
early-to-late O
endosomes O
to O
the O
plasma O
membrane O
via O
microtubules S-protein
. O
Further O
studies O
by O
cofractionation O
analysis O
and O
immunoelectron O
microscopy O
of O
the O
released O
particles O
showed O
that O
NS5A-Core B-protein
complexes E-protein
, O
but O
not O
NS4B S-protein
, O
were O
present O
in O
the O
low-density O
fractions O
, O
but O
not O
in O
the O
high-density O
fractions O
, O
of O
the O
HCV O
RNA-containing O
virions O
and O
associated O
with O
the O
internal O
virion O
core O
. O
Furthermore O
, O
exosomal B-protein
markers E-protein
CD63 S-protein
and O
CD81 S-protein
were O
also O
detected O
in O
the O
low-density O
fractions O
, O
but O
not O
in O
the O
high-density O
fractions O
. O
Overall O
, O
our O
results O
suggest O
that O
HCV B-protein
NS5A E-protein
is O
associated O
with O
the O
core O
of O
the O
low-density O
virus O
particles O
which O
exit O
the O
cell O
through O
a O
preexisting O
endosome/exosome O
pathway O
and O
may O
contribute O
to O
HCV O
natural O
infection O
. O
Unlike O
canonical O
pre-mRNAs B-DNA
, I-DNA
animal I-DNA
replication-dependent I-DNA
histone I-DNA
pre-mRNAs I-DNA
lack I-DNA
introns E-DNA
and O
are O
processed O
at O
the O
3'-end O
by O
a O
mechanism O
distinct O
from O
cleavage O
and O
polyadenylation O
. O
They O
have O
a O
3 B-DNA
' I-DNA
stem I-DNA
loop I-DNA
and I-DNA
histone I-DNA
downstream I-DNA
element E-DNA
( O
HDE S-DNA
) O
that O
are O
recognized O
by O
stem-loop B-protein
binding I-protein
protein E-protein
( O
SLBP S-protein
) O
and O
U7 B-protein
snRNP E-protein
, O
respectively O
. O
The O
N-terminal B-protein
domain E-protein
( O
NTD S-protein
) O
of O
Lsm11 S-protein
, O
a O
component O
of O
U7 B-protein
snRNP E-protein
, O
interacts O
with O
FLASH O
NTD O
and O
these O
two O
proteins O
recruit O
the O
histone B-protein
cleavage I-protein
complex E-protein
containing O
the O
CPSF-73 B-protein
endonuclease E-protein
for O
the O
cleavage O
reaction O
. O
Here O
, O
we O
determined O
crystal O
structures O
of O
FLASH O
NTD O
and O
found O
that O
it O
forms O
a O
coiled-coil B-protein
dimer E-protein
. O
Using O
solution O
light O
scattering O
, O
we O
characterized O
the O
stoichiometry O
of O
the O
FLASH B-protein
NTD-Lsm11 I-protein
NTD I-protein
complex E-protein
and O
found O
that O
it O
is O
a O
2:1 B-protein
heterotrimer E-protein
, O
which O
is O
supported O
by O
observations O
from O
analytical O
ultracentrifugation O
and O
crosslinking O
. O
Citation O
: O
Aik O
WS O
, O
Lin B-cell_line
M-H I-cell_line
, I-cell_line
Tan I-cell_line
D I-cell_line
, I-cell_line
Tripathy I-cell_line
A I-cell_line
, I-cell_line
Marzluff I-cell_line
WF I-cell_line
, I-cell_line
Dominski I-cell_line
Z I-cell_line
, I-cell_line
et I-cell_line
al E-cell_line
. O
( O
2017 O
) O
The O
Nterminal O
domains O
of O
FLASH O
and O
Lsm11 S-DNA
form O
a O
2:1 O
heterotrimer O
for O
histone S-protein
pre-mRNA S-protein
3'-end O
processing O
. O
PLoS S-protein
ONE O
12 O
( O
10 O
) O
: O
e0186034 O
. O
https O
: O
// O
Biochemical O
studies O
of O
the O
3'-end O
processing O
machinery O
that O
cleaves O
replication-dependent B-protein
histone E-protein
pre-mRNAs S-protein
have O
shown O
that O
it O
is O
comprised O
of O
the O
stem-loop B-protein
binding I-protein
protein E-protein
( O
SLBP S-protein
) O
, O
U7 B-protein
small I-protein
nuclear I-protein
ribonucleoprotein E-protein
( O
U7 B-protein
snRNP E-protein
) O
, O
FLASH O
, O
and O
the O
histone B-protein
pre-mRNA I-protein
cleavage I-protein
complex I-protein
( I-protein
HCC I-protein
) I-protein
[ I-protein
1 I-protein
, I-protein
[ I-protein
3 I-protein
] I-protein
[ I-protein
4 I-protein
] I-protein
[ I-protein
5 I-protein
] I-protein
[ I-protein
6 I-protein
] E-protein
. O
SLBP S-protein
binds O
the O
3 B-DNA
' I-DNA
stem-loop E-DNA
in O
the O
pre-mRNA S-protein
and O
remains O
bound O
after O
mRNA O
maturation O
, O
and O
functions O
in O
translation O
[ O
7 O
, O
8 O
] O
. O
The O
3 B-DNA
' I-DNA
stem-loop E-DNA
also O
recruits O
the O
3'-5 B-protein
' I-protein
exoribonuclease E-protein
3'hExo S-protein
[ O
9 O
, O
10 O
] O
, O
which O
is O
not O
essential O
for O
processing O
[ O
11 O
] O
but O
trims O
the O
processed O
histone B-RNA
mRNAs E-RNA
and O
initiates O
degradation O
of O
histone B-RNA
mRNAs E-RNA
in O
the O
cytoplasm O
[ O
12 O
] O
. O
The O
core B-DNA
U7 I-DNA
snRNP E-DNA
consists O
of O
two O
integral O
and O
stably O
associated O
components O
: O
~60-nucleotide B-RNA
U7 I-RNA
snRNA E-RNA
and O
a O
unique B-DNA
Sm I-DNA
ring E-DNA
, O
which O
contains O
Lsm10 S-protein
and O
Lsm11 S-protein
in O
place O
of O
the O
spliceosomal B-DNA
SmD1 I-DNA
and I-DNA
SmD2 I-DNA
[ I-DNA
13 I-DNA
, I-DNA
14 I-DNA
] E-DNA
. O
The O
U7 B-DNA
snRNP E-DNA
recognizes O
the O
pre-mRNA S-DNA
through O
base-pairing O
between O
the O
5'-end O
of O
U7 B-RNA
snRNA E-RNA
and O
the O
HDE B-DNA
[ I-DNA
15 I-DNA
, I-DNA
16 I-DNA
] E-DNA
. O
SLBP S-DNA
bound O
to O
the O
upstream O
stemloop O
stabilizes O
this O
interaction O
, O
likely O
by O
directly O
or O
indirectly O
contacting O
a O
subunit O
( O
s O
) O
of O
U7 B-protein
snRNP I-protein
[ I-protein
17 I-protein
] E-protein
. O
Lsm11 S-protein
has O
an O
extended O
N-terminal B-protein
domain E-protein
( O
Fig B-protein
1A E-protein
) O
that O
is O
unique O
among O
members O
of O
the O
functionally O
characterized O
Sm B-protein
proteins E-protein
. O
Through O
yeast O
two-hybrid O
and O
pull-down O
studies O
, O
this O
region O
was O
found O
to O
interact O
with O
the O
N-terminal B-protein
region E-protein
of O
FLASH B-protein
( I-protein
Fig I-protein
1B I-protein
) I-protein
[ I-protein
3 I-protein
] E-protein
. O
FLASH O
, O
Fliceassociated B-protein
huge I-protein
protein E-protein
, O
was O
originally O
discovered O
as O
a O
protein O
involved O
in O
Fas-mediated O
apoptosis O
[ O
18 O
] O
and O
later O
in O
regulation O
of O
expression O
of O
several O
genes O
, O
including O
oncogenes S-DNA
[ O
19 O
, O
20 O
] O
. O
Subsequent O
studies O
showed O
that O
FLASH O
localizes O
to O
Histone S-protein
Locus O
Bodies O
in O
the O
nucleus O
, O
suggesting O
a O
role O
in O
expression O
of O
histone B-DNA
genes E-DNA
[ O
21 O
] O
, O
and O
that O
it O
is O
essential O
for O
histone B-protein
pre-mRNA E-protein
processing O
[ O
3 O
] O
. O
Biochemical O
studies O
revealed O
that O
the O
interacting O
N-terminal B-protein
regions E-protein
of O
Lsm11 S-protein
and O
FLASH O
form O
a O
docking O
platform O
that O
recruits O
the O
HCC O
to O
the O
U7 B-protein
snRNP I-protein
[ I-protein
22 I-protein
] E-protein
. O
The O
HCC S-protein
is O
composed O
of O
a O
specific O
subset O
of O
proteins O
that O
also O
participate O
in O
cleavage O
and O
polyadenylation O
[ O
23 O
, O
24 O
] O
, O
including O
the O
endonuclease S-protein
CPSF-73 S-protein
, O
CPSF-100 S-protein
, O
symplekin S-protein
and O
CstF-64 B-protein
[ I-protein
1 I-protein
, I-protein
[ I-protein
25 I-protein
] I-protein
[ I-protein
26 I-protein
] I-protein
[ I-protein
27 I-protein
] E-protein
. O
Mutational O
studies O
on O
FLASH O
identified O
an O
LDLY B-DNA
motif E-DNA
( O
residues O
55-58 O
in O
human O
FLASH O
, O
Fig O
1B O
) O
as O
essential O
for O
binding O
the O
HCC O
, O
while O
residues O
100-139 O
are O
involved O
in O
Lsm11 S-protein
binding O
[ O
22 O
, O
28 O
] O
. O
The O
molecular O
details O
of O
how O
FLASH O
acts O
as O
a O
mediator O
between O
Lsm11 S-protein
and O
HCC S-protein
are O
still O
unclear O
. O
To O
shed O
some O
light O
on O
the O
essential O
role O
of O
FLASH O
in O
3'-end O
processing O
of O
replicationdependent B-protein
histone E-protein
pre-mRNA S-protein
processing O
[ O
3 O
] O
, O
we O
carried O
out O
structural O
studies O
on O
the O
human B-protein
FLASH I-protein
N-terminal I-protein
domain I-protein
( I-protein
NTD I-protein
) I-protein
encompassing I-protein
residues I-protein
51-137 E-protein
using O
X-ray O
crystallography O
. O
We O
also O
performed O
biophysical O
studies O
on O
the O
FLASH O
NTD O
and O
the O
FLASH B-protein
NTD-Lsm11 I-protein
NTD I-protein
complex E-protein
to O
characterize O
their O
oligomeric O
states O
and O
the O
stoichiometry O
of O
their O
complex O
. O
Results O
We O
determined O
a O
structure O
of O
the O
wild-type O
human O
FLASH O
NTD O
at O
2.6 O
Å O
resolution O
using O
Xray O
crystallography O
( O
Table O
1 O
) O
. O
The O
initial O
phases O
were O
obtained O
by O
the O
single O
anomalous O
dispersion O
( O
SAD O
) O
method O
using O
crystals O
of O
selenomethionyl O
FLASH O
NTD O
. O
The O
structure O
showed O
that O
FLASH O
NTD O
forms O
a O
coiled-coil B-protein
dimer E-protein
consisting O
of O
two O
parallel O
α-helices O
, O
one O
from O
each O
protomer B-protein
( I-protein
Fig I-protein
2A E-protein
) O
. O
However O
, O
only O
residues O
71 O
to O
137 O
were O
observed O
in O
this O
structure O
, O
even O
though O
the O
expression O
construct O
contained O
residues O
51-137 O
. O
Residues O
51-70 O
, O
which O
include O
the O
LDLY B-protein
motif E-protein
previously O
shown O
to O
be O
essential O
for O
histone B-protein
pre-mRNA E-protein
processing O
[ O
28 O
] O
and O
for O
binding O
the O
HCC B-protein
[ I-protein
22 I-protein
] E-protein
, O
are O
disordered O
in O
this O
crystal O
. O
The O
first O
30 O
residues O
of O
FLASH O
are O
poorly O
conserved O
among O
homologs O
( O
Fig B-protein
1B E-protein
) O
, O
although O
there O
is O
substantial O
conservation O
from O
Drosophila O
to O
mammals O
for O
residues O
55-137 O
in O
the O
N-terminal B-protein
segment E-protein
. O
The O
N-terminal B-protein
domains E-protein
of O
FLASH O
and O
Lsm11 S-protein
form O
a O
2:1 B-protein
heterotrimer E-protein
for O
histone B-protein
pre-mRNA E-protein
3'-end O
processing O
PLOS O
ONE O
| O
https O
: O
//doi.org/10.1371/journal.pone.0186034 O
October O
11 O
, O
2017 O
2 O
/ O
21 O
using O
the O
Pilatus O
6M O
detector O
( O
NIH-ORIP O
HEI O
grant O
S10 O
RR029205 O
) O
. O
Competing O
interests O
: O
The O
authors O
have O
declared O
that O
no O
competing O
interests O
exist O
. O
Fig B-protein
1 E-protein
. O
Multiple O
protein O
sequence O
alignment O
of O
FLASH B-protein
and I-protein
Lsm11 I-protein
N-terminal I-protein
domains E-protein
. O
( O
A O
) O
Lsm11 B-protein
N-terminal I-protein
domain E-protein
. O
( O
B O
) O
FLASH B-protein
N-terminal I-protein
domain E-protein
. O
Alignment O
was O
carried O
out O
with O
Clustal B-protein
Omega I-protein
[ I-protein
60 I-protein
, I-protein
61 I-protein
] E-protein
and O
the O
results O
displayed O
with O
ESPript O
[ O
62 O
] O
. O
Secondary O
structure O
for O
FLASH O
is O
based O
on O
the O
structure O
of O
human B-protein
FLASH I-protein
NTD E-protein
, O
while O
that O
for O
Lsm11 S-protein
is O
based O
on O
Psipred O
[ O
63 O
] O
secondary O
structure O
prediction O
of O
human B-protein
Lsm11 E-protein
. O
Conserved O
residues O
are O
highlighted O
in O
red O
with O
white B-protein
fonts E-protein
, O
semi-conserved B-protein
residues E-protein
in O
red B-cell_type
fonts E-cell_type
, O
and O
other O
residues O
in O
black O
fonts O
. O
Blue O
dots O
indicate O
residues O
at O
the O
FLASH B-protein
dimer E-protein
interface O
. O
Gaps O
are O
indicated O
by O
dotted B-cell_line
lines E-cell_line
. O
Species O
abbreviations O
: O
Hs O
, O
Homo O
sapiens O
( O
human O
) O
; O
Dr S-DNA
, O
Danio O
rerio O
( O
zebrafish O
) O
; O
Dm O
, O
Drosophila O
melanogaster O
( O
fruit O
fly O
) O
. O
Feline O
calicivirus O
( O
FCV O
) O
is O
a O
major O
cause O
of O
upper O
respiratory O
tract O
disease O
in O
cats O
, O
with O
widespread O
distribution O
in O
the O
feline O
population O
. O
Recently O
, O
virulent O
systemic O
diseases O
caused O
by O
FCV O
infection O
has O
been O
associated O
with O
mortality O
rates O
up O
to O
50 O
% O
. O
Currently O
, O
there O
are O
no O
direct-acting O
antivirals O
approved O
for O
the O
treatment O
of O
FCV O
infection O
. O
Here O
, O
we O
tested O
15 O
compounds O
from O
different O
antiviral O
classes O
against O
FCV O
using O
in O
vitro O
protein O
and O
cell O
culture O
assays O
. O
After O
the O
expression O
of O
FCV B-protein
protease-polymerase I-protein
protein E-protein
, O
we O
established O
two O
in O
vitro O
assays O
to O
assess O
the O
inhibitory O
activity O
of O
compounds O
directly O
against O
the O
FCV B-protein
protease E-protein
or O
polymerase O
. O
Using O
this O
recombinant B-protein
enzyme E-protein
, O
we O
identified O
quercetagetin S-protein
and O
PPNDS S-protein
as O
inhibitors O
of O
FCV B-protein
polymerase E-protein
activity O
( O
IC O
50 O
values O
of O
2.8 O
µM O
and O
2.7 O
µM O
, O
respectively O
) O
. O
We O
also O
demonstrate O
the O
inhibition O
of O
FCV B-protein
protease E-protein
activity O
by O
GC376 O
( O
IC O
50 O
of O
18 O
µM O
) O
. O
Using O
cell O
culture O
assays O
, O
PPNDS O
, O
quercetagetin O
and O
GC376 O
did O
not O
display O
antivirals O
effects O
, O
however O
, O
we O
identified O
nitazoxanide O
and O
2 O
-C-methylcytidine O
( O
2CMC O
) O
as O
potent O
inhibitors O
of O
FCV O
replication O
, O
with O
EC S-cell_type
50 O
values O
in O
the O
low O
micromolar O
range O
( O
0.6 O
µM O
and O
2.5 O
µM O
, O
respectively O
) O
. O
In O
conclusion O
, O
we O
established O
two O
in O
vitro O
assays O
that O
will O
accelerate O
the O
research O
for O
FCV O
antivirals O
and O
can O
be O
used O
for O
the O
high-throughput O
screening O
of O
direct-acting O
antivirals O
. O
The O
single-stranded O
, O
positive-sense B-DNA
FCV I-DNA
RNA I-DNA
genome E-DNA
( O
~7.7 O
kb O
) O
is O
VPg S-DNA
linked O
, O
polyadenylated O
, O
and O
includes O
three O
open B-DNA
reading I-DNA
frames E-DNA
( O
ORFs S-DNA
) O
[ O
16 O
] O
. O
ORF1 S-DNA
encodes O
non-structural B-protein
proteins E-protein
, O
including O
the O
3C-like B-protein
protease E-protein
and O
3D-like B-protein
polymerase E-protein
, O
ORF2 S-DNA
encodes O
the O
major B-protein
capsid I-protein
protein E-protein
and O
ORF3 S-DNA
encodes O
a O
minor O
protein O
component O
of O
the O
virion O
[ O
17 O
] O
. O
Wei O
et O
al O
. O
[ O
18 O
] O
have O
demonstrated O
that O
the O
active O
form O
of O
the O
FCV B-protein
polymerase E-protein
is O
the O
bifunctional B-protein
protease-polymerase I-protein
( I-protein
Pro-Pol I-protein
) I-protein
protein E-protein
. O
FCV S-protein
shows O
a O
high O
level O
of O
genetic O
diversity O
due O
to O
the O
lack O
of O
proofreading O
and O
the O
low O
fidelity O
of O
the O
viral B-protein
polymerase E-protein
, O
and O
genome O
recombination O
between O
different O
FCV O
strains O
during O
coinfections B-DNA
[ I-DNA
4 I-DNA
, I-DNA
19 I-DNA
, I-DNA
20 I-DNA
] E-DNA
. O
The O
phylogenetic O
classification O
of O
FCV O
strains O
, O
based O
on O
ORF2 B-DNA
nucleotide I-DNA
sequences E-DNA
, O
have O
demonstrated O
the O
circulation O
of O
a O
single O
genogroup O
( O
GI O
) O
around O
the O
globe O
, O
with O
the O
exception O
of O
Japan O
which O
has O
additional O
circulating O
strains O
that O
belong O
to O
a O
second O
genogroup O
( O
GII O
) O
[ O
21 O
] O
[ O
22 O
] O
[ O
23 O
] O
. O
Live-attenuated O
and O
inactivated O
vaccines O
against O
FCV O
have O
been O
available O
for O
over O
40 O
years O
, O
using O
different O
FCV O
strains O
in O
monovalent O
or O
bivalent O
compositions O
[ O
24 O
] O
. O
Current O
vaccines O
do O
not O
prevent O
infection O
, O
viral O
shedding O
, O
or O
the O
development O
of O
FCV-VSD O
, O
but O
can O
reduce O
or O
even O
prevent O
clinical O
symptoms O
[ O
2 O
, O
7 O
, O
10 O
] O
. O
Moreover O
, O
there O
are O
no O
specific O
antivirals O
available O
against O
FCV O
infections O
and O
treatment O
options O
for O
FCV-VSD O
are O
only O
limited O
to O
supportive O
therapy O
. O
Several O
studies O
have O
reported O
different O
antiviral O
strategies O
against O
FCV O
[ O
25 O
] O
[ O
26 O
] O
[ O
27 O
] O
[ O
28 O
] O
[ O
29 O
] O
. O
One O
of O
the O
earliest O
attempts O
used O
phosphorodiamidate O
morpholino O
oligomers O
( O
PMO O
) O
to O
treat O
cats O
during O
three O
FCV O
outbreaks O
( O
two O
caused O
by O
the O
FCV-VSD O
and O
one O
linked O
with O
a O
non-lethal O
FCV O
pathotype O
) O
, O
showing O
promising O
results O
( O
79.6 O
% O
vs. O
9.7 O
% O
of O
cats O
survived O
with O
or O
without O
PMO O
treatment O
, O
respectively O
) O
[ O
27 O
] O
. O
Mefloquine O
, O
a O
human-approved O
pharmaceutical O
compound O
used O
to O
prevent O
or O
treat O
malaria O
, O
demonstrated O
an O
antiviral O
activity O
against O
FCV O
in O
vitro O
at O
low O
micromolar O
concentrations O
( O
half O
maximal O
effective O
concentration O
, O
EC O
50 O
= O
6.03 O
µM O
) O
, O
although O
it O
demonstrated O
a O
poor O
selectivity O
index O
( O
SI O
= O
3.7 O
) O
. O
The O
in O
vitro O
combination O
treatment O
with O
mefloquine O
and O
recombinant O
feline O
interferon-ω O
showed O
only O
a O
slight O
improvement O
of O
the O
IC O
50 O
[ O
26 O
] O
. O
Another O
class O
of O
compounds O
tested O
against O
FCV O
includes O
protease O
inhibitors O
( O
PIs O
) O
. O
Synthetic O
PIs O
such O
as O
GC376 O
and O
NPI52 O
have O
demonstrated O
antiviral O
activity O
against O
FCV O
( O
EC O
50 O
= O
35.2 O
µM O
and O
0.02 O
µM O
, O
respectively O
) O
. O
They O
were O
more O
effective O
against O
FCV O
when O
compared O
to O
the O
rhinovirus O
developmental O
PI O
rupintrivir O
( O
EC O
50 O
> O
50 O
µM O
) O
and O
are O
considered O
broad-spectrum O
compounds O
showing O
additional O
activity O
against O
the O
feline O
coronavirus O
and O
human O
norovirus O
[ O
29 O
, O
30 O
] O
. O
More O
recently O
, O
fexaramine O
, O
a O
synthetic O
agonist O
of O
the O
farnesoid B-protein
X I-protein
receptor E-protein
, O
which O
plays O
a O
role O
in O
lipid O
metabolism O
, O
was O
shown O
to O
be O
effective O
at O
blocking O
FCV S-protein
entry O
using O
in O
vitro O
assays O
, O
however O
, O
a O
single O
amino O
acid O
change O
( O
A539T O
) O
in O
the O
P2 B-protein
domain E-protein
of O
VP1 S-protein
( O
the O
major O
capsid B-protein
protein E-protein
) O
was O
able O
to O
confer O
resistance O
[ O
25 O
] O
. O
In O
the O
same O
study O
, O
combination O
treatment O
with O
the O
aforementioned O
broad-spectrum O
PI B-protein
( I-protein
NPI52 I-protein
) E-protein
showed O
synergistic O
antiviral O
activity O
( O
synergy O
log O
volume O
of O
8.35 O
µM O
2 O
% O
) O
and O
delayed O
the O
emergence O
of O
virus O
resistance O
. O
Viral B-protein
non-structural I-protein
proteins E-protein
, O
such O
as O
the O
protease O
and O
the O
RNA-dependent B-protein
RNA I-protein
polymerase E-protein
( O
RdRp S-protein
) O
are O
essential O
for O
viral O
replication O
, O
and O
therefore O
offer O
attractive O
antiviral O
targets O
. O
These O
enzymes O
lack O
host O
homologs O
, O
minimizing O
the O
chance O
of O
off-target O
effects O
and O
have O
been O
targeted O
successfully O
for O
the O
treatment O
of O
several O
viruses O
, O
including O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
and O
hepatitis O
C O
virus O
( O
HCV O
) O
[ O
31 O
, O
32 O
] O
. O
Using O
purified B-protein
recombinant I-protein
Pro-Pol E-protein
, O
we O
established O
two O
in O
vitro O
assays O
for O
the O
screening O
of O
new O
FCV O
antiviral O
compounds O
. O
Representative O
nucleoside O
analogues O
( O
NAs O
) O
, O
non-nucleoside O
inhibitors O
( O
NNIs O
) O
, O
PIs O
, O
and O
the O
broad-spectrum O
nitazoxanide O
, O
were O
tested O
for O
FCV O
antiviral O
activity O
using O
both O
in O
vitro O
enzyme O
and O
cell O
culture-based O
methods O
. O
Here O
we O
identify O
two O
antiviral O
agents O
as O
potential O
therapeutic O
options O
for O
the O
FCV O
infection O
. O
Background O
: O
Cytotoxic O
T O
cell O
( O
CTL S-cell_type
) O
cross-reactivity O
is O
believed O
to O
play O
a O
pivotal O
role O
in O
generating O
immune O
responses O
but O
the O
extent O
and O
mechanisms O
of O
CTL O
cross-reactivity O
remain O
largely O
unknown O
. O
Several O
studies O
suggest O
that O
CTL B-cell_line
clones E-cell_line
can O
recognize O
highly O
diverse O
peptides O
, O
some O
sharing O
no O
obvious O
sequence O
identity O
. O
The O
emerging O
realization O
in O
the O
field O
is O
that O
T B-protein
cell I-protein
receptors E-protein
( O
TcR S-protein
) O
recognize O
multiple O
distinct O
ligands O
. O
Principal O
Findings O
: O
First O
, O
we O
analyzed O
peptide O
scans O
of O
the O
HIV B-protein
epitope I-protein
SLFNTVATL E-protein
( O
SFL9 S-protein
) O
and O
found O
that O
TCR S-protein
specificity O
is O
position O
dependent O
and O
that O
biochemically O
similar O
amino O
acid O
substitutions O
do O
not O
drastically O
affect O
recognition O
. O
Inspired O
by O
this O
, O
we O
developed O
a O
general O
model O
of O
TCR S-protein
peptide O
recognition O
using O
amino O
acid O
similarity O
matrices O
and O
found O
that O
such O
a O
model O
was O
able O
to O
predict O
the O
cross-reactivity O
of O
a O
diverse O
set O
of O
CTL B-protein
epitopes E-protein
. O
With O
this O
model O
, O
we O
were O
able O
to O
demonstrate O
that O
seemingly O
distinct O
T B-protein
cell I-protein
epitopes E-protein
, O
i.e. O
, O
ones O
with O
low O
sequence O
identity O
, O
are O
in O
fact O
more O
biochemically O
similar O
than O
expected O
. O
Additionally O
, O
an O
analysis O
of O
HIV O
immunogenicity O
data O
with O
our O
model O
showed O
that O
CTLs S-cell_type
have O
the O
tendency O
to O
respond O
mostly O
to O
peptides O
that O
do O
not O
resemble O
self-antigens S-protein
. O
Conclusions O
: O
T O
cell O
cross-reactivity O
can O
thus O
, O
to O
an O
extent O
greater O
than O
earlier O
appreciated O
, O
be O
explained O
by O
amino O
acid O
similarity O
. O
The O
results O
presented O
in O
this O
paper O
will O
help O
resolving O
some O
of O
the O
long-lasting O
discussions O
in O
the O
field O
of O
T O
cell O
cross-reactivity O
. O
1,3-Dipolar O
cycloaddition O
of O
N-methyl O
C- O
( O
diethoxyphosphoryl O
) O
nitrone O
to O
N3-substituted O
6-bromo-2-vinyl-3H-quinazolin-4-ones O
gave O
( O
3-diethoxyphosphoryl O
) O
isoxazolidines O
substituted O
at O
C5 O
with O
quinazolinones O
modified O
at O
N3 O
. O
All O
isoxazolidine O
cycloadducts O
were O
screened O
for O
antiviral O
activity O
against O
a O
broad O
spectrum O
of O
DNA O
and O
RNA O
viruses O
. O
Several O
isoxazolidines O
inhibited O
the O
replication O
of O
both O
thymidine B-protein
kinase E-protein
wild-type O
and O
deficient O
( O
TK O
+ O
and O
TK O
− O
) O
varicella-zoster O
virus O
strains O
at O
EC O
50 O
in O
the O
5.4-13.6 O
µM O
range O
, O
as O
well O
as O
human O
cytomegalovirus O
( O
EC O
50 O
= O
8.9-12.5 O
µM O
) O
. O
Isoxazolidines B-RNA
trans-11b I-RNA
, I-RNA
trans-11c I-RNA
, I-RNA
trans-11e I-RNA
, I-RNA
trans-11f/cis-11f I-RNA
, I-RNA
trans-11g I-RNA
, I-RNA
trans-11h I-RNA
, I-RNA
and I-RNA
trans-11i/cis-11i E-RNA
exhibited O
moderate O
cytostatic O
activity O
towards O
the O
human B-cell_line
lymphocyte I-cell_line
cell I-cell_line
line I-cell_line
CEM E-cell_line
( O
IC O
50 O
= O
9.6-17 O
µM O
) O
. O
Molecules O
2018 O
, O
23 O
, O
1889 O
2 O
of O
16 O
both O
herpes O
simplex O
viruses O
1 O
and O
2 O
( O
HSV-1 O
and O
HSV-2 O
) O
and O
vaccinia O
virus O
( O
VACV O
) O
( O
EC O
50 O
= O
12 O
µg/mL O
) O
[ O
19 O
] O
, O
whereas O
compound O
2 O
exhibited O
activity O
against O
vaccinia O
virus O
in O
E B-cell_line
6 I-cell_line
SM I-cell_line
cell I-cell_line
cultures E-cell_line
( O
MIC O
of O
1.92 O
µg/mL O
) O
[ O
20 O
] O
. O
Another O
analogue O
, O
i.e. O
, O
2-methyl-3- O
( O
substituted-benzalamino O
) O
-4 O
( O
3H O
) O
-quinazolinone O
3 O
, O
was O
found O
to O
exhibit O
antiviral O
activity O
against O
tobacco O
mosaic O
virus O
( O
TMV O
) O
in O
vivo O
. O
Compound O
3 O
showed O
curative O
effects O
of O
54 O
% O
, O
which O
was O
slightly O
higher O
than O
that O
of O
a O
reference O
drug O
, O
Ningnanmycin O
[ O
21 O
] O
. O
Very O
recently O
quinazolin-4 O
( O
3H O
) O
-ones O
4-6 O
were O
synthesized O
and O
evaluated O
for O
inhibitory O
action O
on O
the O
replication O
of O
influenza O
A O
virus O
( O
H O
5 O
N O
1 O
) O
, O
as O
well O
as O
to O
test O
toxicity O
on O
in O
vitro B-cell_line
cell I-cell_line
lines E-cell_line
. O
In O
general O
, O
quinazolin-4 B-protein
( I-protein
3H I-protein
) I-protein
-ones E-protein
containing O
a O
chalcone O
skeleton O
4 O
, O
thiosemicarbazone O
5 O
, O
and O
hydrazide O
6 O
showed O
moderate O
antiviral O
activity O
against O
H B-protein
5 I-protein
N I-protein
1 E-protein
( O
inhibition O
rate O
: O
38 O
% O
, O
47 O
% O
, O
25 O
% O
, O
respectively O
, O
for O
4 O
, O
5 O
, O
6 O
) O
compared O
to O
a O
reference O
drug O
, O
Zanamivir O
[ O
22 O
] O
. O
In O
addition O
, O
compounds O
7 O
and O
8 O
possessing O
a O
nitro O
group O
at O
C6 O
were O
reported O
as O
potent O
inhibitors O
of O
Venezuelan O
Equine O
Encephalitis O
Virus O
( O
VEEV O
) O
( O
EC O
50 O
= O
0.8 O
µM O
, O
CC O
50 O
= O
50 O
µM O
) O
[ O
23 O
] O
. O
Quinazolinone O
( O
aS O
) O
-9 O
displayed O
high O
selectivity O
for O
PI4KIIIα S-protein
and O
appeared O
to O
be O
potent O
inhibitors O
of O
hepatitis O
C O
virus O
( O
HCV O
) O
replication O
in O
vitro O
. O
Moreover O
, O
compound O
( O
aS O
) O
-9 O
exhibited O
higher O
potency O
for O
PI4KIIIα S-protein
than O
its O
atropisomer O
aR O
( O
pIC O
50 O
of O
8.3 O
vs. O
6.9 O
) O
and O
an O
improved O
selectivity O
range O
( O
2.7-3.2 O
vs. O
1.4-2.1 O
) O
against O
the O
other O
lipid B-protein
kinases E-protein
[ O
24 O
] O
. O
Molecules O
2018 O
, O
23 O
, O
x O
2 O
of O
16 O
Molecules O
2018 O
, O
23 O
, O
1889 O
3 O
of O
16 O
synthesized O
. O
The O
synthetic O
strategy O
for O
our O
new O
isoxazolidine-conjugates O
of O
quinazolinones O
relies O
on O
the O
1,3-dipolar O
cycloaddition O
of O
N-methyl-C- O
( O
diethoxyphosphoryl O
) O
nitrone O
12 O
[ O
26 O
] O
with O
selected O
6-bromo-2-vinyl-3H-quinazolin-4-ones O
13 O
( O
Scheme O
1 O
) O
. O
Molecules O
2018 O
, O
23 O
, O
x O
3 O
of O
16 O
isoxazolidine O
ring O
at O
C2 O
, O
different O
substituents O
at O
N3 O
, O
and O
an O
additional O
bromine O
atom O
at O
C6 O
was O
synthesized O
. O
The O
synthetic O
strategy O
for O
our O
new O
isoxazolidine-conjugates O
of O
quinazolinones O
relies O
on O
the O
1,3-dipolar O
cycloaddition O
of O
N-methyl-C- O
( O
diethoxyphosphoryl O
) O
nitrone O
12 O
[ O
26 O
] O
with O
selected O
6-bromo-2-vinyl-3H-quinazolin-4-ones O
13 O
( O
Scheme O
1 O
) O
. O
Scheme O
1 O
. O
Retrosynthesis O
of O
isoxazolidine O
conjugates O
of O
6-bromoquinazolinones O
. O
Chikungunya O
virus O
( O
CHIKV O
) O
is O
a O
mosquito-borne O
virus O
currently O
transmitted O
in O
about O
60 O
countries O
. O
CHIKV O
causes O
acute O
flu-like O
symptoms O
and O
in O
many O
cases O
prolonged O
musculoskeletal O
and O
joint O
pain O
. O
Detection O
of O
the O
infection O
is O
mostly O
done O
using O
RT-RCR O
or O
ELISA O
, O
which O
are O
not O
suitable O
for O
point-of-care O
diagnosis O
. O
In O
this O
study O
, O
a O
reverse O
transcription O
recombinase O
polymerase O
amplification O
( O
RT-RPA O
) O
assay O
for O
the O
detection O
of O
the O
CHIKV O
was O
developed O
. O
The O
assay O
sensitivity O
, O
specificity O
, O
and O
crossreactivity O
were O
tested O
. O
CHIKV O
RT-RPA S-protein
assay O
detected O
down O
to O
80 O
genome O
copies/reaction O
in O
a O
maximum O
of O
15 O
minutes O
. O
It O
successfully O
identified O
18 O
isolates O
representing O
the O
three O
CHIKV O
genotypes O
. O
No O
cross-reactivity O
was O
detected O
to O
other O
alphaviruses O
and O
arboviruses O
except O
O'nyong'nyong O
virus O
, O
which O
could O
be O
differentiated O
by O
a O
modified O
RPA B-DNA
primer I-DNA
pair E-DNA
. O
Seventy-eight O
samples O
were O
screened O
both O
by O
RT-RPA O
and O
real-time O
RT-PCR O
. O
The O
diagnostic O
sensitivity O
and O
specificity O
of O
the O
CHIKV O
RT-RPA O
assay O
were O
determined O
at O
100 O
% O
. O
The O
developed O
RT-RPA O
assay O
represents O
a O
promising O
method O
for O
the O
molecular O
detection O
of O
CHIKV O
at O
point O
of O
need O
. O
CHIKV O
is O
transmitted O
to O
humans O
via O
mosquitos O
. O
CHIKV O
induces O
clinical O
signs O
similar O
to O
Influenza O
, O
Dengue O
, O
and O
Zika O
viruses O
. O
We O
have O
developed O
a O
molecular O
assay O
for O
the O
detection O
of O
CHIKV B-DNA
genome E-DNA
based O
on O
isothermal O
'' O
recombinase O
polymerase O
amplification O
( O
RPA O
) O
assay O
'' O
performed O
at O
42°C O
. O
The O
result O
was O
obtained O
in O
maximum O
of O
15 O
minutes O
, O
which O
is O
4-6 O
times O
faster O
than O
the O
current O
molecular O
diagnostic O
techniques O
. O
Our O
CHIKV O
RPA O
assay O
is O
rapid O
and O
sensitive O
, O
as O
well O
as O
easy O
to O
use O
at O
the O
point O
of O
need O
. O
Influenza O
poses O
concerns O
about O
epidemic O
respiratory O
infection O
. O
Interventions O
designed O
to O
prevent O
the O
spread O
of O
respiratory O
infection O
within O
family O
physician O
( O
FP O
) O
offices O
could O
potentially O
have O
a O
significant O
positive O
influence O
on O
the O
health O
of O
Canadians O
. O
The O
main O
purpose O
of O
this O
paper O
is O
to O
estimate O
the O
explicit O
costs O
of O
such O
an O
intervention O
. O
A O
cost O
analysis O
of O
a O
respiratory O
infection O
control O
was O
conducted O
. O
The O
costs O
were O
estimated O
from O
the O
perspective O
of O
provincial O
government O
. O
In O
addition O
, O
a O
threshold O
analysis O
was O
conducted O
to O
estimate O
a O
threshold O
value O
of O
the O
intervention O
's O
effectiveness O
that O
could O
generate O
potential O
savings O
in O
terms O
of O
averted O
health-care O
costs O
by O
the O
intervention O
that O
exceed O
the O
explicit O
costs O
. O
The O
informational O
requirements O
for O
these O
implicit O
costs O
savings O
are O
high O
, O
however O
. O
Some O
of O
these O
elements O
, O
such O
as O
the O
cost O
of O
hospitalization O
in O
the O
event O
of O
contacting O
influenza O
, O
and O
the O
number O
of O
patients O
passing O
through O
the O
physicians O
' O
office O
, O
were O
readily O
available O
. O
Other O
pertinent O
points O
of O
information O
, O
such O
as O
the O
proportion O
of O
infected O
people O
who O
require O
hospitalization O
, O
could O
be O
imported O
from O
the O
existing O
literature O
. O
We O
take O
an O
indirect O
approach O
to O
calculate O
a O
threshold O
value O
for O
the O
most O
uncertain O
piece O
of O
information O
, O
namely O
the O
reduction O
in O
the O
probability O
of O
the O
infection O
spreading O
as O
a O
direct O
result O
of O
the O
intervention O
, O
at O
which O
the O
intervention O
becomes O
worthwhile O
. O
The O
5-week O
intervention O
costs O
amounted O
to O
a O
total O
of O
$ O
52,810.71 O
, O
or O
$ O
131,094.73 O
prorated O
according O
to O
the O
length O
of O
the O
flu O
season O
, O
or O
$ O
512,729.30 O
prorated O
for O
the O
entire O
calendar O
year O
. O
The O
variable O
costs O
that O
were O
incurred O
for O
this O
5-week O
project O
amounted O
to O
approximately O
$ O
923.16 O
per O
participating O
medical O
practice O
. O
The O
( O
fixed O
) O
training O
costs O
per O
practice O
were O
equivalent O
to O
$ O
73.27 O
for O
the O
5week O
intervention O
, O
or O
$ O
28.14 O
for O
13-week O
flu O
season O
, O
or O
$ O
7.05 O
for O
an O
entire O
one-year O
period O
. O
Conclusion O
: O
Based O
on O
our O
conservative O
estimates O
for O
the O
direct O
cost O
savings O
, O
there O
are O
indications O
that O
the O
outreach O
facilitation O
intervention O
program O
would O
be O
cost O
effective O
if O
it O
can O
achieve O
a O
reduction O
in O
the O
probability O
of O
infection O
on O
the O
order O
of O
0.83 O
( O
0.77 O
, O
1.05 O
) O
percentage O
points O
. O
A O
facilitation O
intervention O
initiative O
tailored O
to O
the O
environment O
and O
needs O
of O
the O
family O
medical O
practice O
and O
walk-in O
clinics O
is O
of O
promise O
for O
improving O
respiratory O
infection O
control O
in O
the O
physicians O
' O
offices O
. O
Background O
: O
Toxoplasma O
gondii O
is O
an O
obligate O
intracellular O
protozoan O
parasite O
that O
can O
infect O
mammalian B-cell_type
cells E-cell_type
and O
thereby O
regulate O
host O
gene O
expression O
. O
The O
long B-RNA
non-coding I-RNA
RNAs E-RNA
( O
lncRNAs S-DNA
) O
have O
been O
demonstrated O
to O
be O
an O
important O
class O
of O
RNA O
molecules O
that O
regulate O
many O
biological O
processes O
, O
including O
host-pathogen O
interactions O
. O
However O
, O
the O
role O
of O
host O
lncRNAs S-protein
in O
the O
response O
to O
T. O
gondii O
infection O
remains O
largely O
unknown O
. O
Methods O
: O
We O
applied O
a O
microarray O
approach O
to O
determine O
the O
differential O
expression O
profiles O
of O
both O
lncRNAs B-RNA
and I-RNA
mRNAs E-RNA
in O
the O
human B-cell_line
foreskin I-cell_line
fibroblast I-cell_line
( I-cell_line
HFF I-cell_line
) I-cell_line
cells E-cell_line
after O
T. O
gondii O
infection O
. O
The O
Gene O
Ontology O
and O
Kyoto O
Encyclopedia O
of O
Genes O
and O
Genomes O
( O
KEGG S-DNA
) O
pathway O
analyses O
were O
performed O
to O
reveal O
the O
potential O
functions O
of O
T. B-DNA
gondii-induced I-DNA
genes E-DNA
. O
Based O
on O
the O
co-expression O
networks O
of O
lncRNAs B-DNA
and I-DNA
immune-related I-DNA
genes E-DNA
, O
the O
role O
of O
NONSHAT022487 S-protein
on O
the O
regulation O
of O
UNC93B1 S-protein
related O
immune O
signaling O
was O
investigated O
by O
the O
knockdown O
and O
over-expression O
of O
lncRNA S-protein
in O
human B-cell_type
macrophage E-cell_type
derived O
from O
the O
PMA-induced B-cell_line
promonocytic I-cell_line
cell I-cell_line
line E-cell_line
THP-1 S-cell_line
. O
Results O
: O
Our O
data O
showed O
that O
996 B-RNA
lncRNAs I-RNA
and I-RNA
109 I-RNA
mRNAs E-RNA
in O
HFF B-cell_type
cells E-cell_type
were O
significantly O
and O
differentially O
expressed O
following O
T. O
gondii O
infection O
( O
fold O
change O
≥ O
5 O
, O
P O
< O
0.05 O
) O
. O
The O
results O
from O
the O
GO O
and O
KEGG O
pathway O
analyses O
indicated O
that O
the O
mRNAs S-RNA
with O
differential O
expression O
were O
mainly O
involved O
in O
the O
host O
immune O
response O
. O
Remarkably O
, O
we O
identified O
a O
novel O
lncRNA S-protein
, O
NONSHAT022487 S-protein
, O
which O
suppresses O
the O
expression O
of O
the O
immunerelated B-protein
molecule E-protein
UNC93B1 S-protein
. O
After O
T. O
gondii O
infection O
, O
NONSHAT022487 O
impaired O
the O
secretion O
of O
the O
cytokines S-protein
IL-12 S-protein
, O
TNF-α S-protein
, O
IL-1β S-protein
and O
IFN-γ S-protein
by O
downregulating O
UNC93B1 S-protein
expression O
in O
human B-cell_type
macrophage I-cell_type
cells E-cell_type
. O
Conclusions O
: O
Our O
study O
identified O
infection-induced O
lncRNA S-protein
expression O
as O
a O
novel O
mechanism O
by O
which O
the O
Toxoplasma O
parasite O
regulates O
host O
immune O
signaling O
, O
which O
advances O
our O
understanding O
of O
the O
interaction O
of O
T. O
gondii O
parasites O
and O
host B-cell_type
cells E-cell_type
. O
The O
aim O
of O
the O
present O
study O
is O
to O
apply O
simple O
ODE O
models O
in O
the O
area O
of O
modeling O
the O
spread O
of O
emerging O
infectious O
diseases O
and O
show O
the O
importance O
of O
model O
selection O
in O
estimating O
parameters O
, O
the O
basic O
reproduction O
number O
, O
turning O
point O
, O
and O
final O
size O
. O
To O
quantify O
the O
plausibility O
of O
each O
model O
, O
given O
the O
data O
and O
the O
set O
of O
four O
models O
including O
Logistic O
, O
Gompertz O
, O
Rosenzweg O
, O
and O
Richards O
models O
, O
the O
Bayes B-protein
factors E-protein
are O
calculated O
and O
the O
precise O
estimates O
of O
the O
best O
fitted O
model O
parameters O
and O
key O
epidemic O
characteristics O
have O
been O
obtained O
. O
In O
particular O
, O
for O
Ebola O
the O
basic O
reproduction O
numbers O
are O
1.3522 O
( O
95 O
% O
( O
95 O
% O
CI O
( O
25630 O
, O
25958 O
) O
) O
, O
3916 O
( O
95 O
% O
CI O
( O
3865 O
, O
3967 O
) O
) O
, O
9886 O
( O
95 O
% O
CI B-DNA
( I-DNA
9740 I-DNA
, I-DNA
10031 I-DNA
) E-DNA
) O
, O
and O
12633 O
( O
95 O
% O
CI B-DNA
( I-DNA
12515 I-DNA
, I-DNA
12750 I-DNA
) E-DNA
) O
for O
West O
Africa O
, O
Guinea O
, O
Liberia O
, O
and O
Sierra O
Leone O
, O
respectively O
. O
The O
main O
results O
confirm O
that O
model O
selection O
is O
crucial O
in O
evaluating O
and O
predicting O
the O
important O
quantities O
describing O
the O
emerging O
infectious O
diseases O
, O
and O
arbitrarily O
picking O
a O
model O
without O
any O
consideration O
of O
alternatives O
is O
problematic O
. O
Since O
its O
emergence O
in O
the O
1990s O
, O
White O
Spot O
Disease O
( O
WSD O
) O
has O
had O
major O
economic O
and O
societal O
impact O
in O
the O
crustacean O
aquaculture O
sector O
. O
Over O
the O
years O
shrimp O
farming O
alone O
has O
experienced O
billion O
dollar O
losses O
through O
WSD O
. O
The O
disease O
is O
caused O
by O
the O
White O
Spot O
Syndrome O
Virus O
( O
WSSV O
) O
, O
a O
large O
dsDNA O
virus O
and O
the O
only O
member O
of O
the O
Nimaviridae B-protein
family E-protein
. O
Susceptibility O
to O
WSSV S-DNA
in O
a O
wide O
range O
of O
crustacean O
hosts O
makes O
it O
a O
major O
risk O
factor O
in O
the O
translocation O
of O
live O
animals O
and O
in O
commodity O
products O
. O
Currently O
there O
are O
no O
effective O
treatments O
for O
this O
disease O
. O
Understanding O
the O
molecular O
basis O
of O
disease O
processes O
has O
contributed O
significantly O
to O
the O
treatment O
of O
many O
human O
and O
animal O
pathogens O
, O
and O
with O
a O
similar O
aim O
considerable O
efforts O
have O
been O
directed O
towards O
understanding O
host-pathogen O
molecular O
interactions O
for O
WSD S-protein
. O
Work O
on O
the O
molecular O
mechanisms O
of O
pathogenesis O
in O
aquatic O
crustaceans O
has O
been O
restricted O
by O
a O
lack O
of O
sequenced O
and O
annotated O
genomes O
for O
host O
species O
. O
Nevertheless O
, O
some O
of O
the O
key O
host-pathogen O
interactions O
have O
been O
established O
: O
between O
viral B-protein
envelope I-protein
proteins E-protein
and O
host B-protein
cell I-protein
receptors E-protein
at O
initiation O
of O
infection O
, O
involvement O
of O
various O
immune O
system O
pathways O
in O
response O
to O
WSSV S-protein
, O
and O
the O
roles O
of O
various O
host O
and O
virus O
miRNAs O
in O
mitigation O
or O
progression O
of O
disease O
. O
Despite O
these O
advances O
, O
many O
fundamental O
knowledge O
gaps O
remain O
; O
for O
example O
, O
the O
roles O
of O
the O
majority O
of O
WSSV B-protein
proteins E-protein
are O
still O
unknown O
. O
In O
this O
review O
we O
assess O
current O
knowledge O
of O
how O
WSSV O
infects O
and O
replicates O
in O
its O
host O
, O
and O
critique O
strategies O
for O
WSD O
treatment O
. O
An O
acute O
outbreak O
of O
porcine O
hemagglutinating O
encephalomyelitis O
virus O
( O
PHEV O
) O
infection O
in O
piglets O
, O
characterized O
with O
neurological O
symptoms O
, O
vomiting O
, O
diarrhea O
, O
and O
wasting O
, O
occurred O
in O
China O
. O
Coronavirus-like O
particles O
were O
observed O
in O
the O
homogenized O
tissue O
suspensions O
of O
the O
brain O
of O
dead O
piglets O
by O
electron O
microscopy O
, O
and O
a O
wild O
PHEV O
strain O
was O
isolated O
, O
characterized O
, O
and O
designated O
as O
PHEV-CC14 S-protein
. O
Histopathologic O
examinations O
of O
the O
dead O
piglets O
showed O
characteristics O
of O
nonsuppurative O
encephalitis O
, O
and O
some O
neurons O
in O
the O
cerebral O
cortex O
were O
degenerated O
and O
necrotic O
, O
and O
neuronophagia O
. O
Similarly O
, O
mice O
inoculated O
with O
PHEV-CC14 O
were O
found O
to O
have O
central O
nervous O
system O
( O
CNS O
) O
dysfunction O
, O
with O
symptoms O
of O
depression O
, O
arched O
waists O
, O
standing O
and O
vellicating O
front O
claws O
. O
Furthmore O
, O
PHEV-positive O
labeling O
of O
neurons O
in O
cortices O
of O
dead O
piglets O
and O
infected O
mice O
supported O
the O
viral O
infections O
of O
the O
nervous O
system O
. O
Then O
, O
the O
major B-DNA
structural I-DNA
genes E-DNA
of O
PHEV-CC14 S-protein
were O
sequenced O
and O
phylogenetically O
analyzed O
, O
and O
the O
strain O
shared O
95 O
% O
-99.2 O
% O
nt O
identity O
with O
the O
other O
PHEV O
strains O
available O
in O
GenBank O
. O
Phylogenetic O
analysis O
clearly O
proved O
that O
the O
wild O
strain O
clustered O
into O
a O
subclass O
with O
a O
HEV-JT06 O
strain O
. O
These O
findings O
suggested O
that O
the O
virus O
had O
a O
strong O
tropism O
for O
CNS O
, O
in O
this O
way O
, O
inducing O
nonsuppurative O
encephalitis O
as O
the O
cause O
of O
death O
in O
piglets O
. O
Simultaneously O
, O
the O
predicted O
risk O
of O
widespread O
transmission O
showed O
a O
certain O
variation O
among O
the O
PHEV O
strains O
currently O
circulating O
around O
the O
world O
. O
Above O
all O
, O
the O
information O
presented O
in O
this O
study O
can O
not O
only O
provide O
good O
reference O
for O
the O
experimental O
diagnosis O
of O
PHEV O
infection O
for O
pig O
breeding O
, O
but O
also O
promote O
its O
new O
effective O
vaccine O
development O
. O
AE O
, O
Enjuanes O
L. O
2003 O
. O
A O
comparative O
sequence O
analysis O
to O
revise O
the O
current O
taxonomy O
of O
the O
family O
Coronaviridae O
. O
As O
of O
May O
1 O
, O
2017 O
, O
74 O
antibody-based B-protein
molecules E-protein
have O
been O
approved O
by O
a O
regulatory O
authority O
in O
a O
major O
market O
. O
Additionally O
, O
there O
are O
70 O
and O
575 O
antibodybased O
molecules O
in O
phase O
III O
and O
phase O
I/II O
clinical O
trials O
, O
respectively O
. O
These O
total O
719 O
antibody-based O
clinical O
stage O
molecules O
include O
493 O
naked O
IgGs O
, O
87 O
antibodydrug O
conjugates O
, O
61 B-protein
bispecific I-protein
antibodies E-protein
, O
37 O
total O
Fc B-protein
fusion I-protein
proteins E-protein
, O
17 O
radioimmunoglobulins O
, O
13 O
antibody O
fragments O
, O
and O
11 O
immunocytokines O
. O
New O
uses O
for O
these O
antibodies S-protein
are O
being O
discovered O
each O
year O
. O
For O
oncology O
, O
many O
of O
the O
exciting O
new O
approaches O
involve O
antibody O
modulation O
of O
T-cells S-cell_type
. O
There O
are O
over O
80 B-protein
antibodies E-protein
in O
clinical O
trials O
targeting O
T O
cell O
checkpoints O
, O
26 B-protein
T-cellredirected I-protein
bispecific I-protein
antibodies E-protein
, O
and O
145 B-protein
chimeric I-protein
antigen I-protein
receptor E-protein
( O
CAR S-protein
) O
cell-based O
candidates O
( O
all O
currently O
in O
phase O
I O
or O
II O
clinical O
trials O
) O
, O
totaling O
more O
than O
250 O
T O
cell O
interacting O
clinical O
stage O
antibody-based O
candidates O
. O
Finally O
, O
significant O
progress O
has O
been O
made O
recently O
on O
routes O
of O
delivery O
, O
including O
delivery O
of O
proteins O
across O
the O
blood-brain O
barrier O
, O
oral O
delivery O
to O
the O
gut O
, O
delivery O
to O
the O
cellular O
cytosol O
, O
and O
gene-and O
viral-based O
delivery O
of O
antibodies S-protein
. O
Thus O
, O
there O
are O
currently O
at O
least O
864 O
antibody-based O
clinical O
stage O
molecules O
or O
cells O
, O
with O
incredible O
diversity O
in O
how O
they O
are O
constructed O
and O
what O
activities O
they O
impart O
. O
These O
are O
followed O
by O
a O
next O
wave O
of O
novel O
molecules O
, O
approaches O
, O
and O
new O
methods O
and O
routes O
of O
delivery O
, O
demonstrating O
that O
the O
field O
of O
antibody-based O
biologics O
is O
very O
innovative O
and O
diverse O
in O
its O
approaches O
to O
fulfill O
their O
promise O
to O
treat O
unmet O
medical O
needs O
. O
DExD/H-box B-protein
helicase I-protein
36 E-protein
( O
DHX36 S-protein
) O
is O
known O
to O
be O
an O
ATP-dependent B-protein
RNA I-protein
helicase E-protein
that O
unwinds O
the O
guanine-quadruplexes B-DNA
DNA E-DNA
or O
RNA O
, O
but O
emerging O
data O
suggest O
that O
it O
also O
functions O
as O
pattern B-protein
recognition I-protein
receptor E-protein
in O
innate O
immunity O
. O
Porcine O
reproductive O
and O
respiratory O
syndrome O
virus O
( O
PRRSV O
) O
is O
an O
Arterivirus O
that O
has O
been O
devastating O
the O
swine O
industry O
worldwide O
. O
Interstitial O
pneumonia O
is O
considered O
to O
be O
one O
of O
the O
most O
obvious O
clinical O
signs O
of O
PRRSV O
infection O
, O
suggesting O
that O
the O
inflammatory O
response O
plays O
an O
important O
role O
in O
PRRSV O
pathogenesis O
. O
However O
, O
whether O
DHX36 S-protein
is O
involved O
in O
PRRSVinduced B-protein
inflammatory I-protein
cytokine E-protein
expression O
remains O
unclear O
. O
In O
this O
study O
, O
we O
found O
that O
PRRSV O
infection O
increased O
the O
expression O
of O
DHX36 S-protein
. O
Knockdown O
of O
DHX36 S-protein
and O
its O
adaptor B-protein
myeloid I-protein
differentiation I-protein
primary I-protein
response I-protein
gene I-protein
88 E-protein
( O
MyD88 S-protein
) O
by O
small-interfering B-RNA
RNA E-RNA
in O
MARC-145 B-cell_line
cells E-cell_line
significantly O
reduced O
NF-κB S-protein
activation O
and O
pro-inflammatory B-protein
cytokine E-protein
expression O
after O
PRRSV O
infection O
. O
Further O
investigation O
revealed O
that O
PRRSV B-protein
nucleocapsid I-protein
protein E-protein
interacted O
with O
the O
N-terminal B-protein
quadruplex I-protein
binding I-protein
domain E-protein
of O
DHX36 S-protein
, O
which O
in O
turn O
augmented O
nucleocapsid O
protein-induced O
NF-κB S-protein
activation O
. O
Taken O
together O
, O
our O
results O
suggest O
that O
DHX36-MyD88 S-protein
has O
a O
relevant O
role O
in O
the O
recognition O
of O
PRRSV B-protein
nucleocapsid I-protein
protein E-protein
and O
in O
the O
subsequent O
activation O
of O
pro-inflammatory O
NF-κB S-protein
pathway O
. O
Given O
the O
rapid O
rate O
of O
global O
spread O
and O
consequently O
healthcare O
costs O
related O
to O
influenza O
, O
surveillance O
plays O
an O
important O
role O
in O
monitoring O
the O
emerging O
pandemics O
in O
China O
. O
However O
, O
the O
characteristics O
of O
influenza O
in O
Southeast O
of O
China O
have O
n't O
been O
fully O
studied O
. O
Our O
study O
use O
the O
surveillance O
data O
collected O
from O
16 O
sentinel O
hospitals O
across O
Zhejiang O
Province O
during O
March O
2011 O
through O
June O
2015 O
, O
including O
the O
demographic O
information O
and O
respiratory O
specimens O
from O
influenza-like O
illness O
( O
ILI O
) O
patients O
and O
severe O
acute O
respiratory O
illness O
( O
SARI O
) O
patients O
. O
As O
analysis O
results O
, O
most O
SARI O
and O
ILI O
patients O
were O
in O
the O
age O
group O
of O
0-4 O
years O
old O
( O
62.38 O
% O
of O
ILI O
and O
71.54 O
% O
of O
SARI O
) O
. O
The O
respiratory O
specimens O
have O
statistically O
significantly O
higher O
positive O
rate O
for O
influenza O
among O
ILI O
patients O
than O
that O
among O
SARI O
patients O
( O
p O
< O
0.001 O
) O
. O
The O
comparison O
between O
ILI O
patients O
and O
SARI O
patients O
shows O
no O
statistically O
significantly O
difference O
in O
detecting O
influenza O
virus O
type O
and O
influenza O
A O
virus O
subtype O
. O
The O
SARI O
and O
ILI O
patients O
were O
found O
to O
be O
positively O
correlated O
for O
overall O
positive O
rate O
( O
r O
= O
0.63 O
, O
p O
< O
0.001 O
) O
, O
the O
weekly O
percentage O
of O
A O
( O
H1N1 O
) O
pdm09 O
( O
r O
= O
0.51 O
, O
p O
< O
0.001 O
) O
, O
influenza O
B O
virus O
( O
r O
= O
0.17 O
, O
p O
= O
0.013 O
) O
, O
and O
A/H3N2 O
( O
r O
= O
0.43 O
, O
p O
< O
0.001 O
) O
among O
all O
the O
positive O
numbers O
. O
Our O
study O
demonstrated O
that O
the O
activities O
of O
influenza O
virus O
, O
including O
its O
subtypes O
, O
had O
a O
similar O
temporal O
pattern O
between O
ILI O
and O
SARI O
cases O
. O
Enabling O
innovation O
and O
access O
to O
health O
technologies O
remains O
a O
key O
strategy O
in O
combating O
infectious O
diseases O
in O
low-and O
middle-income O
countries O
( O
LMICs O
) O
. O
However O
, O
a O
gulf O
between O
paying O
markets O
and O
the O
endemicity O
of O
such O
diseases O
has O
contributed O
to O
the O
dearth O
of O
R O
& O
D O
in O
meeting O
these O
public O
health O
needs O
. O
While O
the O
pharmaceutical O
industry O
views O
emerging O
economies O
as O
potential O
new O
markets O
, O
most O
of O
the O
world O
's O
poorest O
bottom O
billion O
now O
reside O
in O
middle-income O
countries-a O
fact O
that O
has O
complicated O
tiered O
access O
arrangements O
. O
However O
, O
product O
development O
partnerships-particularly O
those O
involving O
academic O
institutions O
and O
small O
firms-find O
commercial O
opportunities O
in O
pursuing O
even O
neglected O
diseases O
; O
and O
a O
growing O
pharmaceutical O
sector O
in O
BRICS O
countries O
offers O
hope O
for O
an O
indigenous O
base O
of O
innovation O
. O
Such O
innovation O
will O
be O
shaped O
by O
1 O
) O
access O
to O
building O
blocks O
of O
knowledge O
; O
2 O
) O
strategic O
use O
of O
intellectual O
property O
and O
innovative O
financing O
to O
meet O
public O
health O
goals O
; O
3 O
) O
collaborative O
norms O
of O
open O
innovation O
; O
and O
4 O
) O
alternative O
business O
models O
, O
some O
with O
a O
double O
bottom O
line O
. O
Facing O
such O
resource O
constraints O
, O
LMICs O
are O
poised O
to O
develop O
a O
new O
, O
more O
resource-effective O
model O
of O
innovation O
that O
holds O
exciting O
promise O
in O
meeting O
the O
needs O
of O
global O
health O
. O
Glucose-6-phosphate B-protein
dehydrogenase E-protein
( O
G6PD S-protein
) O
deficiency O
may O
affect O
the O
clinical O
presentation O
of O
dengue O
due O
to O
the O
altered O
redox O
state O
in O
immune B-cell_type
cells E-cell_type
. O
We O
aimed O
to O
determine O
the O
association O
between O
G6PD S-protein
deficiency O
and O
severity O
of O
dengue O
infection O
in O
paediatric O
patients O
in O
Myanmar O
. O
A O
cross-sectional O
study O
was O
conducted O
among O
paediatric O
patients O
aged O
2-13 O
years O
with O
dengue O
in O
Yankin O
Children O
Hospital O
, O
Myanmar O
. O
One O
hundred O
and O
ninety-six O
patients O
positive O
for O
dengue O
infection O
, O
as O
determined O
via O
PCR O
or O
ELISA O
, O
were O
enrolled O
. O
Dengue O
severity O
was O
determined O
according O
to O
the O
2009 O
WHO O
classification O
guidelines O
. O
Spectrophotometric O
assays O
determined O
G6PD S-protein
levels O
. O
The O
adjusted O
median O
G6PD S-protein
value O
of O
males O
in O
the O
study O
population O
was O
used O
to O
define O
various O
cut-off O
points O
according O
to O
the O
WHO O
classification O
guidelines O
. O
G6PD S-protein
genotyping O
for O
Mahidol O
, O
Kaiping O
and O
Mediterranean O
mutations O
was O
performed O
for O
128 O
out O
of O
196 O
samples O
by O
real-time O
multiplex O
PCR O
. O
51 O
of O
196 O
( O
26.0 O
% O
) O
patients O
had O
severe O
dengue O
. O
The O
prevalence O
of O
G6PD S-protein
phenotype O
deficiency O
( O
< O
60 O
% O
activity O
) O
in O
paediatric O
patients O
was O
14.8 O
% O
( O
29/196 O
) O
, O
specifically O
, O
13.6 O
% O
( O
14/103 O
) O
in O
males O
and O
16.2 O
% O
( O
15/93 O
) O
in O
females O
. O
Severe O
deficiency O
( O
< O
10 O
% O
activity O
) O
accounted O
for O
7.1 O
% O
( O
14/196 O
) O
of O
our O
cohort O
, O
occurring O
11.7 O
% O
( O
12/103 O
) O
in O
males O
and O
2.2 O
% O
( O
2/93 O
) O
in O
females O
. O
Among O
128 O
samples O
genotyped O
, O
the O
G6PD B-DNA
gene E-DNA
mutations O
were O
detected O
in O
19.5 O
% O
( O
25/128 O
) O
of O
patients O
, O
with O
20.3 O
% O
( O
13/ O
64 O
) O
in O
males O
and O
18.8 O
% O
( O
12/64 O
) O
in O
females O
. O
The O
G6PD S-protein
Mahidol O
mutation O
was O
96.0 O
% O
( O
24/25 O
) O
while O
the O
G6PD S-protein
Kaiping O
mutation O
was O
4.0 O
% O
( O
1/25 O
) O
. O
Severe O
dengue O
was O
not O
associated O
with O
G6PD B-protein
enzyme E-protein
deficiency O
or O
presence O
of O
the O
G6PD B-DNA
gene E-DNA
mutation O
. O
Thus O
, O
no O
association O
between O
G6PD S-protein
deficiency O
and O
dengue O
severity O
could O
be O
detected O
. O
Trial O
registration O
: O
The O
study O
was O
registered O
following O
the O
WHO O
International O
Clinical O
Trials O
Registry O
Platform O
( O
WHO-ICTRP O
) O
on O
Thai O
Clinical O
Trials O
Registry O
( O
TCTR O
) O
website O
, O
registration O
number O
# O
TCTR20180720001 O
We O
monitored O
the O
survival O
of O
human O
pathogenic O
bacteria O
[ O
Escherichia O
coli O
( O
ATCC O
) O
, O
extended-spectrum O
β-lactamase-producing O
E. O
coli O
( O
Clinical O
isolate O
) O
, O
New O
Delhi O
metallo-βlactamase-producing O
E. O
coli O
( O
clinical O
isolate O
) O
, O
Staphylococcus O
aureus O
( O
ATCC O
) O
] O
on O
dry O
materials O
( O
vinyl O
chloride O
, O
aluminum O
, O
plastic O
, O
stainless O
steel O
) O
at O
distinct O
temperatures O
( O
room O
temperature O
or O
15˚C-37˚C O
) O
. O
These O
bacteria O
favored O
a O
lower O
temperature O
for O
their O
prolonged O
survival O
on O
the O
dry O
fomites O
, O
regardless O
of O
the O
material O
type O
. O
Interestingly O
, O
when O
mixed O
with O
S. O
aureus O
, O
E. O
coli O
survived O
for O
a O
longer O
time O
at O
a O
lower O
temperature O
. O
Cardiolipin O
, O
which O
can O
promote O
the O
survival O
of O
S. O
aureus O
in O
harsh O
environments O
, O
had O
no O
effect O
on O
maintaining O
the O
survival O
of O
E. O
coli O
. O
Although O
the O
trends O
remained O
unchanged O
, O
adjusting O
the O
humidity O
from O
40 O
% O
to O
60 O
% O
affected O
the O
survival O
of O
bacteria O
on O
dry O
surfaces O
. O
Scanning O
electron O
microscopic O
analysis O
revealed O
no O
morphological O
differences O
in O
these O
bacteria O
immediately O
before O
or O
after O
one O
day O
of O
dry O
conditions O
. O
In O
addition O
, O
ATP O
assessment O
, O
a O
method O
used O
to O
visualize O
hightouch O
surfaces O
in O
hospitals O
, O
was O
not O
effective O
at O
monitoring O
bacterial O
dynamics O
. O
A O
specialized O
handrail O
device O
fitted O
with O
a O
heater O
, O
which O
was O
maintained O
at O
normal O
human O
body O
core O
temperature O
, O
successfully O
prohibited O
the O
prolonged O
survival O
of O
bacteria O
[ O
Enterococcus O
faecalis O
( O
ATCC O
) O
, O
E. O
coli O
( O
ATCC O
) O
, O
Pseudomonas O
aeruginosa O
( O
ATCC O
) O
, O
S. O
aureus O
( O
ATCC O
) O
, O
Acinetobacter O
baumannii O
( O
clinical O
isolate O
) O
, O
and O
Serratia O
marcescens O
( O
clinical O
isolate O
) O
] O
, O
with O
the O
exception O
of O
spore-forming O
Bacillus O
subtilis O
( O
from O
our O
laboratory O
collection O
) O
and O
the O
yeastlike O
fungus O
Candida O
albicans O
( O
from O
our O
laboratory O
collection O
) O
] O
on O
dry O
surfaces O
. O
Taken O
together O
, O
we O
concluded O
that O
the O
tested O
bacteria O
favor O
lower O
temperatures O
for O
their O
survival O
in O
dry O
environments O
. O
Therefore O
, O
the O
thermal O
control O
of O
dry O
fomites O
has O
the O
potential O
to O
control O
bacterial O
survival O
on O
high-touch O
surfaces O
in O
hospitals O
. O
The O
treatment O
of O
multiple O
sclerosis O
( O
MS O
) O
has O
changed O
over O
the O
last O
20 O
years O
. O
All O
immunotherapeutic O
drugs O
target O
relapsing O
remitting O
MS O
( O
RRMS O
) O
and O
it O
still O
remains O
a O
medical O
challenge O
in O
MS O
to O
develop O
a O
treatment O
for O
progressive O
forms O
. O
The O
most O
common O
injectable O
disease-modifying O
therapies O
in O
RRMS O
include O
β-interferons O
1a O
or O
1b O
and O
glatiramer O
acetate O
. O
However O
, O
one O
of O
the O
major O
challenges O
of O
injectable O
disease-modifying O
therapies O
has O
been O
poor O
treatment O
adherence O
with O
approximately O
50 O
% O
of O
patients O
discontinuing O
the O
therapy O
within O
the O
first O
year O
. O
Herein O
, O
we O
go O
back O
to O
the O
basics O
to O
understand O
the O
immunopathophysiology O
of O
MS O
to O
gain O
insights O
in O
the O
development O
of O
new O
improved O
drug O
treatments O
. O
We O
present O
current O
disease-modifying O
therapies O
( O
interferons S-protein
, O
glatiramer O
acetate O
, O
dimethyl O
fumarate O
, O
teriflunomide O
, O
fingolimod O
, O
mitoxantrone O
) O
, O
humanized B-protein
monoclonal I-protein
antibodies E-protein
( O
natalizumab O
, O
ofatumumab O
, O
ocrelizumab O
, O
alemtuzumab O
, O
daclizumab O
) O
and O
emerging O
immune O
modulating O
approaches O
( O
stem B-cell_type
cells E-cell_type
, O
DNA O
vaccines O
, O
nanoparticles O
, O
altered O
peptide O
ligands O
) O
for O
the O
treatment O
of O
MS. O
twins O
as O
compared O
to O
siblings O
of O
patients O
with O
MS O
[ O
4 O
] O
[ O
5 O
] O
[ O
6 O
] O
. O
In O
addition O
, O
viral O
infections O
can O
trigger O
disease O
where O
parts O
of O
the O
virus O
mimics O
that O
of O
the O
myelin O
sheath O
[ O
7 O
] O
. O
Although O
usually O
not O
life-shortening O
, O
MS O
is O
a O
chronic O
neurological O
disease O
often O
interfering O
with O
life O
and O
career O
plans O
of O
an O
individual O
[ O
8 O
] O
. O
MS O
is O
categorized O
into O
4 O
distinct O
types O
, O
primarily O
based O
on O
its O
clinical O
course O
, O
which O
are O
characterized O
by O
increasing O
severity O
: O
( O
a O
) O
Relapsing/remitting O
MS O
( O
RRMS O
) O
, O
the O
most O
common O
form O
, O
affecting O
85 O
% O
of O
all O
MS O
patients O
which O
involves O
relapses O
followed O
by O
remission O
; O
( O
b O
) O
secondary O
progressive O
MS O
( O
SPMS O
) O
, O
which O
develops O
over O
time O
following O
diagnosis O
of O
RRMS O
; O
( O
c O
) O
primary O
progressive O
MS O
( O
PPMS O
) O
affecting O
8-10 O
% O
of O
patients O
, O
noted O
as O
gradual O
continuous O
neurologic O
deterioration O
; O
and O
( O
d O
) O
progressive O
relapsing O
MS O
( O
PRMS O
) O
the O
least O
common O
form O
( O
< O
5 O
% O
) O
, O
which O
is O
similar O
to O
PPMS O
but O
with O
overlapping O
relapses O
[ O
9 O
] O
[ O
10 O
] O
[ O
11 O
] O
. O
MS O
leads O
to O
a O
wide O
range O
of O
symptoms O
with O
various O
severity O
involving O
different O
parts O
of O
the O
body O
. O
MS O
diagnosis O
is O
mainly O
clinically O
based O
however O
, O
magnetic O
resonance O
imaging O
( O
MRI O
) O
assists O
in O
diagnosis O
[ O
12 O
] O
. O
As O
such O
, O
examination O
of O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
and O
visual O
induced O
potentials O
with O
MRI O
can O
assist O
in O
confirming O
the O
clinical O
suspicion O
of O
MS O
[ O
12 O
, O
13 O
] O
. O
MS O
symptoms O
and O
disease O
progression O
are O
varied O
, O
with O
some O
individuals O
experiencing O
little O
disability O
while O
most O
( O
up O
to O
60 O
% O
) O
require O
a O
wheelchair O
20 O
years O
from O
diagnosis O
[ O
9 O
] O
. O
Although O
treatments O
against O
MS O
are O
able O
to O
decrease O
the O
relapse O
rate O
in O
RRMS O
, O
the O
prevention O
of O
long-term O
effects O
remains O
a O
problem O
; O
medications O
for O
progressive O
forms O
of O
MS O
are O
also O
limited O
in O
their O
efficacy O
. O
Hence O
, O
new O
improved O
drugs O
are O
required O
to O
effectively O
treat O
MS. O
One O
of O
the O
major O
pathophysiological O
mechanisms O
of O
MS O
involves O
autoreactive B-cell_type
T I-cell_type
cells E-cell_type
, O
primarily O
T B-cell_type
helper I-cell_type
( I-cell_type
Th I-cell_type
) I-cell_type
-1 I-cell_type
CD4 I-cell_type
+ I-cell_type
T I-cell_type
cells E-cell_type
and O
Th17 B-cell_type
cells E-cell_type
leading O
to O
cytokine S-protein
secretion O
and O
activation O
of O
an O
inflammatory O
cascade O
resulting O
in O
demyelination O
within O
the O
brain O
and O
spinal O
cord O
and O
axonal O
damage O
; O
autoreactive B-protein
antibodies E-protein
can O
not O
be O
discounted O
. O
Indeed O
, O
MS O
is O
generally O
known O
as O
a O
chronic O
autoimmune O
disorder O
of O
the O
central O
nervous O
system O
( O
CNS O
) O
[ O
14 O
, O
15 O
] O
. O
MS O
causes O
breakdown O
of O
the O
blood O
brain O
barrier O
( O
BBB O
) O
leading O
to O
migration O
of O
immune B-cell_type
cells E-cell_type
( O
macrophages S-cell_type
, O
T B-cell_type
cells E-cell_type
, O
B B-cell_type
cells E-cell_type
) O
and O
secretion O
of O
pro-inflammatory B-protein
cytokines E-protein
and O
chemokines S-protein
[ O
16 O
] O
which O
induces O
inflammation O
, O
formation O
of O
sclerotic O
plaques O
( O
lesions O
) O
, O
demyelination O
and O
neurodegeneration O
[ O
17 O
] O
. O
MS O
lesions O
may O
form O
in O
any O
location O
of O
the O
CNS O
white O
matter O
or O
in O
grey O
matter O
, O
often O
leading O
to O
physical O
disability O
and O
sometimes O
, O
decline O
in O
cognitive O
ability O
[ O
16 O
, O
18 O
] O
. O
It O
is O
therefore O
, O
conceivable O
to O
target B-cell_type
immune I-cell_type
cells E-cell_type
and O
their O
products O
in O
order O
to O
prevent O
tissue O
damage O
by O
modulating O
inflammation O
[ O
9,19 O
] O
while O
reducing O
potential O
side O
effects O
such O
as O
global O
immunosuppression O
[ O
6 O
, O
19 O
, O
20 O
] O
. O
The O
major O
constituents O
of O
the O
myelin O
sheath O
in O
which O
autoreactive B-cell_type
T I-cell_type
cells E-cell_type
and O
antibodies S-protein
recognize O
, O
include O
, O
myelin B-protein
basic I-protein
protein E-protein
( O
MBP S-protein
) O
, O
myelin B-protein
oligodendrocyte I-protein
glycoprotein E-protein
( O
MOG S-protein
) O
and O
proteolipid B-protein
protein E-protein
( O
PLP S-protein
) O
. O
The O
brain O
has O
primarily O
been O
considered O
to O
be O
an O
organ O
which O
is O
highly O
immune-advantaged O
, O
although O
a O
number O
of O
studies O
have O
challenged O
this O
[ O
6 O
] O
. O
In O
the O
last O
10 O
years O
an O
important O
shift O
has O
surfaced O
in O
MS O
research O
, O
suggesting O
that O
MS O
is O
not O
just O
a O
disease O
of O
the O
immune O
system O
, O
but O
equally O
involves O
factors O
contributed O
by O
the O
CNS O
[ O
21 O
, O
22 O
] O
. O
Immune B-cell_type
cells E-cell_type
residing O
in O
the O
CNS O
get O
activated O
following O
damage O
to O
CNS O
tissue O
; O
notably O
microglial B-cell_type
cells E-cell_type
whereby O
they O
upregulate O
MHC B-protein
class I-protein
I I-protein
and I-protein
II I-protein
molecules E-protein
and O
cell B-protein
surface I-protein
co-stimulatory I-protein
molecules E-protein
and O
secrete O
cytokines S-protein
and O
chemokines S-protein
, O
paving O
entry O
for O
T B-cell_type
( I-cell_type
CD4 I-cell_type
and I-cell_type
CD8 I-cell_type
) I-cell_type
cells E-cell_type
, O
B B-cell_type
cells E-cell_type
, O
monocytes S-cell_type
, O
macrophages S-cell_type
and O
dendritic B-cell_type
( I-cell_type
DC I-cell_type
) I-cell_type
-like I-cell_type
cells E-cell_type
into O
CNS O
lesions O
[ O
6 O
] O
. O
Infiltrating O
immune B-cell_type
cells E-cell_type
secrete O
pro-inflammatory B-protein
cytokines E-protein
, O
nitric O
oxide O
, O
and O
matrix B-protein
metalloproteinases E-protein
[ O
23 O
, O
24 O
] O
, O
leading O
to O
destruction O
of O
the O
myelin O
sheath O
. O
It O
has O
been O
generally O
accepted O
that O
chronic O
inflammation O
is O
the O
hallmark O
of O
neurodegenerative O
diseases O
, O
such O
as O
MS O
, O
Alzheimer O
's O
disease O
and O
Parkinson O
's O
disease O
[ O
6 O
, O
7 O
] O
. O
Myelin-reactive B-cell_line
auto-T I-cell_line
cells E-cell_line
cross O
the O
BBB O
[ O
19 O
] O
and O
their O
migration O
into O
the O
CNS O
consequently O
initiates O
an O
inflammatory O
cascade O
followed O
by O
demyelination O
of O
the O
CNS O
and O
axonal O
damage O
. O
These O
cells O
reside O
in O
the O
perivenous O
demyelinating O
lesions O
which O
generate O
distinct O
inflammatory O
demyelinated O
plaques O
situated O
within O
the O
white O
matter O
[ O
25 O
] O
. O
MS O
lesions O
appear O
in O
the O
white O
matter O
inside O
the O
visual O
neuron O
, O
basal O
ganglia O
, O
brain O
stem O
and O
spinal O
cord O
[ O
26 O
] O
. O
White B-cell_type
matter I-cell_type
cells E-cell_type
transmit O
neural O
signals O
from O
grey O
matter O
, O
where O
Brain O
Sci O
. O
2017 O
, O
7 O
, O
78 O
3 O
of O
27 O
information O
is O
gathered O
, O
and O
transferred O
to O
the O
rest O
of O
the O
body O
[ O
25 O
, O
27 O
] O
. O
MS O
involves O
2 O
main O
steps O
, O
( O
i O
) O
myelin O
sheath O
damage O
resulting O
in O
formation O
of O
lesions O
in O
the O
CNS O
and O
( O
ii O
) O
inflammation O
, O
which O
together O
destroy O
the O
neuron O
tissue O
[ O
25 O
, O
28 O
] O
. O
In O
MS O
, O
damage O
of O
oligodendrocytes O
and O
destruction O
of O
myelin O
sheath O
leads O
to O
breakdown O
of O
the O
nerve O
axon O
and O
loss O
of O
neuronal O
function O
[ O
28 O
] O
. O
Demyelination O
increases O
the O
inflammatory O
activation O
processes O
leading O
to O
damage O
of O
BBB O
and O
stimulation O
of O
macrophage O
activation O
and O
oxidative O
stress O
pathways O
[ O
29 O
] O
. O
The O
white O
matter O
lesions O
include O
myelin O
breakdown O
together O
with O
infiltration O
of O
monocytes S-cell_type
, O
B B-cell_type
cells E-cell_type
, O
T B-cell_type
cells E-cell_type
and O
DC S-cell_type
[ O
30 O
] O
. O
Microglia S-cell_type
and O
macrophages S-cell_type
are O
the O
main O
innate O
immune O
cells O
present O
in O
MS O
lesions O
where O
they O
either O
act O
together O
with O
T B-cell_type
and I-cell_type
B I-cell_type
cells E-cell_type
, O
or O
directly O
cause O
neuroinflammatory O
tissue O
damage O
[ O
31 O
] O
. O
Cells O
involved O
in O
the O
inflammatory O
process O
include O
those O
that O
are O
both O
in O
the O
innate O
and O
adaptive O
immune O
systems O
and O
are O
described O
below O
( O
Figure O
1 O
) O
. O
The O
detection O
of O
West O
Nile O
virus O
( O
WNV O
) O
nucleic O
acid O
in O
a O
blood O
donation O
from O
Vienna O
, O
Austria O
, O
as O
well O
as O
in O
Culex O
pipiens O
pupae O
and O
egg O
rafts O
, O
sampled O
close O
to O
the O
donor O
's O
residence O
, O
is O
reported O
. O
Complete O
genomic O
sequences O
of O
the O
human-and O
mosquito-derived O
viruses O
were O
established O
, O
genetically O
compared O
and O
phylogenetically O
analyzed O
. O
The O
viruses O
were O
not O
identical O
, O
but O
closely O
related O
to O
each O
other O
and O
to O
recent O
Czech O
and O
Italian O
isolates O
, O
indicating O
co-circulation O
of O
related O
WNV O
strains O
within O
a O
confined O
geographic O
area O
. O
The O
detection O
of O
WNV O
in O
a O
blood O
donation O
originating O
from O
an O
area O
with O
low O
WNV O
prevalence O
in O
humans O
( O
only O
three O
serologically O
diagnosed O
cases O
between O
2008 O
and O
2014 O
) O
is O
surprising O
and O
emphasizes O
the O
importance O
of O
WNV O
nucleic O
acid O
testing O
of O
blood O
donations O
even O
in O
such O
areas O
, O
along O
with O
active O
mosquito O
surveillance O
programs O
. O
Background O
: O
Human O
papillomavirus O
16 O
( O
HPV16 O
) O
is O
a O
high-risk O
DNA O
tumour O
virus O
, O
which O
is O
a O
major O
causative O
agent O
of O
cervical O
cancer O
. O
Cellular O
transformation O
is O
associated O
with O
deregulated O
expression O
of O
the O
E6 B-DNA
and I-DNA
E7 I-DNA
oncogenes E-DNA
. O
E7 S-protein
has O
been O
shown O
to O
bind O
a O
number O
of O
cellular B-protein
proteins E-protein
, O
including O
the O
cell B-protein
cycle I-protein
control I-protein
protein I-protein
pRb E-protein
. O
In O
this O
study O
, O
RNA B-RNA
aptamers E-RNA
( O
small O
, O
singlestranded O
oligonucleotides O
selected O
for O
high-affinity O
binding O
) O
to O
HPV16 B-protein
E7 E-protein
were O
employed O
as O
molecular O
tools O
to O
further O
investigate O
these O
protein-protein O
interactions O
. O
This O
study O
is O
focused O
on O
one O
aptamer O
( O
termed O
A2 S-protein
) O
. O
Transfection O
of O
this O
molecule O
into O
HPV16-transformed B-cell_line
cells E-cell_line
resulted O
in O
inhibition O
of O
cell O
proliferation O
( O
shown O
using O
real-time O
cell O
electronic O
sensing O
and O
MTT O
assays O
) O
due O
to O
the O
induction O
of O
apoptosis O
( O
as O
demonstrated O
by O
Annexin O
V/propidium O
iodide O
staining O
) O
. O
GST-pull S-protein
down O
and O
bead O
binding O
assays O
were O
used O
to O
demonstrate O
that O
the O
binding O
of O
A2 S-protein
required O
N-terminal B-protein
residues E-protein
of O
E7 S-protein
known O
to O
be O
involved O
in O
interaction O
with O
the O
cell B-protein
cycle I-protein
control I-protein
protein E-protein
, O
pRb S-protein
. O
Using O
a O
similar O
approach O
, O
A2 S-protein
was O
shown O
to O
disrupt O
the O
interaction O
between O
E7 S-protein
and O
pRb S-protein
in O
vitro O
. O
Furthermore O
, O
transfection O
of O
HPV16-transformed B-cell_line
cells E-cell_line
with O
A2 S-protein
appeared O
to O
result O
in O
the O
loss O
of O
E7 S-protein
and O
rise O
in O
pRb S-protein
levels O
, O
as O
observed O
by O
immunoblotting O
. O
Conclusions/Significance O
: O
This O
paper O
includes O
the O
first O
characterisation O
of O
the O
effects O
of O
an O
E7 B-RNA
RNA E-RNA
aptamer O
in O
a O
cell B-cell_line
line E-cell_line
derived O
from O
a O
cervical O
carcinoma O
. O
Transfection O
of O
cells O
with O
A2 S-protein
was O
correlated O
with O
the O
loss O
of O
E7 S-protein
and O
the O
induction O
of O
apoptosis O
. O
Aptamers O
specific O
for O
a O
number O
of O
cellular B-protein
and I-protein
viral I-protein
proteins E-protein
have O
been O
documented O
previously O
; O
one O
aptamer O
( O
Macugen O
) O
is O
approved O
for O
clinical O
use O
and O
several O
others O
are O
in O
clinical O
trials O
. O
In O
addition O
to O
its O
role O
as O
a O
molecular O
tool O
, O
A2 S-protein
could O
have O
further O
applications O
in O
the O
future O
. O
Background O
: O
Allogeneic O
hematopoietic O
stem O
cell O
transplantation O
( O
HSCT O
) O
is O
the O
only O
curative O
treatment O
available O
for O
severe O
combined O
immunodeficiency O
( O
SCID O
) O
; O
although O
, O
there O
is O
a O
high O
incidence O
of O
severe O
infections O
and O
an O
increased O
risk O
of O
graft-versus O
host-disease O
( O
GvHD O
) O
with O
HSCT O
. O
Early O
intervention O
is O
a O
crucial O
prognostic O
factor O
and O
a O
HLA-haploidentical O
parental O
donor O
is O
often O
available O
. O
Haploidentical O
HSCT O
protocols O
utilizing O
extensively O
ex O
vivo O
T-cell O
depleted O
grafts O
( O
CliniMACs O
system O
) O
have O
proven O
efficient O
in O
preventing O
GvHD O
, O
but O
cause O
a O
delay O
in O
early O
T-cell O
recovery O
that O
increases O
the O
risk O
of O
viral O
infections O
. O
Here O
, O
we O
present O
a O
novel O
approach O
for O
treating O
SCID O
that O
combines O
selective O
depletion O
of O
GvHD-inducing B-cell_line
alpha/beta I-cell_line
( I-cell_line
α/β I-cell_line
) I-cell_line
T-cells E-cell_line
from O
the O
haploidentical O
HSCT O
graft O
with O
a O
subsequent O
donor O
lymphocyte O
infusion O
( O
DLI O
) O
enriched O
for O
CD45RO+ B-cell_type
memory I-cell_type
T-cells E-cell_type
. O
Results O
: O
Our O
patient O
was O
diagnosed O
with O
SCID O
( O
T-B O
+ O
NK+ O
phenotype O
) O
. O
At O
9 O
months O
of O
age O
, O
he O
received O
a O
T B-protein
cell I-protein
receptor I-protein
( I-protein
TCR I-protein
) I-protein
α/β-cell E-protein
depleted O
graft O
from O
his O
haploidentical O
mother O
, O
following O
a O
reduced O
intensity O
conditioning O
regimen O
with O
no O
additional O
GvHD O
prophylaxis O
. O
Engraftment O
was O
rapid O
with O
complete O
donor O
chimerism O
and O
no O
signs O
of O
GvHD O
. O
However O
, O
at O
12 O
weeks O
post O
HSCT O
, O
the O
patient O
was O
still O
T-cell O
lymphopenic O
with O
clinical O
symptoms O
of O
multiple O
severe O
viral O
infections O
. O
Consequently O
, O
therapeutic O
DLIs O
were O
initiated O
for O
enhanced O
anti-viral O
immunity O
. O
The O
patient O
was O
treated O
with O
CD45RA+ O
depleted O
haploidentical O
maternal O
donor O
lymphocytes S-cell_type
enriched O
from O
unmobilized O
whole O
blood O
, O
and O
a O
total O
T-cell O
dose O
of O
no O
more O
than O
25 O
x10 O
3 O
CD3+ O
cells/kg O
with O
> O
99.9 O
% O
purity O
of O
CD3 S-protein
+ O
CD45RO+ B-cell_type
memory I-cell_type
T-cells E-cell_type
was O
transferred O
. O
Following O
the O
DLI S-protein
, O
a O
prompt O
increase O
in O
CD3 S-protein
+ O
CD4+ S-protein
and O
CD3 S-protein
+ O
CD8+ O
counts O
was O
observed O
with O
a O
subsequent O
clearance O
of O
viral O
infections O
. O
No O
acute O
or O
chronic O
GvHD O
was O
observed O
. O
Conclusions O
: O
Automated O
depletion O
of O
CD45RA+ B-cell_type
naïve I-cell_type
T-cells E-cell_type
from O
unmobilized O
whole O
blood O
is O
a O
simple O
and O
rapid O
strategy O
to O
provide O
unmanipulated O
DLIs O
, O
with O
a O
potentially O
broad O
repertoire O
of O
pathogen O
specific O
memory B-cell_type
T-cells E-cell_type
. O
In O
the O
haploidentical O
setting O
, O
CD45RA+ O
depleted O
DLIs O
can O
be O
safely O
administered O
at O
low O
T-cell O
doses O
for O
efficient O
enhancement O
of O
viral O
immunity O
and O
limited O
risk O
of O
GvHD O
. O
We O
demonstrate O
the O
successful O
use O
of O
this O
approach O
following O
TCR-α/β-cell O
depleted O
HSCT O
for O
the O
treatment O
of O
SCID O
. O
ORF4b S-protein
antagonizes O
the O
early O
antiviral O
alpha/beta B-protein
interferon E-protein
( O
IFN-α/β S-protein
) O
response O
, O
which O
may O
significantly O
contribute O
to O
MERS-CoV O
pathogenesis O
; O
however O
, O
the O
underlying O
mechanism O
is O
poorly O
understood O
. O
Here O
, O
we O
found O
that O
ORF4b S-protein
in O
the O
cytoplasm O
could O
specifically O
bind O
to O
TANK B-protein
binding I-protein
kinase I-protein
1 E-protein
( O
TBK1 S-protein
) O
and O
IκB B-protein
kinase I-protein
epsilon E-protein
( O
IKKε S-protein
) O
, O
suppress O
the O
molecular O
interaction O
between O
mitochondrial B-protein
antiviral I-protein
signaling I-protein
protein E-protein
( O
MAVS S-protein
) O
and O
IKKε S-protein
, O
and O
inhibit O
IFN B-protein
regulatory I-protein
factor I-protein
3 E-protein
( O
IRF3 S-protein
) O
phosphorylation O
and O
subsequent O
IFN-β S-protein
production O
. O
Further O
analysis O
showed O
that O
ORF4b S-protein
could O
also O
inhibit O
IRF3 S-protein
and O
IRF7-induced O
production O
of O
IFN-β S-protein
, O
whereas O
deletion O
of O
the O
nuclear O
localization O
signal O
of O
ORF4b S-protein
abrogated O
its O
ability O
to O
inhibit O
IRF3 S-protein
and O
IRF7-induced O
production O
of O
IFN-β S-protein
, O
but O
not O
IFN-β S-protein
production O
induced O
by O
RIG-I S-protein
, O
HCoVs S-protein
have O
yet O
to O
be O
identified O
. O
MERS-CoV B-protein
ORF4b E-protein
antagonizes O
the O
early O
antiviral O
response O
, O
which O
may O
contribute O
to O
MERS-CoV O
pathogenesis O
. O
Here O
, O
we O
report O
the O
identification O
of O
the O
interferon S-protein
( O
IFN S-protein
) O
antagonism O
mechanism O
of O
MERS-CoV B-protein
ORF4b E-protein
. O
MERS-CoV B-protein
ORF4b E-protein
inhibits O
the O
production O
of O
type B-protein
I I-protein
IFN E-protein
through O
a O
direct O
interaction O
with O
IKKε B-protein
/TBK1 E-protein
in O
the O
cytoplasm O
, O
and O
also O
in O
the O
nucleus O
with O
unknown O
mechanism O
. O
These O
findings O
provide O
a O
rationale O
for O
the O
novel O
pathogenesis O
of O
MERS-CoV O
as O
well O
as O
a O
basis O
for O
developing O
a O
candidate O
therapeutic O
against O
this O
virus O
. O
Interferences O
between O
pathogenic O
bacteria O
and O
specific O
commensals O
are O
known O
. O
We O
determined O
the O
interactions O
between O
nasopharyngeal O
microbial O
pathogens O
and O
commensals O
during O
viral O
upper O
respiratory O
tract O
infection O
( O
URI O
) O
and O
acute O
otitis O
media O
( O
AOM O
) O
in O
infants O
. O
We O
analyzed O
971 O
specimens O
collected O
monthly O
and O
during O
URI O
and O
AOM O
episodes O
from O
139 O
infants O
. O
The O
16S B-DNA
rRNA I-DNA
V4 I-DNA
gene I-DNA
regions E-DNA
were O
sequenced O
on O
the O
Illumina O
MiSeq O
platform O
. O
Among O
the O
high O
abundant O
genus-level O
nasopharyngeal O
microbiota O
were O
Moraxella O
, O
Haemophilus O
, O
and O
Streptococcus O
( O
3 O
otopathogen O
genera O
) O
, O
Corynebacterium O
, O
Dolosigranulum O
, O
Staphylococcus O
, O
Acinetobacter O
, O
Pseudomonas O
, O
and O
Bifidobacterium O
. O
Bacterial O
diversity O
was O
lower O
in O
culture-positive O
samples O
for O
Streptococcus O
pneumoniae O
, O
and O
Haemophilus O
influenzae O
, O
compared O
to O
cultured-negative O
samples O
. O
URI O
frequencies O
were O
positively O
associated O
with O
increasing O
trend O
in O
otopathogen O
colonization O
. O
AOM O
frequencies O
were O
associated O
with O
decreasing O
trend O
in O
Micrococcus O
colonization O
. O
During O
URI O
and O
AOM O
, O
there O
were O
increases O
in O
abundance O
of O
otopathogen O
genera O
and O
decreases O
in O
Pseudomonas O
, O
Myroides O
, O
Yersinia O
, O
and O
Sphingomonas O
. O
Otopathogen O
abundance O
was O
increased O
during O
symptomatic O
viral O
infection O
, O
but O
not O
during O
asymptomatic O
infection O
. O
The O
risk O
for O
AOM O
complicating O
URI O
was O
reduced O
by O
increased O
abundance O
of O
Staphylococcus O
and O
Sphingobium O
. O
Zika O
virus O
( O
ZIKV O
) O
has O
been O
associated O
with O
serious O
health O
conditions O
, O
and O
an O
intense O
search O
to O
discover O
different O
ways O
to O
prevent O
and O
treat O
ZIKV O
infection O
is O
underway O
. O
Berberine O
and O
emodin O
possess O
several O
pharmacological O
properties O
and O
have O
been O
shown O
to O
be O
particularly O
effective O
against O
the O
entry O
and O
replication O
of O
several O
viruses O
. O
We O
show O
that O
emodin O
and O
berberine O
trigger O
a O
virucidal O
effect O
on O
ZIKV O
. O
When O
the O
virus O
was O
exposed O
to O
160 O
µM O
of O
berberine O
, O
a O
reduction O
of O
77.6 O
% O
in O
the O
infectivity O
was O
observed O
; O
when O
emodin O
was O
used O
( O
40 O
µM O
) O
, O
this O
reduction O
was O
approximately O
83.3 O
% O
. O
Dynamic O
light O
scattering O
data O
showed O
that O
both O
compounds O
significantly O
reduce O
the O
hydrodynamic O
radius O
of O
virus O
particle O
in O
solution O
. O
We O
report O
here O
that O
berberine O
and O
emodin O
, O
two O
natural O
compounds O
, O
have O
strong O
virucidal O
effect O
in O
Zika O
virus O
. O
Infectious O
diseases O
are O
a O
significant O
burden O
on O
public O
health O
and O
economic O
stability O
of O
societies O
all O
over O
the O
world O
. O
They O
have O
for O
centuries O
been O
among O
the O
leading O
causes O
of O
death O
and O
disability O
and O
presented O
growing O
challenges O
to O
health O
security O
and O
human O
progress O
. O
The O
threat O
posed O
by O
infectious O
diseases O
is O
further O
deepened O
by O
the O
continued O
emergence O
of O
new O
, O
unrecognized O
, O
and O
old O
infectious O
disease O
epidemics O
of O
global O
impact O
. O
Over O
the O
past O
three O
and O
half O
decades O
at O
least O
30 O
new O
infectious O
agents O
affecting O
humans O
have O
emerged O
, O
most O
of O
which O
are O
zoonotic O
and O
their O
origins O
have O
been O
shown O
to O
correlate O
significantly O
with O
socioeconomic O
, O
environmental O
, O
and O
ecological O
factors O
. O
As O
these O
factors O
continue O
to O
increase O
, O
putting O
people O
in O
increased O
contact O
with O
the O
disease O
causing O
pathogens O
, O
there O
is O
concern O
that O
infectious O
diseases O
may O
continue O
to O
present O
a O
formidable O
challenge O
. O
Constant O
awareness O
and O
pursuance O
of O
effective O
strategies O
for O
controlling O
infectious O
diseases O
and O
disease O
emergence O
thus O
remain O
crucial O
. O
This O
review O
presents O
current O
updates O
on O
emerging O
and O
neglected O
infectious O
diseases O
and O
highlights O
the O
scope O
, O
dynamics O
, O
and O
advances O
in O
infectious O
disease O
management O
with O
particular O
focus O
on O
WHO O
top O
priority O
emerging O
infectious O
diseases O
( O
EIDs O
) O
and O
neglected O
tropical O
infectious O
diseases O
. O
Strand O
exchange O
nucleic O
acid O
circuitry O
can O
be O
used O
to O
transduce O
isothermal O
nucleic O
acid O
amplification O
products O
into O
signals O
that O
can O
be O
readable O
on O
an O
off-the-shelf O
glucometer O
. O
Loop-mediated O
isothermal O
amplification O
( O
LAMP O
) O
is O
limited O
by O
the O
accumulation O
of O
non-specific O
products O
, O
but O
nucleic O
acid O
circuitry O
can O
be O
used O
to O
probe O
and O
distinguish O
specific O
amplicons O
. O
By O
combining O
this O
high O
temperature O
isothermal O
amplification O
method O
with O
a O
thermostable O
invertase S-protein
, O
we O
can O
directly O
transduce O
Middle-East O
respiratory O
syndrome O
coronavirus O
and O
Zaire O
Ebolavirus O
templates O
into O
glucose O
signals O
, O
with O
a O
sensitivity O
as O
low O
as O
20-100 O
copies/μ O
l O
, O
equating O
to O
atto-molar O
( O
or O
low O
zepto-mole O
) O
. O
Virus O
from O
cell O
lysates O
and O
synthetic O
templates O
could O
be O
readily O
amplified O
and O
detected O
even O
in O
sputum O
or O
saliva O
. O
An O
OR O
gate O
that O
coordinately O
triggered O
on O
viral O
amplicons O
further O
guaranteed O
fail-safe O
virus O
detection O
. O
The O
method O
describes O
has O
potential O
for O
accelerating O
point-of-care O
applications O
, O
in O
that O
biological O
samples O
could O
be O
applied O
to O
a O
transducer O
that O
would O
then O
directly O
interface O
with O
an O
off-the-shelf O
, O
approved O
medical O
device O
. O
The O
Middle-East O
respiratory O
syndrome O
coronavirus O
( O
MERS-CoV O
) O
belongs O
to O
the O
human B-protein
betacoronavirus I-protein
family E-protein
of O
coronaviruses O
, O
which O
are O
large O
positive-stranded O
RNA O
viruses O
whose O
genomes O
typically O
range O
between O
~27 O
to O
~31 O
kb O
in O
size O
. O
The O
first O
case O
of O
MERS-CoV O
infection O
was O
identified O
in O
2012 O
in O
a O
Saudi O
Arabian O
patient O
who O
died O
from O
a O
severe O
respiratory O
illness O
1-3 O
. O
Since O
then O
, O
the O
infection O
has O
spread O
globally O
and O
through O
the O
middle O
of O
2014 O
had O
caused O
614 O
laboratory-confirmed O
cases O
and O
181 O
deaths O
2,4,5 O
. O
MERS-CoV O
is O
thus O
one O
of O
the O
most O
serious O
emergent O
viral O
pathogens O
since O
its O
relative O
, O
SARS-CoV O
6 O
. O
In O
order O
to O
control O
spreading O
infections O
and O
receive O
timely O
treatment O
, O
sensitive O
and O
specific O
detection O
of O
MERS-CoV S-protein
at O
point-of-need O
or O
point-of-care O
is O
extremely O
important O
. O
While O
methods O
such O
as O
immunofluorescence O
assays O
( O
targeting O
MERS-CoV B-protein
N I-protein
and I-protein
S I-protein
proteins E-protein
) O
7 O
and O
real-time O
reverse O
transcription O
polymerase O
chain O
reaction O
( O
RT-PCR O
, O
targeting O
viral B-DNA
genes E-DNA
in O
or O
around O
ORF1A S-DNA
, O
ORF1B S-DNA
and O
upE S-DNA
) O
have O
been O
successfully O
used O
for O
clinical O
diagnosis O
8-10 O
, O
these O
methods O
are O
not O
readily O
adapted O
to O
point-of-care O
applications O
. O
A O
simple O
molecular O
assay O
for O
MERS-CoV O
can O
potentially O
be O
developed O
by O
relying O
on O
the O
exquisite O
sensitivity O
and O
extreme O
simplicity O
of O
isothermal O
amplification O
reactions O
11-16 O
, O
such O
as O
loop-mediated O
isothermal O
amplification O
( O
LAMP O
) O
, O
which O
yields O
up O
to O
10 O
10 O
-fold O
amplification O
within O
10 O
min O
to O
two O
hours O
17,18 O
. O
Unfortunately O
, O
LAMP O
also O
creates O
many O
non-specific O
amplicons O
that O
often O
yield O
false O
positive O
results O
and O
because O
of O
this O
its O
potential O
for O
point-of-care O
assays O
has O
not O
been O
realized O
. O
We O
recently O
found O
that O
sequence-specific O
, O
nucleic O
acid O
strand O
exchange O
reactions O
can O
be O
used O
to O
efficiently O
distinguish O
between O
specific O
and O
non-specific O
LAMP O
amplicons O
[ O
19 O
] O
[ O
20 O
] O
[ O
21 O
] O
. O
We O
now O
show O
that O
LAMP O
reactions O
can O
be O
made O
user-friendly O
and O
field-based O
by O
integrating O
LAMP O
, O
strand O
exchange O
signal O
transduction O
, O
and O
a O
commercial-off-the-shelf O
device O
, O
a O
glucometer O
, O
for O
pathogen O
detection O
. O
The O
use O
of O
glucometers O
to O
monitor O
non-glucose O
targets O
was O
pioneered O
by O
Lu O
's O
group O
, O
who O
adapted O
this O
device O
for O
aptamer-or O
DNAzyme-based O
detection O
of O
cocaine O
, O
ATP O
and O
metal O
ions O
22-25 O
. O
These O
and O
other O
efforts O
26-30 O
inspired O
our O
more O
generalizable O
approach O
to O
molecular O
diagnostics O
. O
The O
addition O
of O
a O
thermostable B-protein
invertase E-protein
allows O
all O
reactions O
to O
occur O
in O
the O
same O
tube O
at O
a O
wide O
temperature O
range O
, O
and O
the O
simplicity O
of O
the O
format O
ultimately O
yields O
atto-molar O
( O
or O
low O
zepto-mole O
) O
detection O
of O
pathogens O
such O
as O
MERS-CoV O
or O
Zaire O
Ebolavirus O
( O
ZEBOV O
or O
Zaire O
Ebola O
) O
, O
even O
in O
sputum O
or O
saliva O
samples O
. O
The O
strand O
exchange O
reactions O
ensure O
low O
false O
positives O
, O
while O
the O
use O
of O
an O
OR O
gate O
guards O
against O
false O
negative O
detection O
. O
Moreover O
, O
the O
reaction O
components O
are O
modular O
and O
can O
be O
readily O
adapted O
to O
different O
protocols O
covering O
different O
reaction O
temperatures O
, O
times O
, O
volumes O
, O
and O
vagaries O
of O
reagent O
storage O
. O

